WorldWideScience

Sample records for risperdal consta risperidone

  1. In Vitro-In Vivo Correlation of Parenteral Risperidone Polymeric Microspheres

    OpenAIRE

    2015-01-01

    The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal® Consta® was used to prepare risperidone microspheres. Various manufacturing processe...

  2. 棕榈酸帕利哌酮与利培酮微球治疗精神分裂症的临床研究%Clinical effect of paliperidone palmitate and risperdal consta in the treatment of patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王健; 周雪丽; 刘伟; 张贤峰; 李薇; 陈冬; 颜景祥; 杜波

    2015-01-01

    Objective To evaluate clinical efficacy and safety of paliperi-done palmitate injection and risperdal consta in treatmenting schizophre-nia.Methods A total of 60 subjects with schizophrenia were randomly assigned into treatment group and control group, 30 cases in each group. Patients in treatment group were injected with paliperidone palmitate 50-150 mg on day 1,8,36 and 64.Those in control group were injected with risperdal consta 25-50 mg on day 8, 22, 36, 50, 64 and 78.The observation lasted for 92 days.The positive and negative syndrome scale ( PANSS ) , the clinical global impression -severity of illness scale ( CGI-S) , adverse drug reactions, personal and social performance scale(PSP) and laboratory tests were compared on day 1, 8, 36, 64 and 92.Results Compared with the first day, the data of PANSS score at each time point were reduced( P0.05).The adverse reactions of two groups were similar and the abnormal involuntary movement scale ( AIMS ) in two groups were not statistically different(Z=0.673, P>0.05).Conclusion The efficacy of paliperidone palmitate for schizophrenia is clear, and it benefits the continuing drug therapy as well as improves social function of patients.%目的:评价棕榈酸帕利哌酮注射液与注射用利培酮微球治疗精神分裂症的疗效和安全性。方法60例精神分裂症患者随机分为帕利哌酮组30例(试验组)和利培酮组30例(对照组),试验组在第1,8,36,64天注射帕利哌酮50~150 mg,对照组在第8,22,36,50,64,78天注射利培酮25~50 mg。观察时间为92 d。于治疗第1,8,36,64,92天用阳性和阴性症状量表(PANSS),临床总体印象-严重度量表(CGI-S),个人和社会功能量表(PSP),观察药物不良反应和化验检查。结果2组PANSS评分在各个时间点与第1天相比均减低( P<0.01)。第92天,2组间PANSS评分、CGI评分、PSP评分差异无统计学意义(P>0.05)。2

  3. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.

    Science.gov (United States)

    Shen, Jie; Choi, Stephanie; Qu, Wen; Wang, Yan; Burgess, Diane J

    2015-11-28

    The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal® Consta® was used to prepare risperidone microspheres. Various manufacturing processes were investigated to produce the risperidone microspheres with similar drug loading (approx. 37%) but distinctly different physicochemical properties (e.g. porosity, particle size and particle size distribution). In vitro release of the risperidone microspheres was investigated using different release testing methods (such as sample-and-separate and USP apparatus 4). In vivo pharmacokinetic profiles of the risperidone microsphere formulations following intramuscular administration were determined using a rabbit model. Furthermore, the obtained pharmacokinetic profiles were deconvoluted using the Loo-Riegelman method and the calculated in vivo release was compared with the in vitro release of these microspheres. Level A IVIVCs were established and validated for the compositionally equivalent risperidone microspheres based on the in vitro release data obtained using USP apparatus 4. The developed IVIVCs demonstrated good predictability and were robust. These results showed that the developed USP apparatus 4 method was capable of discriminating PLGA microspheres that are equivalent in formulation composition but with manufacturing differences and predicting their in vivo performance in the investigated animal model.

  4. Risperidone

    Science.gov (United States)

    ... bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Risperidone is also used to treat behavior problems such as aggression, self-injury, and ... repetitive behavior, difficulty interacting with others, and problems ...

  5. Evaluación comparativa de la liberación in vitro de risperidona 3 mg producida en Cuba contra Risperdal® Comparative assessment of in vitro release of 3 mg Risperidone produced in Cuba versus Risperidal®

    Directory of Open Access Journals (Sweden)

    Caridad Margarita García Peña

    2010-06-01

    Full Text Available Se compararon los perfiles de disolución de las tabletas de risperidona 3 mg medicamento genérico producido en Cuba y del Risperdal® (Laboratorios Janssen-Cilag SA, para demostrar su similitud. También se realizó la comparación en varios medios de disolución a diferentes pH para evaluar una posible bioexoneración. Para la cuantificación del principio activo, se utilizó un método por cromatografía líquida de alta resolución, previamente validado. La comparación se realizó sobre la base de los factores de diferenciación y similitud. Los resultados mostraron que no existían diferencias en los perfiles de liberación para las tabletas producidas en Cuba y del producto innovador, así como para los diferentes medios de disolución a los pH utilizados.The 3 mg Risperidone tablets dissolution profiles, a generic drug produced in Cuba and the Risperidal® (Janssen-Cilag S.A. Labs were compared to demonstrate its similarity. Also, we compared some dissolution means at different pH to assess a potential bio-exoneration. To quantify the active principle, a previously validated high-performance liquid chromatography was used. The comparison was conducted on the base of differentiation and similarity factors. Results demonstrated that there weren't differences en release profiles for tablets produced in Cuba and of innovative product, as well as for the different dissolution means at pH used.

  6. Risperidone Injection

    Science.gov (United States)

    ... control slow movements or shuffling walk falling painful erection of the penis that lasts for hours Risperidone extended-release injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.If you experience a ...

  7. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents.

    Science.gov (United States)

    Scott, Lesley J; Dhillon, Sohita

    2007-01-01

    Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin (5-HT [5-hydroxytryptamine])(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also approved for the treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years, for the treatment of schizophrenia in adolescents aged 13-17 years and, as monotherapy, for the short-term treatment of acute manic and mixed episodes associated with bipolar I disorder in children and adolescents aged 10-17 years. Oral risperidone treatment was better than placebo treatment in reducing irritability and other behavioral symptoms associated with autistic disorder in children and adolescents in two well designed short-term trials, with these benefits maintained in those receiving risperidone for up to 6 months. The drug had a clinically manageable tolerability profile, with most adverse events being of mild to moderate intensity. There are some aspects of treatment, such as weight gain, somnolence, and hyperglycemia, that require monitoring, and the long-term safety of risperidone in children and adolescents with autistic disorder remains to be fully determined. With these issues in mind, risperidone offers a valuable emerging option for the treatment of irritability associated with autistic disorder in children and adolescents.

  8. 喹硫平与利培酮对女性精神分裂症患者血清催乳素及体重指数的影响分析%Effect of quetiapine and risperdal on serum prolactin levels and body mass index of female patients with schizophrenic

    Institute of Scientific and Technical Information of China (English)

    徐炳聪; 涂健铭; 张明辉

    2014-01-01

    目的 探讨喹硫平与利培酮对女性精神分裂症患者血清催乳素和体重指数BMI的影响.方法 选取未用药或停药1月的100例女性精神分裂症患者,随机分为喹硫平组和利培酮组治疗,分别给予喹硫平与利培酮单独治疗12周.在治疗前后分别测定血清催乳素水平和体重,计算体重指数BMI.结果 治疗12周后喹硫平组血清催乳素和体重指数BMI无明显增加,利培酮组则显著增加,体重指数BMI和催乳素水平变化呈正相关.结论 喹硫平对女性患者催乳素和体重BMI指数无明显影响,利培酮对女性患者催乳素和体重指数BMI影响明显.%Objective To investigate the influence of quetiapine and risperdal on the serum prolactin levels and body mass index (BMI) of female patients with schizophrenic.Methods 100 female schizophrenic patients,who had never used medication or had discontinued medication for a month,were randomly divided into two groups,the quetiapine group and the risperdal group.Each group was provided with quetiapine or risperdal,respectively,for 12 weeks.The serum prolactin level and body weight were recorded and BMI was calculated for each patient,before and after the treatment.Results After 12 weeks of treatment,the serum prolactin level and BMI in the quetiapine group had no significant increase,while they increased significantly in the risperidone group.It also showed that BMI and serum prolactin level changes had positive correlation.Conclusion Risperdal has significant effect on the serum prolactin and BMI of female schizophrenic patients,but quetiapine has not.

  9. Interpreting serum risperidone concentrations.

    Science.gov (United States)

    Boerth, Joel M; Caley, Charles F; Goethe, John W

    2005-02-01

    Risperidone is an atypical antipsychotic commonly used for treatment of schizophrenia and other psychotic disorders. Although therapeutic drug monitoring is not routine for any of the atypical antipsychotics, serum antipsychotic concentrations are measured routinely to assess treatment nonadherence. In humans, risperidone is metabolized by cytochrome P450 2D6 to 9-hydroxyrisperidone; together these constitute the active moiety. Dose-proportional increases in serum concentrations have not been reported for the parent drug, but have been reported for 9-hydroxyrisperidone and the active moiety (i.e., the combined concentrations of risperidone and 9-hydroxyrisperidone). We describe a 34-year-old Caucasian man of Sicilian descent with a history of schizophrenia, disorganized type. He was suspected to be noncompliant with his risperidone therapy. Initially, active moiety risperidone concentrations increased linearly with prescribed dosage increases. However, with continued increases, active moiety concentrations adjusted downward and remained 17-36% below anticipated levels. We propose a method for estimating target active moiety concentrations of risperidone based on dosage-a method that may be used to guide clinicians in assessing nonadherence to risperidone treatment.

  10. Bioequivalence study of a generic Risperidone (Iperdal® in healthy Thai male volunteers

    Directory of Open Access Journals (Sweden)

    Werawath Mahatthanatrakul

    2008-05-01

    Full Text Available The objective of this study was to compare the rate and extent of absorption of a generic risperidone (Iperdal® with a reference formulation (Risperdal® when given orally. The study was an open label, randomized, two-period, two-sequence,single dose cross-over design with a 2 weeks washout period in 16 healthy Thai male volunteers. Single oral dose of two 2-mg tablets of risperidone were administered and serial blood samples were collected from the antecubital vein before and at0.17, 0.33, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 and 48 hours post dose. Risperidone plasma concentrations were assayed using a validated High Performance Liquid Chromatographic (HPLC-UV method modified from Avenosoet al. (2000. Pharamcokinetic parameters i.e. Cmax, AUC0à48 and Tmax were analyzed by noncompartment analysis. Variations of the data were analyzed by “Two Way Analysis of Variance” (ANOVA. Statistics were tested as stated in USP 28 guidelinefor bioequivalence study. The maximum concentration (Cmax, ng/ml of risperidone for the innovator and the generic product were 31.11±17.24 (range 5.64-56.78 and 32.58±19.77 (range 5.29-84.56 ng/ml, respectively. The area under theplasma concentration-time curve (AUC0®48 of the innovator and the generic product were 160.64±152.89 (range 18.57- 550.32 and 144.03±127.37 (range 16.27-456.0 ng.hr/ml, respectively. The time to maximum concentration (Tmax of theinnovator and the generic product were 0.97±0.41(range 0.5-2 and 1.02±0.32 (range 0.5-1.5 hr, respectively. The 90% confidence interval of the ratio of the ln-transformed of Cmax and AUC0à48 of both preparations were 89.39-112.99% and80.02-107.28% respectively which were within the acceptance range of 80.00-125.00%. Therefore, it can be concluded that both preparations used in this study are bioequivalent in terms of both the rate and extent of absorption.

  11. Postmortem Femoral Blood Concentrations of Risperidone

    DEFF Research Database (Denmark)

    Linnet, Kristian; Johansen, Sys Stybe

    2014-01-01

    Postmortem femoral blood concentrations of the antipsychotic drug risperidone and the active metabolite 9-hydroxyrisperidone were determined by an achiral LC-MS/MS method in 38 cases. The cause of death was classified as unrelated to risperidone in 30 cases, in which the sum of the concentration ...

  12. Development of Risperidone PLGA Microspheres

    Directory of Open Access Journals (Sweden)

    Susan D’Souza

    2014-01-01

    Full Text Available The aim of this study was to design and evaluate biodegradable PLGA microspheres for sustained delivery of Risperidone, with an eventual goal of avoiding combination therapy for the treatment of schizophrenia. Two PLGA copolymers (50 : 50 and 75 : 25 were used to prepare four microsphere formulations of Risperidone. The microspheres were characterized by several in vitro techniques. In vivo studies in male Sprague-Dawley rats at 20 and 40 mg/kg doses revealed that all formulations exhibited an initial burst followed by sustained release of the active moiety. Additionally, formulations prepared with 50 : 50 PLGA had a shorter duration of action and lower cumulative AUC levels than the 75 : 25 PLGA microspheres. A simulation of multiple dosing at weekly or 15-day regimen revealed pulsatile behavior for all formulations with steady state being achieved by the second dose. Overall, the clinical use of Formulations A, B, C, or D will eliminate the need for combination oral therapy and reduce time to achieve steady state, with a smaller washout period upon cessation of therapy. Results of this study prove the suitability of using PLGA copolymers of varying composition and molecular weight to develop sustained release formulations that can tailor in vivo behavior and enhance pharmacological effectiveness of the drug.

  13. Risperidone for Aggressive Behavior in ADHD

    Directory of Open Access Journals (Sweden)

    J Gordon Millichap

    2007-05-01

    Full Text Available The effects of risperidone augmentation for treatment-resistant aggression in children with ADHD were evaluated in a placebo-controlled pilot study at the University of Miami Miller School of Medicine, FL.

  14. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.

    Science.gov (United States)

    Holzer, Laurent; Eap, Chin B

    2006-04-01

    Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea. However, the largest study performed in children and adolescents showed a weak effect of risperidone on prolactin concentrations during short-term treatment and a negligible effect during long-term treatment, which was probably because of the relatively low dosages of risperidone used [approximately 0.04 mg/(kg x d)]. Among the 10 psychotic adolescents treated with risperidone in our unit, we had 3 cases of gynecomastia in 3 male patients and 2 cases of galactorrhea in 2 female patients. The prolactin blood levels in these cases and in 3 other patients without apparent prolactin-related side effects were all above the normal range (median, 59 ng/mL; range, 30-123 ng/mL). Thus, risperidone administered to adolescents at doses commonly used for the treatment of psychotic symptoms can strongly increase prolactin levels, with clinical consequences such as gynecomastia and/or galactorrhea. Given that the long-term effects of antipsychotic drug-induced hyperprolactinemia are not well documented, especially regarding osteopenia, infertility, growth, and pubertal delay, risperidone should be administered with caution to children and adolescents.

  15. RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA

    Science.gov (United States)

    Agarwal, A.K.; Bashyam, V.S.P; Channabasavanna, S.M.; Dhavale, H.S.; Khan, M.A.M.; Khanna, Sumant; Pradhan, P.V.; Katiyar, M.; Rajkumar, R.; Niazi, Faiz R.; Jalali, R.K.; Gowrishankar, R.; Mishra, S.K.; Sood, O.P.

    1998-01-01

    Conventional antipsychotic agents are not effective against negative symptoms of schizophrenia and are also noted for their extrapyramidal side effects. Risperidone is a noval antipsychotic agent whose dual antagonism of dopamine and serotonin receptors is believed to underlie its efficacy against negative symptoms and the low incidence of extrapyramidal side effects. An open, non-comparative study of seven weeks duration was performed to evaluate risperidone in the treatment of schizophrenia in Indian patients. Previous antipsychotic therapy was discontinued for a week before risperidone therapy was initiated. At the end of six weeks of risperidone therapy, clinical improvement (≥ 20% reduction in total score on positive and negative syndrome scale for schizophrenia (PANSS;; was shown by 128 (87.7%) of the 146 evaluable patients. Statistically significant reduction (p < 0.05) occurred in the total score of this scale and in the subscale scores for positive, negative and general psychopathology symptoms and in the clinical global impression severity score. The number of patients with adverse experiences were 108 (65.5%) at baseline and 120 (72.7%) at the end of risperidone therapy. Extrapyramidal symptoms, seen in 65 (39.4%) patients compared to 22 (13.3%) patients at baseline, were largely mild to moderate in intensity. PMID:21494480

  16. Risperidone associated paralytic ileus in schizophrenia

    Directory of Open Access Journals (Sweden)

    Parthasarathy Ramamourthy

    2013-01-01

    Full Text Available A 32-year-old man, diagnosed with catatonic schizophrenia, was treated with risperidone and lorazepam in the general hospital psychiatry setup. He developed signs of intestinal obstruction, which was diagnosed as paralytic ileus and was treated conservatively along with stopping the offending drug. Risperidone is said to be devoid of anticholinergic side effects, but prevalence of these varies from 7% to 13% in patients receiving treatment for schizophrenia. Constipation has been reported but fatal adverse effect like paralytic ileus with risperidone is rarely reported. Timely diagnosis can save the need for surgical interventions and fatal complications. This predisposition in schizophrenia could be due to neurodevelopmentally shared abnormality of brain and gut nervous system.

  17. Gynecomastia with risperidone-fluoxetine combination.

    Science.gov (United States)

    Benazzi, F

    1999-01-01

    Gynecomastia (breast enlargement) is a side effect of neuroleptic antipsychotic drugs, related to prolactin elevation caused by dopamine D2 receptor blockade (Richelson, 1996). The atypical antipsychotic risperidone is less likely to cause gynecomastia at low doses (Casey, 1996). It can cause a dose-dependent increase in serum prolactin concentration (Peuskens, 1995), by blocking dopamine D2 receptors (Richelson, 1996). I would like to describe a patient who did not have gynecomastia with risperidone at a dose of 3 mg/day, but had it when risperidone, at a dose of 0.5 mg/day, was combined with fluoxetine. A MEDLINE search failed to find any reports about such an interaction.

  18. Risperidone for the treatment of delusional disorder.

    Science.gov (United States)

    Fear, Christopher F; Libretto, Susan E

    2002-01-01

    The overlap between diagnostic criteria for schizophrenia and delusional disorder (DD) may cause diagnostic confusion. This is important if response to treatment differs. Risperidone, an atypical antipsychotic, is established in the treatment of schizophrenia, although less so in other psychotic conditions. We report the case of a woman who developed DD, persecutory type, at the age of 50 years. Treatment with sulpiride 200-800 mg daily caused side-effects of drowsiness and 'hangover' and, consequently, non-compliance. Written informed consent was gained for a 24-week, randomized, double-blind, placebo-controlled, crossover trial of risperidone, initiated at 1 mg daily and increasing to 2 mg daily. Significant improvement was found, as assessed by the Brief Psychiatric Rating Scale, Positive and Negative Symptom Schedule and Maudsley Assessment of Delusions Schedule. We believe that this is the first case study reporting the resolution of persecutory DD with risperidone. A controlled clinical trial of risperidone in the treatment of patients with DD is warranted. (Int J Psych Clin Pract 2002; 6: 113-116).

  19. Risperidone versus other atypical antipsychotics for schizophrenia

    Science.gov (United States)

    Komossa, Katja; Rummel-Kluge, Christine; Schwarz, Sandra; Schmid, Franziska; Hunger, Heike; Kissling, Werner; Leucht, Stefan

    2014-01-01

    Background In many countries of the industrialised world second-generation (“atypical”) antipsychotics (SGAs) have become the first line drug treatment for people with schizophrenia. The question as to whether and if so how much the effects of the various SGAs differ is a matter of debate. In this review we examined how the efficacy and tolerability of risperidone differs from that of other SGAs. Objectives To evaluate the effects of risperidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis. Search methods 1. Electronic searching We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. 2. Reference searching We inspected the references of all identified studies for more trials. 3. Personal contact We contacted the first author of each included study for missing information. 4. Drug companies We contacted the manufacturers of all atypical antipsychotics included for additional data. Selection criteria We included all randomised, blinded trials comparing oral risperidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis. Data collection and analysis We extracted data independently. For dichotomous data we calculated risk ratio (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated mean differences (MD), again based on a random-effects model. Main results The review currently includes 45 blinded RCTs with 7760 participants. The number of RCTs available for each comparison varied: four studies compared risperidone with amisulpride, two with aripiprazole, 11 with clozapine, 23 with olanzapine, eleven with

  20. RISPERIDONE - INDUCED TARDIVE DYSKINESIA : CASE REPORT AND REVIEW OF LITERATURE

    OpenAIRE

    Kumar, P.N. Suresh; Andrade, Chittaranjan

    2001-01-01

    Risperidone is an atypical antipsychotic with broad spectrum of antipsychotic activity and lower potential for extrapyramidal side effects at therapeutic doses. This case report illustrates the development of tardive dyskinesia with therapeutic dose of risperidone in a paranoid schizophrenic patient who was not on any antipsychotic medication previously.

  1. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.

    Science.gov (United States)

    Pratheesh, P J; Praharaj, Samir Kumar; Srivastava, Ashish

    2011-01-01

    Risperidone is associated with hyperprolactinemia and its consequent symptoms such as gynecomastia, galactorrhea and sexual dysfunction in adults, and less so in adolescents. Rarely, serotonin reuptake inhibitors are also associated with such adverse effects. We report a case of gynecomastia and galactorrhea in an adolescent male while on a combination of risperidone and fluvoxamine, although the serum prolactin was within normal range.

  2. Discovering risperidone: the LSD model of psychopathology.

    Science.gov (United States)

    Colpaert, Francis C

    2003-04-01

    In the 1970s and 1980s, Janssen Pharmaceutica Research, which had a broad interest in central nervous system disorders and nurtured intellectual freedom, developed original, and at times heretical, concepts. It took decades for the scientific community to endorse some of these concepts. Among them were such notions as an elementary particle of behaviour, the introduction of response quality in receptor theory, and the idea that tolerance does not develop to opioids. These concepts enabled the discovery of the antipsychotic risperidone, a unique full antagonist of the interoceptive effects of LSD.

  3. Prolactin levels and adverse events in patients treated with risperidone.

    Science.gov (United States)

    Kleinberg, D L; Davis, J M; de Coster, R; Van Baelen, B; Brecher, M

    1999-02-01

    Hyperprolactinemia is a common clinical disorder that may lead to sexual dysfunction or galactorrhea. It may arise from a variety of etiologies, including the use of antipsychotic agents, presumably because of a dopamine receptor blockade. This analysis was designed to characterize the relationship between risperidone, serum prolactin levels, and possible clinical sequelae. All data from randomized, double-blind studies of risperidone in patients with chronic schizophrenia were analyzed. The two largest studies (the North American and multinational trials) included 841 patients (259 women, 582 men) with paired prolactin level data and 1,884 patients (554 women, 1,330 men) with data on six adverse events possibly associated with increased prolactin levels (amenorrhea, galactorrhea, and decreased libido in women; erectile dysfunction, ejaculatory dysfunction, gynecomastia, and decreased libido in men). Both risperidone and haloperidol produced dose-related increases in plasma prolactin levels in men and women. Among women, the risperidone dose was not correlated with adverse events, nor were the adverse events correlated with endpoint prolactin levels. Among men, the incidence of adverse events was positively correlated with risperidone dose; however, at risperidone doses of 4 to 10 mg/day the incidence of adverse events was not significantly higher than that observed in patients receiving placebo. Furthermore, adverse events in men were unrelated to plasma prolactin levels. Risperidone-associated increase in serum prolactin levels was not significantly correlated to the emergence of possible prolactin-related side effects.

  4. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments

    DEFF Research Database (Denmark)

    Ejsing, Thomas B.; Pedersen, Anne D.; Linnet, Kristian

    2005-01-01

    P-glycoprotein, risperidone, nortriptyline, cyclosporine A, drug-drug interaction, blood-brain barrier, knock-out mice......P-glycoprotein, risperidone, nortriptyline, cyclosporine A, drug-drug interaction, blood-brain barrier, knock-out mice...

  5. Peripheral Edema Occurring during Treatment with Risperidone Combined with Citalopram

    Directory of Open Access Journals (Sweden)

    Seyed Hamzeh Hosseini

    2012-01-01

    Full Text Available An 80-year-old female presented with symptoms of depression, worthlessness, hopelessness, loss of energy, insomnia, impatience, and forgetfulness associated with persecutory delusion that had begun about one year before her visit. She was diagnosed with major depression with psychotic signs and began treatment with risperidone (2 mg/night and citalopram (20 mg/day. After 20 days, she returned and reported partial improvement in her symptoms, although she had developed severe swelling of the hands and feet. The results of liver and renal function tests and rheumatologic tests were found to be within normal limits. Risperidone was discontinued for a week, and the swelling resolved completely. Risperidone was then administered again, and the swelling returned so that the patient had to discontinue taking the drug. The reappearance of edema on rechallenge is strong evidence implicating risperidone as the cause of the swelling.

  6. Risperidone treatment increases CB1 receptor binding in rat brain

    DEFF Research Database (Denmark)

    Secher, Anna; Husum, Henriette; Holst, Birgitte

    2010-01-01

    BACKGROUND/AIMS: Body weight gain is a common side effect of treatment with antipsychotics, but the mechanisms underlying this weight gain are unknown. Several factors may be involved in antipsychotic-induced body weight gain including the cannabinoid receptor 1 (CB(1)), the serotonin receptor 2C...... positively correlated with visceral fat mass. Risperidone treatment increased CB(1) receptor binding in the arcuate nucleus (40%), hippocampus (25-30%) and amygdala (35%) without concurrent alterations in the CB(1) receptor mRNA. Risperidone treatment increased adiponectin mRNA. CONCLUSION: The present study...... showed that risperidone treatment altered CB(1) receptor binding in the rat brain. Risperidone-induced adiposity and metabolic dysfunction in the clinic may be explained by increased CB(1) receptor density in brain regions involved in appetite and regulation of metabolic function....

  7. A Case of Priapism with Risperidone

    Directory of Open Access Journals (Sweden)

    Almari Ginory

    2014-01-01

    Full Text Available Priapism is a urologic emergency defined as a prolonged, possibly painful, penile erection. There are several known causes of priapism including psychotropic medications. One of the mechanisms by which antipsychotics are believed to induce priapism is through alpha-1 antagonism. This is case of a 50-year-old male with a history of schizophrenia with previous priapism related to trazodone, who presents with new onset priapism associated with risperidone. In this case, the treatment of priapism includes discontinuation of the offending agent and drainage of the corpus cavernosum twice along with intracavernosal phenylephrine injections. It is important to educate patients on priapism as a possible side effect of medications. It is also important to consider previous episodes of medication-induced priapism when prescribing psychotropic medications as this may increase the patient’s future risk of priapism.

  8. Risperidone versus pimozide in Tourette's disorder : A comparative double-blind parallel-group study

    NARCIS (Netherlands)

    Bruggeman, R; van der Linden, C.; Buitelaar, JK; Gericke, GS; Hawkridge, SM; Temlett, JA

    2001-01-01

    Background: The treatment of Tourette's disorder with classical neuroleptics is limited by their side effects. Risperidone is a new efficacious antipsychotic with a low propensity for extrapyramidal side effects. To establish risperidone's therapeutic potential in Tourette's disorder, we studied the

  9. A Case of Diabetic Ketoacidosis Associated with Risperidone Treatment

    Directory of Open Access Journals (Sweden)

    Zeynel Beyhan

    2008-12-01

    Full Text Available The association between schizophrenia and diabetes has been previously documented. Case reports have also demonstrated that initiation of atypical antipsychotic agents may induce or exacerbate diabetes mellitus. A 26-year-old man without a family history of diabetes mellitus presented with deep coma after 5 months of treatment with risperidone. He was diagnosed with diabetic ketoacidosis, was given insulin and saline infusion, and his antipsychotic agent was changed from risperidone to ziprasidone.Insulin therapy and oral agent was discontinued within two months of follow-up. The rapid onset of diabetes, and the disappearance of hyperglycemia after discontinuation of the drug suggested that risperidone had been a factor in his diabetic ketoacidosis. During three years of subsequent follow-up, testing revealed no evidence of elevated serum glucose levels or impaired glucose tolerance. In our opinion psychiatrists should routinely ask patients treated with antipsychotic agents such as risperidone for diabetic symptoms, weight loss, lethargy, polydipsia and/or polyuria, and monitor serum glucose levels. Although there is no consensus on the best way to switch from one antipsychotic drug to another, for those patients who develop diabetes during therapy with risperidone a change to ziprasidone treatment may maintain normal glucose levels.

  10. RP-HPLC estimation of risperidone in tablet dosage forms

    Directory of Open Access Journals (Sweden)

    Bladania S

    2008-01-01

    Full Text Available A simple, specific, accurate, and precise reverse phase liquid chromatographic method was developed and validated for the estimation of risperidone in tablet dosage forms. A Phenomenex Gemini C-18, 5 µm column having 250x4.6 mm i.d. in isocratic mode, with mobile phase containing methanol: acetonitrile: 50 mM potassium dihydrogen orthophosphate (80:10:10 v/v was used. The flow rate was 1.3 ml/min and effluents were monitored at 234 nm. Clozapine was used as an internal standard. The retention time of risperidone and clozapine were 2.5 min and 3.3 min, respectively. The method was validated for linearity, accuracy, precision, specificity, limit of quantification, limit of detection, robustness and stability. The limit of detection and limit of quantification for estimation of risperidone was found to be 500 ng/ml and 990 ng/ml, respectively. Recovery of risperidone was found to be in the range of 99.02-101.68%. Proposed method was successfully applied for the quantitative determination of risperidone in tablet formulations.

  11. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine

    NARCIS (Netherlands)

    Schillevoort, I; de Boer, A; Herings, R M; Roos, R A; Jansen, P A; Leufkens, H G

    2001-01-01

    OBJECTIVE: To compare the risk of extrapyramidal syndrome (EPS) between risperidone, olanzapine, and haloperidol, taking into account patients' past antipsychotic drug use and past EPS. METHODS: Data were obtained from the PHARMO-database, containing filled prescriptions of 450,000

  12. Risperidone and Adaptive Behavior in Children with Autism

    Science.gov (United States)

    Williams, Susan K.; Scahill, Lawrence; Vitiello, Benedetto; Aman, Michael G.; Arnold, L. Eugene; McDougle, Christopher J.; McCracken, James T.; Tierney, Elaine; Ritz, Louise; Posey, David J.; Swiezy, Naomi B.; Hollway, Jill; Cronin, Pegeen; Ghuman, Jaswinder; Wheeler, Courtney; Cicchetti, Domenic; Sparrow, Sara

    2006-01-01

    Objective: To evaluate the impact of risperidone on adaptive behavior in children with autistic disorder who have serious behavior problems and to examine different methods of scoring the Vineland Adaptive Behavior Scales to measure change. Method: Forty-eight children (5 years to 16 years, 5 months) who showed behavioral improvement during acute…

  13. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine

    NARCIS (Netherlands)

    Schillevoort, I; de Boer, A; Herings, R M; Roos, R A; Jansen, P A; Leufkens, H G

    2001-01-01

    OBJECTIVE: To compare the risk of extrapyramidal syndrome (EPS) between risperidone, olanzapine, and haloperidol, taking into account patients' past antipsychotic drug use and past EPS. METHODS: Data were obtained from the PHARMO-database, containing filled prescriptions of 450,000 community-dwellin

  14. Costs and efficacy ofolanzapine and risperidone in schizophrenia

    Directory of Open Access Journals (Sweden)

    Vittorio Mapelli

    2007-06-01

    Full Text Available Introduction: schizophrenia is a serious and long lasting psychiatric disease. The new “atypical” antipsychotic drugs, introduced in the 90s, have substantially improved the effectiveness of medical treatments, compared to previous neuroleptic drugs. Nowadays they tend to be used as first choice drugs. The ddd cost of atypicals may differ by 20% and health authorities may have an incentive to deliver the less costly drug, especially if they are generic. However the various drugs show differential effectiveness rates and a rational choice should consider both cost and effectiveness.
Objective: the purpose of this analysis is to review the existing evidence on cost-effectiveness studies of olanzapine and risperidone, the two most prescribed drugs in Italy. Six published studies were identified, but attention was focused on two articles that reported consistent and methodologically sound results.
Results: most reviewed studies are cost-minimization analyses, since effectiveness indicators show no significant statistical difference between the two drugs, and are inconclusive since the results depend on the evaluation setting. However one observational retrospective study showed a significant severity reduction over 12 months for patients treated with olanzapine (-2.46 on HoNOS scale; p<0.05, compared to a smaller non significant reduction of the risperidone group (-0.57. Despite the higher drug cost, the average total cost per reduced severity score was lower for olanzapine than for risperidone patients (€ 4,554 vs. € 10,897. The only medical and related health care costs for risperidone patients were higher than total costs for olanzapine patients. Another study comparing cohorts of patients with similar starting severity showed a significant severity reduction and global functioning increase over 12 months for olanzapine but no significant increase for risperidone patients (-0.35, p<0.01 on CGI scale; +3.66, p <0.05 on GAF scale

  15. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.

    Science.gov (United States)

    Quiroz, Jorge A; Yatham, Lakshmi N; Palumbo, Joseph M; Karcher, Keith; Kushner, Stuart; Kusumakar, Vivek

    2010-07-15

    Treatment adherence is a significant problem in patients with bipolar disorder. This study was designed to determine the efficacy of risperidone long-acting injectable (LAI) in the maintenance treatment of bipolar I disorder. Eligible patients with current or recent manic or mixed episodes (n = 559, aged 18-65 years) were treated with open-label oral risperidone for 3 weeks (period II) and open-label risperidone LAI for 26 weeks (n = 501; period III). Patients who maintained response (n = 303) were randomly allocated 1:1 to placebo injections (n = 149) or to continue risperidone LAI (n = 154) for up to 24 months (period IV). Most (77%) patients on risperidone LAI received a dose of 25 mg every 2 weeks during period IV. Time to recurrence for any mood episode (primary outcome variable) was significantly longer in the risperidone LAI group versus placebo (p or = 7% (compared with the period's baseline) occurred in 15% of patients in period III; in 12% of patients on risperidone LAI and 3% of patients on placebo in period IV. Risperidone LAI monotherapy significantly delayed the time to recurrence of mood episodes, versus placebo, in this controlled, randomized study in patients with bipolar I disorder. Risperidone LAI was tolerable and no new safety concerns emerged compared with previous studies of risperidone LAI. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

  16. Risperidone-induced enuresis in a 12-year-old child

    Directory of Open Access Journals (Sweden)

    Reetika Dikshit

    2017-01-01

    Full Text Available Risperidone has been documented to be effective in the management of behavior problems, aggression, and conduct disorder in children. While metabolic side effects like weight gain and obesity have been attributed to Risperidone use in children, side effects of the drug related to the urinary bladder are rare. We present a case of Risperidone-induced enuresis in a 12-year-old boy with conduct disorder that resolved completely after stopping the medication.

  17. Risperidone-induced Enuresis in a 12-year-old Child

    Science.gov (United States)

    Dikshit, Reetika; Karia, Sagar; De Sousa, Avinash

    2017-01-01

    Risperidone has been documented to be effective in the management of behavior problems, aggression, and conduct disorder in children. While metabolic side effects like weight gain and obesity have been attributed to Risperidone use in children, side effects of the drug related to the urinary bladder are rare. We present a case of Risperidone-induced enuresis in a 12-year-old boy with conduct disorder that resolved completely after stopping the medication. PMID:28149096

  18. Using Glycopyrrolate as an alternative option in case of Risperidone induced sialorrhoea

    Directory of Open Access Journals (Sweden)

    Dr. Hemanta Dutta

    2015-03-01

    Full Text Available Drug induced hypersalivation has been playing an unique factor in terms of noncompliance of antipsychotics. Hypersalivation has been described commonly with clozapine. Although Risperidone is also seen to be notorious to be causing hypersalivation. Use of Glycopyrrolate in Risperidone induced hypersalivation has not been covered though reported studies till yet. Here we are depicting the use of Glycopyrrolate as an alternative treatment option for hypersalivation induced by Risperidone.

  19. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    Zhi-ling ZHOU; Qiu-xiong LIN; Chuan-yue WANG; Wen-biao LI; Shu-guang LIN; Huan-de LI; Xin LI; Huai-yan PENG; Xi-yong YU; Ming YANG; Feng-li SU; Feng WANG; Rong-hua ZHU; Chun-yu DENG

    2006-01-01

    Aim: To study the multiple dose clinical pharmacokinetics of risperidone and its main active metabolite, 9-hydroxyrisperidone, in Chinese female patients with schizophrenia. Methods: The subjects were 23 Chinese female inpatients aged 18-65 years who met the CCMD-Ⅲ (third revision of the Chinese Criteria of Mental Disorders) criteria for schizophrenia. Subjects were tested after 17 d of treatment with 2 mg risperidone twice daily. Plasma concentrations of risperidone and 9-hydroxy-risperidone were assayed by using validated high performance liquid chromatography-mass spectrometry (HPLC-MS) methods. Results: Risperidone was rapidly absorbed (Tmax was 1.6 h) and its Tin in plasma was short (3.2 h).9-hydroxy-risperidone was quickly metabolized from the parent drug with a mean Tmax of 2.5 h. It had a long half-life of 24.7 h. The Cssav of risperidone and 9-hydroxyrisperidone were 36.9±33.1 and 110.6±30.5 μg·h·L-1, respectively, and the AUCss0-12 were 443.2±397.4 and 1327.2±402.3 μg·h·L-1, respectively. CL/F and V/F of risperidone were 8.7±6.2 L/h and 34.1±24.3 L, respectively. Interindividual variations for pharmacokinetic parameters were quite large for risperidone. All 23 subjects experienced high prolactin levels when treated with risperidone. However there was no correlation between prolactin level and the concentration of risperidone, 9-hydroxy-risperidone, or the active moiety. Conclusion: Risperidone showed large interindividual variations in pharmacokinetics. Administration of risperidone resulted in high serum prolactin levels. The results indicate that systemic exposure to risperidone and 9-hydroxy-risperidone in female Chinese schizophrenic patients is higher relative to published data for white Caucasian patients. Larger studies regarding the PK/PD relationship may be required to develop a reasonable clinical dosage regimen for Chinese female patients.

  20. Neuroleptic malignant syndrome due to risperidone misdiagnosed as status epilepticus

    Directory of Open Access Journals (Sweden)

    Ali Ertug Arslankoylu

    2011-06-01

    Full Text Available Neuroleptic malignant syndrome (NMS is a rare but potentially fatal disease characterized by fever, muscle rigidity, delirium and autonomic instability. Here we report a child, with NMS due to the risperidone misdiagnosed as status epilepticus. Nine year old boy, who had been under high dose risperidone treatment for 8 weeks, admitted to the emergency room because of the contractions (evaluated as status epilepticus persisting for 7 hours. Since there was neuroleptic treatment in the past medical history and, unconsciousness, muscular rigidity, diaphoresis, hypertermi and, hypotension in physical examination, leucocytosis and elevated creatininphosphokinase levels in laboratory tests, the patient was evaluated as NMS and discharged without any complications. We reported this case to point out that; NMS may be misdiagnosed as status epilepticus in children when EEG monitoring is unavailable. When a child admitted to the emergency room because of suspicious convulsion neuroleptic drug use must surely be asked.

  1. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.

    Science.gov (United States)

    Hatta, Kotaro; Otachi, Taro; Sudo, Yasuhiko; Kuga, Hironori; Takebayashi, Hiroshi; Hayashi, Hideaki; Ishii, Ryusuke; Kasuya, Masataka; Hayakawa, Tatsuro; Morikawa, Fumiyoshi; Hata, Kazuya; Nakamura, Mitsuru; Usui, Chie; Nakamura, Hiroyuki; Hirata, Toyoaki; Sawa, Yutaka

    2012-07-30

    We examined whether augmentation with olanzapine would be superior to increased risperidone dose among acute schizophrenia patients showing early non-response to risperidone. We performed a rater-blinded, randomized controlled trial at psychiatric emergency sites. Eligible patients were newly admitted patients with acute schizophrenia. Early response was defined as Clinical Global Impressions-Improvement Scale score ≤3 following 2 weeks of treatment. Early non-responders were allocated to receive either augmentation with olanzapine (RIS+OLZ group) or increased risperidone dose (RIS+RIS group). The 78 patients who completed 2 weeks of treatment were divided into 52 early responders to risperidone and 26 early non-responders to risperidone (RIS+OLZ group, n=13; RIS+RIS group, n=13). No difference in the achievement of ≥50% improvement in Positive and Negative Syndrome Scale total score was observed between RIS+OLZ and RIS+RIS groups. Although time to treatment discontinuation for any cause was significantly shorter in the RIS+RIS group (6.8 weeks [95% confidence interval, 5.2-8.4]) than in early responders to risperidone (8.6 weeks [7.9-9.3]; P=0.018), there was no significant difference between the RIS+OLZ group (7.9 weeks [6.3-9.5]) and early responders to risperidone. Secondary outcomes justify the inclusion of augmentation arms in additional, larger studies comparing strategies for early non-responders.

  2. Prolactin release in children treated with risperidone - Impact and role of CYP2D6 metabolism

    NARCIS (Netherlands)

    Troost, Pieter W.; Lahuis, Bertine E.; Hermans, Mirjam H.; Buitelaar, Jan K.; van Engeland, Herman; Scahill, Lawrence; Minderaa, Ruud B.; Hoekstra, Pieter J.

    2007-01-01

    Objective: Little is known about the role of CYP2136 polymorphism in risperidone-induced prolactin release in children. Method: Twenty-five children (aged 5-15 years) with pervasive developmental disorders were genotyped for CYP2D6 polymorphisms. Serum prolactin, risperidone, and 9-hydroxyrisperidon

  3. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone.

    Science.gov (United States)

    Aggarwal, Geeta; Dhawan, Sanju; Hari Kumar, S L

    2013-01-01

    The efficacy of oral risperidone treatment in prevention of schizophrenia is well known. However, oral side effects and patient compliance is always a problem for schizophrenics. In this study, risperidone was formulated into matrix transdermal patches to overcome these problems. The formulation factors for such patches, including eudragit RL 100 and eudragit RS 100 as matrix forming polymers, olive oil, groundnut oil and jojoba oil in different concentrations as enhancers and amount of drug loaded were investigated. The transdermal patches containing risperidone were prepared by solvent casting method and characterized for physicochemical and in vitro permeation studies through excised rat skin. Among the tested preparations, formulations with 20% risperidone, 3:2 ERL 100 and ERS 100 as polymers, mixture of olive oil and jojoba oil as enhancer, exhibited greatest cumulative amount of drug permeated (1.87 ± 0.09 mg/cm(2)) in 72 h, so batch ROJ was concluded as optimized formulation and assessed for pharmacokinetic, pharmacodynamic and skin irritation potential. The pharmacokinetic characteristics of the optimized risperidone patch were determined using rabbits, while orally administered risperidone in solution was used for comparison. The calculated relative bioavailability of risperidone transdermal patch was 115.20% with prolonged release of drug. Neuroleptic efficacy of transdermal formulation was assessed by rota-rod and grip test in comparison with control and marketed oral formulations with no skin irritation. This suggests the transdermal application of risperidone holds promise for improved bioavailability and better management of schizophrenia in long-term basis.

  4. Clinical utility of the risperidone formulations in the management of schizophrenia

    Directory of Open Access Journals (Sweden)

    Madaan V

    2011-10-01

    Full Text Available Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use. Keywords: risperidone, schizophrenia, formulation, antipsychotic, side effects

  5. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning

    NARCIS (Netherlands)

    Knegtering, H; Boks, M; Blijd, C; Castelein, S; Van den Bosch, RJ; Wiersma, D

    2006-01-01

    The objective of this study was to compare sexual functioning in patients treated with olanzapine or risperidone. This open-label trial included 46 patients randomized to olanzapine (5-15mg/d) or risperidone (1-6mg/d) for 6 weeks. We used sexual dysfunction was assessed by a semistructured interview

  6. Risperidone in the management of agitation and aggression associated with psychiatric disorders.

    NARCIS (Netherlands)

    Deyn, P.P. de; Buitelaar, J.K.

    2006-01-01

    OBJECTIVE: This review provides an overview of the prevalence and treatment of agitation and aggression, and focuses on the use of risperidone to treat these symptoms in patients from different age groups. METHODS: MEDLINE and EMBASE databases were used to identify controlled studies of risperidone

  7. Combination treatment of tamoxifen with risperidone in breast cancer.

    Directory of Open Access Journals (Sweden)

    Wei-Lan Yeh

    Full Text Available Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the accumulation of cells in the G0/G1 phase of the cell cycle. Apoptotic activity can also be exerted by tamoxifen which involves cleavage of caspase 9, caspase 7, caspase 3, and poly-ADP-ribose polymerase (PARP. Down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of pro-apoptotic proteins Bax and Bak have also been observed. In addition, stress response protein of GRP 94 and GRP 78 have also been induced by tamoxifen in our study. However, side effects occur during tamoxifen treatment in breast cancer patients. Researching into combination regimen of tamoxifen and drug(s that relieves tamoxifen-induced hot flushes is important, because drug interactions may decrease tamoxifen efficacy. Risperidone has been shown to be effective in reducing or eliminating hot flushes on women with hormonal variations. In this present study, we demonstrated that combination of tamoxifen with risperidone did not interfered tamoxifen-induced cytotoxic effects in both in vitro and in vivo models, while fluoxetine abrogated the effects of tamoxifen. This is the first paper suggesting the possibility of combination treatment of tamoxifen with risperidone in breast cancer patients, providing a conceivable resolution of tamoxifen-induced side effects without interfering the efficacy of tamoxifen against breast cancer.

  8. Evidence based administration of risperidone and paliperidone for the treating conduct disorder

    Directory of Open Access Journals (Sweden)

    Ahmad Ghanizadeh

    2013-01-01

    Full Text Available Background: This study evaluates the evidence-based administration of risperidone and paliperidone for the treating children and adolescents with conduct disorder (CD. Materials and Methods: A review of the current literature from clinical trials that investigated the efficacy of risperidone and paliperidone on CD considering the inclusion criteria and search strategies was performed by a search of PubMed and Google Scholar databases. Results: Out of 53 titles, 31 were irrelevant. The abstract of 22 potentially related articles were studied. Only six articles reported the results of clinical trial. However, one of them reported the effect of risperidone on conduct behaviors in autistic disorders. One study was a re-analysis of two previous studies, one study reported the effects of maintenance versus withdrawal of risperidone treatment and two studies included children with sub-average intelligence. Headache, somnolence and increased appetite are among the most common reported adverse effects. No study examined the effect of paliperidone on CD was found. Conclusion: Current literature suggests that risperidone could be effective for treating some conduct behaviors in children and adolescents. The effect of risperidone on CD is not a well-researched area. There is no well-controlled evidence based reports about the safety and efficacy of risperidone for the treatment of CD. Further trials should examine the efficacy of these medications on CD rather than conduct behaviors or disruptive behavior disorders.

  9. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis

    Directory of Open Access Journals (Sweden)

    Schooler Nina

    2011-02-01

    Full Text Available Abstract Background To compare the efficacy and tolerability of paliperidone extended-release (ER with risperidone immediate-release using propensity score methodology. Methods Six double-blind, randomized, placebo-controlled, short-term clinical trials for acute schizophrenia with availability of individual patient-level data were identified (3 per compound. Propensity score pairwise matching was used to balance observed covariates between the paliperidone ER and risperidone patient populations. Scores were generated using logistic regression models, with age, body mass index, race, sex, baseline Positive and Negative Syndrome Scale (PANSS total score and baseline Clinical Global Impressions–Severity (CGI-S score as factors. The dosage range of paliperidone ER (6-12 mg/day was compared with 2 risperidone dosage ranges: 2-4 and 4-6 mg/day. The primary efficacy measure was change in PANSS total score at week 6 end point. Tolerability end points included adverse event (AE reports and weight. AEs with rates ≥5% and with a ≥2% difference between paliperidone ER and risperidone were identified. Results Completion rates for placebo-treated subjects in paliperidone ER trials (n = 95 and risperidone trials (n = 122 groups were 36.8% and 51.6%, respectively; end point changes on PANSS total scores were similar (p = 0.768. Completion rates for subjects receiving paliperidone ER 6-12 mg/day (n = 179, risperidone 2-4 mg/day (n = 113 or risperidone 4-6 mg/day (n = 129 were 64.8%, 54.0% and 66.7%, respectively (placebo-adjusted rates: paliperidone ER vs risperidone 2-4 mg/day, p = 0.005; paliperidone ER vs risperidone 4-6 mg/day, p = 0.159. PANSS total score improvement with paliperidone ER was greater than with risperidone 2-4 mg/day (difference in mean change score, -6.7; p Conclusions This indirect database analysis suggested that paliperidone ER 6-12 mg/day may be more efficacious than risperidone 2-4 mg/day and as efficacious as risperidone 4-6 mg

  10. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.

    Science.gov (United States)

    Ochi, Shinichiro; Kawasoe, Koichiro; Abe, Masao; Fukuhara, Ryuji; Sonobe, Kantaro; Kawabe, Kentaro; Ueno, Shu-ichi

    2011-01-01

    We present a schizophrenic patient who experienced neuroleptic malignant syndrome with risperidone treatment due to variants of the CYP2D6 gene with reduced function. Clinicians need to be aware of this potential complication.

  11. Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice

    Directory of Open Access Journals (Sweden)

    David Holthoewer

    2010-06-01

    Full Text Available Pharmacokinetic interactions, e.g. modulation of drug transporters like P-glycoprotein at the blood-brain barrier, can be a reason for treatment non-response. This study focuses on the influence of induction of drug transporters on the disposition of the antipsychotic drugs risperidone and 9-hydroxyrisperidone. Brain and serum concentrations of risperidone and its active metabolite 9-hydroxyrisperidone, which are known P-glycoprotein substrates, were measured after drug transporter induction with rifampicin, dexamethasone or 5-pregnene-3beta-ol-20-on-16alpha-carbonitrile using high performance liquid chromatography. Disposition of risperidone and 9-hydroxyrisperidone was dramatically decreased in mouse brain and serum after drug transporter induction. The metabolism of risperidone was also affected.

  12. 78 FR 52777 - Draft Guidance for Industry on Bioequivalence Recommendations for Risperidone Injection...

    Science.gov (United States)

    2013-08-26

    ... on Bioequivalence Recommendations for Risperidone Injection; Availability AGENCY: Food and Drug... provides specific recommendations on the design of bioequivalence (BE) studies to support abbreviated new... availability of a draft guidance for industry entitled ``Bioequivalence Recommendations for Specific...

  13. Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone : a review

    NARCIS (Netherlands)

    Knegtering, H; Lambers, PA; Prakken, G; ten Brink, C

    2000-01-01

    Classical antipsychotic drugs increase the level of serum prolactin. The atypical antipsychotic clozapine barely increases prolactin levels. An open naturalistic study in the University Hospital of Groningen suggests that treatment with risperidone in comparison to classical antipsychotics seems to

  14. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

    NARCIS (Netherlands)

    Knegtering, R; Baselmans, P; Castelein, S; Bosker, F; Bruggeman, R; van den Bosch, RJ

    2005-01-01

    Objective: The atypical antipsychotic risperidone significantly raises plasma prolactin levels in patients, but clozapine, olanzapine, and quetiapine do not. The differences in neuroendocrine response may be connected with the metabolism of the medications. The authors examined the contributory role

  15. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies

    OpenAIRE

    2014-01-01

    The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC) studies. Different implants (F1-F8) containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000) either alone or as their blends, and PLGA (75:25). The implants contained 40% of the drug. After f...

  16. Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia

    Science.gov (United States)

    Zhao, Yueren; Kishi, Taro; Iwata, Nakao; Ikeda, Manabu

    2013-01-01

    A recent meta-analysis showed that long-acting injectable (LAI) antipsychotics were not superior to oral antipsychotics for preventing relapse in patients with schizophrenia. We therefore designed a treatment strategy combining risperidone LAI and COMPASS (COMprehensive Psycho-educational Approach and Scheme Set), an original psychoeducational program supporting treatment with risperidone LAI and evaluating subjective treatment satisfaction, transition of symptoms, and effectiveness in preventing symptomatic relapse. The aim of this study was to examine whether addition of COMPASS to risperidone LAI was more effective in preventing relapse in schizophrenia patients than risperidone LAI alone, with the latter group consisting of patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients were followed up for 6 months, with COMPASS continuously implemented from the transition to the observation phase. The primary efficacy measurements were relapse rate (rates of rehospitalization and discontinuation due to inefficacy). Secondary efficacy measurements were the Brief Psychiatric Rating Scale (BPRS) and Global Assessment of Functioning (GAF) scores. Of the 96 patients originally enrolled, 19 (19.8%) were discontinued from all causes. During the 6-month study period, ten of the 96 patients (10.4%) relapsed, compared with a 12.2% relapse rate in patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients showed significant improvements in BPRS total scores (P = 0.0031), BPRS positive (P = 0.0451), BRPS negative (P < 0.0001), and general subscale scores (P = 0.0031), and GAF (P < 0.0001) from baseline to 6 months. In conclusion, the lower relapse rate observed in patients treated with COMPASS plus risperidone LAI than in patients treated with risperidone LAI alone suggests that COMPASS may have benefits in the treatment of schizophrenia, indicating a need for randomized, controlled trials in larger numbers of patients. PMID:24194642

  17. Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults.

    Science.gov (United States)

    Darwish, Mona; Bond, Mary; Yang, Ronghua; Hellriegel, Edward T; Robertson, Philmore

    2015-11-01

    Patients with bipolar I disorder and schizophrenia have an increased risk of obstructive sleep apnea. The effects of armodafinil, a weak cytochrome P450 (CYP) 3A4 inducer, on pharmacokinetics and safety of risperidone, an atypical antipsychotic used to treat major psychiatric illness, were investigated. Healthy subjects received 2 mg risperidone alone and after armodafinil pretreatment (titrated to 250 mg/day). Pharmacokinetic parameters were derived from plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone (formed via CYP2D6 and CYP3A4), collected before and over 4 days after risperidone administration, and from steady-state plasma concentrations of armodafinil and its circulating metabolites, R-modafinil acid and modafinil sulfone. Safety and tolerability were assessed. Thirty-six subjects receiving study drug were evaluable for safety; 34 were evaluable for pharmacokinetics. Risperidone maximum plasma concentration (C max) decreased from mean 16.5 ng/mL when given alone to 9.2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0.55 [0.50-0.61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92.3 to 44.5 ng·h/mL (geometric mean ratio [90 % CI] 0.51 [0.46-0.55]). C max and AUC0-∞ for 9-hydroxyrisperidone were also reduced (geometric mean ratios [90 % CI] 0.81 [0.77-0.85] and 0.73 [0.69-0.77], respectively). Adverse events were consistent with known safety profiles. Consistent with CYP3A4 induction, risperidone and 9-hydroxyrisperidone systemic exposure was reduced in the presence of armodafinil. Concomitant armodafinil and risperidone use may necessitate risperidone dosage adjustment, particularly when starting or stopping coadministration of the two drugs. However, any such decision should be based on patient disease state and clinical status.

  18. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria

    OpenAIRE

    FAYYAZi, Afshin; Salari, Elham; Ali KHAJEH; GAJARPOUR, Abdi

    2014-01-01

    How to Cite This Article: Fayyazi A, Salari E, Khajeh A, Ghajarpour A. A Comparison of Risperidone and Buspirone for Treatment ofBehavior Disorders in Children with Phenylketonuria. Iran J Child Neurol. 2014 Autumn; 8(4):33-38.AbstractObjectiveMany patients with late-diagnosed phenylketonuria (PKU) suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.Materials & MethodsIn this crossover clinical...

  19. Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder.

    Science.gov (United States)

    Nikvarz, Nikvarz; Alaghband-Rad, Javad; Tehrani-Doost, Mehdi; Alimadadi, Abbas; Ghaeli, Padideh

    2017-01-01

    Introduction: This study was aimed to compare the efficacy and side effects of memantine, an antagonist of the NMDA receptor of glutamate, with risperidone given the fact that glutamate has been noted for its possible effects in the pathogenesis of autism. Risperidone, an atypical antipsychotic, has been approved by FDA for the management of irritability associated with autism. Methods: 30 children, aged 4-17 years, entered an 8-week, randomized trial. Patients were randomly assigned to receive either risperidone or memantine. Autism Behavior Checklist (ABC), Childhood Autism Rating Scale (CARS), Clinical Global Impressions - Improvement (CGI-I) and Clinical Global Impression-Severity (CGI-S) scales were used to assess behavioral symptoms of the patients. Results: Both risperidone and memantine reduced the scores of 4 subscales of ABC as well as the 10-item and the total score of CARS significantly. However, differences between the 2 drugs in the scores of each evaluating scale were not found to be significant. Relatively, larger number of patients on risperidone showed "very much improvement" when assessed by CGI-I scale when compared with those on memantine. Discussion and conclusion: The present study suggests that memantine may have beneficial effects in the treatment of many core symptoms of autism. Therefore, memantine may be considered as a potential medication in the treatment of those autistic children who do not respond or cannot tolerate side effects of risperidone.

  20. Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.

    Science.gov (United States)

    O'Sullivan, David; Green, Laura; Stone, Sarrabeth; Zareie, Pirooz; Kharkrang, Marie; Fong, Dahna; Connor, Bronwen; La Flamme, Anne Camille

    2014-01-01

    Recent studies have demonstrated that atypical antipsychotic agents, which are known to antagonize dopamine D2 and serotonin 5-HT2a receptors, have immunomodulatory properties. Given the potential of these drugs to modulate the immune system both peripherally and within the central nervous system, we investigated the ability of the atypical anti-psychotic agent, risperidone, to modify disease in the animal model of multiple sclerosis (MS)4, experimental autoimune encephalomyelitis (EAE). We found that chronic oral administration of risperidone dose-dependently reduced the severity of disease and decreased both the size and number of spinal cord lesions. Furthermore, risperidone treatment substantially reduced antigen-specific interleukin (IL)-17a, IL-2, and IL-4 but not interferon (IFN)-γ production by splenocytes at peak disease and using an in vitro model, we show that treatment of macrophages with risperidone alters their ability to bias naïve T cells. Another atypical antipsychotic agent, clozapine, showed a similar ability to modify macrophages in vitro and to reduce disease in the EAE model but this effect was not due to antagonism of the type 1 or type 2 dopamine receptors alone. Finally, we found that while risperidone treatment had little effect on the in vivo activation of splenic macrophages during EAE, it significantly reduced the activation of microglia and macrophages in the central nervous system. Together these studies indicate that atypical antipsychotic agents like risperidone are effective immunomodulatory agents with the potential to treat immune-mediated diseases such as MS.

  1. Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series.

    Science.gov (United States)

    Saxena, Kirti; Chang, Kiki; Steiner, Hans

    2006-08-01

    To evaluate the effectiveness and safety of risperidone in children and adolescents with bipolar disorder characterized by aggression and mania, despite treatment with mood stabilizers. A retrospective chart review of patients seen in an outpatient pediatric mood disorders clinic over an 18-month period was performed. Data were extracted from charts of patients who had a diagnosis of bipolar disorder with aggression that was uncontrolled on a mood stabilizer; as a result, these patients had risperidone added to their regimen. Four boys (aged 7-15 years) and two girls (aged 8 and 14 years) were treated with risperidone (mean dosage, 0.85 mg/day) for 3-16 months. Aggressive behavior improved in all patients after risperidone was started and remained improved for the duration of follow-up. Other symptoms of mania also improved. Risperidone was generally well tolerated. Sedation and akathisia were reported in one patient. The addition of risperidone to a mood stabilizer may improve aggression and other symptoms of mania in pediatric patients with bipolar disorder who do not respond adequately to a mood stabilizer alone. The long-term efficacy and safety of this regimen should be evaluated in a controlled clinical trial.

  2. Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder.

    Science.gov (United States)

    Peitl, Marija Vucić; Peitl, Vjekoslav; Grahovac, Tanja; Pavlović, Eudard

    2010-03-01

    Risperidone, as all atypical antipsychotics, can cause hyperprolactinemia which can in turn lead to galactorrhea. Mood stabilizers, one of which is valproic acid and its derivate "Depakine Chrono", are rarely linked with symptomatic hyperprolactinemia and do not alter prolactin concentrations. This case is based around a patient suffering from a bipolar disorder that has been psychiatrically treated in an outpatient clinic during four years. Bipolar disorder treatment was started with carbamazepine, but later it was discontinued due to adverse events and extreme increase of liver transaminases. Treatment was continued with introduction of lithium, but the patient stated that she could not tolerate it. Subsequently, her endocrinologist advised for lithium discontinuation due to very severe osteoporosis. At the beginning of 2009, lithium was discontinued and Depakine Chrono was introduced. Due to patient's psychotic decompensation it was necessary to introduce risperidone into treatment and soon afterwards her psychotic symptoms settled. After several months of treatment her mood lowered, she began to feel sedated, psychomotorically retarded and that lead to dose lowering of Depakine Chrono and risperidone, at which point galactorrhea as a serious adverse event occurred. Occurrence of galactorrhea at lower risperidone doses in this case might be partially explained by recent studies that showed that lower doses of risperidone can also improve psychic state, but could also cause adverse events. Although galactorrhea, as a direct consequence of hyperprolactinemia caused by risperidone has mainly been researched with higher doses of this atypical antipsychotic, we have to keep in mind that lower doses could also cause serious adverse events.

  3. A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia

    Directory of Open Access Journals (Sweden)

    Saeed Shoja Shafti

    2014-01-01

    Full Text Available Introduction. Since a variety of comparisons between risperidone and olanzapine have resulted in diverse outcomes, so safety and efficacy of them were compared again in a new trial. Method. Sixty female schizophrenic patients entered into one of the assigned groups for random allocation to olanzapine or risperidone (n=30 in each group in a double-blind, 12-week clinical trial. Scale for Assessment of Positive Symptoms (SAPS and Scale for Assessment of Negative Symptoms (SANS were used as the primary outcome measures. Clinical Global Impressions-Severity Scale (CGI-S, Schedule for Assessment of Insight (SAI, and finally Simpson Angus Scale (SAS as well were employed as secondary scales. Results. While both of olanzapine and risperidone were significantly effective for improvement of positive symptoms (P<0.0001, as regards negative symptoms, it was so only by means of olanzapine (P<0.0003. CGI-S and SAI, as well, were significantly improved in both of the groups. SAS increment was significant only in the risperidone group (P<0.02. Conclusion. While both of olanzapine and risperidone were equally effective for improvement of positive symptoms and insight, olanzapine showed superior efficacy with respect to negative symptoms, along with lesser extrapyramidal side effects, in comparison with risperidone.

  4. Early onset of treatment effects with oral risperidone

    Directory of Open Access Journals (Sweden)

    Naber Dieter

    2007-01-01

    Full Text Available Abstract Background The dogma of a delayed onset of antipsychotic treatment effects has been maintained over the past decades. However, recent studies have challenged this concept. We therefore performed an analysis of the onset of antipsychotic treatment effects in a sample of acutely decompensated patients with schizophrenia. Methods In this observational study, 48 inpatients with acutely decompensated schizophrenia were offered antipsychotic treatment with oral risperidone. PANSS-ratings were obtained on day 0, day 1, day 3, day 7 and day 14. Results Significant effects of treatment were already present on day 1 and continued throughout the study. The PANSS positive subscore and the PANSS total score improved significantly more than the PANSS negative subscore. Conclusion Our results are consistent with the growing number of studies suggesting an early onset of antipsychotic treatment effects. However, non-pharmacological effects of treatment also need to be taken into consideration.

  5. A Randomized Open Label Comparison of the Effects ofRisperidone and Haloperidol on Sexual Function

    Directory of Open Access Journals (Sweden)

    S. Jaber Mousavi

    2009-12-01

    Full Text Available "n Objective: "nSexual dysfunction in patients who take antipsychotics causes adecline in their quality of life and medication acceptance. Considering the restrictions in cross sectional design of many earlier researches, we used a clinical trial aimed at assessing sexual dysfunction by substituting Risperidone, an atypical antipsychotic drug, with Haloperidol, a typical one . "n "n "nMethod: This clinical trial was conducted on 51 patients who had been using Risperidone with a minimum dose of 2 mg/daily for at least 2 months. The patients were randomly divided into 2 groups. The first group continued taking Risperidone, whereas the second group was given Haloperidol. Sexual function prior to and after the drug substitution was assessed using a sexual questionnaire designed to assess four stages of sexual function . "nResults: Compared to those who changed their medication to Haloperidol, the patients who remained on Risperidone therapy suffered from more sexual dysfunction, especially in their tendency towards having sexual activities (P= 0.01, post menstrual sexual activity (P= 0.002, and reaching orgasm in their sexual activities (P= 0.04; however in the Haloperidol group, no significant difference was observed before and after the change in medication . "nConclusion: Although Risperidone and Haloperidol can both disturb patients'sexual function, the side effects of Risperidone are stronger. Hence toprevent the decline of medication acceptance or irregular consumption by patients which may lead to possible relapse, substitution of Risperidone withanother drug with fewer side effects on sexual activities is definitely to the advantage of the patients .

  6. CYP2D6 polymorphisms and their influence on risperidone treatment

    Directory of Open Access Journals (Sweden)

    Puangpetch A

    2016-12-01

    Full Text Available Apichaya Puangpetch,1 Natchaya Vanwong,1 Nopphadol Nuntamool,2 Yaowaluck Hongkaew,1 Monpat Chamnanphon,1 Chonlaphat Sukasem1 1Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, 2Molecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand Abstract: Cytochrome P450 enzyme especially CYP2D6 plays a major role in biotransformation. The interindividual variations of treatment response and toxicity are influenced by the polymorphisms of this enzyme. This review emphasizes the effect of CYP2D6 polymorphisms in risperidone treatment in terms of basic knowledge, pharmacogenetics, effectiveness, adverse events, and clinical practice. Although the previous studies showed different results, the effective responses in risperidone treatment depend on the CYP2D6 polymorphisms. Several studies suggested that CYP2D6 polymorphisms were associated with plasma concentration of risperidone, 9-hydroxyrisperidone, and active moiety but did not impact on clinical outcomes. In addition, CYP2D6 poor metabolizer showed more serious adverse events such as weight gain and prolactin than other predicted phenotype groups. The knowledge of pharmacogenomics of CYP2D6 in risperidone treatment is increasing, and it can be used for the development of personalized medication in term of genetic-based dose recommendation. Moreover, the effects of many factors in risperidone treatment are still being investigated. Both the CYP2D6 genotyping and therapeutic drug monitoring are the important steps to complement the genetic-based risperidone treatment. Keywords: CYP2D6, risperidone, polymorphisms, adverse drug reaction, pharmacogenetics, pharmacokinetics, pharmacodynamics

  7. Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia

    Directory of Open Access Journals (Sweden)

    Zhao Y

    2013-10-01

    Full Text Available Yueren Zhao,1–3 Taro Kishi,1 Nakao Iwata,1 Manabu Ikeda3,4 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care Center, Toyoake, Aichi, Japan; 3Department of Neuropsychiatry, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan; 4Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan Abstract: A recent meta-analysis showed that long-acting injectable (LAI antipsychotics were not superior to oral antipsychotics for preventing relapse in patients with schizophrenia. We therefore designed a treatment strategy combining risperidone LAI and COMPASS (COMprehensive Psycho-educational Approach and Scheme Set, an original psychoeducational program supporting treatment with risperidone LAI and evaluating subjective treatment satisfaction, transition of symptoms, and effectiveness in preventing symptomatic relapse. The aim of this study was to examine whether addition of COMPASS to risperidone LAI was more effective in preventing relapse in schizophrenia patients than risperidone LAI alone, with the latter group consisting of patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients were followed up for 6 months, with COMPASS continuously implemented from the transition to the observation phase. The primary efficacy measurements were relapse rate (rates of rehospitalization and discontinuation due to inefficacy. Secondary efficacy measurements were the Brief Psychiatric Rating Scale (BPRS and Global Assessment of Functioning (GAF scores. Of the 96 patients originally enrolled, 19 (19.8% were discontinued from all causes. During the 6-month study period, ten of the 96 patients (10.4% relapsed, compared with a 12.2% relapse rate in patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients showed significant improvements in BPRS total

  8. Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

    Science.gov (United States)

    Pandina, Gahan J.; Bossie, Cynthia A.; Youssef, Eriene; Zhu, Young; Dunbar, Fiona

    2007-01-01

    Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n =…

  9. Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

    Science.gov (United States)

    Kent, Justine M.; Kushner, Stuart; Ning, Xiaoping; Karcher, Keith; Ness, Seth; Aman, Michael; Singh, Jaskaran; Hough, David

    2013-01-01

    Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg] or high-dose: 1.25 mg/day [20 to 45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change…

  10. Risperidone – Solid-state characterization and pharmaceutical compatibility using thermal and non-thermal techniques

    Energy Technology Data Exchange (ETDEWEB)

    Daniel, Josiane Souza Pereira; Veronez, Isabela Pianna; Rodrigues, Larissa Lopes [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil); Trevisan, Marcello G. [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil); National Institute of Bioanalytics Science and Technology – INCTBio, Institute of Chemistry – UNICAMP, 13084-653, Campinas, São Paulo (Brazil); Garcia, Jerusa Simone, E-mail: jerusa.garcia@unifal-mg.edu.br [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil)

    2013-09-20

    Highlights: • DSC was used to characterize Risperidone and study its compatibility with excipients. • FT-IR associated with PCA was used to complement DSC data. • LC analyzes confirmed the DSC and FT-IR/PCA results. • Risperidone was incompatible with three among five excipients evaluated. - Abstract: A full solid-state characterization of risperidone was conducted using differential scanning calorimetry (DSC), thermogravimetry (TG), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM) to examine its physicochemical properties and polymorphism. The primary aim of this work was to study the compatibility of risperidone with pharmaceutical excipients using DSC to obtain and compare the curves of the active pharmaceutical ingredient (API) and the excipients with their 1:1 (w/w) binary mixtures. These same binary mixtures were turned to room temperature and analyzed by FT-IR combined with principal component analysis (PCA) to evaluate solid-state incompatibilities. The chemical incompatibilities of these samples were verified using a stability-indicating liquid chromatography (LC) method to assay for the API and evaluate the formation of degradation products. All of these methods showed incompatibilities between risperidone and the excipients magnesium stearate, lactose and cellulose microcrystalline.

  11. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.

    Directory of Open Access Journals (Sweden)

    Maria Jimena Prieto

    Full Text Available Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%. Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer was achieved with a mixture of chloroform:methanol 50∶50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.

  12. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.

    Science.gov (United States)

    Prieto, Maria Jimena; del Rio Zabala, Nahuel Eduardo; Marotta, Cristian Hernán; Carreño Gutierrez, Hector; Arévalo Arévalo, Rosario; Chiaramoni, Nadia Silvia; del Valle Alonso, Silvia

    2014-01-01

    Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%). Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer) was achieved with a mixture of chloroform:methanol 50∶50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.

  13. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia

    Directory of Open Access Journals (Sweden)

    Jeffrey R Bishop

    2008-03-01

    Full Text Available Jeffrey R Bishop1,2, Mani N Pavuluri21Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA; 2Department of Psychiatry, Pediatric Mood Disorders Program and Center for Cognitive Medicine, University of Illinois at Chicago College of Medicine, Chicago, IL, USAAbstract: Risperidone is a commonly used medication for the treatment of bipolar disorder and schizophrenia in children and adolescents. It has been studied as a monotherapy treatment in early onset schizophrenia and as both monotherapy and combination therapy for pediatric bipolar disorder. Studies to date indicate that risperidone is an effective treatment for positive and negative symptoms of schizophrenia and mania symptoms of bipolar disorder. In young patient populations, side effects such as weight gain, extrapyramidal side effects, and prolactin elevation require consideration when evaluating the risk benefit ratio for individual patients. Here we review published studies of risperidone for the treatment of bipolar disorder and schizophrenia in children and adolescents to provide practitioners with an overview of published data on the efficacy and safety of risperidone in these patient populations.Keywords: risperidone, bipolar disorder, schizophrenia, children, adolescents

  14. High-Dose Risperidone Induced Latent Syndrome of Inappropriate Antidiuretic Hormone Secretion With Seizure Presentation.

    Science.gov (United States)

    Lee, Yen-Feng; Tsai, Chia-Kuang; Liang, Chih-Sung

    2015-01-01

    We report a case of a patient with schizophrenia treated with high-dose risperidone, who developed syndrome of inappropriate antidiuretic hormone secretion (SIADH) with the only early symptom of tonic-clonic seizures. A 40-year-old woman with schizophrenia was treated with risperidone 2 mg/d. After the dosage was titrated to 6 mg/d, she experienced generalized seizure attacks. Laboratory screening revealed that the serum sodium level was 106 mmol/L, the urine sodium concentration was 41.2 mmol/L, and the urine osmolality was 371 mOsm/kg H2O. A diagnosis of SIADH was made, and risperidone was stopped. After infusion of hypertonic saline, the serum sodium returned to normal levels, and seizures did not recur. In this patient, SIADH advanced in a latent manner because the first and only symptom of SIADH was seizure attack. High-dose risperidone treatment is the most probable cause, and the mechanisms may be related to risperidone's high affinity for the 5-hydroxytryptamine 2A and dopamine 2 receptors. Patients with schizophrenia can display atypical features of medical illnesses. Routine physical and laboratory examinations may prevent silent disease progression.

  15. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.

    Science.gov (United States)

    Vaisburd, Sinaya; Shemer, Zeev; Yeheskel, Adva; Giladi, Eliezer; Gozes, Illana

    2015-11-10

    Mutated disrupted in schizophrenia 1 (DISC1), a microtubule regulating protein, leads to schizophrenia and other psychiatric illnesses. It is hypothesized that microtubule stabilization may provide neuroprotection in schizophrenia. The NAP (NAPVSIPQ) sequence of activity-dependent neuroprotective protein (ADNP) contains the SxIP motif, microtubule end binding (EB) protein target, which is critical for microtubule dynamics leading to synaptic plasticity and neuroprotection. Bioinformatics prediction for FDA approved drugs mimicking SxIP-like motif which displace NAP-EB binding identified Risperidone. Risperidone or NAP effectively ameliorated object recognition deficits in the mutated DISC1 mouse model. NAP but not Risperidone, reduced anxiety in the mutated mice. Doxycycline, which blocked the expression of the mutated DISC1, did not reverse the phenotype. Transcripts of Forkhead-BOX P2 (Foxp2), a gene regulating DISC1 and associated with human ability to acquire a spoken language, were increased in the hippocampus of the DISC1 mutated mice and were significantly lowered after treatment with NAP, Risperidone, or the combination of both. Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.

  16. Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders.

    Science.gov (United States)

    Srisawasdi, Pornpen; Vanwong, Natchaya; Hongkaew, Yaowaluck; Puangpetch, Apichaya; Vanavanan, Somlak; Intachak, Boontarika; Ngamsamut, Nattawat; Limsila, Penkhae; Sukasem, Chonlaphat; Kroll, Martin H

    2017-08-01

    To evaluate the influence of dose and duration of risperidone treatment on cardiovascular and diabetes risk biomarkers in children and adolescents with autistic spectrum disorders (ASDs). In this cross-sectional analysis, a total of 168 ASDs patients (89% male) treated with a risperidone-based regimen for ≥12months were included. Blood samples were analyzed for glucose and lipid metabolic markers, adiponectin, leptin, prolactin, cortisol and high sensitive C-reactive protein. The mean concentrations of glucose, insulin, prolactin and leptin and HOMA-IR significantly rose with risperidone dosage (all Pleptin, prolactin and glucose concentrations and HOMA-IR show significant association with dosage. None of the markers except adiponectin showed dependence on duration of treatment. However, insulin and leptin concentrations and HOMA-IR clearly increased with increasing both dosage and duration. Dosage and duration of treatment had minimal effect on standard lipid profile and lipoprotein subclasses. Risperidone treatment disturbed glucose homeostasis and endocrine regulation (particularly leptin) in children and adolescents with ASDs, in a dose- and duration-dependent manner, being suggestive of leptin and insulin resistance mechanisms. Metabolic adverse effects, especially development of type 2 diabetes mellitus should be closely monitored, particularly in individuals receiving high doses and/or long-term risperidone treatment. Copyright © 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

  17. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster.

    Science.gov (United States)

    Gulick, Danielle; Chau, David T; Khokhar, Jibran Y; Dawson, Ree; Green, Alan I

    2014-08-30

    The atypical antipsychotic clozapine reduces alcohol drinking in patients with schizophrenia. We have proposed that clozapine׳s ability to decrease alcohol drinking relates to its weak blockade of the dopamine D2 receptor and potent blockade of the norepinephrine α-2 receptor, as well as its ability to elevate plasma and brain norepinephrine. Another atypical antipsychotic, risperidone, which is a potent blocker of both the dopamine D2 receptor and norepinephrine α-2 receptor, does not decrease alcohol drinking. In this study, we used the Syrian golden hamster to test whether the ability of risperidone to reduce alcohol drinking would be enhanced if it was used in combination with the norepinephrine reuptake inhibitor desipramine. Hamsters were given free access to water and alcohol (15% v/v) until they reached a steady drinking baseline. They were then treated daily with each drug or drug combination for 20 days. Risperidone (0.2mg/kg) only transiently decreased alcohol drinking. However, 5.0mg/kg, and possibly 1.0mg/kg, desipramine added to 0.2mg/kg risperidone appeared to produce a more substantial and relatively sustained effect than risperidone alone. Data from this study provide leads toward the development of new treatments for patients with schizophrenia and alcoholism, and also for those with alcoholism alone.

  18. Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder.

    Science.gov (United States)

    Kozicky, Jan-Marie; Torres, Ivan J; Bond, David J; Lam, Raymond W; Yatham, Lakshmi N

    2012-03-01

    Although associations between antipsychotic use and neuropsychological impairment in bipolar I disorder have been observed, there is a lack of studies comparing the effects of specific agents used in this population. We compared performance between patients receiving maintenance treatment with mood stabilizer monotherapy (n=15), adjunctive risperidone (n=15) or quetiapine (n=17), and a group of demographically matched healthy controls (n=28) on tests of executive function (working memory, set shifting, and inhibition) and verbal learning. Despite having a similar clinical profile, patients being treated with risperidone showed significantly impaired working memory, set-shifting, and verbal learning (Pdisorder, preliminary results indicate that addition of risperidone to a mood stabilizer has a negative impact on executive function and verbal learning, an effect not shared with quetiapine.

  19. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review

    DEFF Research Database (Denmark)

    Ennis, Zandra Nymand; Damkier, Per

    2015-01-01

    To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first......-trimester exposure and pregnancy outcome with respect to congenital malformations. Cumulated data for olanzapine were 1090 first-trimester-exposed pregnancies with 38 malformations resulting in a malformation rate of 3.5%. The corresponding numbers for quetiapine, risperidone and aripiprazole were 443/16 (3.6%), 432...... of congenital malformation. Data for quetiapine and risperidone do not suggest a substantially increased risk, while the risk estimate for aripiprazole remains imprecise owing to a low amount of data....

  20. Iron Deficiency in Pediatric Patients in Long-Term Risperidone Treatment

    Science.gov (United States)

    Ziegler, Ekhard E.

    2013-01-01

    Abstract Objective Atypical antipsychotics, increasingly used in children and adolescents, modulate brain dopamine. Iron plays a critical role in dopaminergic signaling. Therefore, we explored whether body iron status is related to psychiatric symptom severity, treatment response, and tolerability following extended antipsychotic therapy. Methods Between November 2005 and August 2009, medically healthy 7–17-year-old risperidone-treated participants enrolled in a cross-sectional study examining the long-term safety of this antipsychotic. Anthropometric measurements were obtained. Psychiatric symptom severity and dietary intake were assessed. Serum ferritin, transferrin receptor, and prolactin concentrations were measured. Linear multivariable regression analysis tested the association among body iron, symptom severity, the dose of risperidone and psychostimulants, and serum prolactin concentration. Results The sample consisted of 115 patients (87% males) with a mean (±SD) age of 11.6 (±2.8) years. The majority had externalizing disorders, and they had taken risperidone for 2.4 (±1.7) years. Body iron was low, with 45% having iron depletion and 14% having iron deficiency. Iron status was inversely associated with weight gain during risperidone treatment and with interleukin-6. Body iron was neither associated with psychiatric symptom severity nor with the daily dose of risperidone and psychostimulants. It was, however, inversely associated with prolactin concentration, which was nearly 50% higher in the iron-deficient group. Conclusions Iron depletion and deficiency are prevalent in children and adolescents chronically treated with risperidone. Iron deficiency accentuates the antipsychotic-induced elevation in prolactin. Future studies should confirm this finding and investigate the potential benefit of iron supplementation in antipsychotic-treated patients. PMID:23480322

  1. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    Directory of Open Access Journals (Sweden)

    Amir Akhavan Rezayat

    2014-01-01

    Full Text Available Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients with acute episodes of mania were enrolled in this study, and they were randomly assigned into a risperidone group of 24 cases and an aripiprazole group of 26 cases. In group A, aripiprazole with a dose of 5-30 mg/day and in group B, risperidone with a dose of 2-8 mg/day was given to patients. The average dose of aripiprazole was 27 mg/day, and the average dose of risperidone was 6 mg/day. The effects of each drug for the treatment of acute mania were assessed on the 1 st day of admission and on days 2, 4, 6, 8 and at weeks 2, 4 and 6 after therapy using the young mania rating scale (YMRS and at the baseline and on weeks 3 and 6 after admission using the clinical global impression (CGI scale. Results: The mean age of the group of risperidone was 34 ± 8.6 years and in a group of aripiprazole it was 34 ± 9.1 years (P = 0.83. Comparison of YMRS scores over the period of 6 weeks revealed a statistically significant difference in both groups (P < 0.0001.There was also a statistically significant difference in YMRS scores between risperidone and aripiprazole at day 8 (P = 0.026 and weeks 2 (P = 0.035 and 4 (P = 0.042. There was also a statistically significant difference in CGI-Severity scale score at weeks 3 (P = 0.003 and 6 (P = 0.000 and in CGI-Improvement scale score at weeks 3 (P = 0.005 and 6 (P = 0.002. The most common side-effect observed in both groups was headache (0%15/4 in aripiprazole vs. %16/7 in risperidone Conclusion: Aripiprazole that is readily

  2. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.

    Science.gov (United States)

    Lancelin, Frédérique; Bourcier, Elsa; Le Masson, Valérie; Lemeille, Yolande; Brovedani, Sophie; Paubel, Pascal; Piketty, Marie-Liesse

    2010-12-01

    Administration of cyamemazine, an antipsychotic drug with anxiolytic properties, together with other antipsychotic agents is common in patients with schizophrenia. This retrospective study investigated the effects of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in 47 patients treated with 1 to 12 mg/day of risperidone. Of these 47 patients, 24 were receiving cyamemazine comedication ("cyamemazine" group) and 23 patients were treated with risperidone alone ("control" group). Plasma concentrations were measured using a high-performance liquid chromatographic method with photodiode-array ultraviolet detection. The median plasma concentration of risperidone was significantly higher in the cyamemazine group (31.5 ng/mL) than in the control group (5.0 ng/mL), whereas the 9-hydroxyrisperidone median concentration was significantly lower in the cyamemazine group (16.5 ng/mL versus 39.0 ng/mL in the control group). However, the sum of risperidone plus 9-hydroxyrisperidone (active moiety) plasma concentration was not significantly affected by cyamemazine comedication. A combination with cyamemazine resulted in an inverted metabolic ratio (risperidone/9-hydroxyrisperidone). These findings suggest that cyamemazine inhibits the 9-hydroxylation of risperidone and is probably an inhibitor of cytochrome P450 2D6 as are many other phenothiazine drugs.

  3. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.

    Science.gov (United States)

    Ghanizadeh, Ahmad; Haghighi, Alireza

    2014-10-01

    There are some uncontrolled studies about the efficacy and safety of both aripiprazole and risperidone for treating tic disorder. Moreover, the efficacy of these medications has never been compared. This is the first double blind randomized clinical trial comparing the safety and efficacy of aripiprazole and risperidone for treating patients with tic disorder. Sixty children and adolescents with tic disorder were randomly allocated into one of the two groups to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was the score of Yale Global Tic Severity Scale. In addition, health related quality of life and adverse events were assessed. Both aripiprazole and risperidone decreased the Yale Global Tic Severity Scale score during this trial. Moreover, both medications increased the health related quality of life score. Both aripiprazole and risperidone were tolerated well. Aripiprazole [3.22 (1.9) mg/day] decreased tic score as much as risperidone [0.6 (0.2) mg/day]. Their adverse effects and their effects on health related quality of life were comparable. However, risperidone increased the patients' social functioning more than aripiprazole in short term.

  4. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure

    Directory of Open Access Journals (Sweden)

    Sarah M. Bahr

    2015-11-01

    Full Text Available Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.

  5. Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice.

    Science.gov (United States)

    Rogóż, Zofia; Kabziński, Marcin

    2011-01-01

    The aim of the present study was to examine the effect of antidepressants (ADs) belonging to different pharmacological groups and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J mice. The antidepressants: citalopram, fluvoxamine, sertraline, reboxetine, milnacipran (5 and 10 mg/kg), or risperidone in low doses (0.05 and 0.1 mg/kg) given alone did not change the immobility time of mice in the forced swimming test. Co-treatment with reboxetine or milnacipran (10 mg/kg) and risperidone in a lower dose of 0.05 mg/kg or with sertraline, reboxetine (5 and 10 mg/kg), citalopram, fluvoxamine, milnacipran (10 mg/kg) and risperidone in a higher dose of 0.1 mg/kg produced antidepressant-like effect in the forced swimming test. WAY100635 (a 5-HT(1A) receptor antagonist) inhibited the effects induced by co-administration of ADs and risperidone. Active behavior in the forced swimming test was not a consequence of an increased general activity, since the combined treatment with ADs and risperidone failed to enhance the locomotor activity of mice. The obtained results indicate that a low dose of risperidone enhances the activity of ADs in an animal model of depression, and that, among other mechanisms, 5-HT(1A) receptors may play a role in these effects.

  6. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria

    Directory of Open Access Journals (Sweden)

    Afshin FAYYAZI

    2014-12-01

    Full Text Available How to Cite This Article: Fayyazi A, Salari E, Khajeh A, Ghajarpour A. A Comparison of Risperidone and Buspirone for Treatment ofBehavior Disorders in Children with Phenylketonuria. Iran J Child Neurol. 2014 Autumn; 8(4:33-38.AbstractObjectiveMany patients with late-diagnosed phenylketonuria (PKU suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.Materials & MethodsIn this crossover clinical trial study, patients with severe behavior disorders after medical examination were randomly divided into two groups of two 8-week crossover treatments with risperidone or buspirone. Patient behavioral disorders before and after treatment by each drug was rated by parents on the Nisonger Child Behavior Rating Form (NCBRF, and after treatment by each drug, were assessed by a physician through clinical global impression (CGI.ResultsThirteen patients were able to complete the therapy period with these two medications.The most common psychiatric diagnoses were intellectual disability accompanied by pervasive developmental disorder NOS, and intellectual disability accompanied by autistic disorder. Risperidone was significantly effective in reducing the NCBRF subscales of hyperactivity disruptive/ stereotypic, and conduct problems. Treatment by buspirone only significantly decreased the severity of hyperactivity, but other behavior aspects showed no significant differences. Assessment of the severity of behavior disorder after treatment by risperidone and buspirone showed significant differences in reducing hyperactivity and masochistic/stereotype.ConclusionAlthough buspirone is effective in controlling hyperactivity in patients with PKU, it has no preference over risperidone. Therefore, it is recommended as an alternative to risperidone.ReferencesSmith I, Nowles JK. Behaviour in early treated phenylketonuria: a systematic review. Eur J Pediatr 2000;159:89-93.Targum SD

  7. 奥美拉唑对利培酮和9-羟利培酮血药浓度影响的研究%Influence study of omeprazole on blood drug concentration of risperidone and 9-hydroxy risperidone

    Institute of Scientific and Technical Information of China (English)

    巫艳芬; 王玉梅; 陈宝燕

    2014-01-01

    目的:观察奥美拉唑对利培酮和9-羟利培酮血药浓度的影响。方法20例精神分裂症合并胃溃疡患者,给予利培酮联合奥美拉唑治疗1周。检测奥美拉唑治疗后利培酮以及9-羟利培酮血药浓度。结果未使用奥美拉唑前,利培酮与9-羟利培酮血药浓度为(29.25±7.82)μg/L;使用奥美拉唑后,利培酮与9-羟利培酮血药浓度为(37.15±11.68)μg/L,差异有统计学意义(P<0.05)。结论奥美拉唑能够提高利培酮与9-羟利培酮血药浓度,因此,临床上治疗精神分裂症合并胃溃疡患者,给予奥美拉唑联合利培酮治疗时,应该监测患者利培酮与9-羟利培酮血药浓度,及时对药物剂量进行调整。%Objective To observe the influence of omeprazole on blood drug concentration of risperidone and 9-hydroxy risperidone. Methods A total of 20 schizophrenia with gastric ulcer cases were treated by risperidone combined with omeprazole for 1 week. Detections of blood drug concentration of risperidone and 9-hydroxy risperidone were made after the omeprazole treatment. Results Before application of omeprazole, blood drug concentration of risperidone and 9-hydroxy risperidone was (29.25±7.82)μg/L. After using omeprazole, blood drug concentration of risperidone and 9-hydroxy risperidone was (37.15±11.68) μg/L. The difference had statistical significance (P<0.05). Conclusion Omeprazole can increase the blood drug concentration of risperidone and 9-hydroxy risperidone, which should be monitored in the risperidone combined with omeprazole treatment of schizophrenia with gastric ulcer, and timely adjustment of drug dose is necessary.

  8. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

    Directory of Open Access Journals (Sweden)

    Möller Hans-Jürgen

    2009-02-01

    Full Text Available Abstract Background As schizophrenia patients are typically suspicious of, or are hostile to changes they may be reluctant to accept generic substitution, possibly affecting compliance. This may counteract drug costs savings due to less symptom control and increased hospitalization risk. Although compliance losses following generic substitution have not been quantified so far, one can estimate the possible health-economic consequences. The current study aims to do so by considering the case of risperidone in Germany. Methods An existing DES model was adapted to compare staying on branded risperidone with generic substitution. Differences include the probability of non-compliance and medication costs. Incremental probability of non-compliance after generic substitution was varied between 2.5% and 10%, while generic medication costs were assumed to be 40% lower. Effect of medication price was assessed as well as the effect of applying compliance losses to all treatment settings. The probability of staying on branded risperidone being cost-effective was calculated for various outcomes of a hypothetical study that would investigate non-compliance following generic substitution of risperidone. Results If the incremental probability of non-compliance after generic substitution is 2.5%, 5.0%, 7.5% and 10% respectively, incremental effects of staying on branded risperidone are 0.004, 0.007, 0.011 and 0.015 Quality Adjusted Life Years (QALYs. Incremental costs are €757, €343, -€123 and -€554 respectively. Benefits of staying on branded risperidone include improved symptom control and fewer hospitalizations. If generic substitution results in a 5.2% higher probability of non-compliance, the model predicts staying on branded risperidone to be cost-effective (NICE threshold of ₤30,000 per QALY gained. Compliance losses of more than 6.9% makes branded risperidone the dominant alternative. Results are sensitive to the locations at which compliance

  9. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.

    Science.gov (United States)

    An, Taekun; Choi, Juhyuen; Kim, Aram; Lee, Jin Ho; Nam, Yoonjin; Park, Junsung; Sun, Bo kyung; Suh, Hearan; Kim, Cherng-ju; Hwang, Sung-Joo

    2016-04-30

    Risperidone-loaded poly (D,L-lactide-co-glycolide) (PLGA) microspheres were prepared with a suspension-evaporation process with an aqueous suspension containing an in situ-formed aluminum hydroxide inorganic gel (SEP-AL process) and evaluated for encapsulation efficiency, particle size, surface morphology, glass transition temperature, in vitro drug release profile, and in vivo behavior. The SEP-AL microspheres were compared with conventional oil-in-water (O/W) emulsion solvent evaporation method using polyvinylalcohol (PVA) as an emulsifier (CP-PVA process). The microspheres were spherical in shape. DSC measurements showed that risperidone crystallinity was greatly reduced due to the homogeneous distribution of risperidone in PLGA microspheres. In vitro drug release profile from the microspheres showed a sigmoidal pattern of negligible initial burst up to 24h and minimal release (time-lag) for 7 days. After the lag phase, slow release took a place up to 25 days and then rapid release occurred sharply for 1 week. In vivo rat pharmacokinetic profile from the microspheres showed very low blood concentration level at the initial phase (up to 24h) followed by the latent phase up to 21 days. At the 3rd week, main phase started and the blood concentration of the drug increased up to the 5th week, and then gradually decreased. The risperidone-loaded PLGA microspheres produced by SEP-AL process showed excellent controlled release characteristics for the effective treatment of schizophrenia patients.

  10. Dietary Status and Impact of Risperidone on Nutritional Balance in Children with Autism: A Pilot Study

    Science.gov (United States)

    Lindsay, Ronald L.; Arnold, L. Eugene; Aman, Michael G.; Vitiello, Benedetto; Posey, David J.; McDougle, Christopher J.; Scahill, Lawrence; Pachler, Maryellen; McCracken, James T.; Tierney, Elaine; Bozzolo, Dawn

    2006-01-01

    Background: Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain. Method: Using a quantitative Food Frequency Questionnaire (FFQ), we prospectively examined the nutritional intake of 20 children with autism participating in a randomised…

  11. Risperidone versus olanzapine in the acute treatment of Persistent Delusional Disorder: A retrospective analysis.

    Science.gov (United States)

    Kulkarni, Karishma; Arasappa, Rashmi; Prasad M, Krishna; Zutshi, Amit; Chand, Prabhat K; Murthy, Pratima; Philip, Mariamma; Muralidharan, Kesavan

    2017-07-01

    There is a dearth of prospective trials studying treatment response in Persistent Delusional Disorder (PDD) to guide clinical practice. Available retrospective data indicate good response to second-generation antipsychotics (SGAs). We selected the data of patients prescribed either olanzapine or risperidone from a retrospective chart review of PDD (n=455) at our centre. We compared the two groups olanzapine (n =86) versus risperidone (n =280) on dose, drug adherence, response and adverse effects. The two groups were comparable on socio-demographic and clinical characteristics of PDD. There was no statistically significant difference between the two groups on adherence (>80%) and response to treatment (>52% good response). Olanzapine was effective at lower mean chlorpromazine equivalents than risperidone. Logistic regression analysis identified shorter mean duration of illness, good adherence and absence of substance dependence as predictors of good response to both drugs. Our study indicates that acute PDD responds well to treatment with both risperidone and olanzapine, provided adherence can be ensured. In the absence of specific treatment guidelines and randomized controlled trials for PDD, our analysis reaffirms the efficacy of SGAs. Copyright © 2017. Published by Elsevier B.V.

  12. Risperidone treatment for ADHD in children and adolescents with bipolar disorder

    Directory of Open Access Journals (Sweden)

    Joseph Biederman

    2008-03-01

    Full Text Available Joseph Biederman, Paul Hammerness, Robert Doyle, Gagan Joshi, Megan Aleardi, Eric MickPediatric Psychopharmacology Research Department, Massachusetts General Hospital, Boston, MA, USAObjective: Children and adolescents with bipolar disorder are also at high risk of having comorbid attention-deficit hyperactivity disorder (ADHD. The objective of this study was to estimate improvement in ADHD symptoms in children with bipolar disorder.Methods: This was an open-label, study of risperidone monotherapy for the treatment of pediatric bipolar disorder. Thirty-one children and adolescents 4–15 years of age (7.2 ± 2.8 years of both sexes (71%, N = 22 male with pediatric bipolar disorder (YMRS score = 32.9 ± 8.8 and ADHD (ADHD-RS score = 37.9 ± 8.9 were included in these analyses.Results: Improvement in ADHD symptoms was contingent on improvement in manic symptoms. Although both hyperactive/impulsive (−7.5 ± 5.5.6, p < 0.05 and inattentive (−6.8 ± 5.0, p < 0.05 ADHD symptoms were significantly improved with risperidone, improvement was modest, and only 29% of subjects (N = 6 showed a 30% reduction in ADHD rating scale scores and had a CGI-I ≤ 2.Conclusions: These results suggest that that treatment with risperidone is associated with tangible but generally modest improvement of symptoms of ADHD in children with bipolar disorder.Keywords: ADHD, bipolar disorder, children, risperidone

  13. Neuropsychological effects of risperidone in children with pervasive developmental disorders : A blinded discontinuation study

    NARCIS (Netherlands)

    Troost, Pieter W.; Althaus, Monika; Lahuis, Bertine E.; Buitelaar, Jan K.; Minderaa, Ruud B.; Hoekstra, Pieter J.

    2006-01-01

    Objective: Little is known about the neuropsychological effects of risperidone in children with pervasive developmental disorders. Method: Twenty-four children (aged 5-17 years) with pervasive developmental disorders and co-morbid disruptive behavior who responded favorably to open-label treatment

  14. Tic Reduction with Risperidone Versus Pimozide in a Randomized, Double-Blind, Crossover Trial

    Science.gov (United States)

    Gilbert, Donald L.; Batterson, J. Robert; Sethuraman, Gopalan; Sallee, Floyd R.

    2004-01-01

    Objective: To compare the tic suppression, electrocardiogram (ECG) changes, weight gain, and side effect profiles of pimozide versus risperidone in children and adolescents with tic disorders. Method: This was a randomized, double-blind, crossover (evaluable patient analysis) study. Nineteen children aged 7 to 17 years with Tourette's or chronic…

  15. Switching to quetiapine for risperidone-induced amenorrhea: Report of two cases

    Directory of Open Access Journals (Sweden)

    P K Pardal

    2010-01-01

    Full Text Available Almost all the antipsychotics can cause hyperprolactinemia-related side-effects like amenorrhea. Quetiapine has been reported to have minimal propensity to cause hyperprolactinemia. We report here two cases of risperidone-induced amenorrhea, who resumed their normal cycle on switching over the medication to quetiapine.

  16. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.

    Science.gov (United States)

    Liu, Pang-Yen; Wu, Pei-Chuan; Chen, Chun-Yen; Chen, Yi-Chyan

    2011-01-01

    We present the case of a woman with paranoid schizophrenia who was receiving oral risperidone. She developed neuroleptic malignant syndrome (NMS) following the addition of depot fluphenazine for the treatment of refractory delusions. NMS subsided and psychotic features were controlled after both antipsychotics were discontinued and the patient was treated instead with olanzapine.

  17. Paediatric European Risperidone Studies (PERS) : context, rationale, objectives, strategy, and challenges

    NARCIS (Netherlands)

    Glennon, Jeffrey; Purper-Ouakil, Diane; Bakker, Mireille; Zuddas, Alessandro; Hoekstra, Pieter; Schulze, Ulrike; Castro-Fornieles, Josefina; Santosh, Paramala J.; Arango, Celso; Koelch, Michael; Coghill, David; Flamarique, Itziar; Penzol, Maria J.; Wan, Mandy; Murray, Macey; Wong, Ian C. K.; Danckaerts, Marina; Bonnot, Olivier; Falissard, Bruno; Masi, Gabriele; Fegart, Joerg M.; Vicari, Stefano; Carucci, Sara; Dittmann, Ralf W.; Buitelaar, Jan K.

    2014-01-01

    In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and

  18. Spontaneous seizures after ECT in a patient medicated with bupropion, sertraline and risperidone

    Directory of Open Access Journals (Sweden)

    Orlando von Doellinger

    Full Text Available Abstract Objective: To report a case of post-electroconvulsive therapy spontaneous seizures in a patient medicated with sertraline, bupropion and risperidone. Case description: A 53-year-old woman with recurrent major depression was admitted to our psychiatry department for a major depressive episode of 6 weeks' duration, with psychotic symptoms. She was already on 200 mg/day of sertraline and 2 mg/day of risperidone. After 8 weeks on 200 mg/day of sertraline, 4 mg/day of risperidone and slow release bupropion (titrated to 300 mg/day, with no objective improvements, the decision was taken to initiate a course of 8-10 electroconvulsive therapy (ECT sessions. Two days after the first treatment, three generalized tonic-clonic seizures occurred within 6 hours. Phenytoin and sodium valproate were added to the patient's daily medication and no further spontaneous seizures were observed. After neurologic assessment and discussion of the case, phenytoin and bupropion were withdrawn at once (two days after the spontaneous seizures and the decision was taken to resume the ECT treatment. No further spontaneous seizures occurred and, at discharge, the patient exhibited significant improvements and was free from major depressive symptoms. Comments: This report illustrates a case of post-ECT spontaneous seizures that might have been due to a specific pharmacological etiological pathway, namely, bupropion's proconvulsive properties, although both sertraline and risperidone also lower the convulsive threshold.

  19. Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges

    NARCIS (Netherlands)

    Glennon, J.C.; Purper-Ouakil, D.; Bakker, M; Zuddas, A.; Hoekstra, P.; Schulze, U.; Castro-Fornieles, J.; Santosh, P.J.; Arango, C.; Kolch, M.; Coghill, D.; Flamarique, I.; Penzol, M.J.; Wan, M.; Murray, M.; Wong, I.C.; Danckaerts, M.; Bonnot, O.; Falissard, B.; Masi, G.; Fegert, J.M.; Vicari, S.; Carucci, S.; Dittmann, R.W.; Buitelaar, J.

    2014-01-01

    In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and

  20. Paediatric European Risperidone Studies (PERS) : context, rationale, objectives, strategy, and challenges

    NARCIS (Netherlands)

    Glennon, Jeffrey; Purper-Ouakil, Diane; Bakker, Mireille; Zuddas, Alessandro; Hoekstra, Pieter; Schulze, Ulrike; Castro-Fornieles, Josefina; Santosh, Paramala J.; Arango, Celso; Koelch, Michael; Coghill, David; Flamarique, Itziar; Penzol, Maria J.; Wan, Mandy; Murray, Macey; Wong, Ian C. K.; Danckaerts, Marina; Bonnot, Olivier; Falissard, Bruno; Masi, Gabriele; Fegart, Joerg M.; Vicari, Stefano; Carucci, Sara; Dittmann, Ralf W.; Buitelaar, Jan K.

    2014-01-01

    In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and

  1. Stability Indicating HPLC Determination of Risperidone in Bulk Drug and Pharmaceutical Formulations

    Directory of Open Access Journals (Sweden)

    Zarna R. Dedania

    2011-01-01

    Full Text Available The objective of the current study was to develop a validated stability-indicating assay method (SIAM for risperidone after subjecting it to forced decomposition under hydrolysis, oxidation, photolysis, and thermal stress conditions. The liquid chromatographic separation was achieved isocratically on a symmetry C18 column (5 μm size, 250 mm × 4.6 mm i.d. using a mobile phase containing methanol: acetonitrile (80 : 20, v/v at a flow rate of 1 mL/min and UV detection at 280 nm. Retention time of risperidone was found to be 3.35±0.01. The method was linear over the concentration range of 10–60 μg/mL(2=0.998 with a limit of detection and quantitation of 1.79 and 5.44 μg/mL, respectively. The method has the requisite accuracy, specificity, sensitivity, and precision to assay risperidone in bulk form and pharmaceutical dosage forms. Degradation products resulting from the stress studies did not interfere with the detection of Risperidone, and the assay is thus stability indicating.

  2. Long-term effects of risperidone in children with autism spectrum disorders : A placebo discontinuation study

    NARCIS (Netherlands)

    Troost, PW; Lahuis, BE; Steenhuis, MP; Ketelaars, CEJ; Buitelaar, JK; Van Engeland, H; Scahill, L; Minderaa, RB; Hoekstra, PJ

    2005-01-01

    Objective: The short-term benefit of risperidone in ameliorating severe disruptive behavior in pediatric patients with autism spectrum disorders is well established; however, only one placebo-controlled, long-term study of efficacy is available. Method: Thirty-six children with an autism spectrum di

  3. Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder

    NARCIS (Netherlands)

    Dinnissen, Mariken; Dietrich, Andrea; van den Hoofdakker, Barbara J.; Hoekstra, Pieter J.

    2015-01-01

    Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is often accompanied by psychiatric comorbidity. Although there is no medication currently available to treat the core symptoms of ASD, risperidone was the first drug to be approved for use in ASD and is still the bes

  4. Antipsychotic-induced extrapyramidal syndromes - Risperidone compared with low- and high-potency conventional antipsychotic drugs

    NARCIS (Netherlands)

    Schillevoort, [No Value; de Boer, A; Herings, RMC; Roos, RAC; Jansen, PAF; Leufkens, HGM

    2001-01-01

    Aim: To compare the risk of extrapyramidal syndromes (EPS) between patients using risperidone and those using low-potency conventional antipsychotic drugs (APDs) in outpatient clinical practice, as measured by the use of anticholinergic medication. We tried to replicate results from previous clinica

  5. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.

    NARCIS (Netherlands)

    Troost, P.W.; Althaus, M.; Lahuis, B.E.; Buitelaar, J.K.; Minderaa, R.B.; Hoekstra, P.J.

    2006-01-01

    OBJECTIVE: Little is known about the neuropsychological effects of risperidone in children with pervasive developmental disorders. METHOD: Twenty-four children (aged 5-17 years) with pervasive developmental disorders and co-morbid disruptive behavior who responded favorably to open-label treatment w

  6. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.

    Science.gov (United States)

    El-Sayed El-Sisi, Alaa; Sokkar, Samia Salem; El-Sayed El-Sayad, Magda; Sayed Ramadan, Ehab; Osman, Enass Yossef

    2016-08-01

    The implications of oxidative stress and neuro-inflammation in the pathogenesis of schizophrenia have been elucidated. Despite their effectiveness against positive symptoms of schizophrenia, antipsychotics have limited effectiveness against negative and cognitive symptoms and are associated with remarkable adverse effects. The use of celecoxib or omega-3 in schizophrenia may have beneficial effects. This study aimed to evaluate the possible efficacies of celecoxib, omega-3 or the combination of celecoxib+risperidone and omega-3+ risperidone compared to risperidone on the behavior and brain biochemistry in rats. In the present study, an amphetamine-induced model of schizophrenia in adult male rats was used to evaluate the effects of celecoxib, omega-3, celecoxib+risperidone and omega-3+ risperidone on the behavior of animals and on brain lipid peroxidation or tumor necrosis factor-alpha. In the water maze task, celecoxib, omega-3, celecoxib+risperidone, omega-3+ risperidone significantly decreased the latency time compared to amphetamine-treated group. Celecoxib, omega-3, celecoxib+risperidone, omega-3+risperidone also significantly reversed the decreased spontaneous alternation induced by amphetamine in the Y-maze task. In the social interaction task, groups treated with celecoxib, omega-3, celecoxib+risperidone, omega-3+ risperidone spent less time to recognize foreign animals than animals in the amphetamine-treated group. Increased brain MDA and TNF-α levels due to amphetamine were significantly reduced in groups treated with celecoxib+risperidone or omega-3+ risperidone. The present findings showed that celecoxib or omega-3 can attenuate amphetamine- induced behavioral impairment and these effects may be associated with their ability to decrease lipid peroxidation and cytokine release. Celecoxib or omega-3 may be promising candidates as adjuvant therapy for schizophrenia.

  7. Deltoid injections of risperidone long-acting injectable in patients with schizophrenia.

    Science.gov (United States)

    Quiroz, Jorge A; Rusch, Sarah; Thyssen, An; Palumbo, Joseph M; Kushner, Stuart

    2011-06-01

    Risperidone long-acting injectable was previously approved for treatment of schizophrenia as biweekly injections in the gluteal muscle only. We present data on local injection-site tolerability and safety of risperidone long-acting injectable and comparability of systemic exposure of deltoid versus gluteal injections. Risperidone long-acting injectable was administered in an open-label, single-dose, two-way crossover study, with patients randomized to receive either 25mg gluteal/37.5mg deltoid crossover in two treatment periods or 50mg gluteal/50mg deltoid injections crossover; each treatment period was separated by an 85-day observation period (Study 1) and an open-label, multiple-dose study (4 sequential 37.5mg or 50mg deltoid injections every 2 weeks) (Study 2). The pharmacokinetic results from both the studies have already been published. In Study 1 (n=170), the majority of patients had no local injection-site findings, based on investigator and patient-rated evaluations. In Study 2 (n=53), seven of the 51 patients who received at least two deltoid injections discontinued (primary endpoint). However, none of the discontinuations were due to injection-site related reasons. The 90-percent upper confidence limit of the true proportion of injection-site issue withdrawals was 5.7 percent. No moderate or severe injection-site reactions were reported. Intramuscular injections via the deltoid and gluteal sites are equivalent routes of administration of risperidone long-acting injectable with respect to local injection-site tolerability. The overall safety and tolerability profile of risperidone long-acting injectable was comparable when administered as an intramuscular injection in the deltoid (37.5mg and 50mg) and gluteal (25mg and 50mg) sites.

  8. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.

    Science.gov (United States)

    Kato, Takahiro; Monji, Akira; Hashioka, Sadayuki; Kanba, Shigenobu

    2007-05-01

    Microglia has recently been regarded to be a mediator of neuroinflammation via the release of proinflammatory cytokines, nitric oxide (NO) and reactive oxygen species (ROS) in the central nervous system (CNS). Microglia has thus been reported to play an important role in the pathology of neurodegenerative disease, such as Alzheimer's disease (AD) and Parkinson's disease (PD). The pathological mechanisms of schizophrenia remain unclear while some recent neuroimaging studies suggest even schizophrenia may be a kind of neurodegenerative disease. Risperidone has been reported to decrease the reduction of MRI volume during the clinical course of schizophrenia. Many recent studies have demonstrated that immunological mechanisms via such as interferon (IFN)-gamma and cytokines might be relevant to the pathophysiology of schizophrenia. In the present study, we thus investigated the effects of risperidone on the generation of nitric oxide, inducible NO synthase (iNOS) expression and inflammatory cytokines: interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha by IFN-gamma-activated microglia by using Griess assay, Western blotting and ELISA, respectively. In comparison with haloperidol, risperidone significantly inhibited the production of NO and proinflammatory cytokines by activated microglia. The iNOS levels of risperidone-treated cells were much lower than those of the haloperidol-treated cells. Antipsychotics, especially risperidone may have an anti-inflammatory effect via the inhibition of microglial activation, which is not only directly toxic to neurons but also has an inhibitory effect on neurogenesis and oligodendrogenesis, both of which have been reported to play a crucial role in the pathology of schizophrenia.

  9. Comparative study on clinically latent aggressiveness inoutpatients with schizophrenia treated with classical antipsychotics and with risperidone

    Directory of Open Access Journals (Sweden)

    Konstantinos Tsirigotis

    2014-03-01

    Full Text Available Objective: The use of neuroleptics causes not only regression of psychotic symptoms; neuroleptics affect also the patients’ mental state which is changing not only due to medications effects but also secondarily, as a result of regression of psychotic symptoms. The aim of this study was evaluation of subjectively felt “silent” (clinically latent hostility and aggressiveness in patients with paranoid schizophrenia treated with typical neuroleptics and risperidone. Material and methods: Sixty patients (30 patients treated with typical neuroleptics and the other 30 – with risperidone were examined with the Polish version of the following tools: Minnesota Multiphasic Personality Inventory (MMPI, Adjective Check List (ACL and Stern Activities Index (SAI. Results: The statistical analysis of the obtained results yielded many statistically significant differences within the intensity of hostility and aggressiveness in the examined groups. Conclusions: The results of this study showed a higher severity of psychological and personality problems in patients treated with typical neuroleptics, as compared to those treated with risperidone. In patients with paranoid schizophrenia treated with risperidone a lower severity of psychopathological, especially schizophrenic and paranoid, symptoms and lower hostility and aggressiveness were found. Considering that risperidone improves verbal functions, it can be assumed that this entails an improvement in the patients’ communicative competences, thereby improving also their interpersonal relationships. The results of this study indicate a higher susceptibility of people in this group to social influences and less hostility and negativity experienced by them.

  10. Combination of Risperidone and Paroxetine for inappropriate sexual behaviors in an adolescent with autism and mental retardation/Otizm ve zeka geriligi olan bir ergende uygunsuz cinsel davranislar icin Risperidone ve Paroxetine birlikte kullanimi

    National Research Council Canada - National Science Library

    Herguner, Sabri; Herguner, Arzu; Cicek, Erdinc

    2012-01-01

    .... In this paper, we describe an adolescent with autistic disorder and mental retardation who developed severe inappropriate sexual behaviors and has been treated successfully with risperidone-paroxetine combination...

  11. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial

    DEFF Research Database (Denmark)

    Lublin, Henrik; Haug, Hans-Joachim; Koponen, Hannu

    2009-01-01

    The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic tr...

  12. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.

    Science.gov (United States)

    Yang, Jaewon; Bahk, Won-Myong; Cho, Hyun-Sang; Jeon, Yang-Whan; Jon, Duk-In; Jung, Hee-Yeon; Kim, Chan-Hyung; Kim, Hee-Cheol; Kim, Yong-Ku; Kim, Young-Hoon; Kwon, Jun-Soo; Lee, Sang-Yeol; Lee, Seung-Hwan; Yi, Jung-Seo; Yoon, Bo-Hyun; Kim, Seung-Hyun

    2010-07-01

    The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was -23.48 +/- 19.73 for the blonanserin group and -25.40 +/- 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and increased level blood prolactin (P = 0.0012). On the other hand, the adverse events that occurred more frequently in the blonanserin than in the risperidone group was hand tremor (P = 0.0006). Blonanserin was effective in the treatment of Korean patients with schizophrenia compared with risperidone and was more tolerable with a better safety profile, particularly with respect to prolactin elevation. These findings suggest that blonanserin is useful in the treatment of schizophrenia.

  13. A case of resistant schizophrenia responding at a higher than recommended dose of risperidone without significant side effects

    Directory of Open Access Journals (Sweden)

    Anirban Ray

    2013-01-01

    Full Text Available A patient, diagnosed with schizophrenia, non-responsive to two atypical antipsychotics and partially responsive to the third (risperidone in therapeutic dose, ultimately showed complete response without any unacceptable side-effect in a dose (20mg that was untried previously. This case makes an important observation that high dose of risperidone can be tried in a patient with good results if his clinical condition permits.

  14. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia

    Directory of Open Access Journals (Sweden)

    Hongyan Zhang

    2011-03-01

    Full Text Available Hongyan Zhang1, Huafang Li2, Liang Shu1, Niufan Gu2, Gang Wang3, Yongzhen Weng3, Shiping Xie4, Xinbao Zhang4, Ting Li5, Cui Ma5, Wei Yu6, Bruce Parsons7, Manjula Schou81Institute of Mental Health, Peking University, Beijing, China; 2Shanghai Mental Health Center, Shanghai, China; 3Capital Medical University, Beijing An Ding Hospital, Beijing, China; 4Nanjing Brain Hospital, Nanjing, China; 5Guangzhou Brain Hospital, Guangzhou, China; 6Pfizer China, Beijing, China; 7Pfizer Inc, New York, NY, USA; 8Pfizer Australia, Sydney, AustraliaBackground: The aim of the study was to evaluate the efficacy and safety of ziprasidone versus risperidone in Chinese subjects with acute exacerbation of schizophrenia.Methods: In patients meeting the Chinese Classification of Mental Disorders criteria for schizophrenia and with a Positive and Negative Syndrome Scale (PANSS total score ≥60 were randomly assigned to six weeks of double-blind treatment with ziprasidone 40–80 mg twice daily or risperidone 1–3 mg bid, flexibly dosed. Noninferiority was demonstrated if the upper limit of the two-sided 95% confidence interval (CI for the difference in PANSS total score improvement from baseline in the evaluable population was smaller than the prespecified noninferiority margin of 10 units.Results: The intent-to-treat population comprised 118 ziprasidone-treated and 121 risperidone-treated subjects. Improvement (reduction from baseline to week 6 in PANSS total score was (-35.6 [95% CI: -38.6, -32.6] for ziprasidone and (-37.1 [95% CI: -39.9, -34.4] for risperidone. Noninferiority was demonstrated in the evaluable population with a difference score of 1.5 [95% CI: -2.5, 5.5]. Mean prolactin levels decreased at week 6 compared with baseline for ziprasidone (-3.5 ng/mL, but significantly increased for risperidone (61.1 ng/mL; P < 0.001. More risperidone-treated subjects (14.9% than ziprasidone-treated subjects (4.2% reported weight gain ≥7%. Akathisia and somnolence in

  15. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.

    Science.gov (United States)

    Ruaño, G; Goethe, J W; Caley, C; Woolley, S; Holford, T R; Kocherla, M; Windemuth, A; de Leon, J

    2007-05-01

    Atypical antipsychotics induce pre-diabetic symptoms in some but not all patients, characterized most notably by elevated weight. The side effect profiles of the various drugs in the class differ, however, raising the possibility of drug-specific mechanisms for similar side effects. We used physiogenomic analysis, an approach previously employed to study the genetics of drug and diet response, to discover and compare genetic associations with weight profiles observed in patients treated with olanzapine and risperidone as an approach to unraveling contrasting mechanistic features of both drugs. A total of 29 single nucleotide polymorphisms (SNPs) were selected from 13 candidate genes relevant to two potential pharmacological axes of psychotropic-related weight profiles, appetite peptides and peripheral lipid homeostasis. We applied physiogenomic analysis to a cross-section of 67 and 101 patients being treated with olanzapine and risperidone, respectively, and assessed genetic associations with the weight profiles. Weight profiles in patients treated with olanzapine were significantly associated with SNPs in the genes for apolipoprotein E, apolipoprotein A4 and scavenger receptor class B, member 1. Weight profiles in patients treated with risperidone were significantly associated with SNPs in the genes for leptin receptor, neuropeptide Y receptor Y5 and paraoxonase 1. These results are consistent with contrasting mechanisms for the weight profile of patients treated with these drugs. Genes associated with olanzapine weight profiles may be related to peripheral lipid homeostatic axes, whereas those associated with risperidone's may be related to brain appetite peptide regulation. Future physiogenomic studies will include neurotransmitter receptor SNPs and validation in independent samples.

  16. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies.

    Science.gov (United States)

    Navitha, Aerrolla; Jogala, Satheesh; Krishnamohan, Chinnala; Aukunuru, Jithan

    2014-04-01

    The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC) studies. Different implants (F1-F8) containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000) either alone or as their blends, and PLGA (75:25). The implants contained 40% of the drug. After fabrication, the implants were characterized for various in vitro properties such as drug release and physical strength. Prior to conducting drug release studies, optimum drug release method was developed based on IVIVC studies. An optimized formulation based on drug release and physical strength at the end of fabrication was selected from the various implants fabricated. The bioactivity, reversibility, and IVIVC of optimized formulation were determined using pharmacokinetic studies in rats. Short-term stability studies were conducted with optimized formulation. Drug release depended on polymer molecular weight. Implant fabricated using 50:50 polycaprolactone 45,000 and polycaprolactone 80,000 was considered optimized implant. Optimized formulation selected released the drug for 3-months in vitro and was physically rigid. The optimized implant was able to release the drug in vivo for a period of 3 months, the implants are reversible throughout the delivery interval and, a 100% IVIVC was achieved with optimized implant, suggesting the development of 3-month drug-releasing implant for risperidone. The optimized implant was stable for 6 months at room temperature (25°C) and 45°C. A novel implant for risperidone was successfully prepared and evaluated.

  17. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies

    Directory of Open Access Journals (Sweden)

    Aerrolla Navitha

    2014-01-01

    Full Text Available The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC studies. Different implants (F1-F8 containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000 either alone or as their blends, and PLGA (75:25. The implants contained 40% of the drug. After fabrication, the implants were characterized for various in vitro properties such as drug release and physical strength. Prior to conducting drug release studies, optimum drug release method was developed based on IVIVC studies. An optimized formulation based on drug release and physical strength at the end of fabrication was selected from the various implants fabricated. The bioactivity, reversibility, and IVIVC of optimized formulation were determined using pharmacokinetic studies in rats. Short-term stability studies were conducted with optimized formulation. Drug release depended on polymer molecular weight. Implant fabricated using 50:50 polycaprolactone 45,000 and polycaprolactone 80,000 was considered optimized implant. Optimized formulation selected released the drug for 3-months in vitro and was physically rigid. The optimized implant was able to release the drug in vivo for a period of 3 months, the implants are reversible throughout the delivery interval and, a 100% IVIVC was achieved with optimized implant, suggesting the development of 3-month drug-releasing implant for risperidone. The optimized implant was stable for 6 months at room temperature (25°C and 45°C. A novel implant for risperidone was successfully prepared and evaluated.

  18. Risperidone-induced priapism in an autistic child: a case report

    OpenAIRE

    Aabbassi, Bouchra; Benali, Abdeslam; Asri, Fatima

    2016-01-01

    Background Priapism is a prolonged stimulation with painful, persistent penile erection unaccompanied by sexual desire. It is a rare but serious urological emergency. Risperidone is an atypical antipsychotic widely prescribed for the treatment of behavior problems in children with autism spectrum disorder. It seems associated with priapism in children. Case presentation We present a case of a 12-year-old Moroccan boy diagnosed with autism spectrum disorder who developed priapism while on an e...

  19. Risperidone Long-Acting Injections: Successful Alternative Deltoid Muscle Injections for Refractory Schizophrenia

    OpenAIRE

    Saxena, Arjun; Grace, Jeffery; Olympia, Josie L.; Trigoboff, Eileen; Watson, Thomas; Cushman, Sharon; Newcomer, David

    2008-01-01

    Treatment-resistant paranoid schizophrenia is often addressed with long-term intramuscular preparations of conventional antipsychotics (haloperidol and fluphenazine), which can be associated with the development of painful, lumpy nodules at the injection site. In this article, we present a case example of a 58-year-old male patient with paranoid schizophrenia who was treated with risperidone long-acting injection given into the deltoid muscle instead of the US Food and Drug Administration (FD...

  20. Amenorrhoea - consequence of combined treatment with sulpiride and risperidone in a patient suffering from schizophrenia.

    Science.gov (United States)

    Peitl, Marija Vucić; Pavlović, Eudard; Peitl, Antun; Peitl, Vjekoslav

    2010-03-01

    It is well documented that sulpiride causes hormonal adverse events, like amenorrhoea and galactorrhea, due to its mechanism of action. Furthermore, risperidone can produce amenorrhoea and galactorrhea also, due to its mechanism of action, which differs from that of sulpiride. This case report is of a patient that was treated with large doses of sulpiride, but did not develop an adverse event like amenorrhoea. However, when risperidone was introduced into therapy it leads to the onset of amenorrhoea. Gynecologist saw it as the beginning of menopause. General practitioner questioned the existence of an intra-cerebral process that could produce amenorrhoea as well. Therefore, the patient was sent to perform an MRI of the brain, under work diagnosis of pituitary adenoma, which was later ruled out as a cause of the illness. Well experienced psychiatrist linked the loss of menstruation with the adverse event profile of sulpiride and therefore gradually discontinued sulpiride from therapy, while risperidone was left and subsequently menstrual cycle was restored. Good knowledge of adverse events profile of antipsychotic medication used, especially when used in a combination, allows us to correctly question appearance of adverse events, to adequately treat them and lowers the cost of unneeded medical procedures.

  1. Risperidone oral disintegrating mini-tablets: A robust-product for pediatrics

    Directory of Open Access Journals (Sweden)

    El-Say Khalid M.

    2015-12-01

    Full Text Available This study was aimed at developing risperidone oral disintegrating mini-tablets (OD-mini-tablets as age-appropriate formulations and to assess their suitability for infants and pediatric use. An experimental Box-Behnken design was applied to assure high quality of the OD-mini-tablets and reduce product variability. The design was employed to understand the influence of the critical excipient combinations on the production of OD-mini-tablets and thus guarantee the feasibility of obtaining products with dosage form uniformity. The variables selected were mannitol percent in Avicel (X1, swelling pressure of the superdisintegrant (X2, and the surface area of Aerosil as a glidant (X3. Risperidone-excipient compatibilities were investigated using FTIR and the spectra did not display any interaction. Fifteen formulations were prepared and evaluated for preand post-compression characteristics. The prepared ODmini- tablet batches were also assessed for disintegration in simulated salivary fluid (SSF, pH 6.2 and in reconstituted skimmed milk. The optimized formula fulfilled the requirements for crushing strength of 5 kN with minimal friability, disintegration times of 8.4 and 53.7 s in SSF and skimmed milk, respectively. This study therefore proposes the risperidone OD-mini-tablet formula having robust mechanical properties, uniform and precise dosing of medication with short disintegration time suitable for pediatric use.

  2. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.

    Science.gov (United States)

    Kaminska, K; Rogoz, Z

    2016-06-01

    Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders. In the present study, we investigated the effect of treatment with the antidepressant escitalopram (SSRI) given separately or jointly with a low dose of risperidone (an atypical antipsychotic) in the forced swim test and in the elevated plus-maze test in rats. The obtained results showed that escitalopram at doses of 2.5 or 5 mg/kg evoked antidepressant-like effect in the forced swim test. Moreover, risperidone at low doses (0.05 or 0.1 mg/kg) enhanced the antidepressant-like activity of escitalopram (1 mg/kg) in this test by increasing the swimming time and decreasing the immobility time in those animals. WAY 100635 (a serotonin 5-HT1A receptor antagonist) at a dose of 0.1 mg/kg abolished the antidepressant-like effect induced by co-administration of escitalopram and risperidone. The active behavior in that test did not reflect an increase in general activity, since the combined treatment with escitalopram and risperidone failed to enhance the exploratory activity of rats. In the following experiment, we showed that escitalopram (5 mg/kg) and mirtazapine (5 or 10 mg/kg) or risperidone (0.1 mg/kg) induced an anxiolytic-like effect in the elevated plus-maze test, and the combined treatment with an ineffective dose of risperidone (0.05 mg/kg) enhanced the anxiolytic-like effects of escitalopram (2.5 mg/kg) or mirtazapine (1 and 2.5 mg/kg) in this test. The obtained results suggest that risperidone applied at a low dose enhances the antidepressant-like activity of escitalopram in the forced swim test, and that 5-HT1A receptors may play some role in these effects. Moreover, a low dose of risperidone may also enhance the anxiolytic-like action of the studied

  3. Risperidone and Divalproex Differentially Engage the Fronto-Striato-Temporal Circuitry in Pediatric Mania: A Pharmacological Functional Magnetic Resonance Imaging Study

    Science.gov (United States)

    Pavuluri, Mani N.; Passarotti, Alessandra M.; Fitzgerald, Jacklynn M.; Wegbreit, Ezra; Sweeney, John A.

    2012-01-01

    Objective: The current study examined the impact of risperidone and divalproex on affective and working memory circuitry in patients with pediatric bipolar disorder (PBD). Method: This was a six-week, double-blind, randomized trial of risperidone plus placebo versus divalproex plus placebo for patients with mania (n = 21; 13.6 [plus or minus] 2.5…

  4. Risperidone and Divalproex Differentially Engage the Fronto-Striato-Temporal Circuitry in Pediatric Mania: A Pharmacological Functional Magnetic Resonance Imaging Study

    Science.gov (United States)

    Pavuluri, Mani N.; Passarotti, Alessandra M.; Fitzgerald, Jacklynn M.; Wegbreit, Ezra; Sweeney, John A.

    2012-01-01

    Objective: The current study examined the impact of risperidone and divalproex on affective and working memory circuitry in patients with pediatric bipolar disorder (PBD). Method: This was a six-week, double-blind, randomized trial of risperidone plus placebo versus divalproex plus placebo for patients with mania (n = 21; 13.6 [plus or minus] 2.5…

  5. Adverse Effects of Risperidone in Children with Autism Spectrum Disorders in a Naturalistic Clinical Setting at Siriraj Hospital, Thailand

    Directory of Open Access Journals (Sweden)

    Vitharon Boon-yasidhi

    2014-01-01

    Full Text Available A cross-sectional study was conducted to evaluate adverse effects associated with risperidone in 45 children with autism spectrum disorders (ASD, aged 2–15 years, who were treated at Siriraj Hospital, Thailand, between the years 2006 and 2007. Adverse effects were assessed by parent interview, using a semistructure questionnaire, and medical records review. The mean ± SD age of the children at starting risperidone was 8.15±2.98 years. The mean ± SD of risperidone dose was 0.94±0.74 mg/day and the mean ± SD duration of treatment was 36.8±27.8 months. Adverse effects were reported in 39 children (86.7%. Common adverse effects included increased appetite, somnolence, and rhinorrhea and most of the adverse effects were tolerable. Tardive dyskinesia or other serious adverse events were not found in this study. The child’s mean ± SD weight gain was 4.18±2.82 kg/year, which exceeded developmentally expected norms. The results from this study suggest that risperidone treatment in children with ASD is associated with frequent mild and tolerable adverse effects. However, excessive weight gain could be found to be a concerning adverse effect and weight monitoring is warranted when risperidone is being prescribed.

  6. Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: Design, characterization and in vivo pharmacokinetic evaluation.

    Science.gov (United States)

    Đorđević, Sanela M; Cekić, Nebojša D; Savić, Miroslav M; Isailović, Tanja M; Ranđelović, Danijela V; Marković, Bojan D; Savić, Saša R; Timić Stamenić, Tamara; Daniels, Rolf; Savić, Snežana D

    2015-09-30

    This paper describes design and evaluation of parenteral lecithin-based nanoemulsions intended for brain delivery of risperidone, a poorly water-soluble psychopharmacological drug. The nanoemulsions were prepared through cold/hot high pressure homogenization and characterized regarding droplet size, polydispersity, surface charge, morphology, drug-vehicle interactions, and physical stability. To estimate the simultaneous influence of nanoemulsion formulation and preparation parameters--co-emulsifier type, aqueous phase type, homogenization temperature--on the critical quality attributes of developed nanoemulsions, a general factorial experimental design was applied. From the established design space and stability data, promising risperidone-loaded nanoemulsions (mean size about 160 nm, size distribution emulsifier, were produced by hot homogenization and their ability to improve risperidone delivery to the brain was assessed in rats. Pharmacokinetic study demonstrated erratic brain profiles of risperidone following intraperitoneal administration in selected nanoemulsions, most probably due to their different droplet surface properties (different composition of the stabilizing layer). Namely, polysorbate 80-costabilized nanoemulsion showed increased (1.4-7.4-fold higher) risperidone brain availability compared to other nanoemulsions and drug solution, suggesting this nanoemulsion as a promising carrier worth exploring further for brain targeting. Copyright © 2015 Elsevier B.V. All rights reserved.

  7. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study

    Directory of Open Access Journals (Sweden)

    Sacristán Jose A

    2001-12-01

    Full Text Available Abstract Background In order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice. Method Outpatients with schizophrenia entered this prospective, naturalistic study when they received a new prescription for an antipsychotic drug. Treatment assignment was based on purely clinical criteria, as the study did not include any experimental intervention. Patients treated with olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was measured using the 10-item version of the Drug Attitude Inventory (DAI-10, and treatment compliance was measured using a physician-rated 4 point categorical scale. Results A total of 2128 patients initiated treatment (as monotherapy with olanzapine, 417 with risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10 scores and significantly better treatment compliance compared to both risperidone- and haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients. Conclusion Subjective response and compliance were superior in olanzapine-treated patients, compared to patients treated with risperidone and haloperidol, in routine clinical practice. Differences in subjective response were explained largely, but not completely, by differences in incidence of EPS.

  8. Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults

    DEFF Research Database (Denmark)

    Pasternak, Björn; Svanström, Henrik; Ranthe, Mattis F

    2014-01-01

    risperidone (n = 14,134). The primary outcome was any major cardiovascular event (composite of cardiovascular mortality, acute coronary syndrome, or ischemic stroke) within 1 year following treatment initiation. Cox regression was used to estimate hazard ratios (HRs) while on current antipsychotic monotherapy......BACKGROUND: A number of serious cardiovascular safety concerns related to the use of atypical antipsychotics, compared with no use, have emerged, but nearly all reports are from studies of older patients. We aimed to compare the risk of cardiovascular events between the three most commonly used...... in the outpatient setting, adjusting for an outcome-specific disease risk score. RESULTS: The crude rate of any major cardiovascular event was 5.3 per 1,000 person-years among olanzapine users, 3.4 in quetiapine users, and 5.2 in risperidone users. Compared with risperidone, the risk of any major cardiovascular...

  9. Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders.

    Science.gov (United States)

    Handen, Benjamin L; Johnson, Cynthia R; Butter, Eric M; Lecavalier, Luc; Scahill, Lawrence; Aman, Michael G; McDougle, Christopher J; Arnold, L Eugene; Swiezy, Naomi B; Sukhodolsky, Denis G; Mulick, James A; White, Susan W; Bearss, Karen; Hollway, Jill A; Stigler, Kimberly A; Dziura, James; Yu, Sunkyung; Sacco, Kelley; Vitiello, Benedetto

    2013-06-01

    A Structured Observational Analog Procedure (SOAP), an analogue measure of parent-child interactions, was used to assess treatment outcome in children with Autism Spectrum Disorder and serious behavior problems. It served as a secondary outcome measure in a 24-week, randomized trial of risperidone (MED; N=49) versus risperidone plus parent training (COMB; n=75) (ages 4-13 years). At 24-weeks, there was 28 % reduction in child inappropriate behavior during a Demand Condition (p=.0002) and 12 % increase in compliance to parental requests (p=.004) for the two treatment conditions combined. Parents displayed 64 % greater use of positive reinforcement (p=.001) and fewer repeated requests for compliance (ppositive reinforcement (p=.01) and fewer restrictive statements (p<.05) than MED parents. The SOAP is sensitive to change in child and parent behavior as a function of risperidone alone and in combination with PMT and can serve as a valuable complement to parent and clinician-based measures.

  10. Risperidone regulates Dopamine D2-like receptors expression in rat brain in a time-dependent manner

    Directory of Open Access Journals (Sweden)

    Ni Peiyan

    2015-03-01

    Full Text Available Background and Objectives: Antipsychotics can elicit dopamine super-sensitivity by up-regulation of D2-like receptors (DRD2, DRD3, and DRD4 expression. Nevertheless, the expression profile of dopamine D2-like receptors in different brain regions and peripheral blood mononuclear cells (PBMCs, and changes following risperidone administration were still unclear. In this study, we would investigate the expression of D2-like receptors mRNA in different brain regions and the peripheral blood mononuclear cells (PBMCs in rats after 2, 6 weeks risperidone administration. Methods: The experimental rats were given risperidone (0.25mg/kg/day, i.p., and the control rats were given 0.9% NaCl. The rats were sacrificed at 0 week, 2 weeks and 6 weeks after the drug administration. Expression of the dopamine D2-like receptors was quantified by Real-time PCR method. Results: Dopamine D2-like receptors expressed in all the examined regions of rat brain. Their expression significantly increased 2weeks after risperidone administration in different brain regions. However, the changed expression of DRD2 and DRD3 turned back to the basal level 6weeks later, while the increased DRD4 expression remained in left parietal cortex. Meanwhile, DRD2 and DRD3 but not DRD4 expressed in PBMCs, however, the risperidone could not affect their expression. Conclusions: The risperidone could change the dopamine D2-like receptors expression in a time-dependent manner in different brain regions, which might guide the clinical use in the near future.

  11. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.

    Science.gov (United States)

    Carter, C S; Mulsant, B H; Sweet, R A; Maxwell, R A; Coley, K; Ganguli, R; Branch, R

    1995-01-01

    Risperidone, a new antipsychotic drug, was recently approved by the Food and Drug Administration (FDA) on the basis of its having comparable efficacy and less toxicity than haloperidol. In a preliminary study to evaluate the therapeutic efficiency of this drug, we conducted a survey of resperidone utilization, cost, and safety during its first year of availability at an academic psychiatric hospital. Data were obtained from a computerized, centralized medical record system, from an adverse drug reaction monitoring system, and from pharmacy purchasing records. In its first year of availability, risperidone became the second most widely used antipsychotic agent at our institution. Most of this use extended beyond the adult schizophrenia population, for whom pre-marketing safety and efficacy data are available. The direct institutional cost of risperidone treatment exceeded the entire budget for antipsychotic drugs during the year before its release. Results from the adverse drug reaction reporting system did not indicate a strong advantage of risperidone over more established antipsychotic agents with respect to extrapyramidal side effects. Furthermore, the mean dose of risperidone associated with extrapyramidal symptoms was 3.5 mg/day, considerably lower than that suggested by pre-marketing studies in a more select patient group. These results confirm that new pharmacological agents are generally used in much broader patient populations than those for which efficacy and safety have been established prior to FDA approval. This study also raises questions about the therapeutic efficiency of risperidone compared with other antipsychotic drugs. We conclude that systematic studies of outcome, safety, and cost of new pharmaceuticals in naturalistic settings are needed to provide the data necessary to establish local standards of cost-effective care.

  12. Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates.

    Science.gov (United States)

    Mishra, Akash C; Mohanty, Banalata

    2010-05-25

    Body weight gain, sexual/reproductive dysfunction and hematological abnormalities are serious consequences of atypical antipsychotics treatment. No attempts however have been made preclinically to elucidate the adverse hematological impacts. Presently, effects of lactational exposure of olanzapine (4, 8 and 10 mg/kg) and risperidone (1 and 2 mg/kg) on hematology as well as lymphoid organ histopathology of mice neonates were investigated. Both olanzapine and risperidone transfers through milk and make the neonates susceptible to their adverse side effects. Corticosterone elevation tendency of both the drugs further enhance the susceptibility for immune dysfunction. Analysis of total and differential leukocytes counts revealed neutropenia with all the doses of olanzapine but only with risperidone 2mg/kg. Weight analysis and histopathology of thymus and spleen indicated a state of suppression; less in the risperidone-exposed groups. Significant plasma corticosterone elevation occurred on 4 and 8 mg/kg olanzapine exposures but not with 10 mg/kg as well as with both the risperidone doses. Elevation of plasma prolactin levels occurred dose-dependently for both the drugs. Hematological toxicity (neutropenia) might be the direct toxic effects of the drugs/unstable metabolites on circulating neutrophils and/or on the bone marrow hemopoietic cells. Direct toxicity of the drugs might also have suppressed the lymphoid organs thymus and spleen. Further, it could be associated to hormonal imbalance induced by adverse pharmacological effects of the drugs on the endocrine system. Suppression of lymphoid organs in olanzapine groups might have resulted because of corticosteronemia and hyperprolactinemia, while in risperidone it could be mediated by pronounced hyperprolactinemic effect alone.

  13. Choline acetyltransferase expression in rat prefrontal cortex and hippocampus after acute and chronic exposure to amisulpride, haloperidol, and risperidone.

    Science.gov (United States)

    Huang, Guang-Biao; Zhao, Tong; Li, Chun-Rong; Sui, Zhi-Yan; Kang, Nam-In; Han, Eui-Hyeog; Chung, Young-Chul

    2012-10-24

    Recently, there has been an increasing concern that atypical antipsychotics as well as typical ones may cause detrimental effects on cognitive function. Supporting evidence comes from many preclinical studies demonstrating that long-term administration of haloperidol, risperidone, and ziprasidone reduced choline acetyltransferase (ChAT) expression in rat hippocampus (HIP). However, to the best of our knowledge, no studies have examined the effects of amisulpride on ChAT expression in rats. Therefore, the aim of this study was to investigate the effects of acute and chronic administration of amisulpride, haloperidol, and risperidone on ChAT expression in the rat prefrontal cortex (PFC) and HIP. Animals received daily intraperitoneal (i.p.) injections of amisulpride (5 or 100mg/kg), haloperidol (1 or 2mg/kg), risperidone (1 or 2mg/kg) or vehicle for 7 or 45 days. One day after the last injection, rats were sacrificed. ChAT immunoreactivity was assessed with immunofluorescence staining. Target areas of brain were PFC and HIP (CA1, CA3 and DG). The short-term administration of haloperidol and risperidone produced significant decrease of ChAT immunoreactivity in the PFC and HIP compared to vehicle whereas amisulpride had no effects on ChAT immunoreactivity in the PFC and HIP. In long-term study, haloperidol and risperidone decreased ChAT-positive cells and/or fiber pixel density in the PFC and HIP whereas amisulpride decreased ChAT-positive cells in the PFC and had no effects on fiber pixel density of ChAT in the HIP. The results suggest that both short-term and long-term administration of haloperidol and risperidone, and long-term administration of amisulpride may produce detrimental effects on cognitive function by reducing ChAT expression in the PFC and/or HIP.

  14. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.

    Science.gov (United States)

    Li, Huafang; Yao, Chen; Shi, Jianguo; Yang, Fude; Qi, Shuguang; Wang, Lili; Zhang, Honggeng; Li, Jie; Wang, Chuanyue; Wang, Chuansheng; Liu, Cui; Li, Lehua; Wang, Qiang; Li, Keqing; Luo, Xiaoyan; Gu, Niufan

    2015-10-01

    This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and blonanserin or risperidone using a gradual dose-titration method (blonanserin tablets: 8-24 mg/day; risperidone tablets: 2-6 mg/day), twice daily. Treatment populations consisted of 128 blonanserin-treated patients and 133 risperidone-treated patients. Intention-to-treat analysis was performed using the last observation carried forward method. Reductions of PANSS total scores by blonanserin and risperidone treatment were -30.59 and -33.56, respectively. Risperidone treatment was associated with elevated levels of serum prolactin (67.16% risperidone versus 52.31% blonanserin) and cardiac-related abnormalities (22.39% risperidone versus 12.31% blonanserin), and blonanserin patients were more prone to extrapyramidal side effects (48.46% blonanserin versus 29.10% risperidone). In conclusion, blonanserin was as effective as risperidone for the treatment of Chinese patients with schizophrenia. The overall safety profiles of these drugs are comparable, although blonanserin was associated with a higher incidence of EPS and risperidone was associated with a higher incidence of prolactin elevation and weight gain. Thus, blonanserin is useful for the treatment of Chinese schizophrenia patients. Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

  15. An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

    Directory of Open Access Journals (Sweden)

    Pandina Gahan

    2012-06-01

    Full Text Available Abstract Background Data on the long-term efficacy, safety, and tolerability of risperidone in adolescents with schizophrenia are limited. The objective of this study was to evaluate the efficacy and safety of maintenance risperidone treatment in adolescents with schizophrenia. Methods This open-label study of adolescents aged 13 to 17 years with schizophrenia was a single extension study of two short-term double-blind risperidone studies and also enrolled subjects directly in open-label risperidone treatment. The risperidone dose was flexible and ranged from 2 to 6 mg/day. Most subjects enrolled for 6 months; a subset enrolled for 12 months. Assessment tools included the Positive and Negative Syndrome Scale total and factor scores, Clinical Global Impressions, Children’s Global Assessment Scale, adverse event (AE monitoring, vital signs, laboratory testing, and extrapyramidal symptom rating scales. Results A total of 390 subjects were enrolled; 48 subjects had received placebo in a previous double-blind study; 292 subjects had received risperidone as part of their participation in one of two previous controlled studies; and 50 subjects were enrolled directly for this study. A total of 279 subjects enrolled for 6 months of treatment, and 111 subjects enrolled for 12 months of treatment. Overall, 264 (67.7% subjects completed this study: 209 of the 279 subjects (75% in the 6-month group and 55 of the 111 subjects (50% in the 12-month group. The median mode dose was 3.8 mg/day. At 6 months, all three groups experienced improvement from open-label baseline in symptoms of schizophrenia as well as general assessments of global functioning. Improvements were generally maintained for the duration of treatment. The most common AEs (≥10% of subjects were somnolence, headache, weight increase, hypertonia, insomnia, tremor, and psychosis. Potentially prolactin-related AEs (PPAEs were reported by 36 (9% subjects. The AE profile in this study was

  16. Effect of acute and chronic treatment with risperidone on the serotonin and dopamine receptors in the rat brain

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Yun Young; Moon, Dae Hyuk; Son, Hye Kyung; Kim, Chang Yoon; Lee, Chul; Lee, Hee Kyung [College of Medicine, Ulsan Univ., Seoul (Korea, Republic of)

    1997-03-01

    The therapeutic efficacy of antipsychotic drugs is generally attributed to their ability to block dopamine D{sub 2} receptors. Classical D{sub 2} antagonists are not effective to treat negative symptoms and produce extrapyramidal side effects. On the other hand, atypical antipsychotic agents ameliorate negative symptoms without producing extrapyramidal side effects, and it is reported to be associated with blockade of serotonin 5-HT{sub 2} receptors. The purpose of this study was to evaluate the effect of risperidone on neuroreceptors in the rat brain by quantitative autoradiography method. In acute treatment group, risperidone was injected into peritoneal cavity of male Wistar rats with dose of 0, 0.1, 0.25, 0.5, 1.0 and 2.0mg/kg in each group (5/group), and they were decapitated after 2 hours. In chronic treatment group, risperidone was injected with dose of 0, 0.1, and 1m/kg (I.P.) for 21 ays and decapitated after 24 hours following last treatment. The effect of risperodone on the binding of [{sup 3}H) spiperone to 5-HT{sub 2} and D{sub 2} receptors were analysed in 4 discrete regions of the striatum, nucleus accumbens, and frontal cortex by quantitative autoradiography. Acute treatment with risperidone reduced cortical 5-HT{sub 2} specific [{sup 3}H]spiperone binding to 32% of vehicle-treated control. Subcortical 5-HR{sub 2} specific [{sup 3}H]spiperone binding was not affected at all dose groups whereas a significant reduction (57%) in D{sub 2} specific [{sup 3}H]spiperone binding was observed in risperidone treated group at doses of 1-2mg/kg. Chronic treatment with risperidone produced a decrease in the maximal number of cortical 5-HT{sub 2} receptors to 51% and 46% of control in 0.1mg/kg and 1mg/kg treated group respectively. In conclusion, risperidone is a cortical serotonin receptor antagonist with relatively weak antagonistic action on dopamine receptors. These effects on neuroreceptors may explain the therapeutic effect of risperidone as a atypical

  17. Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study

    Directory of Open Access Journals (Sweden)

    Adel Gabriel

    2010-10-01

    Full Text Available Adel GabrielDepartments of Psychiatry and Community Health Sciences, University of Calgary, Alberta, CanadaBackground: There is a great need in the treatment of schizophrenia for a drug, or drug ­combinations, to improve clinical response with fewer serious side effects. The objective of this study was to explore the therapeutic effects and tolerability of the anticonvulsant gabapentin as an adjunctive in the treatment of patients with partially responsive schizophrenia.Methods: Ten consenting patients with a confirmed Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision diagnosis of schizophrenia were identified. All patients failed at least one 12-week treatment trial with risperidone or olanzapine. Gabapentin was added to ongoing antipsychotic treatment with olanzapine or risperidone for eight weeks. The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS. Other scales included the Calgary Depression Scale (CDSS and the Abnormal Involuntary Movement Scale (AIMS. Repeated-measures multivariate analysis of variance was utilized to examine changes in outcome measures over time with adjunctive treatment with gabapentin.Results: There was a significant drop in the PANSS and CDSS scores at endpoint (week 8. There were no significant differences between the two treatment groups with regard to changes in all outcome measures or in AIMS score. The adjunctive treatments were well tolerated and side effects were transient.Conclusion: Gabapentin could be used successfully as an adjunct to novel antipsychotics in partially responsive schizophrenia. However, large controlled studies are needed to examine the effectiveness of gabapentin in psychotic disorders.Keywords: schizophrenia, refractory, adjunctive treatment, gabapentin, risperidone, olanzapine

  18. Report of a Rare Case of Olanzapine and Risperidone Induced Hypomania

    Directory of Open Access Journals (Sweden)

    AR Zahiroddin

    2006-07-01

    Full Text Available Introduction & Objective: Hypomania is a mood disorder with symptoms of constantly high expansive or irritable mood. After a 4-day period, the patient feels to be in need of less sleep, being talkative, or feeling pressure if not treated kindly, having flight of ideas, distractibility, and increase in goal oriented activities (including social, occupational, educational or sexual activities and being extravagant. Hypomania could be a mood episode of bipolar I and II mood disorder or cyclothymia and could be resulted from consumption of drugs, materials, Electro Convulsive Therapy (ECT or photo therapy. Case: The present report is the case of a 57-year old married woman, who has had a record of bipolar I mood disorder since 30 years ago. The patient was hospitalized once in psychiatry hospital and referred to psychiatry office 2 years ago. She has been under medication therapy by lithium 600 mg, nortriptyline 75 mg, and colonazpam 1 mg. She has taken risperidone 2 mg, the symptoms of hypomania have revealed. After stopping the consumption of risperidone, the treatment continued by lithium tablet 900 mg, eskazina tablet 4 mg, nortriptyline 75 mg for one day. She was under care for 15 months and then due to muscle complications of lithium, pessimism, auditory and visual hallucination, she was recommended to take olanzapine tablet 5 mg once every night. Two days after taking olanzapine the symptoms of hypomania revealed. Consumption of olanzapine was then stopped and the symptoms disappeared and she was brought under control after taking sodiumvalproate tablet. Conclusion: Rarely could Hypomania be a mood episode induced by consuming atypical antipsychotics such as risperidone and olanzapine.

  19. Evaluation of teratogenic effects of risperidone following simultaneous administration with antihypertensive and antiemetic drugs.

    Science.gov (United States)

    Tauqeer, Shaista; Khan, Rafeeq Alam; Siddiqui, Afaq Ahmed

    2012-01-01

    Multiple drug administration is an important aspect of clinical practice particularly in specific physiological situation such as in neonates, elderly or pregnancy, since in all such situations, possibility of unwanted effects increases due to altered body physiology. In present study, the teratogenic effects of multiple drug administration risperidone, meclizine/pyridoxine and hydralazine have been compared with the teratogenic effects of individual drugs in pregnant mice. Moreover the role of folic acid and α-tocopherol if any had also been investigated in reducing the teratogenic effects of these drugs in combinations.

  20. Efficacy of ziprasidone and risperidone in treatment of vagrants with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    Zhan-Hua Li; Zhi-Xiang Li

    2016-01-01

    Objective:To explore the clinical efficacy of ziprasidone and risperidone in the treatment of vagrants with schizophrenia.Methods:A total of 70 vagrants with schizophrenia who were admitted in our hospital from December, 2014 to December, 2015 were included in the study and divided into the observation group (ziprasidone) and the control group (risperidone) according to different treatment protocols. In the observation group, the initial dosage of ziprasidone was 20 mg/d, and was gradually increased to 80-160 mg/d within 10 d, with an average dosage of (105.6±38.7) mg/d. In the control group, the initial dosage of risperidone was 1 mg/d, and was gradually increased to 3-5 mg/d within 10 d, with an average dosage of (3.6±0.9) mg/d. Eight-week treatment was regarded as one course. PANSS was used for grading before and after treatment. The levels of FBG, TG, TC, and HDL-C before and after treatment were detected. The adverse reactions after treatment were observed.Results:With the extending of treatment time, PANSS positive symptoms, negative symptoms, psychosis symptoms, and total scores in the two groups were significantly reduced when compared with before treatment (P0.05). After treatment, the levels of FBG, TG, TC, and HDL-C in the observation group were not significantly different from those before treatment (P>0.05), while those levels in the control group were significantly elevated when compared with before treatment (P<0.05), and those in the observation group were significantly superior to those in the control group (P<0.05). After treatment, the occurrence rate of adverse reactions in the observation was significantly lower than that in the control group (P<0.05).Conclusions: The clinical efficacy of ziprasidone and risperidone in the treatment of vagrants with schizophrenia is equal, but ziprasidone has a small effect on the blood sugar and lipid, with less adverse reactions and preferable compliance; therefore, it deserves to be widely recommended in

  1. Deep vein thrombosis associated with long-term use of risperidone

    Directory of Open Access Journals (Sweden)

    Kuldeep Singh Yadav

    2016-01-01

    Full Text Available There are increasing number of deep vein thrombosis (DVT cases that are associated with the use of atypical antipsychotics. We are presenting a case report of a female patient who suffered from DVT. She was a known case of schizophrenia and was on risperidone 4 mg for the last 5 years. She had good physical health before that and there were no known risk factors for DVT. The family history of DVT was also found to be negative. She was managed by intravenous heparin followed by oral warfarin and amisulpride 100 mg/day. Atypical antipsychotics can induce DVT, and psychiatrist should be careful about it.

  2. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.

    Science.gov (United States)

    Haas, Magali; Delbello, Melissa P; Pandina, Gahan; Kushner, Stuart; Van Hove, Ilse; Augustyns, Ilse; Quiroz, Jorge; Kusumakar, Vivek

    2009-11-01

    To evaluate the efficacy, safety, and tolerability of risperidone monotherapy for the treatment of an acute mixed or manic episode in children and adolescents with bipolar I disorder. This randomized, placebo-controlled, double-blind, 3-arm study (N = 169) included children and adolescents (ages 10-17 years) with a DSM-IV diagnosis of bipolar I disorder, experiencing a manic or mixed episode. Study participants were randomized to placebo (n = 58), risperidone 0.5-2.5 mg/day (n = 50), or risperidone 3-6 mg/day (n = 61) for 3 weeks. The primary efficacy measure was change in Young Mania Rating Scale (YMRS) total score from baseline to end point. Safety assessments included adverse event (AE) monitoring and scores on extrapyramidal symptom rating scales. Improvement in mean YMRS total score was significantly greater in risperidone-treated subjects than in placebo-treated subjects [mean change (SD) -9.1 (11.0) for placebo; -18.5 (9.7) for risperidone 0.5-2.5 mg (p children and adolescents experiencing acute manic or mixed episodes of bipolar I disorder. Results indicate that risperidone 0.5-2.5 mg has a better benefit-risk profile than risperidone 3-6 mg.

  3. A retrospective study of risperidone oral solution versus risperidone tablets in treating schizophrenia%利培酮口服液与片剂治疗精神分裂症的回顾性分析

    Institute of Scientific and Technical Information of China (English)

    钟智勇; 吴小立; 韩自力; 张晋碚

    2011-01-01

    AIM To retrospectively evaluate the efficacy and safety of risperidone oral solution and risperidone tablets in treating schizophrenia. METHODS A total of 204 patients, who met diagnostic criteria of CCMD-3 for schizophrenia and were hospitalized in our department of psychiatry from May 2007 to May 2011, included 85 patients in risperidone oral solution group and 119 patients in risperidone tablets group. Before the treatment and at the end of the 4 th week of the treatment, all patients were assessed by Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS), Treatment Emergent Symptom Scale (TESS) and laboratory tests. RESULTS There were significant differences in total scales of TESS and the rates of ECG abnormalities and extrapyramidal side effects between the risperidone oral solution group and risperidone tablets group (6.62 ± 3.65 vs. 7.97 ± 4.93, 16.5%vs. 28.6%, 23.5% vs. 40.3%, P0.05) in the total scales of BPRS, SANS, SAPS and other index of safety. CONCLUSION The efficacy of risperidone oral solution and risperidone tablets in treating schizophrenia was equal, but risperidone oral solution is superior to risperidone tablets on the safety.%目的 比较利培酮口服液与利培酮片剂治疗精神分裂症的疗效与安全性.方法 回顾性分析2007年5月至201 1年5月在本科室住院4 wk以上,符合CCMD-3精神分裂症诊断标准的患者共204例,其中利培酮口服液组85例,利培酮片剂组119例.比较2组患者治疗前与治疗4 wk末简明精神病评定量表、阳性症状量表、阴性症状量表、副反应量表总分以及实验室检查的差异.结果 2组治疗4 wk末简明精神病评定量表、阳性症状量表、阴性症状量表分值无显著差异(P>0.05).利培酮口服液组副反应量表总分、心电图异常发生率以及锥体外系反应发生率明显低于利培酮片剂组(6.62±3.65 vs.7.97±4.93,16.5

  4. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.

    Science.gov (United States)

    Aman, Michael; Rettiganti, Mallikarjuna; Nagaraja, Haikady N; Hollway, Jill A; McCracken, James; McDougle, Christopher J; Tierney, Elaine; Scahill, Lawrence; Arnold, L Eugene; Hellings, Jessica; Posey, David J; Swiezy, Naomi B; Ghuman, Jaswinder; Grados, Marco; Shah, Bhavik; Vitiello, Benedetto

    2015-08-01

    Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolerability, safety, and therapeutic benefit of risperidone exposure over a 1-2 year follow-up period. In a naturalistic study, 84 children and adolescents 5-17 years of age (from an original sample of 101) were assessed an average of 21.4 months after initial entry into a placebo-controlled 8 week trial of risperidone for children and adolescents with autism and severe irritability. They were assessed at baseline and at follow-up on safety and tolerability measures (blood, urinalysis, electrocardiogram [ECG], medical history, vital signs, neurological symptoms, other adverse events), developmental measures (adaptive behavior, intelligence quotient [IQ]), and standardized rating instruments. Treatment over the follow-up period, after completion of protocol participation, was uncontrolled. Statistical analyses assessed outcome over time with or without prolonged risperidone therapy. Two-thirds of the 84 subjects continued to receive risperidone (mean 2.47 mg/day, S.D. 1.29 mg). At follow-up, risperidone was associated with more enuresis, more excessive appetite, and more weight gain, but not more adverse neurological effects. No clinically significant events were noted on blood counts, chemistries, urinalysis, ECG, or interim medical history. Regardless of drug condition at follow-up, there was considerable improvement in maladaptive behavior compared with baseline, including core symptoms associated with autism. Height and weight gains were elevated with risperidone. Social skills on Vineland Adaptive Behavior Scale (VABS) improved with risperidone. Parent-rated Aberrant Behavior Checklist (ABC) Irritability subscale scores were reduced in those taking risperidone at follow

  5. An open-label trial of risperidone and fluoxetine in children with autistic disorder

    Directory of Open Access Journals (Sweden)

    Desousa Avinash

    2010-01-01

    Full Text Available Objective: Various studies have shown the effectiveness of risperidone and fluoxetine in the management of behavioral problems in autism. Aim: The purpose of this study was to compare these two drugs in the management of behavioral problems in autism. Materials and Methods: Forty children with autism were divided into 2 groups in a 16-week open trial that compared these two drugs. Parents rated the children using the Aberrant Behavior Checklist (ABC and the Conners′ Parent Rating Scale - Revised (CPRS-R. The author rated the children using the Children′s Psychiatric Rating Scale and Clinical Global Impression (CGI Scale. Results: The risperidone group showed significant improvement in areas like irritability and hyperactivity, while the fluoxetine group showed significant improvement in speech deviance, social withdrawal and stereotypy. When the two drugs were compared, fluoxetine showed greater improvement in stereotypy, while both drugs showed improvement on the general autism scale; and on anger, hyperactivity and irritability scales. Conclusions : In this open trial, both drugs were well tolerated and appeared to be beneficial in the treatment of common behavioral problems in children with autism. Further controlled and double-blind studies in larger samples are warranted.

  6. Delayed drug interactions in psychiatry: armodafinil and risperidone as a potential case in point.

    Science.gov (United States)

    Andrade, Chittaranjan

    2015-12-01

    Modafinil or armodafinil (ar/mod) augmentation of antipsychotic medication in schizophrenia patients may be considered with a view to reduce negative symptoms associated with the illness or excessive daytime drowsiness due to any cause. The available data suggest that there is no role for ar/mod in reducing negative symptom burden. A recent pharmacokinetic (PK) study suggested that armodafinil (250 mg/d) reduces key PK parameters of risperidone by about 50%, and key PK parameters of 9-hydroxyrisperidone (paliperidone) by about 20%-30%, probably through induction of CYP3A4. Ar/mod augmentation is therefore best avoided in patients receiving risperidone or paliperidone (and most other atypical antipsychotic drugs, as well, because most atypical antipsychotics are metabolized by enzymes that ar/mod induce). If the ar/mod-antipsychotic drug combination is necessary, for whatever reason, then the dose of the atypical antipsychotic drug may need to be appropriately raised. If this is not done, relapse may occur; because the relapse may postdate the introduction of ar/mod by many months, the causal role of a metabolic drug interaction may not be suspected, and physicians may attribute the relapse to the natural course of the illness. Physicians need to be aware that any agent that induces the metabolism of psychotropic drugs that are used in maintenance therapy may, through lowered psychotropic drug levels, result in a delayed drug interaction that is characterized by illness relapse.

  7. Risperidone long-acting injection: a review of its long term safety and efficacy

    Directory of Open Access Journals (Sweden)

    Michael K Rainer

    2008-08-01

    Full Text Available Michael K RainerMemory-Clinic and Psychiatric Department, Donauspital, Vienna, AustriaAbstract: A long-acting form of the second-generation antipsychotic drug risperidone is now broadly available for the treatment of schizophrenia and closely related psychiatric conditions. It combines the advantage of previously available depot formulations for first-generation drugs with the favorable characteristics of the modern “atypical” antipsychotics, namely higher efficacy in the treatment of the negative symptoms of schizophrenia and reduced motor disturbances. Published clinical studies show an objective clinical efficacy (as per psychiatric symptom scores and relapse data that exceeds that of oral atypical antipsychotics when patients are switched to the long-acting injectable form, a low incidence of treatment-emergent extrapyramidal side effects, and very good acceptance by patients. Available data for maintenance treatment of bipolar disorder show equivalence with the oral form instead of superiority, but are still limited. As it seems likely that efficacy benefits are mostly due to the fact that the injectable form reduces the demand for patient compliance to one physician visit every 2 weeks instead of self-administration on a daily or twice-daily basis, additional potential could exist in other psychiatric disorders where atypical antipsychotic drugs are of benefit but where patient adherence to treatment schedules is typically low.Keywords: risperidone, schizophrenia, psychotic disorders, patient compliance; delayed-action preparations, injections, intramuscular

  8. Selective acquired long QT syndrome (saLQTS upon risperidone treatment

    Directory of Open Access Journals (Sweden)

    Lazarczyk Maciej

    2012-12-01

    Full Text Available Abstract Background Numerous structurally unrelated drugs, including antipsychotics, can prolong QT interval and trigger the acquired long QT syndrome (aLQTS. All of them are thought to act at the level of KCNH2, a subunit of the potassium channel. Although the QT-prolonging drugs are proscribed in the subjects with aLQTS, the individual response to diverse QT-prolonging drugs may vary substantially. Case presentation We report here a case of aLQTS in response to small doses of risperidone that was confirmed at three independent drug challenges in the absence of other QT-prolonging drugs. On the other hand, the patient did not respond with QT prolongation to some other antipsychotics. In particular, the administration of clozapine, known to be associated with higher QT-prolongation risk than risperidone, had no effect on QT-length. A detailed genetic analysis revealed no mutations or polymorphisms in KCNH2, KCNE1, KCNE2, SCN5A and KCNQ1 genes. Conclusions Our observation suggests that some patients may display a selective aLQTS to a single antipsychotic, without a potassium channel-related genetic substrate. Contrasting with the idea of a common target of the aLQTS-triggerring drugs, our data suggests existence of an alternative target protein, which unlike the KCNH2 would be drug-selective.

  9. Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study

    Directory of Open Access Journals (Sweden)

    Sukhtej Sahni

    2016-01-01

    Interpretation & conclusions: The findings of this preliminary study showed clozapine as a better choice than risperidone in terms of efficacy, tolerability and better quality of life in treatment-naive, first-episode schizophrenia. However, further studies need to be done on a larger group of patients to confirm the findings.

  10. A Double-Blind Placebo Controlled Trial of "Ginkgo Biloba" Added to Risperidone in Patients with Autistic Disorders

    Science.gov (United States)

    Hasanzadeh, Elmira; Mohammadi, Mohammad-Reza; Ghanizadeh, Ahmad; Rezazadeh, Shams-Ali; Tabrizi, Mina; Rezaei, Farzin; Akhondzadeh, Shahin

    2012-01-01

    "Ginkgo biloba" has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of "Ginkgo biloba" extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of…

  11. Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: An open label study

    Directory of Open Access Journals (Sweden)

    Padideh Ghaeli

    2014-01-01

    Full Text Available Background: The aim of the present study was to evaluate the effect of risperidone in patients afflicted by autistic disorder especially with regards to its three core symptoms, including "relating to others", "communication skills", and "stereotyped behaviors" based on Childhood Autism Rating Scale (CARS. Materials and Methods: An 8-week open-label study of risperidone for treatment of autistic disorder in children 4-17 years old was designed. Risperidone dose titration was as follow: 0.02 mg/kg/day at the first week, 0.04 mg/kg/day at the second week, and 0.06 mg/kg/day at the third week and thereafter. The outcome measures were scores obtained by CARS, Aberrant Behavior Checklist (ABC, and Clinical Global Impression-Improvement (CGI-I scale. Results: Fifteen patients completed this study. After 8 weeks, CARS total score decreased significantly, (P=0.001. At the end of the study, social interactions and verbal communication skills of the patients were significantly improved (P<0.001, P=0.03, respectively. However, stereotypic behaviors did not show any significant change in this study. Increase in appetite and somnolence were the most reported side effects. Conclusion: This study suggests that risperidone may be an effective treatment for the management of core symptoms of autistic disorder.

  12. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.

    Science.gov (United States)

    Qiao, Ying; Yang, Fuzhong; Li, Chunbo; Guo, Qian; Wen, Hui; Zhu, Suoyu; Ouyang, Qiong; Shen, Weidi; Sheng, Jianhua

    2016-03-30

    This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period. The prolactin levels at the end of the 8th week were significantly lower in the treatment group than in the control group. The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. The Positive and Negative Syndrome Scale score improved significantly during the 8-week study period in both groups. The incidence of treatment-emergent adverse event was similar in two groups. Low-dose aripiprazole adjunctive treatment is effective in relieving risperidone- and paliperidone-induced hyperprolactinemia in female schizophrenic patients without increasing adverse event.

  13. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients.

    Science.gov (United States)

    Wei, Zhiyun; Wang, Lei; Zhang, Mengmeng; Xuan, Jiekun; Wang, Yang; Liu, Baocheng; Shao, Liyan; Li, Jun; Zeng, Zhen; Li, Tao; Liu, Jie; Wang, Ti; Zhang, Ming; Qin, Shengying; Xu, Yifeng; Feng, Guoyin; He, Lin; Xing, Qinghe

    2012-06-01

    Evidence suggests that the human histamine H3 receptor (HRH3) may be involved in the pharmacodynamics of risperidone and influence clinical efficacy. More information on the pharmacogenetics of this receptor may therefore be useful in developing individualized therapy. However, to our knowledge, no study has been reported in this area. The aim of this investigation was to clarify whether H3 receptor polymorphism could affect risperidone efficacy. We genotyped tag single nucleotide polymorphisms (SNPs) of the HRH3 gene (rs3787429 and rs3787430) and analyzed their association with the reduction of Brief Psychiatric Rating Scale (BPRS) score in Chinese Han schizophrenia patients (N = 129), following an eight-week period of risperidone monotherapy. The confounding effects of non-genetic factors were estimated, and then the significant one was included as the covariate for adjustment in statistical analysis. Baseline symptom score was the only significant confounding effect and thus the covariate. After adjustment, significant association of HRH3 with antipsychotic efficacy was detected (for rs3787429, p = 0.013, 0.087 after 4 weeks and 8 weeks of treatment, respectively; for rs3787430, p = 0.024, 0.010 after 4 weeks and 8 weeks of treatment, respectively) and stood up to conservative Bonferroni correction. Our results demonstrate that polymorphism of the HRH3 gene may be a potential genetic marker for predicting the therapeutic effect of risperidone, and suggest novel pharmacological links between HRH3 and risperidone. Further studies with larger samples and different ethnic populations are warranted to confirm our results.

  14. Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.

    Directory of Open Access Journals (Sweden)

    Irina Vasilyeva

    Full Text Available BACKGROUND: Despite concerns over the potential for severe adverse events, antipsychotic medications remain the mainstay of treatment of behaviour disorders and psychosis in elderly patients. Second-generation antipsychotic agents (SGAs; e.g., risperidone, olanzapine, quetiapine have generally shown a better safety profile compared to the first-generation agents (FGAs; e.g., haloperidol and phenothiazines, particularly in terms of a lower potential for involuntary movement disorders. Risperidone, the only SGA with an official indication for the management of inappropriate behaviour in dementia, has emerged as the antipsychotic most commonly prescribed to older patients. Most clinical trials evaluating the risk of movement disorders in elderly patients receiving antipsychotic therapy have been of limited sample size and/or of relatively short duration. A few observational studies have produced inconsistent results. METHODS: A population-based retrospective cohort study of all residents of the Canadian province of Manitoba aged 65 and over, who were dispensed antipsychotic medications for the first time during the time period from April 1, 2000 to March 31, 2007, was conducted using Manitoba's Department of Health's administrative databases. Cox proportional hazards models were used to determine the risk of extrapyramidal symptoms (EPS in new users of risperidone compared to new users of FGAs. RESULTS: After controlling for potential confounders (demographics, comorbidity and medication use, risperidone use was associated with a lower risk of EPS compared to FGAs at 30, 60, 90 and 180 days (adjusted hazard ratios [HR] 0.38, 95% CI: 0.22-0.67; 0.45, 95% CI: 0.28-0.73; 0.50, 95% CI: 0.33-0.77; 0.65, 95% CI: 0.45-0.94, respectively. At 360 days, the strength of the association weakened with an adjusted HR of 0.75, 95% CI: 0.54-1.05. CONCLUSIONS: In a large population of elderly patients the use of risperidone was associated with a lower risk of EPS

  15. Comparison Of Effect Of Addition Of Fluvoxamine Or Risperidone To Clozapine In Chronic Partially Responsive Schizophrenic Patients On Clinical Response, QTc interval And Lipid profile

    Directory of Open Access Journals (Sweden)

    Sunil Mahakalkar

    2016-07-01

    Full Text Available Objective – To study & compare the augmentation effect of addition of fluvoxamine or risperidone in chronic partially responsive schizophrenic patients receiving clozapine on clinical and laboratory parameters.Methods - A prospective, randomized, parallel, open label 12 weeks study. The schizophrenic patients, aged 20-60 years, who followed the DSM-IV diagnostic criteria and receiving clozapine therapy, showing partial response to the treatment were recruited and the study was carried out from January 2007 to June 2008. Subjects were randomized into two groups: Group A (n=28: fluvoxamine (25-50mg/day was added to clozapine (25-200mg/day & Group B (n=27: risperidone (1-5mg/day was added to clozapine therapy. The effect of drugs was assessed by PANSS, BPRS scale and ECG and lipid profile were done at 6 and 12 weeks.Result - There was significant decrease in PANSS and BPRS score in both groups.Fluvoxamine + clozapine significantly reduced PANSS score as compared to risperidone + clozapine compared to baseline and between 6 and 12 weeks. Risperidone +clozapine prolonged QTc interval (at 12 weeks and elevated serum TG, VLDL, HDL significantly at 6 and 12 weeks.Conclusion – Although addition of fluvoxamine and risperidone to clozapine are effective in management of chronic partially responsive schizophrenia on clozapine, fluvoxamine is more effective as well as safer compared to Risperidone when compared for 6 and 12 weeks in these patients.

  16. Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice.

    Science.gov (United States)

    Rogóż, Zofia

    2010-01-01

    The aim of the present study was to examine the effect of mirtazapine (MIR) and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J mice. Fluoxetine (FLU) was used as a reference drug. MIR (2.5, 5 and 10 mg/kg) and FLU (5 and 10 mg/kg), or risperidone in low doses (0.05 and 0.1 mg/kg) given alone did not change the immobility time of mice in the forced swimming test. Joint administration of MIR (5 and 10 mg/kg) or FLU (10 mg/kg) and risperidone (0.1 mg/kg) produced antidepressant-like activity in the forced swimming test. WAY100636 (a 5-HT(1A) receptor antagonist) inhibited, while yohimbine (an α(2)-adrenergic receptor antagonist) potentiated the antidepressant-like effect induced by co-administration of MIR and risperidone. Active behavior in that test did not reflect an increase in general activity, since combined administration of antidepressants and risperidone failed to enhance the locomotor activity of mice. The obtained results indicate that risperidone applied in a low dose enhances the antidepressant-like activity of MIR and that, among other mechanisms, 5-HT(1A)-, and α(2)-adrenergic receptors may play a role in this effect.

  17. Risperidone and lorazepam concomitant use in clonazepam refractory catatonia: a case report.

    Science.gov (United States)

    Grenier, Ernesto; Ryan, Molly; Ko, Elizabeth; Fajardo, Karina; John, Vineeth

    2011-12-01

    The DSM-IV recognizes catatonia as a subtype of schizophrenia characterized by at least two of the following: motor immobility, excessive motor activity not influenced by external stimuli, and peculiarities of voluntary movement. Catatonia may also occur secondary to mania, depression, or a general medical condition including encephalitis, focal neurological lesions, metabolic disturbances, and drug intoxications and withdrawals. Benzodiazepines remain the first line of treatment; up to 80% of patients respond promptly to Lorazepam challenge; failure to respond to lorazepam may be followed by electroconvulsive therapy. Atypical antipsychotics may be a new alternative in the treatment of catatonia. Successful reduction of the catatonic symptoms has been demonstrated with atypical antipsychotics. A possible mechanism of action for the efficacy of this class of drugs involves the antagonism of the 5-HT2A receptor. We are now reporting a case of treatment response to risperidone in a patient with chronic catatonia resistant to benzodiazepines.

  18. Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent.

    Science.gov (United States)

    Baytunca, Muharrem Burak; Kose, Sezen; Ozbaran, Burcu; Erermis, Serpil

    2016-01-01

    Priapism is the prolonged, painful erection of penile tissue not accompanied by sexual arousal. Priapism has been established as a rare adverse drug reaction to drugs such as antipsychotics, psychostimulants, antidepressants, and mood stabilizers. Immediate intervention is needed to prevent destructive and irreversible complications, such as erectile dysfunction, disfigurement, inability of the penis to stay erect, and related social/emotional problems. Antipsychotic-induced priapism may result from the alpha receptor occupancy property of those drugs. We report the case of a 13-year-old suffering from attention deficit-hyperactivity disorder plus conduct disorder with priapism related to antipsychotics. Episodes occurred with risperidone plus methylphenidate, quetiapine plus methylphenidate, and chlorpromazine alone. © 2015 Japan Pediatric Society.

  19. Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents.

    Science.gov (United States)

    Ceylan, Mehmet Fatih; Erdogan, Betül; Tural Hesapcioglu, Selma; Cop, Esra

    2017-07-19

    Although the use of oral risperidone in children and adolescents has been well studied, there is little information on the intramuscular use of long-acting injectable risperidone (LAIR). The aims of this study were to investigate the effectiveness and adverse effects of LAIR in children and adolescents with conduct disorder, bipolar disorder, and schizophrenia. In total, 42 patients (age range 12-17 years) who were non-adherent to oral antipsychotic drugs, received 25 mg/day of LAIR intramuscularly every 2 weeks. The drug was administered at least four times and up to 66 times (median drug use: 9.50 times). The effectiveness and adverse effects of the treatment were examined. There was an improvement in 13 (92.8%) of the 14 patients diagnosed with bipolar disorder, in 25 (78.1%) of 32 patients diagnosed with conduct disorder and in one (50%) of two patients diagnosed with schizophrenia. Six patients had comorbid conduct disorder and bipolar disorder. Totally, 81% of the patients improved with LAIR. Weight-gain, daytime somnolence, muscle stiffness and spasms, impaired concentration, and fatigue were the most common side effects through the whole sample. Menstrual problems were common in girls. In the study, 57.1% of the patients continued to receive their injections regularly until the end of the treatment, under physician control. A total of 16.7% discontinued the treatment due to non-adherence. The LAIR treatment was terminated in 26.2% of the patients, due to weight-gain, dystonia, and galactorrhea. In children and adolescents with conduct disorder, bipolar disorder and schizophrenia who show noncompliance with oral drugs, LAIR may improve treatment compliance. LAIR is a reliable treatment in terms of its effectiveness. Weight-gain, dystonia, and galactorrhea were the adverse effects that were responsible for LAIR treatment cessation.

  20. Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone

    Directory of Open Access Journals (Sweden)

    Hori H

    2014-03-01

    Full Text Available Hikaru Hori, Kenji Yamada, Dan Kamada, Yuka Shibata, Asuka Katsuki, Reiji Yoshimura, Jun NakamuraDepartment of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, JapanBackground: This study aims to determine the effectiveness of blonanserin (BNS on the cognitive and social functions of patients with schizophrenia compared with risperidone (RIS during acute-phase (8-week treatment.Methods: A total of 39 schizophrenia inpatients were included in this study. The subjects received either BNS (N=20 or RIS (N=19, and the clinical responses were evaluated periodically. The concomitant use of mood stabilizers was not allowed. Efficacy was assessed with the Positive and Negative Syndrome Scale for schizophrenia. Cognition was assessed using the Brief Assessment of Cognition in Schizophrenia, Japanese-language version. Social function was assessed using the Life Assessment Scale for the Mentally Ill.Results: For both groups, each assessment exhibited a decrease in the mean change from baseline on the Positive and Negative Syndrome Scale. The depression subscale was significantly improved in the BNS group compared with the RIS group at 8 weeks after administration. BNS improved verbal fluency and executive function (cognitive function and daily living and work skills (social function. Compared with the RIS group, BNS was observed to improve daily living.Conclusion: BNS may improve psychotic symptoms, cognitive function, and daily living in patients with acute-phase schizophrenia. BNS may be superior to RIS in the improvement of daily living.Keywords: risperidone, blonanserin, schizophrenia, cognitive function, social function, acute-phase

  1. Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female.

    Science.gov (United States)

    Afzal, Khalid I; Briones, David F; DeVargas, Cecilia

    2007-11-01

    A 15-year-old Hispanic female was started on risperidone for new-onset psychosis. The patient responded well to the gradual dose increase but developed rapid weight gain secondary to polydipsia and polyphagia. She also began complaining of nipple discharge and griping abdominal pain on the left lower quadrant by the third week of treatment. Her prolactin level escalated to three times normal with a weight gain of 12 pounds in 16 days. Risperidone was switched to another antipsychotic. Her prolactin level then dropped to a normal level within 7 days and she lost 7 pounds in the next 2 weeks. Her abdominal pain, galactorrhea, polydipsia, and polyphagia subsided within the first few days of the cessation of risperdione.

  2. Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys.

    Science.gov (United States)

    Banks, Matthew L; Blough, Bruce E

    2015-08-01

    Preclinical and human laboratory choice procedures have been invaluable in improving our knowledge of the neurobiological mechanisms of drug reinforcement and in the drug development process for candidate medications to treat drug addiction. However, little is known about the neuropharmacological mechanisms of methamphetamine vs food choice. The aims of this study were to develop a methamphetamine vs food choice procedure and determine treatment effects with two clinically relevant compounds: the monoamine uptake inhibitor bupropion and the dopamine antagonist risperidone. Rhesus monkeys (n=6) responded under a concurrent schedule of food delivery (1-g pellets, fixed-ratio (FR) 100 schedule) and intravenous methamphetamine injections (0-0.32 mg/kg/injection, FR10 schedule) during 7-day bupropion (0.32-1.8 mg/kg/h) and risperidone (0.001-0.0056 mg/kg/h) treatment periods. For comparison, effects of removing food pellets or methamphetamine injections and FR response requirement manipulations were also examined. Under saline treatment conditions, food was preferred over no methamphetamine or small unit methamphetamine doses (0.01-0.032 mg/kg/injection). Larger methamphetamine doses resulted in greater methamphetamine preference and 0.32 mg/kg/injection methamphetamine maintained near exclusive preference. Removing food availability increased methamphetamine choice, whereas removing methamphetamine availability decreased methamphetamine choice. Methamphetamine choice was not significantly altered when the FR response requirements for food and drug were the same (FR100:FR100 or FR10:FR10). Risperidone treatment increased methamphetamine choice, whereas bupropion treatment did not alter methamphetamine choice up to doses that decreased rates of operant behavior. Overall, these negative results with bupropion and risperidone are concordant with previous human laboratory and clinical trials and support the potential validity of this preclinical methamphetamine vs food

  3. Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

    Directory of Open Access Journals (Sweden)

    Roya Samadi

    2017-01-01

    Full Text Available Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7, in 2012–2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4–8 mg/d of ondansetron (n=18 or with a placebo (n=20 for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS, Wechsler’s Adult Intelligence Scale-Revised (WAIS-R, and Hamilton’s Rating Scale for Depression (HRSD at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16 were used to analyze the data. The statistical significance was set at P<0.05. Results: Ondansetron plus risperidone was associated with a significantly larger improvement in the PANSS overall scale and subscales for negative symptoms and cognition than was risperidone plus placebo (P<0.001. The WAIS-R scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. The administration of ondansetron significantly improved visual memory based on the subtests of the WAIS (P<0.05. Ondansetron had no positive effects on depressive symptoms (effect size=0.13. Conclusion: This study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. Trial Registration Number: IRCT201112125280N7

  4. Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders

    Science.gov (United States)

    Johnson, Cynthia R.; Butter, Eric M.; Lecavalier, Luc; Scahill, Lawrence; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; Swiezy, Naomi B.; Sukhodolsky, Denis G.; Mulick, James A.; White, Susan W.; Bearss, Karen; Hollway, Jill A.; Stigler, Kimberly A.; Dziura, James; Yu, Sunkyung; Sacco, Kelley; Vitiello, Benedetto

    2013-01-01

    A Structured Observational Analog Procedure (SOAP), an analogue measure of parent-child interactions, was used to assess treatment outcome in children with Autism Spectrum Disorder and serious behavior problems. It served as a secondary outcome measure in a 24-week, randomized trial of risperidone (MED; N=49) versus risperidone plus parent training (COMB; n=75) (ages 4–13 years). At 24-weeks, there was 28 % reduction in child inappropriate behavior during a Demand Condition (p=.0002) and 12 % increase in compliance to parental requests (p=.004) for the two treatment conditions combined. Parents displayed 64 % greater use of positive reinforcement (p=.001) and fewer repeated requests for compliance (p<.0001). In the analysis of covariance (ANCOVA), COMB parents used significantly more positive reinforcement (p=.01) and fewer restrictive statements (p<.05) than MED parents. The SOAP is sensitive to change in child and parent behavior as a function of risperidone alone and in combination with PMT and can serve as a valuable complement to parent and clinician-based measures. PMID:23730123

  5. Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome?

    Science.gov (United States)

    Nikolaou, Kalliopi N; Gournellis, Rossetos; Michopoulos, Ioannis; Dervenoulas, Georgios; Christodoulou, Christos; Douzenis, Athanasios

    2015-01-01

    To the best of our knowledge, there are no case studies of serotonin syndrome (SS) in patients with autism spectrum disorder. We report the case of a 33-year-old male who presented SS under the combined use of clomipramine and risperidone. More specifically, within 2 days after clomipramine (10 mg/BID-two times a day) was added to risperidone (4 mg/OD-once a day), mirtazapine 45 mg/OD and alprazolam (0,5 mg/TID-three times a day) he began to present mental, neurological and autonomic symptoms. All his psychopathological manifestations and laboratory findings normalized after the above-mentioned drugs' discontinuation, and the administration of supportive medical care and lorazepam 2,5 mg/TID. The diagnosis of serotonin syndrome was challenging due to the relatively low dose of clomipramine, an increase of risperidone which had taken place before clomipramine administration and clinical symptoms which could be attributed to both serotonin and neuroleptic malignant syndrome.

  6. Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances.

    Science.gov (United States)

    Yin, You; Liu, Yan; Zhuang, Jianhua; Pan, Xiao; Li, Peng; Yang, Yuechang; Li, Yan-Peng; Zhao, Zheng-Qing; Huang, Liu-Qing; Zhao, Zhong-Xin

    2015-01-01

    Sleep disturbances (SD) accelerate the progression of Alzheimer's disease (AD) and increase the stress of caregivers. However, the long-term outcome of disturbed nocturnal sleep/wake patterns in AD and on increased stress of spousal caregivers is unclear. This study assessed the 5-year effect of nocturnal SD on the long-term outcome in AD patients. A total of 156 donepezil-treated mild-moderate AD patients (93 AD + SD and 63 AD - SD as a control group) were recruited. The AD + SD patients were formed into 4 subgroups according to the preferences of spousal caregivers for treatment with atypical antipsychotics (0.5-1 mg risperidone, n = 22), non-benzodiazepine hypnotic (5-10 mg zolpidem tartrate, n = 33), melatonin (2.55 mg, n = 9), or no-drug treatment (n = 29). SD were evaluated by polysomnography, sleep scale, and cognitive scale examinations. Moreover, all spousal caregivers of AD patients were assessed using a series of scales, including sleep, anxiety, mood, and treatment attitude scales. Our data showed that nocturnal sleep/wake disturbances were significantly associated with lower 5-year outcomes for AD patients, earlier nursing home placement, and more negative emotions of spousal caregivers. Treatment with low-dose atypical antipsychotic risperidone improved the 5-year outcome in AD + SD patients. In conclusion, low-dose atypical antipsychotic risperidone improves the 5-year outcome in AD patients with SD. Moreover, improvement of nocturnal sleep problems in AD patients will also bring better emotional stability for AD caregivers.

  7. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval

    Directory of Open Access Journals (Sweden)

    Naessens Ineke

    2007-01-01

    Full Text Available Abstract Background Several clinical studies have established the efficacy, safety, and tolerability of long-acting risperidone administered once every 2 weeks in patients with schizophrenia or schizoaffective disorder. This report evaluates preliminary efficacy, safety, tolerability, and pharmacokinetic data for a novel (once-monthly administration of long-acting injectable risperidone 50 mg in patients with schizophrenia or schizoaffective disorder. Methods Clinically stable patients participated in a 1-year, open-label, single-arm, multicenter pilot study. During the 4-week lead-in phase, patients received long-acting risperidone 50 mg injections every 2 weeks, with 2 weeks of oral risperidone supplementation. Injections of long-acting risperidone 50 mg every 4 weeks followed for up to 48 weeks, without oral supplementation. The primary endpoint was relapse; other assessments included PANSS, CGI-S, adverse event reports, and determination of risperidone and 9-hydroxyrisperidone plasma concentrations. Results Twelve patients in the intent-to-treat population (n = 67 met relapse criteria (17.9%. Relapse risk at 1 year was estimated as 22.4%. Non-statistically significant improvements in symptoms (PANSS and clinical status (CGI-S at endpoint were observed. The most common adverse events included schizophrenia aggravated not otherwise specified (19.5%, anxiety (16.1%, insomnia (16.1%, and headache (11.5%. There were no unexpected safety and tolerability findings. Mean plasma concentrations for risperidone and 9-hydroxyrisperidone were generally stable during the study. Conclusion Once-monthly dosing of long-acting risperidone was well tolerated, associated with a relatively low relapse rate (similar to that reported with other antipsychotics, and maintained the clinically stable baseline status of most patients. Although the results suggest that some symptomatically stable patients with schizophrenia or schizoaffective disorder might be safely

  8. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.

    Science.gov (United States)

    Krystal, John H; Rosenheck, Robert A; Cramer, Joyce A; Vessicchio, Jennifer C; Jones, Karen M; Vertrees, Julia E; Horney, Rebecca A; Huang, Grant D; Stock, Christopher

    2011-08-03

    Serotonin reuptake-inhibiting (SRI) antidepressants are the only FDA-approved pharmacotherapies for the treatment of posttraumatic stress disorder (PTSD). To determine efficacy of the second-generation antipsychotic risperidone as an adjunct to ongoing pharmacologic and psychosocial treatments for veterans with chronic military-related PTSD. A 6-month, randomized, double-blind, placebo-controlled multicenter trial conducted between February 2007 and February 2010 at 23 Veterans Administration outpatient medical centers. Of the 367 patients screened, 296 were diagnosed with military-related PTSD and had ongoing symptoms despite at least 2 adequate SRI treatments, and 247 contributed to analysis of the primary outcome measure. Risperidone (up to 4 mg once daily) or placebo. The Clinician-Administered PTSD Scale (CAPS) (range, 0-136). Other measures included the Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Scale (HAMA), Clinical Global Impression scale (CGI), and Veterans RAND 36-Item Health Survey (SF-36V). Change in CAPS scores from baseline to 24 weeks in the risperidone group was -16.3 (95% CI, -19.7 to -12.9) and in the placebo group, -12.5 (95% CI, -15.7 to -9.4); the mean difference was 3.74 (95% CI, -0.86 to 8.35; t = 1.6; P = .11). Mixed model analysis of all time points also showed no significant difference in CAPS score (risperidone: mean, 64.43; 95% CI, 61.98 to 66.89, vs placebo: mean, 67.16; 95% CI, 64.71 to 69.62; mean difference, 2.73; 95% CI, -0.74 to 6.20; P = .12). Risperidone did not reduce symptoms of depression (MADRS mean difference, 1.19; 95% CI, -0.29 to 2.68; P = .11) or anxiety (HAMA mean difference, 1.16; 95% CI, -0.18 to 2.51; P = .09; patient-rated CGI mean difference, 0.20; 95% CI, -0.06 to 0.45; P = .14; observer-rated CGI mean difference, 0.18; 95% CI, 0.01 to 0.34; P = .04), or increase quality of life (SF-36V physical component mean difference, -1.13, 95% CI, -2.58 to 0.32; P = .13; SF-36V mental component mean

  9. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

    Science.gov (United States)

    Laux, Gerd; Heeg, Bart; van Hout, Ben A; Mehnert, Angelika

    2005-01-01

    Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequences of relapse. Long-acting risperidone is a new formulation of an atypical antipsychotic drug that also offers the improvements in compliance associated with haloperidol depot. The aim of this simulation study was to compare the benefits and costs of three pharmacological treatment strategies comprising first-line treatment with long-acting risperidone injection, a haloperidol depot or an oral atypical antipsychotic agent, over a 5-year period in Germany. A discrete event simulation model was developed to compare three treatment scenarios from the perspective of major third-party payers (sickness funds and social security 'Sozialversicherung'). The scenarios comprised first-line treatment with haloperidol depot (scenario 1), long-acting risperidone (scenario 2) and oral olanzapine (scenario 3). Switches to second or third-line options were allowed when side-effects occurred or a patient suffered more than a fixed number of relapses. The model accounted for fixed patient characteristics, and on the basis of these, simulated patient histories according to several time-dependent variables. The time horizon for this model was limited to 5 years, and in accordance with German guidelines, costs and effects were discounted by between 3 and 10%. Direct costs included medication, type of physician visits and treatment location. Indirect costs were not included. Information on treatment alternatives, transition probabilities, model structure and healthcare utilization were derived from the literature and an expert panel. Outcomes were expressed in terms of the number and duration of psychotic episodes, cumulative symptom scores, costs, and quality-adjusted life-years (QALY). Univariate sensitivity analyses were carried out, as were subgroup analyses based on disease severity and

  10. 利培酮和氯氮平、喹硫平对精神分裂症患者脂代谢影响比较%Risperidone and clozapine, quetiapine impact on lipid metabolism in patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    胡红霞; 赵倩; 白天山; 崔素华; 任玉红; 王旭红; 李小全

    2012-01-01

    Objective: To study the influence of risperdal, clozapine and quetiapine on blood -lipid level of patients with schizophrenia. Methods:178 cases of schizophrenia patients were randomly divided into risperdal group ( 90 cases ) , clozapine group ( 68 cases) , quetiapine group ( 20 cases ). Before treatment and treatment at the fourth and eighth, weekend, the levels of total cholesterol (TC) , triglycerides (TG), high - density iipoprotein (HDL), low density Iipoprotein (LDL) , apolipoprotein A ( ApoA) , apolipoprotein B ( ApoB) in the fasting plasma were determined. Results: CHOL level had statistical difference in clozapine group before and after treatment(P 0,05). Other indicators had no significant difference before and after treatment(P > 0.05 ) . The effect of clozapine on TG and CHOL were greater than that of risperdal. Conclusion: Risperdal and clozapine both had effect on blood - lipid of patients with schizophrenia, and clozapine had greater effect on lipid metabolism than risperdal, while quetiapine had the least effect.%目的:探讨利培酮、氯氮平与喹硫平对精神分裂症患者血脂的影响.方法:将178例精神分裂症患者随机分为利培酮组90例,氯氮平组68例,喹硫平组20例;于治疗前及治疗第4、8周末晨间空腹采血,测定总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、载脂蛋白A(ApoA)、载脂蛋白B(ApoB).结果:治疗前后氯氮平组的CHOL差异均有统计学意义(P<0.05),TG较治疗前显著升高(P<0.01);利培酮组TG浓度差值(0.58 ±0.41) mmol/L,差异有统计学意义(P<0.05).喹硫平组TG浓度差值(0.16 ±0.20) mmol/L,无统计学差异(P>0.05).其他各项指标与治疗前比较差异无显著性(P>0.05).氯氮平和利培酮对TG、CHOL的影响程度氯氮平大于利培酮.结论:利培酮与氯氮平对精神分裂症患者血脂均有影响,氯氮平对脂代谢的影响大于利培酮,喹硫平最低.

  11. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.

    Science.gov (United States)

    Silva, A C; Kumar, A; Wild, W; Ferreira, D; Santos, D; Forbes, B

    2012-10-15

    A solid lipid nanoparticles (SLN) formulation to improve the oral delivery of risperidone (RISP), a poorly water-soluble drug, was designed and tested. Initially, lipid-RISP solubility was screened to select the best lipid for SLN preparation. Compritol(®)-based formulations were chosen and their long-term stability was assessed over two years of storage (at 25 °C and 4 °C) by means of particle size, polydispersity index (PI), zeta potential (ZP) and encapsulation efficiency (EE) measurements. SLN shape was observed by transmission electron microscopy (TEM) at the beginning and end of the study. The oxidative potential (OP) of the SLN was measured and their biocompatibility with Caco-2 cells was evaluated using the (4,5-dimethylthiazol-2-yl)2,5-dyphenyl-tetrazolium bromide (MTT) assay. In vitro drug release and transport studies were performed to predict the in vivo release profile and to evaluate the drug delivery potential of the SLN formulations, respectively. The RISP-loaded SLN systems were stable and had high EE and similar shape to the placebo formulations before and after storage. Classical Fickian diffusion was identified as the release mechanism for RISP from the SLN formulation. Biocompatibility and dose-dependent RISP transport across Caco-2 cells were observed for the prepared SLN formulations. The viability of SLN as formulations for oral delivery of poorly water-soluble drugs such as RISP was illustrated.

  12. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report

    Directory of Open Access Journals (Sweden)

    Psarros Constantin

    2006-09-01

    Full Text Available Abstract Background The use of atypical antipsychotics in schizophrenic patients has been associated with a risk of weight gain. Similarly, recovery from depression is often followed by improved appetite, greater food intake and potential increase in weight. Case presentation A Caucasian 33-year-old schizophrenic female patient was being treated with 6 mg/day of risperidone and 15 mg/day of clorazepate. She developed depressive symptomatology and 40 mg/day of fluoxetine was gradually added to her treatment regimen for about 9 months. After the remission of depression, and the discontinuation of fluoxetine, she experienced an increase in appetite and subsequently excessive weight gain of 52 kg. Re-administration of fluoxetine did not reverse the situation. The patient developed diabetes mellitus, which was successfully controlled with metformin 1700 mg/day. The addition at first of orlistat 360 mg/day and later of topiramate 200 mg/day has helped her to lose a significant part of the weight gained (30 kg. Conclusion The case suggests a probable association between the remission of depressive symptomatology and weight gain in a schizophrenic patient.

  13. Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection

    Directory of Open Access Journals (Sweden)

    Wissam El-Hage

    2010-07-01

    Full Text Available Wissam El-Hage1, Simon A Surguladze21Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; 2Institute of Psychiatry, King’s College London, UKAbstract: Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. ­Risperidone long acting injection (RLAI as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting injections will also be discussed.Keywords: second generation, antipsychotics, patient attitudes, lithium, valproate, monotherapy

  14. Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone.

    Science.gov (United States)

    Hori, Hikaru; Yamada, Kenji; Kamada, Dan; Shibata, Yuka; Katsuki, Asuka; Yoshimura, Reiji; Nakamura, Jun

    2014-01-01

    This study aims to determine the effectiveness of blonanserin (BNS) on the cognitive and social functions of patients with schizophrenia compared with risperidone (RIS) during acute-phase (8-week) treatment. A total of 39 schizophrenia inpatients were included in this study. The subjects received either BNS (N=20) or RIS (N=19), and the clinical responses were evaluated periodically. The concomitant use of mood stabilizers was not allowed. Efficacy was assessed with the Positive and Negative Syndrome Scale for schizophrenia. Cognition was assessed using the Brief Assessment of Cognition in Schizophrenia, Japanese-language version. Social function was assessed using the Life Assessment Scale for the Mentally Ill. For both groups, each assessment exhibited a decrease in the mean change from baseline on the Positive and Negative Syndrome Scale. The depression subscale was significantly improved in the BNS group compared with the RIS group at 8 weeks after administration. BNS improved verbal fluency and executive function (cognitive function) and daily living and work skills (social function). Compared with the RIS group, BNS was observed to improve daily living. BNS may improve psychotic symptoms, cognitive function, and daily living in patients with acute-phase schizophrenia. BNS may be superior to RIS in the improvement of daily living.

  15. Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution.

    Science.gov (United States)

    Al-Hashel, Jasem Y; Ismail, Ismail Ibrahim; John, John K; Ibrahim, Mohammed; Ali, Mahmoud

    2016-01-01

    Myasthenia gravis is an autoimmune disease characterized by muscle weakness due to autoantibodies affecting the neuromuscular junction. Co-occurrence of myasthenia gravis and schizophrenia is very rare and raises a challenge in management of both diseases. Antipsychotic drugs exhibit anticholinergic side effects and have the potentials of worsening myasthenia. Long-acting risperidone is an injectable atypical antipsychotic drug that has not been previously reported to worsen myasthenia gravis in literature. We report the first case report of worsening of myasthenia after receiving long-acting risperidone injection for schizophrenia in a 29-year-old female with both diseases. She started to have worsening 2 weeks following the first injection and her symptoms persisted despite receiving plasma exchange. This could be explained by the pharmacokinetics of the drug. We recommend that long-acting risperidone should be used with caution in patients with myasthenia gravis, and clinicians must be aware of the potential risks of this therapy.

  16. Synthesis, recognition and evaluation of molecularly imprinted polymer nanoparticle using miniemulsion polymerization for controlled release and analysis of risperidone in human plasma samples

    Energy Technology Data Exchange (ETDEWEB)

    Asadi, Ebadullah; Azodi-Deilami, Saman; Abdouss, Majid [Amirkabir University of Technology, Tehran (Iran, Islamic Republic of); Kordestani, Davood [Razi University, Kermanshah (Iran, Islamic Republic of); Rahimi, Alireza [Research Institute of Petroleum Industry (RIPI), Tehran (Iran, Islamic Republic of); Asadi, Somayeh [Kermanshah University of Medical Sciences, Kermanshah (Iran, Islamic Republic of)

    2014-06-15

    We prepared high selective imprinted nanoparticle polymers by a miniemulsion polymerization technique, using risperidone as the template, MAA as the functional monomers, and TRIM as the cross-linker in acetonitrile as solvent. The morphology of the nanoparticles determined by scanning electron microscopy (SEM) images and drug release, binding properties and dynamic light scattering (DLS) of molecularly imprinted polymers (MIPs) were studied. Controlled release of risperidone from nanoparticles was investigated through in 1% wt sodium dodecyl sulfate aqueous solution and by measuring the absorbance by HPLC-UV. The results showed that the imprinted nanoparticles exhibited a higher binding level and slower release rate than non-imprinted nanoparticles, which contributed to interaction of risperidone with imprinted cavities within nanoparticles. Furthermore, the results from HPLC showed good precision (5% for 50.0 µg L{sup -1}) and recoveries (between 86-91) using MIP from human plasma samples.

  17. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study

    Directory of Open Access Journals (Sweden)

    Galynker Igor I

    2009-05-01

    Full Text Available Abstract Background Because a large proportion of patients with panic attacks receiving approved pharmacotherapy do not respond or respond poorly to medication, it is important to identify additional therapeutic strategies for the management of panic symptoms. This article describes a randomized, rater-blind study comparing low-dose risperidone to standard-of-care paroxetine for the treatment of panic attacks. Methods Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine. The subjects were then followed for eight weeks. Outcome measures included the Panic Disorder Severity Scale (PDSS, the Hamilton Anxiety Scale (Ham-A, the Hamilton Depression Rating Scale (Ham-D, the Sheehan Panic Anxiety Scale-Patient (SPAS-P, and the Clinical Global Impression scale (CGI. Results All subjects demonstrated a reduction in both the frequency and severity of panic attacks regardless of treatment received. Statistically significant improvements in rating scale scores for both groups were identified for the PDSS, the Ham-A, the Ham-D, and the CGI. There was no difference between treatment groups in the improvement in scores on the measures PDSS, Ham-A, Ham-D, and CGI. Post hoc tests suggest that subjects receiving risperidone may have a quicker clinical response than subjects receiving paroxetine. Conclusion We can identify no difference in the efficacy of paroxetine and low-dose risperidone in the treatment of panic attacks. Low-dose risperidone appears to be tolerated equally well as paroxetine. Low-dose risperidone may be an effective treatment for anxiety disorders in which panic attacks are a significant component. Trial Registration ClinicalTrials.gov Identifier: NCT100457106

  18. Dopamine transporter density assessed with [{sup 123}]IPT SPECT before and after risperidone treatment in children with tourette's disorder

    Energy Technology Data Exchange (ETDEWEB)

    Ryu, Young Hoon; Kim, Tae Hoon; Ryu, Won Gee [College of Medicine, Yonsei Univ., Seoul (Korea, Republic of)] [and others

    2004-02-01

    Tourette's disorder (TD), which is characterized by multiple waxing and waning motor tics and one or more vocal tics, is known to be associated with abnormalities in the dopaminergic system. To testify our hypothesis that risperidone would improve tic symptoms of TD patients through the change of the dopaminergic system, we measured the dopamine transporter (DAT) densities between drug-naive children with TD and normal children, and investigated the DAT density before and after treatment with risperidone in drug-naive children with TD, using iodine-123 labelled N-(3-iodopropen-2-yl)-2{beta}-carbomethoxy-3beta-(4-chlorophenyl)tropane ([{sup 123}I]IPT) single photon emission computed tomography (SPECT). [{sup 123I}]IPT SPECT imaging and Yale Global Tic Severity Scale-Korean version (YGTSS-K) for assessing the tic symptom severity were carried out before and after treatment with risperidone for 8 weeks in nine drug-naive children with TD. Eleven normal children also underwent SPECT imaging 2 hours after an intravenous administration of [{sup 123}I]IPT. Drug-naive children with TD had a significantly greater increase in the specific/nonspecific DAT binding ratio of both basal ganglia compared with the normal children. However, no significant difference in the specific/nonspecific DAT binding ratio of the basal ganglia before and after treatment with risperidone in children with TD was found, although tic symptoms were significantly improved with risperidone. These findings suggest that DAT densities are directly associated with the pathophysiology of TD, however, that the effect of risperidone on tic symptoms in children with TD is not attributed to the change of dopaminergic system.

  19. 利培酮合并氯氮平治疗难治性精神分裂症对照研究%Comparative Study on Risperidone Combined Clozapine and Risperidone in the Treatment of Refractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    高亚娇; 安红伟; 靳红强

    2011-01-01

    Objective To compare the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia. Methods 63 cases were divided into two groups randomly,32 cases of treatment-refractory schizophrenia were treated with risperidone combined clozapine( the treatment group ) and 31 cases were treated with risperidone( the control group ). The clinical effect of patients were measured with positive and negative symptoms scale( PANSS ), and side effects were assessed with treatment emergent symptoms scale( TESS )respectively before and after 4,8,12 week treatment. Results There were significant differences in the curative effect between the two groups( P <0.05 ). After eight weeks treatment, total score of PANSS in two groups were much lower than before,the treatment group had greater decreases. After twelve weeks treatment,total score of PANSS in the treatment group was lower than that in the control group. There were statistical differences between the two groups( P <0. 05 ). Conclusion Clozapine combined with risperidone has curative effect affirmation to treat TRS,this deserves utilization in the clinical area.%目的 探讨利培酮联合氯氮平治疗难治性精神分裂症(TRS)的疗效及安全性.方法 将63例TRS患者随机分为利培酮合并氯氮平组(治疗组)32例和利培酮组(对照组)31例,两组治疗后4、8、12周均以阳性与阴性症状量表(PANSS)评定疗效,治疗意外症状量表(TESS)评定不良反应.结果 治疗组和对照组治疗TRS的疗效比较差异有统计学意义(P<0.05).治疗后8周,两组PANSS总分均较治疗前下降,治疗组下降更明显.两组治疗12周后PANSS总分比较,治疗组明显低于对照组,差异有统计学意义(P<0.05).结论 利培酮联合氯氮平治疗TRS的疗效肯定,值得临床应用.

  20. 利培酮的臨床應用與進展%Clinical Application and Advancement of Risperidone

    Institute of Scientific and Technical Information of China (English)

    查彩慧; 肖計劃

    2001-01-01

    Objective This article reviews the mechanism, pharmcokinetics and the clinical use ofrisperidone.Materials The data base on updated literature recently. Conclusion Risperidone, a benzisoxazol derivative, is a novel typical antipsychotic agent which combines 5-hydroxytryptamine-2 (5-HT2) and dopamine-2 (D2) receptors antagonism. It can improve both positive and negative symptoms of schizophrenia. The efficacy of risperidone is well positive and effective in patients with chronic schizophrenia who had been resistant to or intolerant of conventiona neuroleptics. Risperidone can be used to treat mood disorder, obsessive-compulsive disorder, metal retardation,brain injury associated behavioral and psychiatric disorder and now it is already used in clinic widely. Risperidone is absorbed rapidly when taken orally and mainly metabolized in the liver .The principal active metabolite is 9-hydroxyrisperidone which has obvious pharmacological function. The metabolized production of risperidone is mainly discharged via urine. Risperidone has high efficacy and good safety. Now it is already used in clinic widely.%目的本文對利培酮的作用機制、藥代動力學、臨床應用和不良反應作一綜述,供同道們參考.資料所有資料均來自近幾年最新的相關文獻.結論利培酮是苯異惡唑衍生物,是一種新型的非典型抗精神病藥物.利培酮對5羥色胺Ⅱ型和多巴胺Ⅱ型受體均有拮抗作用,能有效改善精神分裂症陽性和陰性症狀,對於傳統抗精神病藥物治療失敗的難治性精神分裂症患者可首選利培酮治療.利培酮還可用於治療心境障礙、強迫症、精神發育遲滯及腦損害伴發的行為和精神障礙.利培酮口服吸收迅速,主要經肝臟代謝,在體內的代謝産物為9-羥基利培酮,亦具有藥理活性.利培酮主要通過尿液排出.利培酮的常見副反應為激越、頭痛、失眠、噁心、嗜睡等,較少出現錐體外系副反應,惡性綜合徵發

  1. A case of psychosis due to Fahr's syndrome and response to behavioral disturbances with risperidone and oxcarbazepine

    Science.gov (United States)

    Faye, Abhijeet Dhawalram; Gawande, Sushil; Tadke, Rahul; Kirpekar, Vivek C.; Bhave, Sudhir H.

    2014-01-01

    Calcification of basal ganglia or Fahr's syndrome is a rare disease characterized by bilateral and symmetrical intracranial deposition of calcium mainly in cerebral basal ganglia. Motor and neuropsychiatric symptoms are prominent features. We report a case presented with a few motor symptoms, features of delirium and prominent psychiatric symptoms (disorganized behavior) predominantly evident after the improvement in delirium. Radiological findings were suggestive of bilateral basal ganglia calcification. Parathyroid hormone levels were low with no significant findings in other investigations and negative family history. Patient showed significant improvement in behavioral disturbances with risperidone, low dose of lorazepam, oxcarbazepine, and memantine. PMID:24891710

  2. Inflammation in Patients with Schizophrenia: the Therapeutic Benefits of Risperidone Plus Add-On Dextromethorphan

    Science.gov (United States)

    Chen, Shiou-Lan; Lee, Sheng-Yu; Chang, Yun-Hsuan; Chen, Shih-Heng; Chu, Chun-Hsieh; Tzeng, Nian-Sheng; Lee, I-Hui; Chen, Po-See; Yeh, Tzung Lieh; Huang, San-Yuan; Yang, Yen-Kuang; Lu, Ru-Band; Hong, Jau-Shyong

    2013-01-01

    Objectives Increasing evidence suggests that inflammation contributes to the etiology and progression of schizophrenia. Molecules that initiate inflammation, such as virus- and toxin-induced cytokines, are implicated in neuronal degeneration and schizophrenia-like behavior. Using therapeutic agents with anti-inflammatory or neurotrophic effects may be beneficial for treating schizophrenia. Methods One hundred healthy controls and 95 Han Chinese patients with schizophrenia were tested in this double-blind study. Their PANSS scores, plasma interleukin (IL)-1β, TNF-α and brain-derived neurotrophic factor (BDNF) levels were measured before and after pharmacological treatment. Results Pretreatment, plasma levels of IL-1β and TNF-α were significantly higher in patients with schizophrenia than in controls, but plasma BDNF levels were significantly lower. Patients were treated with the atypical antipsychotic risperidone (Risp) only or with Risp+add-on dextromethorphan (DM). PANSS scores and plasma IL-1β levels significantly decreased, but plasma TNF-α and BDNF levels significantly increased after 11 weeks of Risp treatment. Patients in the Risp+DM group showed a greater and earlier reduction of symptoms than did those in the Risp-only group. Moreover, Risp+DM treatment attenuated Risp-induced plasma increases in TNF-α. Conclusion Patients with schizophrenia had a high level of peripheral inflammation and a low level of peripheral BDNF. Long-term Risp treatment attenuated inflammation and potentiated the neurotrophic function but also produced a certain degree of toxicity. Risp+DM was more beneficial and less toxic than Risp-only treatment. PMID:22730040

  3. Study on the luminescence behavior of sulfobutylether-β-cyclodextrin with risperidone and its analytical application

    Science.gov (United States)

    Wu, Min; Chen, Donghua; Song, Zhenghua

    2012-10-01

    The interaction of sulfobutylether-β-cyclodextrin (SBE-β-CD) with risperidone (RISP) was first described with luminol-SBE-β-CD chemiluminescence (CL) system by flow injection analysis (FIA). In luminol-SBE-β-CD CL system, the 1:1 SBE-β-CD⋯luminol∗ complexation could enhance CL intensity of luminol and produce the effect of complexation enhancement of CL (CEC). It was found that RISP could quench the CL intensity of SBE-β-CD⋯luminol∗ and caused the effect of complexation enhancement of quenching (CEQ), the formation constant KR-CD 3.4 × 104 L mol-1 and the stoichiometric ratio 1:1 of RISP⋯SBE-β-CD complex were obtained by the proposed CL model. Association degree α 0.036 of RISP⋯SBE-β-CD complex was also given by CL method. Based on the linear relationship to the decrement of luminol-SBE-β-CD-RISP CL intensity and the logarithm of RISP concentration, RISP also can be quantified in the linear range of 3.0-500.0 nmol L-1 with a detection limit of 1.0 nmol L-1 (3σ). The proposed method was successfully applied to monitoring excreted RISP in human urine. It was found that RISP reached its maximum after oral administration for 1.5 h with the total excretion of 14.26% within 8.5 h; the elimination rate constant k and half-life time t1/2 were 0.474 and 1.5 h, respectively.

  4. Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats.

    Science.gov (United States)

    Zuo, Jing; Liu, Zhening; Ouyang, Xuan; Liu, Haihong; Hao, Yihui; Xu, Lin; Lu, Xiao-Hong

    2008-02-15

    Antipsychotic treatment during pregnancy is indicated when risk of drug exposure to the fetus is outweighed by the untreated psychosis in the mother. Although increased risk of congenital malformation has not been associated with most available antipsychotic drugs, there is a paucity of knowledge on the subtle neurodevelopmental and behavioral consequences of prenatal receptor blockade by these drugs. In the present study, antipsychotic drugs, sulpiride (SUL, a selective D2 receptor antagonist) and risperidone (RIS, a D2/5HT2 receptor antagonist) were administered to pregnant Sprague-Dawley dams from gestational day 6 to 18. Both RIS and SUL prenatal exposed rats had lower birth body weights compared to controls. RIS exposure had a significant main effect to retard body weight growth in male offspring until postnatal day (PND) 60. Importantly, water maze tests revealed that SUL prenatal exposure impaired visual cue response in visual task performance (stimulus-response, S-R memory), but not place response as reflected in hidden platform task (spatial memory acquisition and retention). In addition, prenatal SUL treatment reduced spontaneous activity as measured in open field. Both behavioral deficits suggest that SUL prenatal exposure may lead to subtle disruption of striatum development and related learning and motor systems. RIS exposure failed to elicit deficits in both water maze tasks and increased rearing in open field test. These results suggest prenatal exposure to SUL and RIS may produce lasting effects on growth, locomotion and memory in rat offspring. And the differences may exist in the effects of antipsychotic drugs which selectively block dopamine D2 receptors (SUL) as compared to second generation drugs (RIS) that potently antagonize serotonin and dopamine receptors.

  5. Development of Nutraceutical Emulsions as Risperidone Delivery Systems: Characterization and Toxicological Studies.

    Science.gov (United States)

    Igartúa, Daniela Edith; Calienni, María Natalia; Feas, Daniela Agustina; Chiaramoni, Nadia Silvia; Valle Alonso, Silvia Del; Prieto, María Jimena

    2015-12-01

    Emulsions are gaining increasing interest to be applied as drug delivery systems. The main goal of this work was the formulation of an oil/water nutraceutical emulsion (NE) for oral administration, enriched in omega 3 (ω3) and omega 6 (ω6), and able to encapsulate risperidone (RISP), an antipsychotic drug widely used in the treatment of autism spectrum disorders (ASD). RISP has low solubility in aqueous medium and poor bioavailability because of its metabolism and high protein binding. Coadministration of ω3, ω3, and vitamin E complexed with RISP might increase its bioavailability and induce a synergistic effect on the treatment of ASD. Here, we developed an easy and quick method to obtain NEs and then optimized them. The best formulation was chosen after characterization by particle size, defects of the oil-in-water interface, zeta potential (ZP), and in vitro drug release. The formulation selected was stable over time, with a particle size of around 3 μm, a ZP lower than -20 mV and controlled drug release. To better understand the biochemical properties of the formulation obtained, we studied in vitro toxicity in the Caco-2 cell line. After 4 h of treatment, an increase in cellular metabolism was observed for all RISP concentrations, but emulsions did not change their metabolic rate, except at the highest concentration without drug (25 μg/mL), which showed a significant reduction in metabolism respect to the control. Additionally, locomotor activity and heart rate in zebrafish were measured as parameters of in vivo toxicity. Only the highest concentration (0.625 μg/mL) showed a cardiotoxic effect, which corresponds to the decrease in spontaneous movement observed previously. As all the materials contained in the formulations were US FDA approved, the NE selected would be good candidate for clinical trials.

  6. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.

    Science.gov (United States)

    Chen, Shiou-Lan; Lee, Sheng-Yu; Chang, Yun-Hsuan; Chen, Shih-Heng; Chu, Chun-Hsieh; Tzeng, Nian-Sheng; Lee, I-Hui; Chen, Po-See; Yeh, Tzung Lieh; Huang, San-Yuan; Yang, Yen-Kuang; Lu, Ru-Band; Hong, Jau-Shyong

    2012-09-01

    Increasing evidence suggests that inflammation contributes to the etiology and progression of schizophrenia. Molecules that initiate inflammation, such as virus- and toxin-induced cytokines, are implicated in neuronal degeneration and schizophrenia-like behavior. Using therapeutic agents with anti-inflammatory or neurotrophic effects may be beneficial for treating schizophrenia. One hundred healthy controls and 95 Han Chinese patients with schizophrenia were tested in this double-blind study. Their PANSS scores, plasma interleukin (IL)-1β, tumor necrosis factor-α (TNF-α) and brain-derived neurotrophic factor (BDNF) levels were measured before and after pharmacological treatment. Pretreatment, plasma levels of IL-1β and TNF-α were significantly higher in patients with schizophrenia than in controls, but plasma BDNF levels were significantly lower. Patients were treated with the atypical antipsychotic risperidone (Risp) only or with Risp+ dextromethorphan (DM). PANSS scores and plasma IL-1β levels significantly decreased, but plasma TNF-α and BDNF levels significantly increased after 11 weeks of Risp treatment. Patients in the Risp+ DM group showed a greater and earlier reduction of symptoms than did those in the Risp-only group. Moreover, Risp+ DM treatment attenuated Risp-induced plasma increases in TNF-α. Patients with schizophrenia had a high level of peripheral inflammation and a low level of peripheral BDNF. Long-term Risp treatment attenuated inflammation and potentiated the neurotrophic function but also produced a certain degree of toxicity. Risp+ DM was more beneficial and less toxic than Risp-only treatment. Protocol Record: HR-93-50; NCT01189006; URL: http://www.clinicaltrials.gov.

  7. 利培酮微球和利培酮治疗精神分裂症对照研究%A comparative study of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    苏磊; 孙自豪; 冯凡; 李龙飞

    2015-01-01

    Objective To explore the efficacy and safety of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia.Methods A total of 160 patients with schizophrenia were randomly divided into study group ( 80 cases) with risperidone long-acting injection and control group(80 cases) with risperidone for treatment of 3 months.They were assessed with Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression-Severity of Illness(CGI-S), Clinical Global Impression-Global Improvement(CGI-I) and Extrapyramidal Symptom Rating Scale(ESRS) at baseline , 1st month end, 2nd month end and 3rd month end of treatment.Results At 1st month end, 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS in two groups were all significantly lower than those at baseline(P<0.05).At 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS and CGI in study group were all significantly lower than those in control group(P<0.05).At 1st month end, 2nd month end and 3rd month end of treatment, the scores of ESRS in study group were significantly lower than those in control group(P<0.05).Conclusion It’s effective and safe for risperidone long-acting injection to treat the patients with schizophrenia.%目的:探寻利培酮微球和利培酮治疗精神分裂症患者的疗效和安全性。方法将160例精神分裂症患者随机分为研究组和对照组各80例,研究组用利培酮微球系统治疗,对照组用利培酮系统治疗,共3个月,在基线和治疗后1、2、3个月末应用阳性和阴性综合征量表( PANSS)、临床疗效总评量表-病情严重程度( CGI-S)、临床疗效总评量表-疗效总评( CGI-I)、锥体外系症状评定量表( ESRS)评价。结果两组在治疗后第1、2、3个月末的PANSS评分均低于基线时相应评分(P<0.05)。在治疗后第2、3个月末,研究组PANSS评分以及CGI

  8. Alginate gel-coated oil-entrapped alginate-tamarind gum-magnesium stearate buoyant beads of risperidone.

    Science.gov (United States)

    Bera, Hriday; Boddupalli, Shashank; Nandikonda, Sridhar; Kumar, Sanoj; Nayak, Amit Kumar

    2015-01-01

    A novel alginate gel-coated oil-entrapped calcium-alginate-tamarind gum (TG)-magnesium stearate (MS) composite floating beads was developed for intragastric risperidone delivery with a view to improving its oral bioavailability. The TG-blended alginate core beads containing olive oil and MS as low-density materials were accomplished by ionotropic gelation technique. Effects of polymer-blend ratio (sodium alginate:TG) and crosslinker (CaCl2) concentration on drug entrapment efficiency (DEE, %) and cumulative drug release after 8 h (Q8h, %) were studied to optimize the core beads by a 3(2) factorial design. The optimized beads (F-O) exhibited DEE of 75.19±0.75% and Q8h of 78.04±0.38% with minimum errors in prediction. The alginate gel-coated optimized beads displayed superior buoyancy and sustained drug release property. The drug release profiles of the drug-loaded uncoated and coated beads were best fitted in Higuchi kinetic model with Fickian and anomalous diffusion driven mechanisms, respectively. The optimized beads yielded a notable sustained drug release profile as compared to marketed immediate release preparation. The uncoated and coated Ca-alginate-TG-MS beads were also characterized by SEM, FTIR and P-XRD analyses. Thus, the newly developed alginate-gel coated oil-entrapped alginate-TG-MS composite beads are suitable for intragastric delivery of risperidone over a prolonged period of time.

  9. Use of haloperidol and risperidone in highly aggressive Swiss Webster mice by applying the model of spontaneous aggression (MSA).

    Science.gov (United States)

    Fragoso, Viviane Muniz da Silva; Hoppe, Luanda Yanaan; de Araújo-Jorge, Tânia Cremonini; de Azevedo, Marcos José; Campos, Jerônimo Diego de Souza; Cortez, Célia Martins; de Oliveira, Gabriel Melo

    2016-03-15

    Aggression is defined as the act in which an individual intentionally harms or injures another of their own species. Antipsychotics are a form of treatment used in psychiatric routine. They have been used for decades in treatment of patients with aggressive behavior. Haloperidol and risperidone promote the control of psychiatric symptoms, through their respective mechanisms of action. Experimental models are obtained by behavioral, genetic, and pharmacological manipulations, and use a reduced number of animals. In this context, we applied the model of spontaneous aggression (MSA), originating the presence of highly aggressive mice (AgR) when reassembled in adulthood. We administered haloperidol and risperidone in escalating doses, for ten consecutive days. Using positive and negative control groups, we evaluated the effectiveness of these drugs and the reversal of the aggressive behavior, performing the tail suspension test (TST) and open field test (OFT) on 10th day of treatment and 10 days after its discontinuation. The results showed that both antipsychotic drugs were effective in AgR and reversed the aggressive phenotype, reducing the number of attacks by AgR and the extent of lesions in the subordinate mice (AgD) exposed to the pattern of aggressive behavior (PAB) of the aggressors. This conclusion is based on the reduction in the animals' motor and exploratory activity, and on the reversal of patterns of aggressive behavior. The association between the MSA and experiments with other therapeutic protocols and different antipsychotics can be an important methodology in the study of aggressive behavior in psychiatric patients.

  10. Risperidone reverses the spatial object recognition impairment and hippocampal BDNF-TrkB signalling system alterations induced by acute MK-801 treatment.

    Science.gov (United States)

    Chen, Guangdong; Lin, Xiaodong; Li, Gongying; Jiang, Diego; Lib, Zhiruo; Jiang, Ronghuan; Zhuo, Chuanjun

    2017-03-01

    The aim of the present study was to investigate the effects of a commonly-used atypical antipsychotic, risperidone, on alterations in spatial learning and in the hippocampal brain-derived neurotrophic factor (BDNF)-tyrosine receptor kinase B (TrkB) signalling system caused by acute dizocilpine maleate (MK-801) treatment. In experiment 1, adult male Sprague-Dawley rats subjected to acute treatment of either low-dose MK801 (0.1 mg/kg) or normal saline (vehicle) were tested for spatial object recognition and hippocampal expression levels of BDNF, TrkB and the phophorylation of TrkB (p-TrkB). We found that compared to the vehicle, MK-801 treatment impaired spatial object recognition of animals and downregulated the expression levels of p-TrkB. In experiment 2, MK-801- or vehicle-treated animals were further injected with risperidone (0.1 mg/kg) or vehicle before behavioural testing and sacrifice. Of note, we found that risperidone successfully reversed the deleterious effects of MK-801 on spatial object recognition and upregulated the hippocampal BDNF-TrkB signalling system. Collectively, the findings suggest that cognitive deficits from acute N-methyl-D-aspartate receptor blockade may be associated with the hypofunction of hippocampal BDNF-TrkB signalling system and that risperidone was able to reverse these alterations.

  11. A Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Adolescents and Young Adults with Anorexia Nervosa: A Pilot Study

    Science.gov (United States)

    Hagman, Jennifer; Gralla, Jane; Sigel, Eric; Ellert, Swan; Dodge, Mindy; Gardner, Rick; O'Lonergan, Teri; Frank, Guido; Wamboldt, Marianne Z.

    2011-01-01

    Objective: The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa. Method: Forty female subjects 12 to 21 years of age (mean, 16 years) with primary anorexia nervosa in an eating disorders program were randomized to receive…

  12. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.

    Science.gov (United States)

    Savina, Ioulia; Beninger, Richard J

    2007-08-01

    Theory of mind (ToM), the ability to attribute mental states to others, is associated with medial prefrontal cortical (mPFC) activity and is impaired in schizophrenia. Olanzapine or clozapine but not typical antipsychotics or risperidone preferentially affect c-fos expression in mPFC in animals. We tested the hypothesis that schizophrenic patients treated with different antipsychotics would perform differently on ToM tasks. Groups receiving Typicals (n=23), Clozapine (n=18), Olanzapine (n=20) or Risperidone (n=23) and a Control group of healthy volunteers (n=24) were matched for age, gender, handedness and education. ToM functioning was assessed with picture sequence, second-order belief and faux-pas tests. Schizophrenic groups performed similarly to controls on non-ToM conditions. The Olanzapine and Clozapine groups performed similarly to Controls on ToM tasks. The Typicals and Risperidone groups performed worse than the other groups on ToM tasks. We concluded that ToM performance of schizophrenic patients is influenced by the antipsychotic they are taking. Our results suggest that olanzapine or clozapine but not typicals or risperidone may improve or protect ToM ability.

  13. Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene

    NARCIS (Netherlands)

    Hoekstra, Pieter J.; Troost, Pieter W.; Lahuis, Bertine E.; Mulder, Hans; Mulder, Erik J.; Franke, Barbara; Buitelaar, Jan K.; Anderson, George M.; Scahill, Lawrence; Minderaa, Ruud B.

    2010-01-01

    Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age-and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-label, fle

  14. Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene.

    NARCIS (Netherlands)

    Hoekstra, P.J.; Troost, P.W.; Lahuis, B.E.; Mulder, H.; Mulder, E.J.H.; Franke, B.; Buitelaar, J.K.; Anderson, G.M.; Scahill, L.; Minderaa, R.B.

    2010-01-01

    Abstract Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age- and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-

  15. A Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Adolescents and Young Adults with Anorexia Nervosa: A Pilot Study

    Science.gov (United States)

    Hagman, Jennifer; Gralla, Jane; Sigel, Eric; Ellert, Swan; Dodge, Mindy; Gardner, Rick; O'Lonergan, Teri; Frank, Guido; Wamboldt, Marianne Z.

    2011-01-01

    Objective: The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa. Method: Forty female subjects 12 to 21 years of age (mean, 16 years) with primary anorexia nervosa in an eating disorders program were randomized to receive…

  16. Risk of Hyperprolactinemia and Sexual Side Effects in Males 10-20 Years Old Diagnosed with Autism Spectrum Disorders or Disruptive Behavior Disorder and Treated with Risperidone

    NARCIS (Netherlands)

    Roke, Yvette; Buitelaar, Jan K.; Boot, Annemieke M.; Tenback, Diederik; van Harten, Peter N.

    2012-01-01

    Objective: The aim of this study was to investigate the long-term treatment effects of risperidone on prolactin levels and prolactin-related side effects in pubertal boys with autism spectrum disorders (ASD) and disruptive behavior disorders (DBD). Method: Physical healthy 10-20-year-old males with

  17. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.

    NARCIS (Netherlands)

    Reyes, M.; Buitelaar, J.K.; Toren, P.; Augustyns, I.; Eerdekens, M.

    2006-01-01

    OBJECTIVE: The authors compared the effects of maintenance versus withdrawal of risperidone treatment in children and adolescents with symptoms of disruptive behavior disorder. METHOD: Patients with disruptive behavior disorder (5-17 years of age and a range of intellect) who had responded to risper

  18. Literature Analysis of 153 Cases of Adverse Drug Reactions Induced by Risperidone%153例利培酮致不良反应的文献分析

    Institute of Scientific and Technical Information of China (English)

    周秋娟; 吴晓燕; 陈颖; 巢楠; 瞿发林; 黄家富

    2014-01-01

    Objective To study the clinical features of adverse reaction induced by risperidone. Methods 122 case reports of adverse drug reaction due to risperidone from 2000 to 2012 in China were collected and analyzed, which involved 153 patients. Results The adverse reactions of risperidone were correlated with individual differences, which mainly occurred in central and peripheral nervous system. Conclusion Pay attention to physical status of patients when use risperidone,slowly increase the dose and comply with the individualized principle.%目的:综合分析利培酮所致不良反应的临床特征。方法对2000~2012年国内文献中有关利培酮所致不良反应的病例报道122篇涉及153例患者进行汇总分析。结果利培酮所致不良反应主要累及的系统-器官为中枢及外周神经系统,不良反应的发生与患者的个体差异有关。结论利培酮用药时应注意给药速度不宜过快,遵循个体化原则,关注患者的身体状况。

  19. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

    OpenAIRE

    Honey, Garry D; Edward T Bullmore; Soni, William; Varatheesan, Malini; Williams, Steve C.R.; Sharma, Tonmoy

    1999-01-01

    Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia. Atypical antipsychotics have been shown to enhance frontal dopaminergic activity in animal models. We predicted that substitution of risperidone for typical antipsychotic drugs in the treatment of schizophrenia would be associated with enhanced functional activation of frontal...

  20. Risperidone Attenuates Modified Stress-Re-stress Paradigm-Induced Mitochondrial Dysfunction and Apoptosis in Rats Exhibiting Post-traumatic Stress Disorder-Like Symptoms.

    Science.gov (United States)

    Garabadu, Debapriya; Ahmad, Ausaf; Krishnamurthy, Sairam

    2015-06-01

    Mitochondria play a significant role in the pathophysiology of post-traumatic stress disorder (PTSD). Risperidone and paroxetine were evaluated for their effect on mitochondrial dysfunction and mitochondria-dependent apoptosis in discrete brain regions in modified stress re-stress (SRS) animal model of PTSD. Male rats were subjected to stress protocol of 2 h restraint and 20 min forced swim followed by halothane anesthesia on day 2 (D-2). Thereafter, rats were exposed to re-stress (forced swim) on D-8 and at 6-day intervals on D-14, D-20, D-26, and D-32. The rats were treated with risperidone (0.01, 0.1, and 1.0 mg/kg p.o.) and paroxetine (10.0 mg/kg p.o.) from D-8 to D-32. Risperidone at median dose and paroxetine ameliorated modified SRS-induced depressive-like symptom (increase in immobility period) in forced swim, anxiety-like behavior (decrease in percentage of open arm entries and time spent) in elevated plus maze and cognitive deficits (loss in spatial recognition memory) in Y-maze tests on D-32. Risperidone, but not paroxetine, attenuated modified SRS-induced decreases in plasma corticosterone levels. Risperidone ameliorated increase in the activity of mitochondrial respiratory complex (I, II, IV, and V), decreases in the levels of mitochondrial membrane potential, cytochrome-C and caspase-9 in the hippocampus, hypothalamus, pre-frontal cortex, and amygdala. However, both drugs attenuated modified SRS-induced increase in the number of apoptotic cells and caspase-3 levels in all the brain regions indicating anti-apoptotic activity of these drugs. Hence, these results suggest that anti-apoptotic activity could be a common mechanism for anti-PTSD-like effect irrespective of the pathways of apoptosis in the modified SRS model.

  1. No change of dopamine transporter density in basal ganglia after risperidone treatment in drug-naive children with Tourette's disorder

    Energy Technology Data Exchange (ETDEWEB)

    Ryu, W. K.; Ryu, Y. H.; Yoon, M. J.; Chun, K. A.; Lee, J. D. [College of Medicine, Univ. of Yonsei, Seoul (Korea, Republic of); Zee, D. Y. [Univ. of Inhwa, Incheon (Korea, Republic of); Choi, T. H. [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    2003-07-01

    Tourette's disorder (TD), which is characterized by multiple waxing and waning motor tics and one or more vocal tics, is known to be associated with abnormalities in the dopaminergic system. To testify our hypothesis that risperidone would improve tic symptoms of TD patients through the change of the dopaminergic system, we measured the DAT densities between drug-naive children with TD and normal children investigated the DAT density before and after treatment with risperidone in drug-naive children with TD, using lodine-123 labelled N-(3-iodopropen-2-yl)-2beta-carbomethoxy-3beta-(4-chlorophenyl) tropane(I-123 IPT) single photon emission computed tomography (SPECT). I-123 IPT SPECT imaging and Yale Global Tic Severity Scale-Korean version (YGTSS-K) for assessing the tic symptom severity were carried out before and after treatment with risperidone for 8 weeks in eight drug-naive children with TD. Eight normal children also underwent SPECT imaging 2 hours after an intravenous administration of I-123 IPT and carried out both quantitative and qualitative analyses using the obtained SPECT data, which were reconstructed for the assessment of the specific/non-specific DAT binding ratio in the basal ganglia. The drug-naive children with TD had a significantly greater increase in the specific/nonspecific DAT binding ratio of both basal ganglia compared with the normal children. However, no significant difference in the specific/nonspecific DAT binding ratio of the basal ganglia before and after treatment with riperidone in children with TD was not found, although tic symptoms were significantly improved with risperidone. These findings suggest that DAT densities are directly associated with the pathophysiology of TD, however, that the effect of risperidone on tic symptoms in children with TD is not attributed to the change of dopaminergic system.

  2. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

    Science.gov (United States)

    Honey, Garry D.; Bullmore, Edward T.; Soni, William; Varatheesan, Malini; Williams, Steve C. R.; Sharma, Tonmoy

    1999-01-01

    Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia. Atypical antipsychotics have been shown to enhance frontal dopaminergic activity in animal models. We predicted that substitution of risperidone for typical antipsychotic drugs in the treatment of schizophrenia would be associated with enhanced functional activation of frontal cortex. We measured cerebral blood oxygenation changes during periodic performance of a verbal working memory task, using functional MRI, on two occasions (baseline and 6 weeks later) in two cohorts of schizophrenic patients. One cohort (n = 10) was treated with typical antipsychotic drugs throughout the study. Risperidone was substituted for typical antipsychotics after baseline assessment in the second cohort (n = 10). A matched group of healthy volunteers (n = 10) was also studied on a single occasion. A network comprising bilateral dorsolateral prefrontal and lateral premotor cortex, the supplementary motor area, and posterior parietal cortex was activated by working memory task performance in both the patients and comparison subjects. A two-way analysis of covariance was used to estimate the effect of substituting risperidone for typical antipsychotics on power of functional response in the patient group. Substitution of risperidone increased functional activation in right prefrontal cortex, supplementary motor area, and posterior parietal cortex at both voxel and regional levels of analysis. This study provides direct evidence for significantly enhanced frontal function in schizophrenic patients after substitution of risperidone for typical antipsychotic drugs, and it indicates the potential value of functional MRI as a tool for longitudinal assessment of psychopharmacological effects on cerebral physiology. PMID:10557338

  3. Preparation and in-vitro characterization of Risperidone-cyclodextrin inclusion complexes as a potential injectable product

    Directory of Open Access Journals (Sweden)

    D Shukla

    2009-12-01

    Full Text Available "n  "n Background and the purpose of the study: This investigation deals with risperidone cyclodextrin (CD complexation for parenteral administration to improve its aqueous solubility which would be beneficial over immediate and sustained release formulations available in market especially for agitated and non-cooperative psychotic patients. "nMethods: The phase solubility study of the drug with β-CD, hydroxypropyl (HP-β-CD and γ-CD was conducted and CDs with higher stability constants were selected for complexation. The complexes of Risperidone with β-CD and HP-β-CD were prepared by precipitation and vacuum drying methods, respectively. Fourier transform-infrared, X-ray diffraction and differential scanning calorimetry techniques were used for characterization of complexes. Drug precipitation study of complex's solution in water for injection and 100 ml of 0.1 M pH 7.4 phosphate buffer saline and stability study in accelerated condition were also carried out. "nResults: The stability constants of the CD were in the following order: β-CD (341.953±11.87 M-1 > HP-β-CD (170.817± 5.93 M-1 > γ-CD (93.716 ± 3.25 M-1. CDs with high stability constants were selected to prepare the drug CD complex. The complexation efficiencies of β-CD and HP-β-CD were 95.23 ± 2.27% and 97.59 ±1.97%, respectively. Both types of CDs exhibited complexation at 1:2 molar stoichiometric ratio. The drug precipitation study indicated complete solubility (100% drug dissolution without a trace of precipitate within 5 mins. The complexes were found to be stable for a period of 3 months under accelerated stability conditions. Major conclusion:Stable complexes of risperidone were successfully formulated using both β-CD and HP-β-CD by simple and highly efficient methods of complexation for parenteral administration.

  4. The Comparison of the Effectiveness of Risperidone and Fluoxetine in Combination with Impulse Control Group Therapy on Improving of Impulsivity, and Relapse in Heroin Crack Addicts under Methadone Maintenance Therapy

    OpenAIRE

    Rohoallah Hadadi; Hamid reza Fathinaz; Mehdi Karimi; Saeed Akbari; Nafiseh Soltannejad

    2013-01-01

    Aim: The aim of the study was to compare the effectiveness of Risperidone and Fluoxetine in combination with impulse control group therapy on improving of impulsivity, and relapse in heroin crack addicts under methadone maintenance therapy. Method: In a semi-experimental study, 39 heroin crack addicts who were under Methadone maintenance treatment selected of addiction withdrawal centers in Tehran. The selected sample was randomly assigned to three groups. First group was under (Risperidone 1...

  5. Solid lipid nanoparticles (SLN)--based hydrogels as potential carriers for oral transmucosal delivery of risperidone: preparation and characterization studies.

    Science.gov (United States)

    Silva, A C; Amaral, M H; González-Mira, E; Santos, D; Ferreira, D

    2012-05-01

    Two different solid lipid nanoparticles (SLN)-based hydrogels (HGs) formulations were developed as potential mucoadhesive systems for risperidone (RISP) oral transmucosal delivery. The suitability of the prepared semi-solid formulations for application on oral mucosa was assessed by means of rheological and textural analysis, during 30 days. Plastic flows with thixotropy and high adhesiveness were obtained for all the tested systems, which predict their success for the oral transmucosal application proposed. The SLN remained within the colloidal range after HGs preparation. However, after 30 days of storage, a particle size increase was detected in one type of the HGs formulations. In vitro drug release studies revealed a more pronounced RISP release after SLN hydrogel entrapment, when compared to the dispersions alone. In addition, a pH-dependent release was observed as well. The predicted in vivo RISP release mechanism was Fickian diffusion alone or combined with erosion.

  6. Obsessive-Compulsive Symptoms Associated with Clozapine and Risperidone Treatment: Three Case Reports and Review of the Literature

    Directory of Open Access Journals (Sweden)

    Chiao-Li Ke

    2004-06-01

    Full Text Available Treatment-emergent obsessive-compulsive symptoms (OCSs have raised concern since the widespread introduction of serotonin-dopamine antagonists (SDAs for the treatment of schizophrenia. Further investigations of SDA-emergent OCSs and their response to anti-obsessional agents will be beneficial for clinicians in helping patients who suffer from this problem. We present three cases of schizophrenia in which distressing OCSs occurred during clozapine or risperidone treatment. OCSs were assessed consecutively using the Yale-Brown Obsessive-Compulsive Scale. The OCSs of these three patients were responsive to anti-obsessional agents, including fluvoxamine, clomipramine, and paroxetine. We also review the current literature and discuss the possible pathophysiology and psychopathology of SDA-emergent OCSs.

  7. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

    Science.gov (United States)

    Bobes, J; Garc A-Portilla, M P; Rejas, J; Hern Ndez, G; Garcia-Garcia, M; Rico-Villademoros, F; Porras, A

    2003-01-01

    Atypical antipsychotics seem to differ mainly in their tolerability profile. The aim of this cross-sectional study, the Estudio de Investigaci n de Resultados en Esquizofrenia (Outcomes Research Study in Schizophrenia; EIRE study), was to assess in a clinical setting the frequency of several side-effects related to haloperidol, risperidone, olanzapine, and quetiapine. This article addresses sexual dysfunction and other reproductive side-effects (gynecomastia, menorrhage, amenorrhea, and galactorrhea). We recruited outpatients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association, 1994) criteria and who had received a single antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) for at least 4 weeks. During a single visit, we collected data, including demographic and clinical characteristics, current antipsychotic and concomitant treatment, and adverse effects listed in a modified version of the UKU Scale. We used a Chi-squared test to determine pairs comparisons of the frequency of adverse reactions between treatments. To estimate risk of a given adverse reaction with a given treatment, we used a logistic regression method. We assessed 636 evaluable patients out of 669 recruited. Frequency of sexual dysfunction was high with haloperidol (38.1%) and also with olanzapine (35.3%), quetiapine (18.2%), and risperidone (43.2%). We found the frequency of other reproductive side-effects to be relatively low with all four drugs: haloperidol (6.9%), olanzapine (6.4%), quetiapine (2.7%), and risperidone (11.7%). Sexual dysfunction appeared to be dose-related with haloperidol, risperidone, and olanzapine. Risperidone and olanzapine showed a higher risk of sexual dysfunction and other reproductive sideeffects than haloperidol. Quetiapine showed a lower risk of sexual dysfunction during short-term treatment ( 12 weeks) are lacking. Our results suggest that none of the atypical

  8. Risperidone Effects on Brain Dynamic Connectivity—A Prospective Resting-State fMRI Study in Schizophrenia

    Science.gov (United States)

    Lottman, Kristin K.; Kraguljac, Nina V.; White, David M.; Morgan, Charity J.; Calhoun, Vince D.; Butt, Allison; Lahti, Adrienne C.

    2017-01-01

    Resting-state functional connectivity studies in schizophrenia evaluating average connectivity over the entire experiment have reported aberrant network integration, but findings are variable. Examining time-varying (dynamic) functional connectivity may help explain some inconsistencies. We assessed dynamic network connectivity using resting-state functional MRI in patients with schizophrenia, while unmedicated (n = 34), after 1 week (n = 29) and 6 weeks of treatment with risperidone (n = 24), as well as matched controls at baseline (n = 35) and after 6 weeks (n = 19). After identifying 41 independent components (ICs) comprising resting-state networks, sliding window analysis was performed on IC timecourses using an optimal window size validated with linear support vector machines. Windowed correlation matrices were then clustered into three discrete connectivity states (a relatively sparsely connected state, a relatively abundantly connected state, and an intermediately connected state). In unmedicated patients, static connectivity was increased between five pairs of ICs and decreased between two pairs of ICs when compared to controls, dynamic connectivity showed increased connectivity between the thalamus and somatomotor network in one of the three states. State statistics indicated that, in comparison to controls, unmedicated patients had shorter mean dwell times and fraction of time spent in the sparsely connected state, and longer dwell times and fraction of time spent in the intermediately connected state. Risperidone appeared to normalize mean dwell times after 6 weeks, but not fraction of time. Results suggest that static connectivity abnormalities in schizophrenia may partly be related to altered brain network temporal dynamics rather than consistent dysconnectivity within and between functional networks and demonstrate the importance of implementing complementary data analysis techniques. PMID:28220083

  9. Costi ed effetti di Risperidone Long Acting (RLA rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia

    Directory of Open Access Journals (Sweden)

    Lorenzo G. Mantovani

    2004-03-01

    Full Text Available Objective: to estimate the costs and effects of long-acting risperidone (LAR in the treatment of schizophrenic patients in Italy, as compared to conventional and oral atypical antipsychotics. Methods: a discrete event model was used. The model simulates patients. history for every single therapeutic alternative and selects incident events, on the basis of pre-defined probability distribution-powered, randomized repetitions. The model operates on two types of parameters: patient characteristics and time-dependent variables. Patient characteristics (age, sex, illness profile and severity, probability of incurring in an adverse event and potential dangerousness remain fixed during the 5 simulated years. Time-dependent variables are subject to changes and include outpatient visits, severity of psychotic episodes, symptom-scores, compliance, incidence of adverse effects, site of treatment and dangerousness. Three treatments have been selected: scenario 1 begins with LAR, switches to olanzapine and then to clozapine; scenario 2 starts with olanzapine, switches to oral risperidone and ends with clozapine. Direct medical costs have been computed on the basis of psychiatric visits, drug costs and costs of the institution in which the patient is treated (hospital, rehabilitation clinic, etc. Outcome measures were number of psychotic episodes in 5 years, total time spent during these episodes and cumulative score of positive and negative symptoms at 5 years. Information on alternatives, transition probabilities, model structure and health resources utilization were derived from the literature and from a panel of experts. Results: it has been estimated that LAR is economically dominant (more effective at lower cost respect to oral atypical antipsychotics, being able to prevent 0.87 psychotic episodes per patient, with a net cost saving of 4,773 euro per patient. Sub-group analysis indicate that LAR is always more effective than the considered alternatives

  10. Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

    Science.gov (United States)

    Samadi, Roya; Soluti, Susan; Daneshmand, Reza; Assari, Shervin; Manteghi, Ali Akhoundpour

    2017-01-01

    Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in 2012–2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4–8 mg/d) of ondansetron (n=18) or with a placebo (n=20) for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Wechsler’s Adult Intelligence Scale-Revised (WAIS-R), and Hamilton’s Rating Scale for Depression (HRSD) at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16) were used to analyze the data. The statistical significance was set atPWAIS-R scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. The administration of ondansetron significantly improved visual memory based on the subtests of the WAIS (P<0.05). Ondansetron had no positive effects on depressive symptoms (effect size=0.13). Conclusion: This study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. Trial Registration Number: IRCT201112125280N7 PMID:28293046

  11. 肌注利培酮微球与口服利培酮治疗精神分裂症疗效研究%Studies on the Eficacy of Intramuscular Risperidone Microspheres and Oral Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    梁松新; 王秋琴; 麦以成; 邓良华

    2013-01-01

      目的探讨肌注利培酮微球与口服利培酮治疗精神分裂症的疗效,为临床选择药物提供依据.方法将80例精神分裂症患者随机分成肌注利培酮微球(RLAI)组及口服利培酮片组,治疗12周.在治疗第1、4、8、12周用阳性与阴性症状量表(PANSS)、临床疗效总评量表(CGI-SI)、不良反应量表(TESS)评定疗效和不良反应.结果两组PANSS总分及CGI-SI评分均比治疗前显著下降(P<0.01),与基线比较,PANSS评分自4周末以后均出现显著差异,两组疗效相当.RLAI组的不良反应明显低于口服利培酮片组(P<0.05).结论肌注利培酮微球与口服利培酮片治疗精神分裂症的疗效相当,RLAI组的不良反应较口服利培酮少而轻.肌注利培酮微球治疗精神分裂症安全有效,患者对治疗依从性比口服利培酮更好.%Objective To investigate the efficacy of intramuscular risperidone microspheres and oral risperidone in the treatment of schizophrenia, and to provide the basis for clinical drug of choice. Methods 80 cases of patients with schizophrenia were randomly divided into intramuscular risperidone microspheres(RLAI) group and the oral risperidone piece group, 12 weeks of treatment. Evaluate the efficacy and adverse reactions in the treatment of 1, 4, 8 and 12 weeks using the Positive and Negative Syndrome Scale(PANSS), the Clinical Global Impression(CGI-SI), adverse reactions Scale(TESS). Results The PANSS total score and CGI-SI score in both groups was significantly decreased(P<0.01) than before treatment. Compared with baseline, there are significant differences in the PANSS score after 4 weeks. Treatment efficiency in two group is very close to. The adverse drug reactions of RLAI group was significantly lower than the oral risperidone group(P<0.05). Conclusion The efficacy of intramuscular risperidone microspheres and oral risperidone tablets in the treatment of schizophrenia is very close to, The RLAI group adverse reactions are

  12. 阿立哌唑与利培酮治疗精神分裂症疗效比较%Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵辉

    2014-01-01

    目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效。方法将我院2012年10月-2013年6月收治的40例精神分裂症患者按随机数字表法随机分为阿立哌唑组和利培酮组各20例,分别使用阿立哌唑和利培酮对两组患者进行治疗,将两组治疗效果按照CCMD-3精神分裂症的诊断标准进行评价,依据副反应量表( TESS )评定副反应,以阳性与阴性症状量表( PANSS)减分率对疗效进行评定。结果阿立哌唑组痊愈9例,7例显著好转,3例好转,1例无效;利培酮组痊愈10例,5例显著好转,3例好转,2例无效。两组间的疗效比较无显著性差异。阿立哌唑组5例出现不良反应,占25%;利培酮组出现不良反应的有12例,占60%,阿立哌唑组不良反应总发生率显著低于利培酮组(χ2=5.013, P<0.05)。结论阿立哌唑与利培酮治疗精神分裂症的疗效显著,在治疗过程中,两种药物各有千秋,但在不良反应发生率方面,阿立哌唑低于利培酮,阿立哌唑的安全性高于利培酮。%Objective To analyze and compare aripiprazole and risperidone in the treatment of schizophrenia treatment .Methods 40 cases of patients with schizophrenia in hospital from October 2012 to June 2013 were randomly divided into aripiprazole group and the risperidone group,respectively,the two groups of patients were evaluated according to CCMD -3 diagnostic criteria,TESS and PANSS. Results In aripiprazole group ,9 cases recure ,7 cases were significantly improved ,3 cases improved ,and one case was invalid .In risper-idone group,10 cases cured,5 cases were significantly improved,3 cases improved,2 cases were ineffective.There was no significant difference in the efficacy between the two groups (P>0.05).Aripiprazole group had 5 cases of adverse reactions (25%),risperidone group had 12 cases of adverse reactions (60%),incidence of adverse reactions in aripiprazole group was

  13. Comparison of the effects of methylphenidate and the combination of methylphenidate and risperidone in preschool children with attention-deficit hyperactivity disorder

    Directory of Open Access Journals (Sweden)

    Parvin Safavi

    2016-01-01

    Full Text Available Attention-deficit hyperactivity disorder (ADHD is a common psychiatric disorder among preschool children but the number of controlled clinical trials regarding psychopharmacological treatment in this age group is limited. The aim of this study was to compare methylphenidate with the combination of methylphenidate and risperidone in preschool children with ADHD. Forty-two preschool children, aged 3-6 years, diagnosed with ADHD by a child and adolescent psychiatrist according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-Text Revision criteria, were enrolled in a 6-week, single-blind clinical trial and administered with methylphenidate (5-30 mg/dl or the combination of methylphenidate and risperidone (0.25-2 mg/dl in Iran. Treatment outcomes were assessed using the Conners′ Rating Scale and Clinical Global Impression (CGI Scale at baseline and 3 and 6 weeks after starting the drugs administration. Side effects were rated by a checklist and body weight was measured at each visit. There were no significant differences between the two protocols in Parent Conners′ Rating Scale scores (P > 0.05 and CGI scores (P > 0.05. Both groups showed a significant improvement in ADHD symptoms over the 6 weeks of treatment for Parent Conners′ Rating Scale (P < 0.001. The combination group used significantly lower doses of methylphenidate compared to the other group (P = 0.002. The most common adverse effects were anorexia (21.7% and daytime drowsiness (17.4% in combination treatment group and insomnia (33.3% and anorexia (25% in methylphenidate group. Risperidone and methylphenidate may be effective and well tolerated in preschool children with ADHD, and adding risperidone to methylphenidate may decrease the occurrence of some side effects of methylphenidate such as insomnia and anorexia and lower the dose of methylphenidate may be needed to control symptoms.

  14. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence.

    Science.gov (United States)

    Marcus, Monica M; Jardemark, Kent; Malmerfelt, Anna; Gertow, Jens; Konradsson-Geuken, Asa; Svensson, Torgny H

    2012-04-01

    Antidepressant drugs are frequently used to treat affective symptoms in schizophrenia. We have recently shown that escitalopram, but not citalopram or R-citalopram, increases firing rate and burst firing of midbrain dopamine neurons, potentiates cortical N-methyl-D-aspartate (NMDA) receptor-mediated transmission and enhances cognition, effects that might influence the outcome of concomitant antipsychotic medication. Here, we studied, in rats, the behavioral and neurobiological effects of adding escitalopram, citalopram, or R-citalopram to the second-generation antipsychotic drug risperidone. We examined antipsychotic efficacy using the conditioned avoidance response (CAR) test, extrapyramidal side effect (EPS) liability using a catalepsy test, dopamine outflow in the medial prefrontal cortex (mPFC) and nucleus accumbens using in vivo microdialysis in freely moving animals, and NMDA receptor-mediated transmission in the mPFC using intracellular electrophysiological recording in vitro. Only escitalopram (5 mg/kg), but not citalopram (10 mg/kg), or R-citalopram (10 mg/kg), dramatically enhanced the antipsychotic-like effect of a low dose of risperidone (0.25 mg/kg), without increasing catalepsy. Given alone, escitalopram, but not citalopram or R-citalopram, markedly enhanced both cortical dopamine output and NMDA receptor-mediated transmission. Addition of escitalopram and to some extent R-citalopram, but not citalopram, significantly enhanced both cortical dopamine output and cortical NMDA receptor-mediated transmission induced by a suboptimal dose/concentration of risperidone. These results suggest that adjunct treatment with escitalopram, but not citalopram, may enhance the effect of a subtherapeutic dose of risperidone on positive, negative, cognitive, and depressive symptoms in schizophrenia, yet without increased EPS liability.

  15. Comparison of the effects of methylphenidate and the combination of methylphenidate and risperidone in preschool children with attention-deficit hyperactivity disorder

    Science.gov (United States)

    Safavi, Parvin; Dehkordi, Ali Hasanpour; Ghasemi, Nasim

    2016-01-01

    Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder among preschool children but the number of controlled clinical trials regarding psychopharmacological treatment in this age group is limited. The aim of this study was to compare methylphenidate with the combination of methylphenidate and risperidone in preschool children with ADHD. Forty-two preschool children, aged 3–6 years, diagnosed with ADHD by a child and adolescent psychiatrist according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-Text Revision criteria, were enrolled in a 6-week, single-blind clinical trial and administered with methylphenidate (5–30 mg/dl) or the combination of methylphenidate and risperidone (0.25–2 mg/dl) in Iran. Treatment outcomes were assessed using the Conners' Rating Scale and Clinical Global Impression (CGI) Scale at baseline and 3 and 6 weeks after starting the drugs administration. Side effects were rated by a checklist and body weight was measured at each visit. There were no significant differences between the two protocols in Parent Conners' Rating Scale scores (P > 0.05) and CGI scores (P > 0.05). Both groups showed a significant improvement in ADHD symptoms over the 6 weeks of treatment for Parent Conners' Rating Scale (P < 0.001). The combination group used significantly lower doses of methylphenidate compared to the other group (P = 0.002). The most common adverse effects were anorexia (21.7%) and daytime drowsiness (17.4%) in combination treatment group and insomnia (33.3%) and anorexia (25%) in methylphenidate group. Risperidone and methylphenidate may be effective and well tolerated in preschool children with ADHD, and adding risperidone to methylphenidate may decrease the occurrence of some side effects of methylphenidate such as insomnia and anorexia and lower the dose of methylphenidate may be needed to control symptoms. PMID:27833894

  16. Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study.

    Science.gov (United States)

    Liemburg, Edith J; van Es, Frank; Knegtering, Henderikus; Aleman, André

    2017-10-03

    Impaired function of prefrontal brain networks may be the source of both negative symptoms and neurocognitive problems in psychotic disorders. Whereas most antipsychotics may decrease prefrontal activation, the partial dopamine D2-receptor agonist aripiprazole is hypothesized to improve prefrontal function. This study investigated whether patients with a psychotic disorder would show stronger activation of prefrontal areas and associated regions after treatment with aripiprazole compared to risperidone treatment. In this exploratory pharmacological neuroimaging study, 24 patients were randomly assigned to either aripiprazole or risperidone. At baseline and after nine weeks treatment they underwent an interview and MRI session. Here we report on brain activation (measured with arterial spin labeling) during performance of two tasks, the Tower of London and the Wall of Faces. Aripiprazole treatment decreased activation of the middle frontal, superior frontal and occipital gyrus (ToL) and medial temporal and inferior frontal gyrus, putamen and cuneus (WoF), while activation increased after risperidone. Activation increased in the ventral anterior cingulate and posterior insula (ToL), and superior frontal, superior temporal and precentral gyrus (WoF) after aripiprazole treatment and decreased after risperidone. Both treatment groups had increased ventral insula activation (ToL) and middle temporal gyrus (WoF), and decreased occipital cortex, precuneus and caudate head activation (ToL) activation. In conclusion, patients treated with aripiprazole may need less frontal resources for planning performance and may show increased frontotemporal and frontostriatal reactivity to emotional stimuli. More research is needed to corroborate and extend these preliminary findings. Copyright © 2017 Elsevier Inc. All rights reserved.

  17. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial

    Science.gov (United States)

    Riahi, Forough; Tashakori, Ashraf; Abdi, Leila

    2016-01-01

    Background Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%. Objective To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children. Methods In a 6-week double-blind clinical trial, the efficacy of Risperidone 0.5–2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3–6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners’ Parent Rating Scale (CPRS-48), Children’s Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher’s exact tests in the SPSS 19. Results During the 6 weeks, the decline in points was seen in Conner’s rating scale and in ADHD-RS score in Risperidone and Haloperidol groups (p0.05). Conclusions Haloperidol and Risperidone possibly can be an acceptable treatment choice in the ADHD treatment of 3- to 6-year-old children. Trial registration The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2015082623766N1. Funding This work was financially supported by grant (ref. no.: U-93130) from the vice chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences. PMID:27790334

  18. Controlled clinical treatment of the domestic Ziprasidone and risperidone%国产齐拉西酮与维思通的临床对照治疗

    Institute of Scientific and Technical Information of China (English)

    李永强; 冯金河

    2013-01-01

    Objective:comparison curative effect and untoward effect between Ziprasidone and risperidone. Methods:Sixty patients with schizophrenia were randomly divided into two groups: thirty patients were in Ziprasidone's group and the other thirty patients were in risperidone's group, after treatment for six weekends, used positive and negative symptom scale (PANSS) and treatment emergent symptoms scale (TESS) to evaluate the efficacy. Results: Ziprasidone and risperidone have equal therapy, but the incidence of adverse reaction and symptom severity of Ziprasidone was significantly lower than risperidone, especially, Ziprasidone has a small influence in mammotropic hormone and weight. Conclusion: Ziprasidone for schizophrenia have a good efficacy, few untoward effects and good compliance.%目的对比国产齐拉西酮与维思通的疗效和不良反应。方法对60例精神分裂症患者随机分为国产齐拉西酮组30例和维思通组30例,进行相应的药物治疗,疗程6周,采用PANSS量表和TESS副反应量表进行评价。结果国产齐拉西酮和维思通疗效相当,但国产齐拉西酮的不良反应发生率和症状严重程度显著低于维思通,特别对催乳素和体重的影响明显较小,同时具有良好的依从性。结论国产齐拉西酮治疗精神分裂症疗效确切,不良反应少,依从性好。

  19. Establishment of the sterility test method for risperidone for depot suspension%注射用利培酮微球无菌检查法的建立

    Institute of Scientific and Technical Information of China (English)

    王似锦; 刘文杰; 高春

    2013-01-01

    Objective:To establish the method of sterility test for risperidone for depot suspension.Methods:Sterility test of risperidone for depot suspension was carried out using the technique of direct inoculation,and the validation test was accomplished according to CP 2010.Results:As a result of the method validation of sterility test,all the test strains grew well.The established method was suitable for the sterility test of risperidone for depot suspension.Conclusion:Sterility test of risperidone for depot suspension is composed of outer sterility test and inner sterility test.Dimethyl sulfoxide (DMSO) can be used for inner sterility test as a solvent because it can dissolve and break the microspheres.%目的:建立注射用利培酮微球的无菌检查法.方法:采用直接接种法进行利培酮微球的无菌检查,并按照《中华人民共和国药典》的要求进行了方法学验证试验研究.结果:经过方法学验证,各验证菌生长良好,所建立的方法可用于注射用利培酮微球的无菌检查.结论:注射用利培酮微球的无菌检查应包括表面无菌检查和内部无菌检查.二甲基亚砜(DMSO)可作为溶剂对微球进行溶解和破碎,从而进行内部无菌检查.

  20. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial

    Directory of Open Access Journals (Sweden)

    Parvin Safavi

    2016-01-01

    Full Text Available Although pharmacotherapy with atypical antipsychotics is common in child psychiatry, there has been little research on this issue. To compare the efficacy and safety of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorders comorbid with attention deficit-hyperactivity disorder (ADHD. Randomized clinical trial conducted in a university-affiliated child psychiatry clinic in southwest Iran. Forty 3-6-year-old children, diagnosed with oppositional defiant disorder comorbid with ADHD, were randomized to an 8-week trial of treatment with risperidone or aripiprazole (20 patients in each group. Assessment was performed by Conners′ rating scale-revised and clinical global impressions scale, before treatment, and at weeks 2, 4, and 8 of treatment. The data were analyzed by SPSS version 16. Mean scores between the two groups were compared by analysis of variance and independent and paired t-test. Mean scores of Conners rating scales were not different between two groups in any steps of evaluation. Both groups had significantly reduced scores in week 2 of treatment (P = 0.00, with no significant change in subsequent measurements. Rates of improvement, mean increase in weight (P = 0.894, and mean change in fasting blood sugar (P = 0.671 were not significantly different between two groups. Mean serum prolactin showed a significant increase in risperidone group (P = 0.00. Both risperidone and aripiprazole were equally effective in reducing symptoms of ADHD and oppositional defiant disorder, and relatively safe, but high rates of side effects suggest the cautious use of these drugs in children.

  1. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.

    Science.gov (United States)

    Ryckmans, V; Kahn, J P; Modell, S; Werner, C; McQuade, R D; Kerselaers, W; Lissens, J; Sanchez, R

    2009-05-01

    This study evaluated the safety/tolerability and effectiveness of aripiprazole titrated-dose versus fixed-dose switching strategies from risperidone in patients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues. Patients were randomized to an aripiprazole titrated-dose (starting dose 5 mg/day) or fixed-dose (dose 15 mg/day) switching strategy with risperidone down-tapering. Primary endpoint was rate of discontinuation due to adverse events (AEs) during the 12-week study. Secondary endpoints included positive and negative syndrome scale (PANSS), clinical global impressions - improvement of illness scale (CGI-I), preference of medication (POM), subjective well-being under neuroleptics (SWN-K) and GEOPTE (Grupo Español para la Optimización del Tratamiento de la Esquizofrenia) scales. Rates of discontinuations due to AEs were similar between titrated-dose and fixed-dose strategies (3.5% vs. 5.0%; p=0.448). Improvements in mean PANSS total scores were similar between aripiprazole titrated-dose and fixed-dose strategies (-14.8 vs. -17.2; LOCF), as were mean CGI-I scores (2.9 vs. 2.8; p=0.425; LOCF) and SWN-K scores (+8.6 vs.+10.3; OC,+7.8 vs.+9.8; LOCF). Switching can be effectively and safely achieved through a titrated-dose or fixed-dose switching strategy for aripiprazole, with down-titration of risperidone.

  2. Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial.

    Science.gov (United States)

    Habibi, Nastaran; Dodangi, Nasrin; Nazeri, Ali

    2017-01-01

    Background: In the treatment of bipolar disorder in youths, often more than one medication should be prescribed. In the current study, we compared the efficacy and tolerability of the combination of lithium and quetiapine with lithium and risperidone in the treatment of manic or mixed episodes in children and adolescents. Methods: Thirty patients (aged 10-18 years) who were hospitalized for a manic or mixed episode were recruited from consecutive inpatient admissions to the Child and Adolescent Psychiatric Unit at Razi Psychiatric Hospital (University of Social Welfare and Rehabilitation Sciences, Tehran, Iran) from June 2012 to September. They were randomly treated with lithium (with the usual dose to achieve blood levels 0.8-1) and quetiapine (400-600 mg per day) or risperidone (0.5-6 mg per day). The primary outcome measure with respect to efficacy was the mean decrease in Young Mania Rating Scale (YMRS) score. Side effects were also assessed. The independent t test and two-factor repeated measure analysis of variance (ANOVA) was used for data analysis. P-value of less than 0.05 was considered statistically significant. Results: The reduction in YMRS scores was similar in both groups. The remission rate (YMRS lithium in manic or mixed episodes of bipolar I disorder in children and adolescents was not superior to lithium and risperidone, but was associated with fewer complications.

  3. 2007年美国专利到期的药物精选(Ⅵ)神经系统药物

    Institute of Scientific and Technical Information of China (English)

    周和平

    2007-01-01

    @@ 1.利培酮 中文商品名:维思通;中文其它名:利哌利酮;英文通用名:risperidone;英文商品名:Risperdal. 美国专利名称:3-哌啶基-取代的 1,2-苯并异(口恶)唑和1,2-苯并异噻唑(专利号:US4804663 )

  4. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.

    Science.gov (United States)

    Arnold, L Eugene; Gadow, Kenneth D; Farmer, Cristan A; Findling, Robert L; Bukstein, Oscar; Molina, Brooke S G; Brown, Nicole V; Li, Xiaobai; Rundberg-Rivera, E Victoria; Bangalore, Srihari; Buchan-Page, Kristin; Hurt, Elizabeth A; Rice, Robert; McNamara, Nora K; Aman, Michael G

    2015-04-01

    In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms. This secondary study explores outcomes other than DBD and attention-deficit/hyperactivity disorder (ADHD) as measured by the Child and Adolescent Symptom Inventory-4R (CASI-4R). A total of 168 children ages 6-12 with severe aggression (physical harm), DBD, and ADHD were randomized to parent training plus stimulant plus placebo (basic treatment) or parent training plus stimulant plus risperidone (augmented treatment) for 9 weeks. All received only parent training plus stimulant for the first 3 weeks, then those with room for improvement received a second drug (placebo or risperidone) for 6 weeks. CASI-4R category item means at baseline and week 9 were entered into linear mixed-effects models for repeated measures to evaluate group differences in changes. Mediation of the primary DBD outcome was explored. Parent ratings were nonsignificant with small/negligible effects, but teacher ratings (n=46 with complete data) showed significant augmented treatment advantage for symptoms of anxiety (p=0.013, d=0.71), schizophrenia spectrum (p=0.017, d=0.45), and impairment in these domains (p=0.02, d=0.26), all remaining significant after false discovery rate correction for multiple tests. Improvement in teacher-rated anxiety significantly (p=0.001) mediated the effect of risperidone augmentation on the primary outcome, the Disruptive-total of the parent-rated Nisonger Child Behavior Rating Form. Addition of risperidone to parent training plus stimulant improves not only parent-rated DBD as previously reported, but also teacher-rated anxiety-social avoidance. Improvement in anxiety mediates improvement in DBD, suggesting anxiety-driven fight-or-flight disruptive behavior with aggression, with implications for potential treatment strategies. Clinicians should attend to

  5. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents.

    Science.gov (United States)

    Geller, Barbara; Luby, Joan L; Joshi, Paramjit; Wagner, Karen Dineen; Emslie, Graham; Walkup, John T; Axelson, David A; Bolhofner, Kristine; Robb, Adelaide; Wolf, Dwight V; Riddle, Mark A; Birmaher, Boris; Nusrat, Nasima; Ryan, Neal D; Vitiello, Benedetto; Tillman, Rebecca; Lavori, Philip

    2012-05-01

    There was a paucity of comparative pharmacological research for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. To investigate which medication to administer first to antimanic medication-naive subjects. The Treatment of Early Age Mania (TEAM) study recruited 6- to 15-year-old children and adolescents with DSM-IV bipolar I disorder (manic or mixed phase) at 5 US sites from 2003 to 2008 into a controlled, randomized, no-patient-choice, 8-week protocol. Blinded, independent evaluators conducted all baseline and end-point assessments. Subjects received a titrated schedule of lithium, divalproex sodium, or risperidone. Medications were increased weekly only if there was inadequate response, and no dose-limiting adverse effects, to maximum doses of lithium carbonate (1.1-1.3 mEq/L), divalproex sodium (111-125 μg/mL), and risperidone (4-6 mg). Primary outcome measures were the Clinical Global Impressions for Bipolar Illness Improvement-Mania and the Modified Side Effects Form for Children and Adolescents. There were 279 antimanic medication-naive subjects (mean [SD] age, 10.1 [2.8] years; 50.2% female) who had the following characteristics: 100% elated mood and/or grandiosity, 77.1% psychosis, 97.5% mixed mania, 99.3% daily rapid cycling, and mean (SD) mania duration of 4.9 (2.5) years. The mean (SD) titrated lithium level was 1.09 (0.34) mEq/L, and the mean (SD) divalproex sodium level was 113.6 (23.0) μg/mL. The mean (SD) titrated risperidone dose was 2.57 (1.21) mg. Higher response rates occurred with risperidone vs lithium (68.5% vs 35.6%; χ(2)(1) = 16.9, P < .001) and vs divalproex sodium (68.5% vs 24.0%; χ(2)(1) = 28.3, P < .001). Response to lithium vs divalproex sodium did not differ. The discontinuation rate was higher for lithium than for risperidone (χ(2)(1) = 6.4, P = .011). Increased weight gain, body mass index, and prolactin level occurred with risperidone vs lithium (F(1,212) = 45.5, P < .001; F(1,212) = 39

  6. Effect of Smoking on Pharmacokinetics and Clinical Efficacy of Risperidone%吸烟对利培酮药代动力学及疗效的影响

    Institute of Scientific and Technical Information of China (English)

    曹民佑

    2014-01-01

    目的:探讨吸烟对利培酮药代动力学和血药浓度的影响,以及利培酮血药浓度与临床疗效及不良反应之间的关系。方法采用反相高效液相色谱法测定利培酮及9-羟利培酮血药浓度,并进行药代动力学参数研究,采用简明精神病症状评定量表(BPRS)、阳性和阴性症状量表(SAPS、SANS)和副反应量表(TESS)评定临床疗效和不良反应。结果吸烟者的利培酮和9-羟利培酮的消除速率较非吸烟者快[消除速率常数(K)更高],且其消除半衰期(T1/2)较短,达峰浓度(Cmax)和第2周末稳态浓度谷值均较低(P<0.05或P<0.01)。利培酮血药浓度及利培酮+9-羟利培酮总浓度与TESS增分值呈正相关(r=0.42~0.62,均P<0.01),与BPRS、SANS和SAPS的减分率无显著相关性(P>0.05)。以治疗8周BPRS总分减分率≥25%为界,划分有效组和无效组进行血药浓度比较,无效组利培酮及利培酮+9-羟利培酮血药浓度低于有效组(P<0.05)。结论吸烟可加快利培酮的代谢,利培酮和9-羟利培酮总的血药浓度在20~60μg·L-1范围内较为适宜,疗效较好,不良反应较少。%Objective To evaluate the influence of smoking on the pharmacokinetics and plasma concentrations of risperidone, and to investigate the relationships of blood risperidone concentrations to clinical efficacies and adverse reactions. Methods The plasma concentrations of risperidone and 9-hydroxyrisperidone were measured by RP-HPLC and pharmacokinetic studies were performed in patients. Clinical efficacies and adverse reactions were evaluated with Brief Psychiatric Reacting Scale (BPRS),Scale for the Assessment of Positive Symptoms (SAPS),Scale for the Assessment of Negative Symptoms(SANS) and Treatment Emergent Symptom Scale(TESS). Results Compared with patients who do not smoke, elimination rate constant of risperidone and 9-hydroxyrisperidone increased and

  7. Estudio de estabilidad de tabletas de risperidona 3 mg Study of stability of Risperidone (3 mg tablets

    Directory of Open Access Journals (Sweden)

    Caridad Margarita García Peña

    2010-06-01

    Full Text Available Se desarrolló el estudio de estabilidad de las tabletas de risperidona 3 mg y se determinó su fecha de vencimiento. Este estudio se realizó por los métodos de vida de estante y de estabilidad acelerada mediante cromatografía líquida de alta eficiencia, validados en el Centro de Investigación y Desarrollo de Medicamentos. El estudio de vida de estante se desarrolló por un periodo de 24 meses a temperatura ambiente; mientras que el estudio de estabilidad acelerada se efectuó sometiendo el producto a la influencia de la luz, la humedad y la temperatura; se realizó el análisis durante 3 meses, para los 2 primeros y durante 6 meses para el estudio de la temperatura. La formulación de risperidona tabletas 3 mg cumplió con las especificaciones de calidad descritas en la Farmacopea. Los resultados del estudio de estabilidad por vida de estante después de transcurridos los 24 meses indican que el producto mantiene los parámetros que determinan su calidad durante ese tiempo, y en los estudios acelerados no se observó degradación del producto. Se estableció 2 años como fecha de vencimiento en las condiciones señaladas.Stability study was conducted of 3 mg Risperidone tablets determining its caducity date and using the shelf life methods and of accelerated stability by high-performance liquid chromatography validated in Drug Development and Research Center. The shelf life study was developed during 24 months at room temperature; whereas the accelerated stability study was performed subjecting the product to light, humidity and temperature influence. The 3 mg Risperidone tablets formula fulfilled the quality specifications described in Pharmacopeia. Results from shelf life study after 24 months show that the product maintains the parameters determining its quality during that time and in accelerated studies product degradation was noted. Under conditions signaled 2 years was established as the expiry date.

  8. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions.

    Science.gov (United States)

    Iasevoli, Felice; Fiore, Germano; Cicale, Maria; Muscettola, Giovanni; de Bartolomeis, Andrea

    2010-05-15

    Homer1a and Yotiao are two post-synaptic density proteins at the crossroad of dopamine-glutamate neurotransmission. Homer1a has been implicated in the pathophysiology of schizophrenia and is differentially induced by typical and atypical antipsychotics, perhaps according to their dopaminergic profile. Yotiao has been involved in glutamate and dopamine post-synaptic signalling. Here, we seek to determine whether Homer1a and Yotiao might be implicated in post-synaptic response to antipsychotics with affinity to different dopamine D(2) receptors: haloperidol (0.8mg kg(-1)), risperidone (3mg kg(-1)), olanzapine (2.5mg kg(-1)) and (-)-sulpiride (50mg kg(-1)). Homer1a expression was significantly induced by haloperidol compared to vehicle and to atypical antipsychotics in almost all striatal sub-regions. Atypical antipsychotics induced the gene in the lateral putamen and in the core of the accumbens only. All antipsychotics, with the exclusion of sulpiride, elicited a dorsolateral-to-ventromedial distribution pattern of Homer1a expression. No significant induction was detected for Yotiao. These results suggest that the quantitative and topographical pattern of Homer1a expression may putatively be related to antipsychotics affinity and/or occupancy at dopamine D(2) receptors.

  9. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound.

    Science.gov (United States)

    Silva, A C; González-Mira, E; García, M L; Egea, M A; Fonseca, J; Silva, R; Santos, D; Souto, E B; Ferreira, D

    2011-08-01

    The suitability of solid lipid nanoparticles (SLN) for the encapsulation of risperidone (RISP), an antipsychotic lipophilic drug, was assessed for oral administration. The hot high pressure homogenization (HPH) and the ultrasound (US) technique were used as production methods for SLN. All the studies on the SLN formulations were done in parallel, in order to compare the results and conclude about the advantages and limitations of both techniques. The particle sizes were in the nanometer range for all prepared SLN formulations and the zeta potential absolute values were high, predicting good long-term stability. Optical analyses demonstrated the achievement of stable colloidal dispersions. Physicochemical characterization of dispersions and bulk lipids, performed by differential scanning calorimetry (DSC) and X-ray assays, support prediction of occurrence of drug incorporation in the SLN and good long term stability of the systems. The toxicity of SLN with Caco-2 cells and the existence of contaminations derived from the production equipments were assessed by the (4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) assay. The results showed 90% of cell viability after SLN exposure, with no significant differences within all prepared formulations (p > 0.05). From this study, we conclude that SLN can be considered as efficient carriers for RISP encapsulation. Moreover, HPH and US revealed to be both effective methods for SLN production.

  10. Stathmin reduction and cytoskeleton rearrangement in rat nucleus accumbens in response to clozapine and risperidone treatment - Comparative proteomic study.

    Science.gov (United States)

    Kedracka-Krok, S; Swiderska, B; Jankowska, U; Skupien-Rabian, B; Solich, J; Dziedzicka-Wasylewska, M

    2016-03-01

    The complex network of anatomical connections of the nucleus accumbens (NAc) makes it an interface responsible for the selection and integration of cognitive and affective information to modulate appetitive or aversively motivated behaviour. There is evidence for NAc dysfunction in schizophrenia. NAc also seems to be important for antipsychotic drug action, but the biochemical characteristics of drug-induced alterations within NAc remain incompletely characterized. In this study, a comprehensive proteomic analysis was performed to describe the differences in the mechanisms of action of clozapine (CLO) and risperidone (RIS) in the rat NAc. Both antipsychotics influenced the level of microtubule-regulating proteins, i.e., stathmin, and proteins of the collapsin response mediator protein family (CRMPs), and only CLO affected NAD-dependent protein deacetylase sirtuin-2 and septin 6. Both antipsychotics induced changes in levels of other cytoskeleton-related proteins. CLO exclusively up-regulated proteins involved in neuroprotection, such as glutathione synthetase, heat-shock 70-kDa protein 8 and mitochondrial heat-shock protein 75. RIS tuned cell function by changing the pattern of post-translational modifications of some proteins: it down-regulated the phosphorylated forms of stathmin and dopamine and the cyclic AMP-regulated phosphoprotein (DARPP-32) isoform but up-regulated cyclin-dependent kinase 5 (Cdk5). RIS modulated the level and phosphorylation state of synaptic proteins: synapsin-2, synaptotagmin-1 and adaptor-related protein-2 (AP-2) complex.

  11. Valutazione dei costi di trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici di un DSM italiano

    Directory of Open Access Journals (Sweden)

    I. Rossi

    2001-12-01

    Full Text Available Objective of the present retrospective analysis was to evaluate resources consumption for psychotic patients treatment with olanzapine (OLZ, risperidone (RIS or typical neuroleptics (NL during year 2000 in the Dipartimento di Salute Mentale (DSM of Ravenna. The screening of total number of psychotic patients followed in the Ravenna DSM during year 2000 generated 26 cases treated with OLZ, 22 treated with RIS and 17 treated with NL that were respecting criteria of equivalence for age and illness severity. For these patients we analyzed pharmacological, non pharmacological (medical visits, nurse visits, social assistance, rehabilitative sessions and hospital interventions during the year of observation, choosing the point of view of the DSM for costs attribution. The analysis of pharmacological interventions evidentiated a major usage of associated neuroleptics in the RIS and NL groups in respect to OLZ (pNL>RIS, p<0,05 for all comparisons. Hospital days during the year of observation in the three groups were 4,42 for OLZ patients, 7,71 for NL patients and 10,95 for RIS patients (p<0,05 for all comparisons: OLZ vs RIS, OLZ vs NL and RIS vs NL. The sum of pharmacological, non pharmacological and hospital costs (from 8.856.000 to 10.818.000 LIT didn’t generated statistically significant differences even if the OLZ group followed more intense rehabilitative activities (+71,65% vs RIS and +24,41% vs NL.

  12. 氟哌啶醇与利培酮对精神分裂症患者生活质量的影响%Effect of Haloperidol and Risperidone on the Life Quality of the Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    任清涛; 闫加民; 李广

    2002-01-01

    Objective: To compare the effects between ha loperidol and rieperidon e on quality of life in patients with schizophrenia. Methods: The patients with schizophrenia treated respectively by haloperidol and risperidone were compared by double blind method. The General Quality of Life Inventory (GQOLI) was used to evaluate the life quality, while the Positive and Negative Symptoms Scale (PA NSS) and the Treatment Emergent Symptom Scale (TESS) were used to assess the eff icacy and side effects. Results: The risperidone group sho wed better effects tha n the haloperidol group in the domains of physical function ,mental health and s ocial function The difference was significant (P<0.01). Conclusion:[ WT5"BZ The quality of life of Schizophrenic patients treated by haloperidol were poorer than that o f risperidone.

  13. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.

    Science.gov (United States)

    Bobes, Julio; Cañas, Fernando; Rejas, Javier; Mackell, Joan

    2004-12-01

    Frequency of adverse reactions (ARs) related with antipsychotics usage is high. Along with clinical implications, economic impact might be important. The purpose of this study was to model the economic consequences of ARs related with ziprasidone, olanzapine, risperidone, and haloperidol in Spain, by means of a cost-effectiveness model developed using a Markov modeling approach. The model simulated treatment of a cohort of 1000 schizophrenics for 12 months, initiating treatment with one of four antipsychotic drugs; haloperidol, risperidone, olanzapine and ziprasidone. Conditional probabilities of developing any of four adverse events were calculated. Treatment was modified (decrease dose, switch medication) according to incidence of ARs and physician judgments, obtained from a local cross-sectional study and clinical trials previously published. The analysis was conducted in year 2002 from a third party payer perspective. Results are shown as annual cost per month with psychotic symptoms controlled and included univariate sensitivity analysis. The therapeutic strategy starting with ziprasidone showed the lower costs and the greater number of months with symptoms controlled in most scenarios evaluated versus the other options considered, although the differences were weak: 9.6, 9.3, 9.5 and 9.5 controlled months per patient in base scenario, with annual cost per patient per month with symptoms controlled of 1035 Euros, 1084 Euros, 1087 Euros and 1090 Euros for ziprasidone, haloperidol, risperidone and olanzapine, respectively. Results were robust to one-way sensitivity analysis. Despite the unlike drug prices of antipsychotics, a considerable economic impact due to adverse reactions was seen in our setting. These results should be taken into account by health decision makers and clinicians in the management of patients with schizophrenia.

  14. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

    Science.gov (United States)

    Nagy, Katalin; Marko, Bernadett; Zsilla, Gabriella; Matyus, Peter; Pallagi, Katalin; Szabo, Geza; Juranyi, Zsolt; Barkoczy, Jozsef; Levay, Gyorgy; Harsing, Laszlo G

    2010-12-01

    The most dominant hypotheses for the pathogenesis of schizophrenia have focused primarily upon hyperfunctional dopaminergic and hypofunctional glutamatergic neurotransmission in the central nervous system. The therapeutic efficacy of all atypical antipsychotics is explained in part by antagonism of the dopaminergic neurotransmission, mainly by blockade of D(2) dopamine receptors. N-methyl-D-aspartate (NMDA) receptor hypofunction in schizophrenia can be reversed by glycine transporter type-1 (GlyT-1) inhibitors, which regulate glycine concentrations at the vicinity of NMDA receptors. Combined drug administration with D(2) dopamine receptor blockade and activation of hypofunctional NMDA receptors may be needed for a more effective treatment of positive and negative symptoms and the accompanied cognitive deficit in schizophrenia. To investigate this type of combined drug administration, rats were treated with the atypical antipsychotic risperidone together with the GlyT-1 inhibitor Org-24461. Brain microdialysis was applied in the striatum of conscious rats and determinations of extracellular dopamine, DOPAC, HVA, glycine, glutamate, and serine concentrations were carried out using HPLC/electrochemistry. Risperidone increased extracellular concentrations of dopamine but failed to influence those of glycine or glutamate measured in microdialysis samples. Org-24461 injection reduced extracellular dopamine concentrations and elevated extracellular glycine levels but the concentrations of serine and glutamate were not changed. When risperidone and Org-24461 were added in combination, a decrease in extracellular dopamine concentrations was accompanied with sustained elevation of extracellular glycine levels. Interestingly, the extracellular concentrations of glutamate were also enhanced. Our data indicate that coadministration of an antipsychotic with a GlyT-1 inhibitor may normalize hypofunctional NMDA receptor-mediated glutamatergic neurotransmission with reduced

  15. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

    Science.gov (United States)

    Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X

    2014-09-01

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.

  16. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.

    Science.gov (United States)

    Woerner, Margaret G; Correll, Christoph U; Alvir, Jose Ma J; Greenwald, Blaine; Delman, Howard; Kane, John M

    2011-07-01

    Tardive dyskinesia (TD) rates with second-generation antipsychotics (SGAs) are considered to be low relative to first-generation antipsychotics (FGAs), even in the particularly vulnerable elderly population. However, risk estimates are unavailable for patients naïve to FGAs. Therefore, we aimed to determine the TD incidence in particularly vulnerable, antipsychotic-naïve elderly patients treated with the SGA risperidone or olanzapine. The present work describes a prospective inception cohort study of antipsychotic-naïve elderly patients aged 55 years identified at New York Metropolitan area in-patient and out-patient geriatric psychiatry facilities and nursing homes at the time of risperidone or olanzapine initiation. At baseline, 4 weeks, and at quarterly periods, patients underwent assessments of medical and medication history, abnormal involuntary movements, and extra-pyramidal signs. TD was classified using Schooler-Kane criteria. Included in the analyses were 207 subjects (age: 79.8 years, 70.0% female, 86.5% White), predominantly diagnosed with dementia (58.9%) or a major mood disorder (30.9%), although the principal treatment target was psychosis (78.7%), with (59.4%) or without (19.3%) agitation. With risperidone (n=159) the cumulative TD rate was 5.3% (95% confidence interval (CI): 0.7, 9.9%) after 1 year (mean dose: 1.0±0.76 mg/day) and 7.2% (CI: 1.4, 12.9%) after 2 years. With olanzapine (n=48) the cumulative TD rate was 6.7% (CI: 0, 15.6%) after 1 year (mean dose: 4.3±1.9 mg/day) and 11.1% (CI: 0, 23.1%) after 2 years. TD risk was higher in females, African Americans, and patients without past antidepressant treatment or with FGA co-treatment. The TD rates for geriatric patients treated with risperidone and olanzapine were comparable and substantially lower than previously reported for similar patients in direct observation studies using FGAs. This information is relevant for all patients receiving antipsychotics, not just the especially

  17. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.

    Science.gov (United States)

    Yasui-Furukori, Norio; Saito, Manabu; Tsuchimine, Shoko; Nakagami, Taku; Sato, Yasushi; Sugawara, Norio; Kaneko, Sunao

    2008-08-01

    Hyperprolactinemia is an inevitable consequence of treatment with antipsychotic agents to some extent because prolactin response to antipsychotics is related to dopamine blockade. Recent studies have suggested that polymorphisms of the dopamine receptors are associated with therapeutic response to antipsychotics. Thus, we studied the effects of major polymorphisms of dopamine-related genes on plasma concentration of prolactin. Subjects were 174 schizophrenic patients (68 males, 106 females) receiving 3 mg twice daily of risperidone for at least 4 weeks. Sample collections were conducted 12 h after the bedtime dosing. Five dopamine-related polymorphisms (Taq1A, -141C ins/del for DRD2, Ser9Gly for DRD3, 48 bp VNTR for DRD4, Val158Met for COMT) were identified. The mean (+/-SD) plasma concentration of prolactin in females was significantly higher than males (54.3+/-27.2 ng/ml versus 126.8+/-70.2 ng/ml, p<0.001). No dopamine-related polymorphisms differed the plasma concentration of prolactin in males or females. Multiple regression analyses including plasma drug concentration and age revealed that plasma concentration of prolactin correlated with gender (standardized partial correlation coefficients (beta)=0.551, p<0.001) and negatively with age (standardized beta=-0.202, p<0.01). No correlations were found between prolactin concentration and dopamine-related polymorphisms. These findings suggest that plasma prolactin concentrations in females are much higher than in males but the dopamine-related variants are not predominantly associated with plasma concentration of prolactin.

  18. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

    Directory of Open Access Journals (Sweden)

    Macfadden Wayne

    2011-04-01

    Full Text Available Abstract Background Because wide variations in mental health care utilization exist throughout the world, determining long-term effectiveness of psychotropic medications in a real-world setting would be beneficial to physicians and patients. The purpose of this analysis was to describe the effectiveness of injectable risperidone long-acting therapy (RLAT for schizophrenia across countries. Methods This was a pragmatic analysis of data from two prospective observational studies conducted in the US (Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation [SOURCE]; ClinicalTrials.gov registration number for the SOURCE study: NCT00246194 and Spain, Australia, and Belgium (electronic Schizophrenia Treatment Adherence Registry [eSTAR]. Two separate analyses were performed to assess clinical improvement during the study and estimate psychiatric hospitalization rates before and after RLAT initiation. Clinical improvement was evaluated using the Clinical Global Impressions-Severity (CGI-S and Global Assessment of Functioning (GAF scales, and change from baseline was evaluated using paired t tests. Psychiatric hospitalization rates were analyzed using incidence densities, and the bootstrap resampling method was used to examine differences between the pre-baseline and post-baseline periods. Results The initial sample comprised 3,069 patients (US, n = 532; Spain, n = 1,345; Australia, n = 784; and Belgium, n = 408. In all, 24 months of study participation, completed by 39.3% (n = 209, 62.7% (n = 843, 45.8% (n = 359, and 64.2% (n = 262 of patients from the US, Spain, Australia, and Belgium, respectively, were included in the clinical analysis. Improvements compared with baseline were observed on both clinical assessments across countries (P P P Conclusions RLAT in patients with schizophrenia was associated with improvements in clinical and functional outcomes and decreased hospitalization rates in the US, Spain, Australia, and Belgium, despite

  19. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

    Directory of Open Access Journals (Sweden)

    Dirani Riad D

    2011-10-01

    Full Text Available Abstract Background To evaluate effectiveness outcomes in a real-world setting in patients with schizophrenia initiating risperidone long-acting therapy (RLAT. Methods This was a 24-month, multicenter, prospective, longitudinal, observational study in patients with schizophrenia who were initiated on RLAT. Physicians could change treatment during the study as clinically warranted. Data were collected at baseline and subsequently every 3 months up to 24 months. Effectiveness outcomes included changes in illness severity as measured by Clinical Global Impression-Severity (CGI-S scale; functional scores as measured by Personal and Social Performance (PSP scale, Global Assessment of Functioning (GAF, and Strauss-Carpenter Levels of Functioning (LOF; and health status (Medical Outcomes Survey Short Form-36 [SF-36]. Life-table methodology was used to estimate the cumulative probability of relapse over time. Adverse events were evaluated for safety. Results 532 patients were enrolled in the study; 209 (39.3% completed the 24-month study and 305 (57.3% had at least 12 months of follow-up data. The mean (SD age of patients was 42.3 (12.8 years. Most patients were male (66.4% and either Caucasian (60.3% or African American (23.7%. All changes in CGI-S from baseline at each subsequent 3-month follow-up visit were statistically significant (p Conclusions Patients with schizophrenia who were initiated on RLAT demonstrated improvements in measures of effectiveness within 3 months, which persisted over 24 months. Trial Registration ClinicalTrials.gov: NCT00246194

  20. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.

    Science.gov (United States)

    Nurmi, E L; Spilman, S L; Whelan, F; Scahill, L L; Aman, M G; McDougle, C J; Arnold, L E; Handen, B; Johnson, C; Sukhodolsky, D G; Posey, D J; Lecavalier, L; Stigler, K A; Ritz, L; Tierney, E; Vitiello, B; McCracken, J T

    2013-06-25

    Second-generation antipsychotic exposure, in both children and adults, carries significant risk for excessive weight gain that varies widely across individuals. We queried common variation in key energy balance genes (FTO, MC4R, LEP, CNR1, FAAH) for their association with weight gain during the initial 8 weeks in the two NIMH Research Units on Pediatric Psychopharmacology Autism Network trials (N=225) of risperidone for treatment of irritability in children/adolescents aged 4-17 years with autism spectrum disorders. Variants in the cannabinoid receptor (CNR)-1 promoter (P=1.0 × 10(-6)), CNR1 (P=9.6 × 10(-5)) and the leptin (LEP) promoter (P=1.4 × 10(-4)) conferred robust-independent risks for weight gain. A model combining these three variants was highly significant (P=1.3 × 10(-9)) with a 0.85 effect size between lowest and highest risk groups. All results survived correction for multiple testing and were not dependent on dose, plasma level or ethnicity. We found no evidence for association with a reported functional variant in the endocannabinoid metabolic enzyme, fatty acid amide hydrolase, whereas body mass index-associated single-nucleotide polymorphisms in FTO and MC4R showed only trend associations. These data suggest a substantial genetic contribution of common variants in energy balance regulatory genes to individual antipsychotic-associated weight gain in children and adolescents, which supersedes findings from prior adult studies. The effects are robust enough to be detected after only 8 weeks and are more prominent in this largely treatment naive population. This study highlights compelling directions for further exploration of the pharmacogenetic basis of this concerning multifactorial adverse event.

  1. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

    Directory of Open Access Journals (Sweden)

    Lambert Tim

    2012-03-01

    Full Text Available Abstract Background This observational study was designed to collect treatment outcomes data in patients using the electronic Schizophrenia Treatment Adherence Registry (e-STAR. Methods Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals. The intent-to-treat population, defined as all patients who received at least one dose of RLAI at baseline, was used for the efficacy and safety analyses. Results At total of 784 patients (74% with schizophrenia, 69.8% male with a mean age of 37.1 ± 12.5 years and 10.6 ± 9.5 years since diagnosis were included in this Australian cohort. A significant improvement in mean Clinical Global Impression - severity score was observed at 24-months (4.52 ± 1.04 at baseline, 3.56 ± 1.10 at 24-months. Most of this improvement was seen by 3-months and was also reflected in mean Global Assessment of Functioning score, which improved significantly at 24-months (42.9 ± 14.5 at baseline, 59 ± 15.4 at 24-months. For patients still receiving RLAI at 24-months there was an increase from a mean baseline RLAI dose of 26.4 ± 5 mg to 43.4 ± 15.7 mg. Sixty-six percent of patients discontinued RLAI before the 24-month period--this decreased to 46% once patients lost to follow-up were excluded. Conclusion Over the 24-month period, initiation of RLAI was associated with improved patient functioning and illness severity in patients with schizophrenia or schizoaffective disorder. Improved outcomes were observed early and sustained throughout the study. Trial Registration Clinical Trials Registration Number, NCT00283517.

  2. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.

    Science.gov (United States)

    San, Luis; Arranz, Belen; Perez, Victor; Safont, Gemma; Corripio, Iluminada; Ramirez, Nicolas; Dueñas, Rosa; Alvarez, Enric

    2012-12-30

    The aim of this study was to compare the 12-month effectiveness of several second-generation antipsychotic drugs, with that of haloperidol in never-treated patients with first-episode psychosis. In total, 114 patients without life time exposure to any psychotropic medication were randomized to haloperidol, olanzapine, risperidone, quetiapine or ziprasidone. Primary outcome was time to all-cause discontinuation. Secondary outcomes included discontinuation rates and symptom change as measured by the Positive and Negative Syndrome Scale (PANSS). The overall discontinuation rate 64%. At 12 months, the proportion of patients discontinuing treatment was 40.0% for olanzapine, 56.5% for quetiapine, 64.0% for risperidone, 80.0% for ziprasidone and 85.7% for haloperidol. Mean time to antipsychotic discontinuation was higher in patients randomized to second-generation antipsychotics than in those taking haloperidol. Significantly lower discontinuation was noted in patients on olanzapine than on haloperidol, or ziprasidone. Our results suggest that olanzapine might lead to longer treatment continuation in treatment naïve FEP patients than haloperidol and, possibly ziprasidone. Global psychopathology was significantly less reduced by haloperidol than with each individual SGA in this earliest phase of treatment. Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

  3. MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission

    Institute of Scientific and Technical Information of China (English)

    LIU Sha; YUAN Yan-bo; GUAN Li-li; WEI Hui; CHENG Zhang; HAN Xue; YANG Lei

    2013-01-01

    Background MicroRNAs (miRNAs) control gene expression by destabilizing target transcripts and inhibiting their translation.Aberrant expression of miRNAs has been described in many human diseases,including schizophrenia.However,the effects on miRNA expression in response to antipsychotic treatment in peripheral circulation have not been thoroughly examined.Methods Using quantitative real-time PCR (qRT-PCR),We quantified the expression of seven candidate miRNAs in plasma samples of 40 first-episode schizophrenics before and after antipsychotic treatment.The patients were all treated with risperidone and achieved remission in 1 year.Results Compared with the baseline,the expression levels of miR-365 and miR-520c-3p were significantly downregulated after 1 year of risperidone treatment (P <0.001).There were no significant correlations between the clinical symptoms and the expression levels of these two miRNAs (P >0.05).Conclusions This study analyzed possible circulating miRNAs in response to antipsychotic monotherapy for schizophrenia,the further mechanism need to be confirmed.

  4. A comparative study between risperidone and ritalin in the treatment of attention deficit hyperactivity disorder%利培酮治疗注意缺陷障碍对照观察

    Institute of Scientific and Technical Information of China (English)

    兰利明; 薛漳

    2001-01-01

    目的:观察小剂量利培酮治疗注意缺陷障碍(ADHD) 的疗效和安全性。 方法:前瞻性研究,以利他林作为对照,采用 康纳多动症评定量表及不良反应症状量表(TESS)评定,观察4周。 结果:利培酮有效率为77%,利他林为78%;未见锥体外系副反应。 结论:利培酮与利他林的疗效相似,小剂量使用时安全有效。%Objective:To observe the efficacy and security of small doses risperidone in the treatment of attention deficit hyperactivity diso rder(ADHD). Method:Compared with ritalin group,the patients wer e treated with small doses risperidone for 4 weeks.Conner hyperactivety rating s cale (CHRS) and the treatment emergent symptom scale (TESS) were completed by th em. Results:The efficacy rate in risperidone group was 77%, a nd in ritalin group was 78%. No extrapyramidal side effect was found. C onclusion:It suggests that small doses risperidone is effective and safe in the treatment of ADHD, being similar to ritalin.

  5. The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

    NARCIS (Netherlands)

    Roke, Y.; Harten, P.N. van; Franke, B.; Galesloot, T.E.; Boot, A.M.; Buitelaar, J.K.

    2013-01-01

    OBJECTIVE: To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptive behavior disorders. METHODS:

  6. The effect of the Taq1A variant in the dopamine D-2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

    NARCIS (Netherlands)

    Roke, Yvette; van Harten, Peter N.; Franke, Barbara; Galesloot, Tessel E.; Boot, Annemieke M.; Buitelaar, Jan K.

    2013-01-01

    Objective To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptive behavior disorders.Methods Fo

  7. The effect of the Taq1A variant in the dopamine D-2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

    NARCIS (Netherlands)

    Roke, Yvette; van Harten, Peter N.; Franke, Barbara; Galesloot, Tessel E.; Boot, Annemieke M.; Buitelaar, Jan K.

    2013-01-01

    Objective To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptive behavior disorders.Methods Fo

  8. 利培酮与阿立哌唑治疗精神分裂症的效果比较%Clinical effects and security of aripiprazole and risperidone on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李正发

    2010-01-01

    Objective To assess the efficacy and safety of aripiprazole and risperidone on the treatment of schizophrenia. Method 80 patients with schizophrenia were randomly divided into risperidone group ( n = 40) and aripiprazole group( n= 40). According to random, controlled principles, all patients were treated for 8 weeks. The positive and negative syndrome scale ( PANSS ), clinical global impression ( CGI ), treatment emergent symptom scale (TESS) and laboratory examinations were used to assess the effectiveness and the safety of the treatment. Results By the end of the 8 weeks treatment,the scores of PANSS in both groups decreased significantly compared to the baseline ( P 0. 05 ). Total clinical effective rates was 90% in risperidone group and 80% in aripiprazole group, without significant difference between two groups. Digestion adverse reactions in aripiprazole group were significantly more than in risperidone group (P 0.05).治疗后,利培酮组有效率90%,阿立哌唑组有效率80%,两组差异无统计学意义(P>0.05).阿立哌唑组消化道反应发生率明显高于利培酮组(P<0.05).结论 利培酮治疗精神分裂症的疗效较阿立哌唑略好,安全性高.

  9. The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

    NARCIS (Netherlands)

    Roke, Y.; Harten, P.N. van; Franke, B.; Galesloot, T.E.; Boot, A.M.; Buitelaar, J.K.

    2013-01-01

    OBJECTIVE: To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptive behavior disorders. METHODS:

  10. 利培酮治疗儿童孤独症谱系障碍11例疗效分析%Clinical efficacy of risperidone in 11 children with autism spectrum disorders

    Institute of Scientific and Technical Information of China (English)

    焦云; 刘李燕; 蔡小凡

    2013-01-01

    目的 观察利培酮治疗孤独症谱系障碍患儿的疗效.方法 11例入选患儿在原有综合治疗的基础上服用利培酮,剂量0.5~1.0 mg/d,分别在接受利培酮治疗前、治疗半年后进行孤独症治疗评定量表(ATEC)评估.结果 治疗后与治疗前比较,患儿在社交、感知觉、行为等方面均有显著改善(P<0.01),疗效明显.结论 利培酮治疗孤独症谱系障碍患儿在不良行为控制的基础上能明显改善认知,提高社交能力,而且副作用轻微,值得推广.%Objective To analyze the effect of risperidone to treat autism spectrum disorders in children. Methods Eleven children with autism spectrum disorders were treated with risperidone for 6 months. Autism treatment evaluation checklist ( ATEC) before and after the treatment was analyzed. The adverse events related to risperidone treatment were observed. Results The score of severity of illness and the ATEC total scores were significantly reduced after 6 month treatment. Great improvements had been shown on the apperception and behavioural symptoms. No severe adverse events related to risperidone treatment were observed. Conclusions Risperidone can significantly improve the behavioral disorders in children with autism spectrum disorders.

  11. 利培酮联合喹硫平治疗老年痴呆精神行为症状的研究%Study on risperidone combined with quetiapine for treating psychiatric and behavioral disturbances in senile dementia

    Institute of Scientific and Technical Information of China (English)

    赵新民; 李远

    2016-01-01

    Objective To investigate the efficacy and safety of risperidone combined with quetiapine in the treatment behavioral and psychiatric symptoms of dementia (BPSD). Methods Ninety cases of BPSD in the geriatric department of our hospital from January 2013 to December 2015 were randomly divided into the combination group , risperidone group and quetiap-ine group according to the completely random method ,30 cases in each group. The combination group was given risperidone com-bined with quetiapine, the risperidone group was given the risperidone therapy and quetiapine group received the quetiapine therapy. The treatment effects were evaluated by using the BEHAVE-AD before treatment and after 2-,4-,8-week treatment. The side effects scale(TESS) was used to evaluate the adverse reactions occurrence situation. Results The AD-BEHAVE scores after 2-,4-,8-week treatment in 3 groups were significantly lower than those before treatment ,the difference was statistically significant (P0.05),but the effect in the combination group was significantly superior to that in the quetiapine group(χ2=15.39,P0.05),但明显优于喹硫平组,差异有统计学意义(χ2=15.39,P<0.01)。利培酮组不良反应发生率明显高于联合组、喹硫平组,差异均有统计学意义(P<0.05)。结论利培酮联合喹硫平治疗老年痴呆BPSD具有较好疗效,不良反应小,更适于老年痴呆患者的治疗。

  12. Clinical Analysis of Oxiracetam combined with Risperidone Treatment of Schizophrenia.%奥拉西坦与利培酮联合治疗精神分裂症的临床分析

    Institute of Scientific and Technical Information of China (English)

    崔会欣; 赵龙; 张娜; 尹艳芳

    2013-01-01

    Objective:To investigate the efficacy of Oxiracetam combined with Risperidone in the treatment of Schizophrenia. Methods:The schizophrenia patients were divided into study group and control group randomly. Study group were given Oxiracetam combined with Risperidone. Control group given Risperidone only for the treatment of 8 weeks. The efficacy and side effects were evaluated with scores of PANSS and TESS. Result:the effective rates were 86.17% in study group and 63.33% in control group. There are statistically difference between the two groups(P<0.05). The adverse reaction of two groups was rare and mild .Conclusion:Oxiracetam combined with Risperidone in the treatment of Schizophrenia were effective and safe and take effects better than single Risperidone.%目的探讨奥拉西坦与利培酮联合治疗精神分裂症的临床效果。方法将我院比例符合标准的精神分裂症患者随即分为研究组和对照组,研究组给予奥拉西坦合并利培酮治疗,对照组单用利培酮,疗程8周。用PANSS,TESS量表评定疗效和安全性。结果研究组有效率86.17%,对照组有效率63.33%。两组比较鉴别有统计学意义(P<0.05),两组不良反应少且轻。结论奥拉西坦合并利培酮治疗精神分裂症疗效可靠,安全性好,优于单用利培酮。

  13. Efficacy and safety analysis of Ziprasidone and Risperidone in treatment of schizophrenic patients%齐拉西酮与利培酮治疗精神分裂症患者的疗效及安全性分析

    Institute of Scientific and Technical Information of China (English)

    文卫

    2015-01-01

    目的::探讨齐拉西酮与利培酮两种药物在精神分裂症患者治疗中的临床效果。方法:将64例精神分裂症患者分为齐拉西酮组和利培酮组,每组各32例。分别给予两组患者齐拉西酮或利培酮治疗,观察两组患者的疗效和安全性。结果:在治疗4周后,两组患者的两项量表评估有明显差异(P<0.05);齐拉西酮组患者不良反应率为9.38%低于利培酮组的18.75%,差异有统计学意义(P<0.05)。结论:齐拉西酮治疗精神分裂症患者的临床效果优于利培酮治疗。%Objective:To investigate clinical effects of Ziprasidone and Risperidone in treatment of schizophrenia. Methods:64 schizophrenic patients were divided into Ziprasidone group ( treated with Ziprasidone) and Risperidone group ( treated with Risperi-done) . The efficacies of safety of the two groups were observed. Results:In 4 weeks after treatment, there were significant differences in the two scales between the two group (P<0. 05). The adverse reaction rates of Ziprasidone group and Risperidone group were 9. 38% and 18. 75%. Conclusions: In the treatment of schizophrenia, Ziprasidone has good clinical effects and higher safety than Risperidone.

  14. Association studies of COMT gene polymorphisms with risperidone treatment in first-episode schizophrenia%首发精神分裂症患者利培酮疗效与COMT基因多态性关联研究

    Institute of Scientific and Technical Information of China (English)

    李波; 黎雪松; 龚道元; 谢国军; 陈家强; 彭艳; 王晓娟

    2013-01-01

    目的:探讨首发精神分裂症患者COMT基因多态性与利培酮疗效的关系.方法:100例首发精神分裂症患者使用利培酮治疗8周,以PANSS量表评定疗效;SNaPshot SNP检测COMT基因rs4680和rs4818多态性.结果:利培酮有效组与无效组相比,精神分裂症患者rs4680基因型G/G与A/G、A/A的分布差异具有显著性(x2=5.334,P<0.05),rs4680 G/G基因型与利培酮疗效之间存在明显关联(OR=1.78,P<0.05).结论:rs4680多态性与利培酮治疗首发精神分裂症的临床疗效相关.%Objective To investigate the association of catechol-O-methyltransferase (COMT) gene polymorphisms with response of risperidone treatment in first-episode schizophrenia. Methods One hundred cases of schizophrenic patients were chosen to treat with risperidone for 8 weeks. The efficacy of antipsychotic medication was evaluated by PANSS scale. Allelic typing of COMT was detected by SNaPshot SNP technique. Results The distribution of rs4680 genotype G/G, A/G and A/A had significant difference between risperidone responder group and nonresponder group (X2 = 5.334,P < 0.05) and rs4680 G/G genotype was correlated with the efficacy of risperidone (OR = 1.78,P< 0.05). Conclusion The polymorphisms of rs4680 related with effects of risperidone on first-episode schizophrenia.

  15. 利培酮与氯氮平治疗精神分裂症对照研究%Effect of risperidone and clozapine on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李月霞

    2009-01-01

    目的 比较利培酮和氯氮平治疗精神分裂症的疗效和不良反应.方法 将40例精神分裂症患者随机分成两组,利培酮组和氯氮平组各20例,于治疗前和治疗第2、4、6周末采用症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应.结果 两组PANSS减分率比较差异无统计学意义(P>0.05),利培酮组不良反应少.结论 利培酮与氯氮平治疗精神分裂症疗效相当,但利培酮不良反应少.%Objective To comparie effect of risperidone and clozapine on the treatment of schizophrenia and adverse reactions. Methods 40 cases were randomly divided into two groups of patients with schizophrenia, risperi-done and clozapine group 20 cases, pre-treatment and treatment in the first weekend 2,4,6 Symptom Rating Scale (PANSS) and the reaction volume Table (TESS) were used to assess the efficacy and adverse reactions. Results Comparison of reduction rate PANSS, there was no significant difference(P > 0. 05), compared with clozapine group, risperidone group had less adverse reactions. Conclusion Risperidone and clozapine group had considerable effect in the treatment of schizophrenia, but risperidone had fewer adverse reactions.

  16. Comparison of plasma concentration of risperidone and serum prolactin level after risperidone treatment between male and female adolescents with schizophrenia%青少年男女精神分裂症患者利培酮治疗后血药浓度与血清催乳素的比较

    Institute of Scientific and Technical Information of China (English)

    韩晓虎; 郑毅; 王红星

    2012-01-01

    目的 比较男女青少年精神分裂症患者服用利培酮后利培酮、9-羟利培酮血药浓度和血清催乳素,并探讨血药浓度与血清催乳素的关系. 方法 符合DSM-V诊断标准的精神分裂症青少年患者41例(男20例,女21例),给予利培酮治疗8周.在治疗基线和第4,8周末测定血清催乳素水平,在治疗第4,8周末监测利培酮和9-羟利培酮的血药浓度. 结果 ①血清催乳素在时间上存在主效应(P<0.001),其中第4周末、第8周末男、女患者血清催乳素水平分别与基线进行自身比较,差异有统计学意义(P<0.001);②男、女患者间血药浓度和血清催乳素水平在第4周末、第8周末进行比较,无统计学差异(P>0.05).③男、女患者利培酮(Ris)、9-羟利培酮(9oh)血药浓度与血清催乳素存在正相关(男:4周末PRis<0.01、P9oh<0.01;8周末PRis<0.01、P9oh <0.05;女:4周末PRis>0.05、P9oh <0.01,8周末PRis<0.05、P9oh<0.01). 结论 ①利培酮能明显升高青少年患者血清催乳素水平;其血药浓度越高,催乳素水平也越高;②性别对血药浓度和血清催乳素水平无影响.%Objective To compare the plasma concentrations of risperidone,9-hydroxyrisperidone and serum prolactin levels after risperidone treatment between the male and female adolescents with schizophrenia, and to explore their relations. Methods A total of 41 patients(20 male and 21 female) met the DSM-IV criteria for schizophrenia. The patients were given risperidone for 8 weeks. Serum prolactin, plasma concentrations of risperidone and 9-hydroxyrisperidone were obtained at the baseline,at the end of 4th and 8th week. Results ?Serum prolactin had a significant main effect on the time of taking medicine ( P 0. 05). (5)In the male and female, serum prolactin was positively correlated with plasma concentration of risperidone( Ris) and 9-hydroxyrisperidone(9oh) ( male; at the end of 4th week PRis 0.05 and P9oh < 0.01; at the end of

  17. 合用阿立哌唑及单用利培酮对精神分裂症体质量的影响%Effects of Aripiprazole Combined with Risperidone and Risperidone on the Body Mass of Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    史玲; 杨云龙; 韩笑; 于丽燕; 严保平; 韩彦超; 周玉娟; 高景娜

    2016-01-01

    Objective:To compare the effects of risperidone combined with aripiprazle with only use of risperidone on body weight and BMI in patients with schizophrenia .Methods:70 patients with schizophrenia who met the criteria were randomized to two groups receiving risperidone combined with aripiprazle(research group)and only risperidone (control group) .Each group consists of 35cases .Clinical efficacies and the indexes body weight and BMI in patients were assessed with PANSS at the base line and at the end of the 4th week ,and 8th week .Results:There were 65 cases finishing the experiment including 31 cases of research group and 34 of control group .After the treatment of the end of the 4th week and 8th week ,there were no significant differences in the scores of PANSS between two groups . There was obvious change in two groups after the treatment I.n comparison with the research group ,the change was higher in control group in body weight and BMI(P<0 0.5) I.n comparison with the control group ,the body BMI was lower in research group(t=2 6.1 ,P<0 0.5) .Conclusion:Risperidone combined with aripiprazole can obviously reduce the effect of risperidone on body quality .%目的:对比利培酮与阿立哌唑合用及单用利培酮对精神分裂症患者体重及体重指数(BM I)的影响。方法:将符合入组标准的70例精神分裂症患者随机分为阿立哌唑合并利培酮组(合用阿立哌唑组)及单用利培酮组(单一利培酮组)。两组各入组35例,在基线及4周末、8周末,用阳性和阴性症状量表(PANSS)评定疗效,并进行体重及体重指数(BM I)的测定。结果:共完成65例,合用阿立哌唑组31例,单一利培酮组34例。治疗4周末及8周末,两组PANSS评分差异均无统计学意义;治疗后两组间有明显的变化,单一利培酮组体重及BMI值均增加明显(P<00.5);组间变化值的比较,合用阿立哌唑组BMI值均较单一利培酮组低(t=26

  18. 齐拉西酮和利培酮治疗精神分裂症比较研究%Study on comparison of ziprasidone and risperidone in treating patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    汪琳; 张涛; 白克镇; 邹文华

    2014-01-01

    Objective It is to compare the effect and the influence on metabolism index of ziprasidone and risperidone in treating patients with schizophrenia .Methods 65 patients with schizophrenia were randomly divided into ziprasidone group and risperidone group .Patients were treated with ziprasidone in ziprasidone group and with risperidone in risperidone group for 8 weeks.The curative effect and adverse reaction was assessed by using Positive and Negative symptom scale ( PANSS) and Treatment Emergent Symptom Scale ( TESS ) , and the metabolism index in both group were analyzed .Results The PANSS scores in ziprasidone group and risperidone group in the 2nd week were significantly reduced than that before treatment (P0.05).The effect of ziprasidone group and risperidone group had no significantly difference (P>0.05).The incidences rate of side effect in ziprasidone group were significantly lower than that in risperidone group (all P0.05).After treat-ment, the body weight , blood glucose and blood lipid in risperidone group were significantly higher than that in ziprasidone group (all P<0.05).Conclusion Ziprasidone has the similar therapeutic effect to risperidone in the treatment of schizophre -nia.However , Ziprasidone have well-tolerated and low effect on serum glucose and lipid metabolism .%目的:比较齐拉西酮和利培酮治疗精神分裂症的疗效及对患者生化指标的影响。方法将65例精神分裂症患者按照治疗方式不同分为齐拉西酮组和利培酮组,分别采用齐拉西酮和利培酮治疗8周,采用阳性与隐性症状量表( PANSS)和副作用量表( TESS)评定2组疗效和不良反应,并对患者实验室指标进行分析。结果治疗2周后,齐拉西酮组和利培酮组PANSS评分较治疗前均显著下降(P均<0.05)。治疗后2组同时间点PANSS总分、阳性症状分、阴性症状分及一般精神病理分比较无显著性差异(P均>0.05)。2组治疗有效率

  19. Treatment of posttraumatic stress disorder - related nightmares and other sleep disturbances with risperidone in combat veterans and victims of domestic and childhood abuse

    Directory of Open Access Journals (Sweden)

    Nina Khachiyants

    2010-09-01

    Full Text Available Sleep disturbances including nightmares are often reported as hallmark of posttraumatic stress disorder (PTSD. The literature related to the pharmacological treatment of PTSD-related nightmares is sparse and inconclusive. After reviewing the literature it was obvious that currently a limited data on studies supporting the use of antipsychotic medications for the treatment of PTSD are published. Moreover, even more limited scientific evidence is now available to formulate evidence-based guidelines for the treatment of PTSD-related nightmares which are often reported as the most intrusive and disruptive symptom. Objective for this study is to review comprehensively the current research literature which reflects use of antipsychotic medication risperidone for the treatment of PTSD-related nightmares of different etiology.

  20. Clinical effect observation of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症临床效果观察

    Institute of Scientific and Technical Information of China (English)

    王俊; 孙毅; 卓越; 吕治宇; 严卫国

    2016-01-01

    Objective:To observe the effect of aripiprazole and risperidone in the treatment of schizophrenia.Methods:64 patients with schizophrenia were selected.32 cases treated with aripiprazole were as aripiprazole group.32 cases treated with risperidone were as risperidone group.The treatment effect and adverse reaction between groups were observed.Results:The headache,dry mouth,insomnia incidence in the aripiprazole group were higher than those in risperidone group(P<0.05).In risperidone group, increase the body weight,akathisia,menstrual changes or lactation and tremor of incidence were higher than those in aripiprazole group(P<0.05).Conclusion:The effect of aripiprazole and risperidone in the treatment of schizophrenia are relatively good, but the adverse reaction of aripiprazole is fewer and milder.%目的:观察阿立哌唑与利培酮治疗精神分裂症的效果。方法:收治精神分裂症患者64例,采用阿立哌唑进行治疗的32例患者为阿立哌唑组,应用利培酮进行治疗的32例患者为利培酮组。观察两组的治疗效果和不良反应。结果:阿立哌唑组头痛、口干、失眠的发生率均高于利培酮组(P<0.05),利培酮组体重增加、静坐不能、月经改变或泌乳和震颤的发生率均高于阿立哌唑组(P<0.05)。结论:阿立哌唑与利培酮治疗精神分裂症的效果均比较好,但阿立哌唑产生的不良反应少且轻。

  1. Treatment of behavioral disorders by risperidone in children with autism%利培酮在治疗孤独症儿童行为问题中的作用

    Institute of Scientific and Technical Information of China (English)

    韦斌垣; 黄飞; 覃小田; 梁巧琦

    2011-01-01

    Objective To study the effect of risperidone treatment on behavioral disorders in children with autism.Methods Forty children with behavioral disorders (aged from 5 to 12 years) were treated with risperidone for 8 weeks.The behavioral symptoms were evaluated by the Clinical Global Impression (CGI) and the Autism Treatment Evaluation Checklist (ATEC) before and after the treatment.The adverse events related to risperidone treatment were observed.Results The score of severity of illness and the ATEC total scores were significanfly reduced 8 weeks after risperidone treatment.Besides the social intercourse ability, great improvements have been shown on the verbal communication, apperception and behavioural symptoms by the ATEC.No severe adverse events related to risperidone treatment were observed.Conclusions Risperidone can significantly improve the behavioral disorders in children with autism and is welltolerated.%目的:研究利培酮在治疗孤独症儿童行为问题中的作用.方法:选取40例5-12岁具有行为问题的孤独症儿童,给予8周的利培酮治疗,在治疗前后进行临床疗效总评量表(CGI)和孤独症治疗评估量表(ATEC)评分,并观察利培酮治疗的不良反应.结果:利培酮治疗后第8周末的病情严重程度、ATEC总分均低于治疗前,且耐受性好;其中在ATEC评分中,除了社交评分在治疗前后无明显改变之外,言语、感知和行为评分均得到明显的改善.结论:利培酮可以显著地改善孤独症儿童的行为问题且具有良好的耐受性.

  2. A control study of olanzapine and risperidone in the treatment of senile delirium%奥氮平与利培酮治疗老年期谵妄患者的对照研究

    Institute of Scientific and Technical Information of China (English)

    冼易平; 王英

    2011-01-01

    Objective; To compare the efficacy and safety of olanzapine and risperidone in the treatment of senile delirium. Method: Fifty patients with senile delirium were randomly divided into olanzapine treatment group (n = 25 ) and risperidone treatment group ( n = 25). They were prospectively observed and assessed with the Chinese revision of confusion assessment method (CAM-CR) .clinical global impression severity scale (CGI-SI) and treatment emergent symptom scales (TESS). Results:The effective rate of olanzapine treatment group and risperidone treatment group were 64. 0% and 68. 0% respectively (P > 0. 05). CGI-SI total scores of olanzapine treatmeng group and that of risperidone treatmen group were both reduced significantly after treatment (t=5. 19,6. 95 ;P 0.05 ). The total incidence rate of side effects in the risperidone group was significantly higher than that in olanzapine group ( χ2 = 5. 88, P < 0. 05). Conclusion; Olanzapine and risperidone have similar effects in treating senile delirium,ahd has fewer side effects.%目的:比较奥氮平和利培酮治疗老年期谵妄的疗效和安全性. 方法:将50例老年期谵妄患者随机分成奥氮平治疗组(n=25),利培酮治疗组(n=25),疗程2周.治疗前后以谵妄评定方法中文修订版(CAM-CR)及临床疗效总评量表-病情严重程度(CGI-SI)评定疗效;以治疗中出现的症状量表(TESS)评定药物不良反应. 结果:奥氮平组和利培酮组显效率分别为64.0%和68.0% (P >0.05).两组CGI-SI总分治疗后均较治疗前明显降低(t=5.19、6.95,P均<0.01);两组间比较,差异无统计学意义(P>0.05).利培酮组不良反应明显高于奥氮平组(x2=5.88,P<0.05). 结论:奥氮平和利培酮治疗老年期谵妄疗效相当,不良反应轻.

  3. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews

    Directory of Open Access Journals (Sweden)

    Tamara Melnik

    Full Text Available CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline (1966-2009, Controlled Trials of the Cochrane Collaboration (2009, Issue 2, Embase (Excerpta Medica (1980-2009, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs (1982-2009. There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.

  4. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

    Directory of Open Access Journals (Sweden)

    Mario Louzã

    2010-12-01

    Full Text Available Rogelio Apiquian1, Rodrigo Córdoba2, Mario Louzã31Americas University, Behavior and Development Sciences Division, Mexico City, Mexico; 2Nervous System Research Center-CISNE, Bogota, Colombia; 3Schizophrenia Research Program, Institute of Psychiatry, Faculty of Medicine, University of São Paulo, BrazilBackground: Risperidone long-acting injection (RLAI has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America.Methods: Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S, Personal and Social Performance (PSP, and Global Assessment of Functioning (GAF scores. Relapse and treatment were also registered.Results: Patients were recruited in Mexico (n = 53, Brazil (n = 11, and Colombia (n = 15. Sixty-five percent (n = 52 were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73 or schizoaffective disorder (n = 6. The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg. The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P < 0.001. Significant changes were registered on CGI-S, GAF, and PSP scores.Conclusions: RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization.Keywords: long-acting, risperidone, schizophrenia, schizoaffective disorder, Latin America

  5. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.

    Science.gov (United States)

    Chen, Jing-Xu; Su, Yun-Ai; Bian, Qing-Tao; Wei, Li-He; Zhang, Rong-Zhen; Liu, Yan-Hong; Correll, Christoph; Soares, Jair C; Yang, Fu-De; Wang, Shao-Li; Zhang, Xiang-Yang

    2015-08-01

    Hyperprolactinemia is an unwanted adverse effect associated with several antipsychotics. The addition of partial dopamine receptor agonist aripiprazole may attenuate antipsychotic-induced hyperprolactinemia effectively. However, the ideal dosing regimen for this purpose is unknown. We aimed to evaluate the dose effects of adjunctive treatment with aripiprazole on prolactin levels and hyperprolactinemia in schizophrenia patients. Stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e., >24 ng/ml for females and >20 ng/ml for males) were randomly assigned to receive 8 weeks of placebo (n=30) or oral aripiprazole 5mg/day (n=30), 10mg/day (n=29), or 20mg/day (n=30) added on to fixed dose risperidone treatment. Serum prolactin levels were measured at baseline and after 2, 4 and 8 weeks; clinical symptoms and side effects were assessed at baseline and week 8 using the Positive and Negative Syndrome Scale, Clinical Global Impressions Severity scale, Barnes Akathisia Scale, Simpson-Angus Scale and UKU Side Effects Rating Scale. Of 119 randomized patients, 107 (89.9%) completed the 8-week study. At study end, all three aripiprazole doses resulted in significantly lower prolactin levels (beginning at week 2), higher response rates (≥30% prolactin reduction) and higher prolactin normalization rates than placebo. Effects were significantly greater in the 10 and 20mg/day groups than the 5mg/day group. No significant changes were observed in any treatment groups regarding psychopathology and adverse effect ratings. Adjunctive aripiprazole treatment was effective and safe for resolving risperidone-induced hyperprolactinemia, producing significant and almost maximal improvements by week 2 without significant effects on psychopathology and side effects.

  6. 利培酮致恶性综合征1例%One Case of Neuroleptic Malignant Syndrome Caused by Risperidone

    Institute of Scientific and Technical Information of China (English)

    孙振晓; 孙宇新; 于相芬

    2016-01-01

    1例66岁女性器质性精神障碍患者应用利培酮0.5 mg,bid,7天后增至3 mg/d,108天后出现发热,意识模糊,肌强直、多汗、心动过速、尿潴留、呼吸加快,血压波动性大,血清肌酸激酶949.4 U/L。经停用利培酮,持续心电监护,吸氧,保持呼吸道通畅,持续导尿,给予营养支持,输液,纠正水、电解质及酸碱平衡,应用抗生素控制感染,并给予多巴胺激动剂溴隐亭治疗,14天后症状缓解。%A 66-year-old female patient with organic mental disorders was treated with risperidone at a dosage of 0 . 5 mg by oral route , twice a day for 7 d while the dosage increased gradually to 3 mg/d . The patient devel-oped fever , unconsciousness , rigidity , sweating , tachycardia , urinary retention , tachypnea , blood pressure variability 108 d after treatment , of whom the blood creatine kinase (CPK)level was 949 . 4 U/L . Risperidone was withdrawn , and the patient was given continuous oxygen inhalation , electrocardiographic monitoring and urinary catheterization , of whom the respiratory tract was kept unobstructed . Supportive treatments such as fluid infusion , correction of water electrolyte and acid base imbalance , and infection prevention were also given . Meanwhile , the patient was treated with dopamine receptor agonist bromocriptine , and the symptoms were relieved 14 d later .

  7. Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.

    Science.gov (United States)

    Paulzen, Michael; Haen, Ekkehard; Stegmann, Benedikt; Hiemke, Christoph; Gründer, Gerhard; Lammertz, Sarah E; Schoretsanitis, Georgios

    2016-11-01

    We sought to unravel the influence of body weight and body mass index (BMI), both consistently reported as pharmacokinetic relevant parameters, on metabolism of risperidone in a naturalistic sample. Conducting non parametrical tests we sought for correlations between plasma concentrations of RIS, 9-OH-RIS and AM and body weight and BMI in patients out of a therapeutic drug monitoring (TDM) database. Further, we stratified patients to three groups based upon BMI values and compared drug concentrations between groups. Although body weight failed to correlate with pharmacokinetic parameters, BMI was positively correlated with plasma concentrations of the active metabolite (9-OH-RIS) (rs=0.121, p=0.002) and active moiety (sum of RIS+9-OH-RIS) (rs=0.128, p=0.001) as well as dose adjusted plasma concentrations of the active moiety (rs=0.08, p=0.04). The comparison of pharmacokinetic parameters between different BMI groups yielded lower plasma concentrations of 9-OH-RIS in patients with low BMI (BMI ≥30kg/m(2)) when compared with the control group (30>BMI≥20kg/m(2)). By comparing low vs. high BMI patients, the latter group showed higher 9-OH-RIS plasma concentrations. Considerable alterations in metabolism of risperidone were detected when comparing obese and cachectic patients with the control group in alignment with the positive correlation between BMI values and plasma concentrations of the active metabolite and active moiety as well as dose adjusted plasma concentrations of the active moiety. We suggest changes in CYP2D6 or CYP3A4 activity or differences in P-glycoprotein function in obese patients with greater BMI as a plausible mechanism underlying these alterations. Copyright © 2016 Elsevier Ltd. All rights reserved.

  8. Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats

    Directory of Open Access Journals (Sweden)

    Amit Taneja

    2016-09-01

    Full Text Available We provide the reader with relevant data related to our recently published paper, comparing two mathematical models to describe prolactin turnover in rats following one or two doses of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride, “A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats” (Taneja et al., 2016 [1]. All information is tabulated. Summary level data on the in vitro potencies and the physicochemical properties is presented in Table 1. Model parameters required to explore the precursor pool model are presented in Table 2. In Table 3, estimated parameter comparisons for both models are presented, when separate potencies are estimated for risperidone and paliperidone, as compared to a common potency for both drugs. In Table 4, parameter estimates are compared when the drug effect is parameterized in terms of drug concentration or receptor occupancy.

  9. 氯氮平与维思通对精神分裂患者血糖影响的比较%Different effects of clozapine and risperidone on levels of blood glucose in patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    曹栋; 谢世平

    2001-01-01

    Objective To investigate the different effects of clozapine and risperidone on levels of blood glucose in patients with schizophrenia. Method 200 qualified cases selected from psychiatric department were divided into two groups randomly, of which 100 cases accepted the treatment with clozapine and the other 100 cases with risperidone. Blood glucose tests were used before treatment ,4 weeks after treatment and 8 weeks after treatment Results There was significantly higher blood glucose level in clozapine- treated group than in risperidone- treated group after 4 or 8 weeks treatment. The number of cases who had elevated blood glucose level (>6.1 mmol/L) in clozapine- treated group was significantly more than in risperidone- treated group. Conclusion The glucoregulatory abnormality which leads to glucose elevation in clozapine- treated patients is greater than in risperidone- treated patients. Additional motivation to clinical monitor for antipsychotic treatment- related hyperglycemia is indicated.

  10. 利培酮合并氯氮平治疗难治性精神分裂症临床分析%Clinical Effect of Risperidone Combined with Clozapine in Treatment of Re-fractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵圣兰; 郭晓静

    2015-01-01

    Objective To investigate the clinical effect of risperidone combined with clozapine in the treatment of refractory schizophrenia. Methods The control group received conventional treatment with risperidone; study group received combined treat-ment of risperidone and clozapine. Outcomes and adverse reaction of the patients with refractory schizophrenia in the two groups were recorded and statistically analyzed. Results Clinical total efficiency of the study group, 88.37%, was significantly higher than that of the control group, 69.77% (P 0.05). Conclusion Risperidone combined with clozapine used in the treatment of patients with refractory schizophrenia can significantly improve the clinical effi-cacy and quality of life and protect the safety of patients.%目的:探讨利培酮合并氯氮平治疗难治性精神分裂症临床应用效果。方法对照组给予利培酮常规治疗;研究组实施利培酮联合氯氮平片疗法。将两组中难治性精神分裂症患者的疗效及不良反应发生状况记录,通过统计学分析得出结论。结果研究组临床治疗的总有效率为88.37%,明显优于对照组临床治疗总有效率69.77%(P0.05)。结论难治性精神分裂症患者经利培酮联合氯氮平治疗可显著提高其临床疗效,有效保障患者生活质量及生命安全。

  11. Analysis of the efficacy and safety of risperidone microsphere injection in treatment of schizophrenia%注射用利培酮微球治疗精神分裂症的疗效和安全性分析

    Institute of Scientific and Technical Information of China (English)

    张东升

    2015-01-01

    Objective:To investigate the efficacy and safety of risperidone microsphere injection in the treatment of schizophrenia. Methods:90 schizophrenia patients were selected.They were divided into the experimental group and the control group average. The control group were given risperidone tablets treatment,and the experimental group were treated with injection of risperidone treatment.Results:The total treatment efficiency and the quality of life score of the patients in the experimental group was significantly higher than those of the control group(P<0.05);the incidence of the adverse reactions of the experimental group was significantly lower than that of the control group(P<0.05).Conclusion:The curative effect of risperidone microspheres in the treatment of schizophrenia is significant and the safety is high.It can improve the quality of life of patients effectively.%目的:探讨注射用利培酮微球治疗精神分裂症的疗效和安全性。方法:收治精神分裂症患者90例,将其平均分为试验组和对照组,对照组采用利培酮片治疗,试验组采用注射利培酮微球治疗。结果:试验组治疗总有效率、生活质量评分明显高于对照组(P<0.05);试验组不良反应发生率明显低于对照组(P<0.05)。结论:注射用利培酮微球治疗精神分裂症的疗效显著且安全性高,有效改善了患者的生活质量。

  12. Pharmacoeconomic analysis of Booz clear and Risperidone in the treatment of schizophrenia%博思清与维思通治疗精神分裂症的药物经济学分析

    Institute of Scientific and Technical Information of China (English)

    李晶武

    2012-01-01

      Objective To compare the Aripirazole and the cost of Risperidone in the treatment of sctfizophreniaresults. Methods 50 hospitalized patients with schizophrenia with Risperidone, Aripirazole treatment,treatment for 6 weeks.Using the cost-ef ectiveness analysis of 2 groups were analyzed.Results Aripirazole and Risperidone in the treatment of schizophrenia rates were between 96.0%and 92.0%, no significant dif erence in ef icacy (P>0.05), the cost, was 638.16 yuan and 647.8 yuan. Conclusion The ef icacy of the treatment of schizophrenia Aripirazole,Risperidone equivalent,but faster onset,Aripirazole in the treatment of schizophrenia than the economy.%  目的比较博思清与维思通治疗精神分裂症的成本-效果.方法对50例住院精神分裂症患者应用博思清与维思通进行治疗,疗程6周.采用成本-效果分析法对两组进行分析.结果博思清与维思通治疗精神分裂症的有效率分别为96.0%和92.0%,两者疗效无显著性差异(P>0.05),成本分别为638.16元和647.8元.结论博思清治疗精神分裂症疗效与维思通相当,但起效更快,博思清(阿立哌唑)治疗精神分裂症较经济.

  13. The effects of risperidone on plasma glucose of the schizophrenic patients%利培酮对精神分裂症患者糖代谢的影响

    Institute of Scientific and Technical Information of China (English)

    梁路

    2012-01-01

    Objective: To study the effect of risperidone for schizophrenia patients on the weight and glycometabolism. Method: we compared the weight and the fasting blood glucose respectively,36 cases of schizophrenic patients treated with risperidone before and after 12 weeks . Result: there was significant difference in the mean weight of the patients treated with risperidone for 12 weeks,which increased by 1.36 kilometres (p<0.05). the average fasting blood glucose of the schizophrenics treated for 12 weeks significant increased by 0.13mmol/L (p<0.05). Result: There are some extent effect on the weight and the fasting blood glucose of the patients who were treated with risperidone.%目的探索利培酮对精神分裂症患者体重与糖代谢的影响.方法收集36例精神分裂症患者使用利培酮治疗,疗程为12周,分别在未用药前和用药12周后测量体重和检测空腹血糖水平进行同体比较.结果本文结果显示,治疗12周后患者平均体重增加1.36 kg,P<0.05,有显著统计学意义;同时在治疗12周后检测空糖血糖与未治疗前空腹血糖比较,平均升高0.13mmol/L,P<0.05,有显著统计学意义.结论利培酮治疗精神分裂症,对患者的体重和空腹血糖有一定程度的影响.

  14. Follow-up study on influence of metabolism by risperidone and chlorpromazine%利培酮与氯丙嗪对代谢影响随访研究

    Institute of Scientific and Technical Information of China (English)

    王强; 瞿正万

    2011-01-01

    Objective:To explore the impact of chlorpromazine ,risperidone treatment on the blood glucose and fat level and body weigh in schizophrenia patients. Method: 198 schizophrenia patients were enrolled in the study. They were randomly admitted to risperidone therapy group and chlorpromazine therapy group. They are followed up one year. Data of the blood glucose and blood fat and body weight were collected at different point in the one year course of the study. Results: Both cholorpromazine group and risperidone group increased significantly in the index of total cholesterol ( TC ), triglyceride ( TG), fasting blood glucose ( FPG),glycated hemoglobin ( HbAlc), body weight and body mass index ( B MI ) while chlorpromazine group was significantly higher in these indexes. Conclusion:While chlorpromazine and risperidone can attect the blood glucose,blood fat and body weight in different ways, but they can both elevated the blood glucose, blood fat level and body weight.%目的:研究氯丙嗪与利培酮对精神分裂症患者血糖、血脂和体质量的影响.方法:198例精神分裂症患者随机分为氯丙嗪组与利培酮组,随访1年,采集患者空腹血糖、总胆固醇、和体质量的数据.结果:氯丙嗪组和利培酮组总胆固醇、三酞甘油、空腹血糖、糖化血红蛋白、体质量、体质量指数在治疗后均显著升高;以氯丙嗪组更显著为高.结论:氯丙嗪与利培酮对血糖、血脂和体质量的影响不同,但都可使之升高.

  15. 利培酮、氯氮平治疗精神分裂症的药物经济学评估%Pharmacoeconomic Evaluation of Schizophrenia in Risperidon and Cloza-pine Treatment

    Institute of Scientific and Technical Information of China (English)

    郑冰

    2014-01-01

    目的:比较利培酮、氯氮平治疗住院精神分裂症的成本-效果。方法对82例住院精神分裂症患者应用利培酮或氯氮平进行治疗,根据PANSS量表减分率评定疗效,对住院花费运用药物经济学成本-效果分析法进行评价。结果利培酮、氯氮平治疗精神分裂症的显效率分别为77.8%、71.4%,二者比较无显著性差异( P>0.05);产生单位效果所需成本二者无显著差异。结论利培酮与氯氮平治疗住院精神分裂症的疗效及费用基本相当。%OBJECTIVE To compare the efficiency and economic cost between Risperidon and Clozapine in the treatment of schizophrenia.METHODS 82 in-patients with schizophrenia were treated with Risperidon or Clozap-ine.PANSS was used to assess the clinical efficacy and pharmacoeconomic cost-effectiveness analysis was used to e-valuate costs.RESULTS The effective rates of Risperidon and Clozapine were 77.8% and 71.4% respectively with no significant difference ( P>0.05 ).There was no significant difference in the costs for an identical effect be-tween two drugs.CONCLUSION The ef-ective and costs of Risperidon and Clozapine are almost equal in the treat-ment of schizophrenia.

  16. 齐拉西酮与利培酮治疗女性精神分裂症的对照研究%Comparative study on ziprasidone and risperidone in the treatment of female schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈永红

    2014-01-01

    Objective To explore the curative effect and safety of ziprasidone and risperidone in the treatment of female schizophrenia. Methods A total of 80 female schizophrenia patients were randomly divided into ziprasidone group and risperidone group, with 40 cases in each group. The retrospective therapies by ziprasidone and risperidone were given to the two groups for 8 weeks. Positive and negative syndrome scale for schizophrenia (PANSS) was applied for curative effect assessment, and treatment emergent symptom scale (TESS) was used to assess the adverse reactions. Results In the ziprasidone group, the excellent effect rate was 84.21%, and the effective rate was 94.74%. These two rates in the risperidone group were 78.38%and 91.89%. There was no statistically significant difference between the two groups (P>0.05). The PANSS scores of the two groups decreased significantly after treatment, compared with those before treatment. The difference had statistical significance (P0.05)。两组患者的PANSS评分治疗后均较治疗前明显下降,差异有统计学意义(P<0.01)。齐拉西酮组体重增加和内分泌改变等不良反应发生率显著低于利培酮组,差异有统计学意义(P<0.05)。结论齐拉西酮与利培酮对女性精神分裂症的疗效相当,齐拉西酮对体重的影响和内分泌改变显著少于利培酮,是治疗女性精神分裂症患者的理想药物。

  17. CONTRAST ANALYSIS OF RISPERIDONE AND CLOZAPINE ON EEG OF PATIENTS WITH SCHIZOPHRENIA%利培酮与氯氮平对精神分裂症患者脑电图的影响

    Institute of Scientific and Technical Information of China (English)

    郑育喜; 陆丽珍; 卢建国; 龙俊荣; 侯英; 梁容梅

    2014-01-01

    Objective To analyze the effects of risperidone and clozapine on EEG of patients with schizophrenia. Methods The two groups of patientstaking clozapine and risperidone respectively were given EEG examination before and af-ter 2nd and 4th week of treatment, the abnormal rate of EEG of two groups of patients were analyzed to compare the effects of the two drugs on electrical activity of the brain.Results The abnormal rate of EEG induced by clozapine was significantly higher than that induced by resperidone (p<0.05).Conclusion The influence of risperidone on EEG is lower than that of clozapine.%目的:分析利培酮与氯氮平对精神分裂症患者脑电图的影响。方法通过对两组分别服用氯氮平、利培酮的患者,在服药前、服药后第2周、第4周分别检查脑电图一次,分析两组病人脑电图的异常率,对比两种药物对脑电活动的影响。结果氯氮平引起脑电图异常率明显高于利培酮( p<0.05)。结论利培酮对脑电图的影响较氯氮平轻。

  18. Comparative Study on Tiapride and Risperidone in Treatment of Behavioral and Psychological Symptoms of Dementia%硫必利与利培酮治疗老年痴呆精神行为症状的对比研究

    Institute of Scientific and Technical Information of China (English)

    袁成勇

    2015-01-01

    Objective To study the clinical application of risperidone in the treatment of behavioral and psychological symptoms of dementia and tiapride therapy differences behavioral and psychological symptoms of dementia and related side effects. Methods Experimental group were treated with tiapride (50~400 mg / qd), the control group received risperidone (0.5~4.0 mg) /qd).6 weeks Differences between the two groups and the PANSS scale Results TESS data. Results Efifciency difference was not statistically significant (P>0.05) tiapride treatment group the number of cases of side effects than risperidone group, the Results were statistically significant (P 0.05).硫必利治疗组发生副反应的病例数少于利培酮治疗组,结果具有统计学意义(P<0.05).结论 硫必利治疗老年期痴呆精神及行为症状效果确切.

  19. Comparison of Efficacy of Ziprasidone and Risperidone in Patients with First-episode Schizophrenia%齐拉西酮与利培酮对首发精神分裂症患者对照研究

    Institute of Scientific and Technical Information of China (English)

    刘娜

    2016-01-01

    目的::探讨齐拉西酮与利培酮治疗首发精神分裂症疗效及不良反应。方法:将100例首发精神分裂症患者随机分为齐拉西酮组和利培酮组各50例,分别于治疗前、治疗12周评定 PANSS 量表,评估不良反应发生率。结果:齐拉西酮组和利培酮组疗效相仿,差异无统计学意义(P >0.05)。齐拉西酮组的不良反应显著少于利培酮组,差异有统计学意义(P 0.05),which has no statis-tical significance.The adverse reactions of ziprasidone group were significantly less than that of the risperi-done group(P <0.05),which is statistically significant.Conclusion:Ziprasidone and risperidone have equal effect in the treatment of First-episode schizophreni,however,the clinical safety and adverse reactions of zi-prasidone are superior to those of the risperidone.Therefore,ziprasidone is worth widely used in the clinical practice.

  20. 喹硫平与利培酮对女性精神分裂症患者血清泌乳素水平的影响%Effects of quetiapine and risperidone on serum prolactin levels of female schizophrenia

    Institute of Scientific and Technical Information of China (English)

    孙海华; 杨焕

    2013-01-01

    Objective To explore the effects of quetiapine and risperidone in the treatmemt of female schizophrenic patients and the effect of levels on serum prolactin. Methods 76 female schizophrenic patients were treated with quetiapine and risperidone randomly. The serum prolactin were measured and the scores of PANSS were evaluated before treatment and at the 1st、2nd、4th、8th week respectively. TESS was used to evaluate side effect. Results There were no significant differences in PANSS basal scores and the decreased scores after the treatment in two groups. The level of serum prolactin in risperidone group increased markedly than quetiapine group, and the serum prolactin level in quetiapine group were not increase significantly. Conclusion Quetiapine and risperidone have similar efficacy in the treatment of femal patients with schizophrenia. Risperidone produced increases in plasma prolactin levels in femal patients.%目的:评价喹硫平与利培酮对女性精神分裂症患者疗效和血清泌乳素水平的影响。方法选择女性精神分裂症患者76例,随机分为喹硫平与利培酮组治疗8周。采用阳性和阴性症状量表(PANSS)在治疗前及治疗第1周、2周、4周、8周末分别评定疗效,检测血清泌乳素水平,同时精神药物副反应量表(TESS)评定药物副反应。结果治疗前和治疗8周,两组在PANSS总分无显著差异。利培酮组血清泌乳素水平显著升高,并显著高于喹硫平组。喹硫平组血清泌乳素水平治疗前后无显著变化。结论喹硫平与利培酮对女性精神分裂症的疗效相似,利培酮对女性精神病患者的血清泌乳素水平有较大影响。

  1. 阿立哌唑与利培酮治疗精神分裂症对比分析%Comparative analysis of aripiprazole and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李红远; 李义会

    2015-01-01

    Objective:To explore the clinical effect and safety of aripiprazole in the treatment of schizophrenia.Methods:120 patients with schizophrenia were randomly divided into two groups.They were treated with aripiprazole and risperidone respectively.The curative effects and adverse reactions of patients in two groups were compared.Results:The treatment total effective rate of the aripiprazole group and the risperidone group were respectively 83.3% and 81.7% .The incidence rate of adverse reaction(33.3%) in the aripiprazole group was significantly lower than 51.7% of the risperidone group(χ 2=4.126,P<0.01).Conclusion:The curative effects of aripiprazole and risperidone in the treatment of schizophrenia are considerable.The adverse reaction of aripiprazole is low than that of risperidone.The safety of aripiprazole is good.%目的:探讨阿立哌唑治疗精神分裂症的临床效果及安全性。方法:将120例精神分裂症患者随机分为两组,分别给予阿立哌唑和利培酮治疗。对两组患者的疗效及不良反应进行比较。结果:阿立哌唑组和利培酮组的总有效率分别为83.3%和81.7%。阿立哌唑组不良反应发生率33.3%明显低于利培酮组的51.7%(χ2=4.126,P<0.01)。结论:阿立哌唑与利培酮治疗精神分裂症的疗效相当,不良反应比利培酮低,安全性好。

  2. Comparison of in vitro Dissolution of Risperidone Pellets from Different Pharmaceutical Factories%不同厂家利培酮片的体外溶出度比较

    Institute of Scientific and Technical Information of China (English)

    陈颖; 汤莉娜; 瞿发林

    2012-01-01

    目的:比较4个厂家利培酮片的体外溶出度,为临床用药提供参考.方法:采用小杯法进行体外溶出度试验,以高效液相色谱法进行含量测定,计算累积溶出百分率.以威布尔方程拟合溶出参数,并用方差分析对组间溶出参数进行统计学处理.结果:四个厂家所生产的利培酮片体外溶出度均符合2010年版规定,但各厂家利培酮片的溶出参数m、T30、T50、Td、T80间差异有统计学意义 (P<0.01).结论:不同厂家利培酮片的体外溶出参数存在差异,临床用药时应加以注意.%Objective: To compare the in vitro dissolution of risperidone pellets from different pharmaceutical factories to offer suggestions for clinical use. Method: Dissolution tests were carried out with small glass method. HPLC method was used to determine the concentration of risperidone. The accumulative dissolution was calculated and the Weibull equation was applied to fit the dissolution parameters. The difference among the groups was statistically evaluated by variance analysis. Result: The in vitro dissolution of these risperidone pellets all met the requirements of Chinese Pharmacopoeia ( 2010 edition ). However, significant difference in dissolution parameters including m, T30,T50, Td and T80, was found ( P <0.01 ) among the risperidone pellets. Conclusion: There is significant difference in dissolution parameters of the risperidone pellets from different pharmaceutical factories, suggesting that attention should be paid to their clinical use.

  3. Clinical Comparison Analysis on Risperidone and Clozapine in The Treatment of Schizophrenia%利培酮与氯氮平治疗精神分裂症临床对比分析

    Institute of Scientific and Technical Information of China (English)

    赵仁香

    2015-01-01

    目的:分析利培酮和氯氮平治疗精神分裂症的临床效果。方法选取我院2013~2014年的91例患者来进行研究分析,分组为利培酮和氯氮平组,前组有42例患者,后组有49例患者,分析两组的精神病量表(BPRS)、阳性症状量表(SAPS)、副反应量表(TESS)。结果利培酮组患者的显效时间为一至两周,平均(10.56±4.23)天,氯氮平为一周左右,平均(7.23±3.57)天,差异无统计学意义,P>0.05。利培酮组有36例显效,氯氮平组有38例显效,两组的治疗效果差异无统计学意义。量表结果显示,两种药物均对精神分裂症阳性症状改善明显,氯氮平组的BPRS和SAPS评分比利培酮组高,差异有统计学意义,P0.05. There were 36 excel ent cases in risperidone group,38 excel ent cases in clozapine group, and the difference of clinical effects were not significant. The clinical effects of two drugs to the positive symptoms of schizophrenia were obvious ,the BPRS and SAPS scores in clozapine group was higher than risperidone group significantly,P<0.05. The clinical effect of risperidone to the activation and bizarre behavior symptoms was worse,and was similar for other symptoms. Conclusion The clinical effect of risperidone and clozapine in the treatment of schizophrenia are excel ent,and the advantages of risperidone are greater.

  4. A clinical study on substitution of risperidone for clozapine in the treatment of schizophrenia%利培酮替换氯氮平治疗精神分裂症临床研究

    Institute of Scientific and Technical Information of China (English)

    梅其一; 王晓龙; 杨小男; 方建中

    2001-01-01

    Objective:To explore a clinical optimal regime of substitutingrisperidone for clozapine. Method:Subjects were randomly enrolled into three groups: risperidone group, combination of risperidone and benzhexol group and combination of risperdone and alprazolam group. The efficacy and side effects were accessed with the positive and negative symptom scale (PANSS), a rating scale for extramidal side-effects (ESRS) and the treatment emergent symptom scale (TESS) before and after treatment. Results:The efficacy of all regimes was significant, and no significant differences were found among them. The female patients had more severe side effects than the male patients. The side effects were slightest in the combination of risperidone and alprazolam group and most severe in the risperidone group. Conclusion:Substituting risperidone and alprazolam for clozapine is the optimal regime in the treatment of schizophrenia.%目的:探索以利培酮替换氯氮平的临床换药方案。 方法:受试患者随机进入3组:单用利培酮组,利培酮+安坦组,利培酮+阿普唑仑组。在治疗前、治疗后1、2、4、6周用阳性症状与阴性症状量表(PANSS)、锥体外系副反应量表(ESRS)、不良反应症状量表(TESS)比较其疗效和副反应。 结果:3组换药后疗效均显著(P0.05)。女性较男性副反应大一些;利培酮+阿普唑仑组副反应最轻,单用利培酮组副反应最大。 结论:利培酮+阿普唑仑替换氯氮平方案较佳。

  5. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO study

    Directory of Open Access Journals (Sweden)

    Hong Jihyung

    2012-12-01

    Full Text Available Abstract Background With many atypical antipsychotics now available in the market, it has become a common clinical practice to switch between atypical agents as a means of achieving the best clinical outcomes. This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting. Methods W-SOHO was a 3-year observational study that involved over 17,000 outpatients with schizophrenia from 37 countries worldwide. The present post hoc study focused on the subgroup of patients who started taking olanzapine at baseline and subsequently made the first switch to risperidone (n=162 and vice versa (n=136. Clinical status was assessed at the visit when the first switch was made (i.e. before switching and after switching. Logistic regression models examined the impact of medication switch on tolerability outcomes, and linear regression models assessed the association between medication switch and change in the Clinical Global Impression-Schizophrenia (CGI-SCH overall score or change in weight. In addition, Kaplan-Meier survival curves and Cox-proportional hazards models were used to analyze the time to medication switch as well as time to relapse (symptom worsening as assessed by the CGI-SCH scale or hospitalization. Results 48% and 39% of patients switching to olanzapine and risperidone, respectively, remained on the medication without further switches (p=0.019. Patients switching to olanzapine were significantly less likely to experience relapse (hazard ratio: 3.43, 95% CI: 1.43, 8.26, extrapyramidal symptoms (odds ratio [OR]: 4.02, 95% CI: 1.49, 10.89 and amenorrhea/galactorrhea (OR: 8.99, 95% CI: 2.30, 35.13. No significant difference in weight change was, however, found between the two groups. While the CGI-SCH overall score improved in both groups after switching, there was a significantly greater change in those who

  6. 多次利培酮治疗致抗精神病药恶性综合征%Neuroleptic malignant syndrome after repeated treatment with risperidone

    Institute of Scientific and Technical Information of China (English)

    丁跃庆; 李华; 谢振强; 张伟娟; 代俊; 孔君; 吴洪军

    2012-01-01

    1例31岁女性患者因精神分裂症给予利培酮1 mg,2次/d口服,1周后剂量增至2 mg,2次/d.此前患者曾3次间断应用利培酮治疗.本次治疗规律服药49 d,患者精神症状缓解.第50~52天未遵医嘱规律服药.第54天患者出现大汗淋漓,体温达38.5 ℃.第55天出现意识障碍、心动过速、双上肢肌强直、肌张力增高.心电图示窦性心动过速.实验室检查示:白细胞计数12.3×109/L,胆碱酯酶 13 268 U /L,肌酸激酶 1447 U/L,利培酮血液浓度70.5 μg/L.诊断为抗精神病药恶性综合征(NMS).立即停用利培酮,进行物理降温、补液、抗心律失常、抗感染、纠正酸碱平衡、护肝等治疗.6 d后患者体温恢复正常,NMS症状消失.换用奥氮平治疗后,未再出现类似症状.%A 31-year-old woman with schizophrenia received risperidone 1 mg twice daily. One week later, the dose was increased to 2 mg twice daily. The patient had previously received risperidone intermittent treatment for three times. After a 49-day regular treatment, the psychiatric symptoms relieved. On days 50 to 52, she did not adhere to the instructions of the physician for regular use of the drug. On day 54, the patient experienced profuse sweating with a temperature of 38. 5 ℃. On day 55, she developed disturbance of consciousness, tachycardia, muscle rigidity of the upper limbs, and hypermyotonia. Her electrocardiograph showed sinus tachycardia. Laboratory tests showed the following findings: white blood cell count 12. 3 × 109/L, cholinesterase 13 268 U/L, creatine kinase 1447 U/L. The blood concentrations of risperidone was 70. 5 μg/L. Neuroleptic malignant syndrome ( NMS ) was diagnosed. The medication was stopped immediately. Physical methods for lowering body temperature, fluid supplement, antiarrhythmics, anti-infective therapy, correction of the acid-base imbalance, and liver-protective treatment were given. Six days later, the temperature returned to normal, the NMS symptoms

  7. 利培酮口服液治疗首发精神分裂症急性期对照观察%A control study of risperidone oral solution in treating first-episode schizophrenia patients in acute phase

    Institute of Scientific and Technical Information of China (English)

    黄卓玮; 龚传鹏

    2011-01-01

    目的:探讨利培酮13服液治疗首发精神分裂症急性期的疗效和安全性.方法:96例精神分裂症的急性期患者随机分为两组,分别给予利培酮口服液(研究组,n=49)和氯氮平(对照组,n=47)单药治疗4周.采用阳性和阴性症状量表(PANSS)评定临床疗效,临床总体印象量表(CGI-SI)评定病情严重程度,治疗中出现的症状量表(TESS)评定不良反应,自编依从性量表评定依从性.结果:治疗后两组患者PANSS及CGI-SI评分显著下降(P0.05).治疗后第4天,研究组兴奋、敌对、不合作、冲动控制缺乏因子分下降较对照组显著(P<0.05);研究组不良反应发生率明显低于对照组(P<0.05);研究组治疗依从性在治疗14 d、28 d、3个月和6个月时均优于对照组(P<0.05).结论:利培酮口服液对首发精神分裂症急性期患者的疗效和氯氮平相当,但利培酮口服液改善兴奋、敌对性等因子分较迅速,耐受性和依从性较好.%Objective: To evaluate the efficacy and safety of risperidone oral solution in the treatment of patients on the acute phase with first-episode schizophrenia. Method:96 schizophrenia patients were randomly assigned to the group treated with risperidone oral solution group ( n = 49 ) and the other group treated with clozapine (n =47 ),respectively for 4 weeks. The positive and negative syndrome scale (PANSS) and clinical global impressions-severity of illness rating scale(CGI-SI) were used to rate the efficacy;the treatment emergent symptom scale (TESS) was used to measure side effects and the compliance scale was used to assess the subjects'compliance with the treatment. Results:Both risperidone and clozapine group significantly showed score decrease on PANSS and CGI-SI after 4 weeks (P <0.01 ), but no significant difference was found between two groups ( P > 0.05 ). Excitement, hostility, uncooperativeness and poor impulse control of PANSS significantly decreased more in risperidone oral solution group

  8. 利培酮或阿立哌唑替换奋乃静治疗分裂症疗效与副反应研究%Risperidone or Aripiprazole Replace Perphenazine Treatment Efficacy and Side Effects of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    汪津洋

    2013-01-01

    目的评价利培酮或阿立哌唑替换奋乃静治疗精神分裂症的疗效与不良反应。方法将257例服用奋乃静治疗的分裂症患者逐渐替换为利培酮和阿立哌唑治疗,采用自然观察研究方法,对研究对象进行1年跟踪研究,评价疗效及副反应。结果治疗终点利醅酮和阿立哌唑组有效率分别为62.5%和69.8%,差异无统计学意义(P>0.05),跟踪中其他时点(2、4、6、8个月)两组有效率差异亦无统计学意义。12个月末利培酮组和阿立哌唑组的复发率(14.3%、12.3%)、持续治疗时间(9.4±3.7月、9.6±3.7月)、复发时间(4.1±2.8月、5.2±2.7月)等差异均无统计学意义(均P>0.05)。不良反应方面,利培酮组锥体外系反应比例高于阿立哌唑组,阿立哌唑组镇静作用弱。结论替换奋乃静后,利培酮与阿立哌唑治疗精神分裂症疗效均好,利培酮组锥体外系反应发生较多,阿立哌唑组镇静作用弱。%Objective To evaluate the ef icacy and adverse reaction of Aripirazole or risperidone in the original treatment of perphenazine. Methods 257 patients with original treatment of perphenazine assigned to Aripirazole group (n=131) or risperidone group(n=126), a 12 months fol ow up was used to evaluate the ef icacy and adverse ef ect. Results The response rates at the end of 12 months of Risperidone group and Aripirazole group were 62.5% and 69.8% respectively (P>0.05). There were no dif erence for the response rates between two groups at any other fol ow-up times.There were no dif erence between Risperidone and Aripirazole groups for the relapse rate (14.5%,12.5%,respectively),the time from response to relapse(9.5±3.8 months,9.7±3.8 months,respectively)and the time to treatment discontinuation for any reason(4.0± 2.9 months,5.1 ±2.8 months,respectively)at the end of 12 month.Aripirazole was associated with lower sedative ef ect and risperidone with more EPS (extrapyramidal syndrome). Conclusion Both

  9. Comparison of clinical effects of quetiapine and risperidone in the treatment of senile schizophrenia%喹硫平与利培酮治疗老年精神分裂症的临床效果对比

    Institute of Scientific and Technical Information of China (English)

    刘春容

    2015-01-01

    目的:比较喹硫平与利培酮治疗老年精神分裂症的临床效果。方法:回顾性分析170例老年精神分裂症患者的临床资料,根据治疗方法不同将其分为喹硫平组与利培酮组,其中喹硫平组74人,利培酮组96人,比较两组治疗前后的PANSS评分及不良反应情况。结果:喹硫平组与利培酮组治疗后2周、4周、6周、8周其各项指标较治疗前均有显著改善,差异具统计学意义(P0.05);喹硫平组锥体外系反应、恶主呕吐、停经泌乳等不良反应发生率显著低于利培酮组,而嗜睡发生率显著高于利培酮组,差异具统计学意义(P0.05)。结论:喹硫平与利培酮对老年精神分裂症均有确切疗效,且安全性较高;喹硫平对症状的改善相对更好。%Objective: To compare the clinical effects of quetiapine and risperidone in the treatment of senile schizophrenia. Methods:retrospective analysis of the clinical data of 170 cases of elderly patients with schizophrenia, according to the different treatment methods were divided into quetiapine group and risperidone group, wherein the quetiapine group of 74 people, 96 people of risperidone group, PANSS scores and adverse reactions were compared between two groups before and after treatment. Results:the quetiapine group and risperidone group after treatment for 2 weeks, 4 weeks, 6 weeks, 8 weeks, the indicators were significantly improved than before treatment, the difference was statistically significant ( P0.05) ;quetiapine flat group extrapyramidal adverse reactions, the evil Lord vomiting, stopping lactation was significantly lower than the risperidone group, and the incidence of somnolence was significantly higher than the risperidone group, the difference was statistically signif-icant (P0.05) . Conclusion: quetiapine and risperidone in schizophrenia have exact curative ef-fect on senile spirit, and high safety;the improvement of symptom of quetiapine is relatively

  10. 注射用利培酮微球治疗精神分裂症的疗效和安全性%The Efficacy and Safety of Injectable Risperidone Microspheres for Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨建华

    2015-01-01

    目的:探讨注射利培酮微球治疗精神分裂症的疗效和安全性。方法将50例精神分裂症病患随机分组,给予病患注射用利培酮微球,在整个治疗过程中3、6、9、12、15周时,对照组采取口服利培酮片剂,以PANSS总分增减和不良反应数量为评定疗效的标准。结果实验组和对照组病患前后治疗PANSS总分的分值无差别变化无统计学意义,实验组与对照组在12周治疗的重点与基线相比PANSS总分有明显降低具有统计学意义(P<0.05)。35例精神分裂症病患在治疗前后血常规、血生化正常变化。实验组中大多数病患在接受25 mg/2周利培酮微球用药后病情得到控制或改善,无明显的不良反应。结论对精神分裂病患以利培酮微球注射治疗3周末即起效,治疗效果与口服利培酮片的相当。注射利培酮微球具有疗效稳定、高安全性的特点。%Objective To efficacy and safety study risperidone microsphere injection in the treatment of schizophrenia.Methods 50 cases of schizophrenic patients randomized,give patient risperidone long-acting injection,in the whole course of treatment,3,6,9,12,15 weeks,the control group took oral risperidone tablets to increase or decrease the number of total PANSS score,and adverse reaction for curative effect standard.ResultsThe experimental group and the control group before and after treatment of PANSS disease score score did not change no significant difference,the experimental group and the control group in the 12 week of treatment compared with baseline PANSS scores of key significantly decreased with statistical significance(P<0.05). 35 cases of schizophrenic patients before and after treatment of blood routine,blood biochemical changes in the normal. The majority of patients in the experimental group in an 25 mg/2 weeks risperidone microsphere obtained control or improve the disease after treatment,no significant adverse reactions

  11. 喹硫平与利培酮治疗精神分裂症的疗效与安全性研究%Study on efficacy and safety of Quetiapine and Risperidone in treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    吴雪娥

    2015-01-01

    Objective To observe efficacy and safety of quetiapine and risperidone to patients with schizophrenia.Methods Participants included 80 patients with schizophrenia ,accepted quetiapine(496 ±65) mg/d and risperidone ( 3.1 ±0.3 ) mg/d respectively for eight weeks, and curative effect and safety were observed.Results The total efficiency rate of quetiapine group and risperidone group was 72.5% and 75%respectively, the effects of quetiapine and risperidone in schizophrenic patients had no significantly difference( p>0.05).The incidence of postural hypotension in quetiapine group was higher than that in risperidone group, but the incidence of extrapyramidal side effects and weight gain in quetiapine group was lower than that in risperidone group, there was significantly difference (P<0.05).Conclusions Quetiapine and risperidone have similar efficiency in the treatment of schizophrenic patients, and are safe and generally well-tolerated.%目的:研究喹硫平与利培酮治疗精神分裂症的疗效及安全性。方法按随机数字表法将2013年在本院精神病科住院的精神分裂症患者随机分为喹硫平组和利培酮组,每组各40例。喹硫平组给予喹硫平(496±65) mg/d治疗,利培酮组给予利培酮(3.1±0.3) mg/d治疗。疗程8周,从PANSS减分率评价其疗效,同时以不良反应症状量表(TESS)评定副反应。结果喹硫平组总有效率为72.5%,利培酮组总有效率为75.0%,两组疗效差异无统计学意义( P>0.05)。喹硫平组体位性低血压发生率明显高于利培酮组,利培酮组体重增加及锥体外系反应发生率显著高于喹硫平组,组间比较差异有统计学意义( P<0.05)。结论喹硫平与利培酮治疗精神分裂症疗效相当,安全性良好。

  12. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.

    Science.gov (United States)

    Bobo, William Victor; Bonaccorso, Stefania; Jayathilake, Karuna; Meltzer, Herbert Yale

    2011-09-30

    Baseline body mass index (BMI), baseline BMI status (normal, overweight, obese) and early (1 month) BMI increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (OLZ)- and 78 risperidone (RIS)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study. Baseline BMI predicted greater fasting glucose and HgbA1c levels at 12 months for both treatments. Early BMI change predicted fasting glucose levels at 6 months, but not HgbA1c or BMI, at either time point. For patients who received no concomitant mood stabilizers, early BMI change predicted 12 month HgbA1c values in the OLZ group, and 6- (but not 12-) month fasting glucose and HgbA1c values in the RIS group. Neither baseline BMI nor early BMI change consistently predicted increases in lipids with either drug. OLZ-treated patients with normal baseline BMI had greater increases in total cholesterol, triglycerides, and non-HDL-cholesterol than those who were overweight or obese. In conclusion, higher baseline BMI predicted adverse glycemic changes after 12 months with OLZ and RIS. Individuals with normal baseline BMI may be most susceptible to OLZ-induced hyperlipidosis. Frequency of metabolic screening should be independent of baseline BMI or rapid increases in BMI.

  13. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism.

    Science.gov (United States)

    Ghaleiha, Ali; Rasa, Soudeh Mohebbi; Nikoo, Mohammadali; Farokhnia, Mehdi; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin

    2015-09-30

    To assess the safety and efficacy of pioglitazone added to risperidone in the treatment of irritability in autistic disorder (AD), we conducted this study. In a 10-week, randomized, double-blind, parallel-group, placebo-controlled clinical trial, 44 outpatients of both genders aged 4-12 years with a diagnosis of AD and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale were included. Mean change of ABC-C irritability subscale score as primary outcome, change in other ABC-C subscale scores and partial and complete responses were compared between two groups. Twenty patients completed the trial in each group. Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group. Vomiting and headache were the most frequent reported side-effects. Results of this preliminary study indicate positive effects of pioglitazone compared with placebo in improving the behavioral symptoms of AD.

  14. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

    Science.gov (United States)

    Apiquian, Rogelio; Córdoba, Rodrigo; Louzã, Mario

    2011-01-01

    Background Risperidone long-acting injection (RLAI) has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America. Methods Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S), Personal and Social Performance (PSP), and Global Assessment of Functioning (GAF) scores. Relapse and treatment were also registered. Results Patients were recruited in Mexico (n = 53), Brazil (n = 11), and Colombia (n = 15). Sixty-five percent (n = 52) were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73) or schizoaffective disorder (n = 6). The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg). The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P < 0.001). Significant changes were registered on CGI-S, GAF, and PSP scores. Conclusions RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization. PMID:21326651

  15. Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone.

    Science.gov (United States)

    Kao, Yu-Han; Chern, Yijuang; Yang, Hui-Ting; Chen, Hui-Mei; Lin, Chun-Jung

    2016-08-01

    Huntington's disease (HD) is a neurodegenerative disease marked by an expanded polyglutamine (polyQ) tract on the huntingtin (HTT) protein that may cause transcriptional dysfunction. This study aimed to investigate the regulation and function of P-glycoprotein, an important efflux transporter, in brain capillaries in HD. The results showed that, compared with the littermate controls, R6/2 HD transgenic mice with the human mutant HTT gene had higher levels of P-glycoprotein mRNA and protein and enhanced NF-κB activity in their brain capillaries. Higher P-glycoprotein expression was also observed in the brain capillaries of human HD patients. Consistent with this enhanced P-glycoprotein expression, brain extracellular levels and brain-to-plasma ratios of the antipsychotic agents risperidone and paliperidone were significantly lower in R6/2 mice than in their littermate controls. Exogenous expression of human mutant HTT protein with expanded polyQ (mHTT-109Q) in HEK293T cells enhanced the levels of P-glycoprotein transcripts and NF-κB activity compared with cells expressing normal HTT-25Q. Treatment with the IKK inhibitor, BMS-345541, decreased P-glycoprotein mRNA level in cells transfected with mHTT-109Q or normal HTT-25Q In conclusion, mutant HTT altered the expression of P-glycoprotein through the NF-κB pathway in brain capillaries in HD and markedly affected the availability of P-glycoprotein substrates in the brain.

  16. Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study.

    Science.gov (United States)

    Siva Selva Kumar, M; Ramanathan, M

    2016-02-01

    A simple and sensitive ultra-performance liquid chromatography (UPLC) method has been developed and validated for simultaneous estimation of olanzapine (OLZ), risperidone (RIS) and 9-hydroxyrisperidone (9-OHRIS) in human plasma in vitro. The sample preparation was performed by simple liquid-liquid extraction technique. The analytes were chromatographed on a Waters Acquity H class UPLC system using isocratic mobile phase conditions at a flow rate of 0.3 mL/min and Acquity UPLC BEH shield RP18 column maintained at 40°C. Quantification was performed on a photodiode array detector set at 277 nm and clozapine was used as internal standard (IS). OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min. The method was validated for selectivity, specificity, recovery, linearity, accuracy, precision and sample stability. The calibration curve was linear over the concentration range 1-100 ng/mL for OLZ, RIS and 9-OHRIS. Intra- and inter-day precisions for OLZ, RIS and 9-OHRIS were found to be good with the coefficient of variation <6.96%, and the accuracy ranging from 97.55 to 105.41%, in human plasma. The validated UPLC method was successfully applied to the pharmacokinetic study of RIS and 9-OHRIS in human plasma.

  17. Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers

    Institute of Scientific and Technical Information of China (English)

    Ming-zhu HUANG; Jian-zhong SHENTU; Junc-hun CHEN; Jian LIU; Hui-li ZHOU

    2008-01-01

    This study presents a rapid, specific and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay for determination of risperidone (RIS) in human serum using paroxetine as an internal standard (IS). An Alltima-C 18separation. The analysis was performed by selected reaction monitoring (SRM) method, and the peak area of the m/z 411.3→ 191.1 transition for RIS was measured versus that of the m/z 330.1→192.1 transition for IS to generate the standard curves. The assay linearity of RIS was confirmed over the range 0.25~50.00 ng/ml and the limit of quantitation was 0.05 ng/ml. The linear range corresponds well with the serum concentrations of the analytes obtained in clinical pharmacokinetic studies. Intraday and interday relative standard deviations were 1.85%~9.09% and 1.56%~4.38%, respectively. The recovery of RIS from serum was in the range of 70.20%~84.50%. The method was successfully applied to investigate the bioequivalence between two kinds of tablets (test versus reference products) in 18 healthy male Chinese volunteers. The result suggests that two formulations are bioequivalent.

  18. Use of Antipsychotics in Children Is Criticized%阻止精神病药"标签外"用途

    Institute of Scientific and Technical Information of China (English)

    Gardiner Harris; 雪梅

    2008-01-01

    @@ Risperdal (risperidone) 和 Zyprexa (olanzapine)是两种近年来十分常用的精神障碍治疗药.随着近年美国被诊断出患有双相情感障碍的儿童数量突然增加,包括上述两种抗精神病药物在内的一系列药物如Seroquel (quetiapine)、Abilify (aripiprazole)和Geodon(ziprasidone)用于儿童的处方量也迅速上升.

  19. 利培酮与舒必利对精神分裂症患者血脂代谢的影响%The side-effects of Risperidone and Sulpiride on the lipid metabolism in the schizophrenic patients

    Institute of Scientific and Technical Information of China (English)

    黄建萍; 崔东红; 张晨; 王祖承; 粟幼嵩

    2011-01-01

    目的:探讨利培酮和舒必利对首发精神分裂症患者血脂代谢的影响.方法:对2008年1月~2010年1月我院住院的精神分裂症患者547例测定利培酮和舒必利治疗8周前后的血胆固醇(TC)及三酰甘油(TG)浓度.结果:①利培酮治疗后,血胆固醇及血三酰甘油明显升高(t=2.94,P=0.003;t=2.56,P=0.011),且男性患者组升高较女性明显(t=2.47,P=0.015;t=2.29,P=0.023);②舒必利组治疗后血胆固醇及血三酰甘油明显升高(t=2.35,P=0.019;t=2.16,P=0.032),且女性TG升高的程度显著大于男性患者(t=3.11,P=0.002).③利培酮对于血胆固醇及三酰甘油的影响大于舒必利(t=3.24,P=0.001;t=2.27,P=0.021).结论:利培酮使血胆固醇及三酰甘油水平升高,对男性影响大.舒必利使血胆固醇及三酰甘油水平升高,对女性影响大.利培酮对TC的影响大于舒必利.%Objective: To explore the side-effects of Risperidone and Sulpiride on the lipid metabolism in schizophrenic patients.Methods: 547 schizophrenic inpatients were recruited from January 2008 to January 2010.The concentrations of TC and TG after 8 week Risperidone or Sulpiride treatment were detected.Results: ①After Risperidone treatment, TC and TG concenations were significantly increased (t=2.94, P=0.003; t=2.56, P=0.011).Moreover, male patients had the more severe side-effects on the lipid metabolism than female (t=2.47, P=0.015; t=229, P=0.023).②After Sulpiride treatment,TC and TG concentrations were significantly increased (t=2.35, P=0.019; t=2.16, P=0.032).Moreover, TG concentrations of female patients increased more highly than those of male (t=3.11, P=0.002).③Risperidone had the more effects on TC and TG than Sulpiride (t=3.24, P=0.001; t=2.27, P=0.021).Conclusion: Risperidone could raise the TC and TG concentrations,and more greatly in male patients.Sulpiride raises the TC and TG concentrations, and more greatly in female patients.Risperidone has the more effects on TC and TG than Sulpiride.

  20. 齐拉西酮与利培酮治疗女性精神分裂症的对照研究%A comparative study of Ziprasidone and Risperidone in the treatment of female patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张桂华; 赵祖安; 李淑香; 丁琳; 白玉红

    2011-01-01

    目的:比较齐拉西酮与利培酮治疗女性精神分裂症的疗效及安全性.方法:将72例女性精神分裂症患者随机分为齐拉两酮组[(131.6±10.3)mg/d]36例,利培酮组[(5.9±1.3)mg/d]36例,疗程均为12周,采用阳性及阴性症状量表(PANSS),治疗中需处理的不良反应症状量表(TESS),在治疗前及治疗第2、4、8、12周末分别评定疗效和不良反应.结果:治疗第2周末开始,两组PANSS评分较入组时均显著降低,差异有统计学意义(P0.05).不良反应的发生率齐拉西酮组为47.2%(17/36)、利培酮组为52.8%(19/36),两组比较,差异无统计学意义(P>0.05).但齐拉西酮组锥体外系反应、体重增加、血脂增高、高泌乳素的发生率明显低于利培酮组,差异有统计学意义(P<0.05).结论:齐拉西酮治疗女性精神分裂症疗效好,不良反应轻微.%Objective: To compare the efficacy and safety of Ziprasidone and Risperidone in the treatment of female patients with schizophrenia.Methods: A total of 72 female patients were randomly assigned to Ziprasidone group (n=36) and Risperidone group (n=36), and received Ziprasidone (131.6±10.3) mg/d and Risperidone (5.9±1.3) mg/d treatment for 12 weeks respectively.The efficacy and adverse reaction were assessed with the Positive and Negative Syndrome Sale (PANSS), the Treatment Emergency Syndrome Scale (TESS) after the tveatment of 2,4, 8, 12 week.Results: The PANSS scores significantly decreased compared with the baseline sores in both groups since the second week (P<0.05); the marked improvement rate was 50.0% and the total clinical effective rate was 77.8% in Ziprasidone group while 47.3% and 75.0% in Risperidone group, there were not significant differences between two groups (P>0.05).There were similar rates of side effects between both groups (P>0.05), Ziprasidone group was 47.2% (17/36) and Risperidone group was 52.8% (19/36) (P>0.05).But the incidence of extrapyramidal symptoms, weight

  1. 利培酮联合舍曲林治疗精神分裂症阴性症状临床研究%Combination of Risperidone and Sertraline in Negative Symptoms of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    江永

    2013-01-01

    Objective:To explore the efficacies and safety of combination of risperidone and sertraline in negative symptoms of schizo -phrenia.Methods:60 schizophrenics were randomly divided into treatment (n=30,took risperidone combined with sertraline ) and control group (n=30,took risperidone ) dose of risperidone was 2~6mg/d and that of sertraline 100~200mg/d for 8 weeks.Before and after treatment , efficacies and side effects were assessed using the Negative Syndrome Scale ( NSS) and the Treatment Emergent Symptom Scale ( TESS) .Results:After treatment total score and factors , score of the NSS of both 2 groups obviously reduced and differences were signifi-cant (P<0.05).compared with the control group the total score of the NSS and factors',score of apathy poverty of thought abulia and in-terest blank obviously reduced in the treatment group and differences were significant (P<0.05).there was no difference in side effects between the 2 groups.Conclusion:combination of risperidone and sertraline is better than single risperidone in the treatment of negative symptoms of schizophrenia .%目的:探讨利培酮联合舍曲林治疗精神分裂症阴性症状的临床疗效和安全性。方法:将60例精神分裂症患者随机分为治疗组(利培酮+舍曲林)和对照组(利培酮)各30例,利培酮治疗剂量2~6mg/d,舍曲林50mg~200mg/d,疗程8周,治疗后采用阴性症状量表和副反应量表[1]评定临床疗效与不良反应。结果:2组治疗后阴性症状量表总分和因子分均显著下降,差异有统计学意义(P<0.05),治疗组阴性症状量表总分、情感平淡、思维贫乏、意志缺乏、兴趣缺乏等因子分较对照组下降明显,差异有统计学意义(P<0.05)。不良反应2组无显著性差异(P>0.05)。结论:利培酮联合舍曲林治疗精神分裂症阴性症状疗效优于单用利培酮治疗。

  2. 利培酮与氯氮平对精神分裂症患者糖脂代谢的影响%Influences of risperidone and clozapine on glucolipid metabo-lism of patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    周海平; 钟远惠; 李桂云; 付美华

    2016-01-01

    Objective To explore the influences of risperidone and clozapine on glucolipid metabolism of patients with schizophrenia.Methods A total of 120 schizophrenia patients were assigned to two groups according to random number table and treated with risperidone or clozapine for 6 weeks.Blood sugar and fat changes were detected before and after treatment.Results After treatment all indexes of only blood sugar in risperidone group increased more significantly compared with pretreatment (P < 0.01 ),so did those of both blood sugar and fat in clozapine group and were significantly higher than those in risperidone group (P <0.01).After treatment the heightening rate of fasting plasma glucose abnormality was 1.7%in risperidone group and 41.7% in clozapine group,the former significantly lower than the latter (P <0. 01).increased abnormality,no diabetes standard has been found.,the difference of two groups of blood. Conclusion Both risperidone and clozapine have influences of different degrees,especially clozpaine,chan-ges of all metabolic indexes should be closely observed when patients are treated with clozapine.%目的:探讨利培酮与氯氮平对精神分裂症患者糖脂代谢的影响。方法将120例精神分裂症患者按照随机数字表法分为两组,分别口服利培酮、氯氮平治疗,观察6周。于治疗前后检测两组患者血糖、血脂水平的变化。结果治疗后利培酮组仅血糖各项指标较治疗前显著升高(P <0.01),而氯氮平组血糖、血脂各项指标均较治疗前显著升高,且显著高于利培酮组(P <0.01)。利培酮组治疗后空糖血糖异常增高率为1.7%,氯氮平组为41.7%,利培酮组显著低于氯氮平组(P <0.01)。结论利培酮与氯氮平对精神分裂症患者的糖脂代谢均有不同程度的影响,氯氮平的影响更明显,临床上选用氯氮平治疗时应密切监测各项代谢指标的变化。

  3. 哌罗匹隆与利培酮治疗首发精神分裂症对照研究%A control study of perospi rone vs .risperidone in the treatment of first-episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨冬冰; 马元业; 王军

    2014-01-01

    目的:探讨哌罗匹隆与利培酮治疗首发精神分裂症患者的临床疗效和安全性。方法将70例首发精神分裂症患者随机分为两组,分别口服哌罗匹隆和利培酮治疗,观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末,哌罗匹隆组总有效率87.9%,利培酮组为85.3%,两组比较差异无显著性(χ2=0.10,P>0.05)。哌罗匹隆组不良反应发生率为60.0%,利培酮组为62.9%,两组比较差异无显著性(χ2=0.06,P>0.05),但哌罗匹隆组内分泌改变及体质量增加发生率显著低于利培酮组(χ2=5.08、5.08,P<0.05)。结论哌罗匹隆与利培酮治疗首发精神分裂症疗效显著,安全性高,依从性好,但哌罗匹隆较少引起内分泌改变和体质量增加,尤其适用于女性首发精神分裂症患者。%Objective To explore the efficacy and safety of perospirone and risperidone in first-episode schizophrenia (FES) .Methods Seventy FES patients were randomly divided into two groups ,they took orally perospirone and risperidone respectively for 8 weeks .Clinical efficacies were assessed with the Posi-tive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week total effective rate was respectively 87 .9% in perospi-rone and 85 .3% in risperidone group ,which showed no significant difference (χ2 =0 .10 ,P>0 .05) .Inci-dences of adverse reactions were 60 .0% in perospirone and 62 .9% in risperidone group ,which showed no significant difference (χ2 =0 .06 ,P>0 .05) ,but those of endocrine alteration and weight gain were signifi-cantly lower in perospirone than risperidone group (χ2 =5 .08 ,5 .08 ;P<0 .05) .Conclusion Perospirone has an evident effect equivalent to risperidone ,higher safety and better compliance in FES ,but the former causes

  4. Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1.

    Science.gov (United States)

    Li, Jiansheng; Li, Chengyan

    2016-09-01

    The aim of this paper was to explore the efficacy of modified electroconvulsive therapy (MECT) combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy, and the effects of insulin-like growth factor-1 mRNA and protein expression. Forty-six cases with seizures and agitation in the acute stage were included from February 2012 to February 2014. This study was approved by the ethics committee in our hospital. Patients were divided randomly into the experimental (23 cases) and control (23 cases) groups. The patients in the experimental group were treated with MECT combined with risperidone oral solution. The patients in the control group were treated with risperidone oral solution. The Positive and Negative Symptom Scale (PANSS) score and Treatment-Emergent Symptom Scale (TESS) score were compared before and after treatment. The insulin-like growth factor-1 (IGF-1) protein and mRNA expression level were detected with enzyme-linked immunosorbent assay (ELISA) and qRT-PCR, respectively. There were no significant differences on positive and negative symptom scores or total score in the two groups before treatment (P>0.05). After treatment, the positive symptom score, negative symptom score, and total score all decreased in both groups, and the decrease was more obvious in the experimental group (P0.05), while after treatment the expression levels of IGF-1 protein and mRNA decreased in both groups. However, the decrease was more obvious in the experimental group. The differences were all significant for scores (Poral solution in the treatment of agitation can improve the clinical efficacy to some extent.

  5. 氨磺必利与利培酮治疗首发精神分裂症的疗效对照研究%Amisulpride and Risperidone Treatment First-episode Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李婕

    2014-01-01

    Objective To analysis efficacy of amisulpride and risperidone treatment first -episode schizophrenia.Methods 74 patients with first -episode schizo-phrenia were given Amisulpride and risperidone therapy,BPRS score,adverse reaction were compared.Result BPRS rating scale values were significantly reduced,be-tween groups was no significant difference;observation group adverse reactions(18.92%) was obviously lower than the control group.Conclusion Amisulpride and risper-idone can be effective in the treatment of first-episode schizophrenia,Amisulpride low adverse reaction,good safety.%目的:分析氨磺必利与利培酮治疗首发精神分裂症的疗效差异。方法选择74例首发精神分裂症患者为研究对象,分别给予氨磺必利及利培酮治疗,比较BPRS量表评分、不良反应发生率。结果观察组与对照组BPRS量表评分值均明显降低,组间比较无明显差异(P>0.05);观察组不良反应发生率(18.92%)明显低于对照组(P<0.05)。结论氨磺必利与利培酮均可有效治疗首发精神分裂症,氨磺必利不良反应较少,具有优良的治疗安全性。

  6. 齐拉西酮与利培酮治疗女性精神分裂症的研究%The study of Ziprasidone and Risperidone in the Treatment of Women Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    潘国良

    2013-01-01

    目的比较齐拉西酮与利培酮治疗女性精神分裂症的疗效及副反应.方法100例符合ICD-10诊断标准的女性精神分裂症患者随机分为两组各50例,分别给与齐拉西酮和利培酮治疗8周,采用阳性症状与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应.结果治疗8周后,齐拉西酮组的显效率为82%,有效率为94%;利培酮组的显效率为80%,有效率为92%.两组疗效无显著性差异(P>0.05).齐拉西酮组的阴性症状减分率更高,齐拉西酮组的不良反应发生率为18%,利培酮组为28%,有显著性差异(P0.05). The reduction rate of negative syndrome was higher in ziprasidone group. The incidence rate of adverse effect was 18% in ziprasidone group and that was 28% in risperidone group, and there had a significant difference between them(P<0.05).The level of PRL in ziprasidone was lower than that of risperidone. Conclusion Ziprasidone is as effective as risperidone for the treatment of women schizophrenia, but ziprasidone can’t affect the level of PRL and it was more fit for women patients.

  7. Efficacy observation of Aripiprazole and Risperidone in treatment of schizophrenia%阿立哌唑和利培酮治疗精神分裂症的疗效观察

    Institute of Scientific and Technical Information of China (English)

    曲秀颖

    2015-01-01

    目的::探讨阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法:选取76例符合CCMD-3精神分裂症诊断标准的患者随机分为阿立哌唑组和利培酮组,每组38例。两组患者分别给予阿立哌唑和利培酮治疗,6周后进行临床疗效评价及不良反应评定。结果:阿立哌唑组患者总有效率为89.47%,利培酮组患者总有效率为86.84%,两组患者总体疗效相当(P>0.05)。两组患者治疗前后PANSS评分比较,差异有统计学意义(P0.05)。治疗6周,阿立哌唑组患者不良反应发生率低于利培酮组(P0. 05). There was a statistical difference in the PANSS score between the two group before and after the treatment (P0. 05). Six weeks after the treatment, the inci-dence rates of adverse reactions of Aripiprazole group were lower than those of Risperidone group (P<0. 05). Conclusions: In the treatment of schizophrenia, Aripiprazole has a similar efficacy with Risperidone, but is superior in influences on extrapyramidal reac-tions, endocrine and weight than Risperidone.

  8. Different effects of taking aripiprazole and risperidone on spontaneous brain activity in schizophrenics%阿立哌唑和利培酮对精神分裂症患者自发脑活动的不同影响

    Institute of Scientific and Technical Information of China (English)

    常鑫; 罗程; 侯昌月; 陈琳; 陈曦; 贺辉; 段明君; 蒋宇超; 尧德中

    2015-01-01

    Objective To explore the difference in effects of taking two different kinds of drugs aripiprazole and risperidone on spontaneous brain activity among schizophrenics. Methods Nineteen patients(9 patients taking aripiprazole and 10 patients taking risperidone),who were recruited in the Fourth Peopleˊs Hospital of Chengdu were underwent a resting - state scanning at the Center for Information in Medicine of University of Electronic Science and Technology of China. Two groupsˊfractional amplitude of low - frequency (fALFF)value were calculated and compared using two sample t - test. Results Compared with the aripiprazole group,risperidone group showed significantly decreasing areas of fALFF,including bilateral putamen,olfactory,caudate,orbitofrontal and right palli-dum;left middle temporal gyrus and left supramarginal gyrus where also shown to have increasing areas. Conclusion Indeed,there are different effects of taking aripiprazole and risperidone on spontaneous brain activity in schizophrenics,which is consistent with the pharmacological mechanism of two drugs.%目的:探究临床常用抗精神病药物阿立哌唑和利培酮对精神分裂症患者自发性脑活动的不同影响。方法纳入就诊于成都市第四人民医院的长期服用阿立哌唑进行单药治疗的精神分裂症患者9例,服用利培酮单药治疗的精神分裂症患者10例,进行静息态功能磁共振(fMRI)扫描。分析两组患者 fMRI 信号的分数低频振幅(fALFF)的组间差异。结果与阿立哌唑组比较,利培酮组 fALFF 显著降低的脑区有双侧壳核、嗅皮质、尾状核、眶部额下回和右侧苍白球;fALFF 显著增高脑区有左侧颞中回和左侧缘上回(P <0.05)。结论阿立哌唑和利培酮会对大脑产生不同影响,差异脑区符合两种药物的不同药理机制。

  9. Risperidone and Clozapine on Blood Glucose and Lipid Metabolism in Patients With Schizophrenia%利培酮和氯氮平对精神分裂症患者血糖和脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    刘召英

    2016-01-01

    目的:研究利培酮和氯氮平对精神分裂症患者血糖和脂代谢的影响。方法选择2014年1月~2015年1月来我院精神科治疗精神分裂症的患者62例,随机分成利培酮组和氯氮平组,各31例,观察两组患者治疗效果。结果治疗后,利培酮组 TC 水平为(4.81±0.15) mmol/L 低于氯氮平组 TC 水平(5.25±0.24)mmol/L,两组血糖及血脂指标相比,差异均有统计学意义(P <0.05)。结论采用利培酮和氯氮平治疗精神分裂症对患者的血糖和脂代谢水平均有影响,相对而言氯氮平影响较大,临床医生在治疗精神分裂症时应该慎重使用药物。%Objective To observe the efficacy of risperidone and clozapine on blood glucose and lipid metabolism in patients with schizophrenia. Methods Selected 62 patients with schizophrenia from January 2014 to January 2015 in our hospital were randomly divided into risperidone group and clozapine group,31 cases,the treatment groups were observed. Results After treatment,the levels of TC risperidone group(4.81±0.15)mmol/L group was significantly lower than clozapine TC levels(5.25±0.24)mmol/L,glucose and lipid levels compared to the two groups,the differences were statistical y significance(P< 0.05). Conclusion Use wil significantly affect the treatment of schizophrenia with risperidone and clozapine on blood glucose and lipid metabolism in patients with relatively greater impact in terms of clozapine,clinicians in the treatment of schizophrenia drugs should be used with caution.

  10. The disability in patients with schizophrenia treated with chlorpromazine and risperidone%氯丙嗪与利培酮片对精神分裂症患者致残影响的对比研究

    Institute of Scientific and Technical Information of China (English)

    李和军; 杨杰

    2012-01-01

    目的 探讨氯丙嗪与利培酮片对精神分裂症患者致残的影响.方法 200例门诊或住院的精神分裂症患者完全随机分为对照组与研究组,各100例,采用残疾水平评定量表( WHODASⅡ)、社会功能缺陷筛选量表(SDSS)、生活质量评定量表(WHOQOL)分别于0.5、1、2年时对患者的残疾程度进行多维度评定并进行对比.结果 究组治疗后0.5、1、2年WHOQOL-BREF评分优于对照组,WHODAS评分[分别为(27±15)分比(38±13)分、(28±13)分比(39±15)分、(26±14)分比(36±18)分]、SDSS评分[分别为(11±2)分比(18±6)分、(8±2)分比(12±3)分、(8±2)分比(11±4)分]均优于对照组,差异均有统计学意义(均P<0.01).结论 利培酮片对改善精神分裂症患者社会功能,减轻残疾程度,降低致残率方面明显 优于氯丙嗪.%Objective To explore the disability in patients treated with schizophrenia with using respectively chlorpromazine and risperidone.Methods Two hundred outpatients or hospitalization patients with schizophrenia were randomly divided into chlorpromazine group( 100 cases) and risperidone group( 100 cases) ; the degree of disability by WHO disability assessment scale Ⅱ (WHO-DAS Ⅱ ),social disability screening schedule(SDSS),WHO quality of life(WHOQOL) at the time of half a year,one year and two years were ananlyzed.Results The scores of risperidone group in all scales were significantly higher in chlorpromazine group in each period ( P < 0.05 or P <0.001 ).The validity of consistency and correlation was high in all scales.Conclusion Risperidone is significantly better than chlorpromazine in terms of reducing the rate of disability,improving the social function and reducing the degree of disability.

  11. 利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状%Paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients

    Institute of Scientific and Technical Information of China (English)

    王永萍; 尤加永; 赵长银

    2012-01-01

    目的:探讨利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状的临床疗效以及安全性.方法:将126例以阴性症状为主的慢性精神分裂症住院患者随机分为研究组(利培酮联合帕罗西汀治疗)和对照组(单用利培酮治疗),疗程12周,采用阳性和阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和安全性. 结果:治疗后两组PANSS评分均较治疗前有显著降低(P<0.05).治疗后4、8、12周末,研究组阴性因子分及情感迟钝、情感退缩、情感交流障碍及社会退缩因子分均显著低于对照组,差异具有统计学意义(P<0.05或P<0.01).两组不良反应均为轻至中度. 结论:利培酮联合帕罗西汀较单用利培酮治疗慢性精神分裂症阴性症状具有起效更快、疗效更好、依从性好的特点.%Objective:To evaluate clinical efficacy and safety of paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients. Method; 126 patients with predominantly negative symptoms of chronic schizophrenia were randomly divided into study group (paroxetine combined risperidone) and the control group (risperidone alone) with 12 weeks'treatment. PANSS and TESS were used to assess the efficacy and safety respectively. Results: compared with before treatment, PANSS scores decreased significantly after treatment (P < 0.05). The scores on blunted affect,emotional withdrawal, poor rapport and passive/apathetic social withdrawal were lower in the study group than in the control group at week 4,8 and 12, the score difference was statistically significant (P < 0.05 or P < 0.01). The adverse events of two groups were mild or moderate. Conclusion; Paroxetine combined risperidone in the treatment of chronic schizophrenia with negative symptoms showed rapid response, better efficacy and good patient compliance.

  12. The Effects of Risperidone on Patients about Plasma Glucose,HOMA-IR,ISI,HBCI%药物利培酮对患者血糖、HOMA-IR、ISI、HBCI的影响研究

    Institute of Scientific and Technical Information of China (English)

    张振

    2013-01-01

      目的:探索药物利培酮对患者体重与糖代谢的影响.方法:收集78例患者使用利培酮治疗,疗程为12周,分别在未用药前和用药12周后测量体重和检测空腹血糖水平、HOMA-IR、ISI、HBCI,进行同体比较.结果:治疗12周后,患者平均体重增加2.61 kg,与治疗前比较,差异有统计学意义(P<0.05);同时在治疗12周后检测空腹血糖,与治疗前空腹血糖比较,平均升高0.84 mmol/L,差异有统计学意义(P<0.05).HOMA-IR 与 HBCI 治疗后均升高,差异有统计学意义(P<0.05).ISI 降低,差异有统计学意义(P<0.05).结论:利培酮治疗精神分裂症,对患者的体重和空腹血糖有一定程度的影响.%Objective:To study the effect of risperidone for patients on the weight and glycometabolism. Method:78 cases of patients treated with risperidone before and after 12 weeks,we compared the weight and the fasting blood glucose 、HOMA-IR、ISI、HBCI respectively.Result:There was significant difference in the mean weight of the patients treated with risperidone for 12 weeks,which increased by 2.41 kilometres(P<0.05).The average fasting blood glucose of the patients treated for 12 weeks significant increased by 0.84mmol/L(P<0.05). HOMA-IR and HBCI were significantly increased after treatment there was statistically significant(P<0.05).ISI reduced,there was statistically significant(P<0.05). Conclusion:There are some extent effect on the weight and the fasting blood glucose of the patients who were treated with risperidone.

  13. Efficacy and adverse reactions of Aripiprazole and Risperidone in treatment of patients with schizophrenia%阿立哌唑与利培酮治疗精神分裂症患者的疗效及不良反应

    Institute of Scientific and Technical Information of China (English)

    臧双九

    2015-01-01

    目的::观察阿立哌唑、利培酮治疗精神分裂症患者的疗效、不良反应及安全性。方法:将60例符合CCMD-3诊断标准的精神分裂症患者随机分为两组,分别给予患者阿立哌唑、利培酮治疗8周,于治疗前以及治疗2、4和8周采用阳性与阴性症状量表( PANSS)评定患者的疗效,不良反应量表( TESS)评定患者的不良反应。结果:两组患者治疗的疗效相当。利培酮组患者的锥体外系反应、内分泌以及体重增加多于阿立哌唑组。结论:阿立哌唑治疗精神分裂症患者的疗效与利培酮相似,但不良反应更少。%Objective: To observe efficacy, adverse reactions and safety of Aripiprazole and Risperidone in treatment of pa-tients with schizophrenia. Methods: 60 cases meeting CCMD3 diagnostic criteria for schizophrenia were randomly divided into 2 groups. They were treated with Aripiprazole and Risperidone for 8 weeks, respectively. Before and 2, 4 and 8 weeks after the treat-ment, PANSS (positive and negative symptom scale) and TESS (treatment emergent symptom scale) were used to evaluate the efficacy and adverse reactions. Results:The two groups had a similar efficacy;however, the extrapyramidal system reactions, endocrine, and weight gain in Risperidone group were more than those of Aripiprazole group. Conclusions:Aripiprazole in the treatment of the patients with schizophrenia has a similar efficacy with Risperidone, but has fewer adverse reactions.

  14. 利培酮抑制3T3-L1前脂肪细胞的分化%Risperidone inhibits 3T3-L1 pre-adipocytes differentiation

    Institute of Scientific and Technical Information of China (English)

    张高丽; 张弋; 于海川; 张新雅

    2016-01-01

    Objective To investigate the influence of risperidone on differentiation of 3T3‐L1 pre‐adipocytes .Methods 3T3‐L1 pre‐adipocytes were induced to differentiate into mature adipocytes by adopting the classic hormone cocktail method and observed by the oil red O staining .Meanwhile ,the inducing medium was added with risperidone for studying its influence on 3T3‐L1 pre‐adi‐pocytes differentiation .Results 3T3‐L1 pre‐adipocytes were successfully differentiated into the mature adipocytes ,0 .1 ,1 ,10μmol/L risperidone all could inhibit the differentiation of 3T3‐L1 pre‐adipocytes .Conclusion Risperidone can inhibit the differentiation of 3T3‐L1 pre‐adipocytes .%目的:研究利培酮对3T3‐L1前脂肪细胞分化的影响。方法采用经典的激素鸡尾酒法诱导3T3‐L1前脂肪细胞分化为成熟的脂肪细胞,油红O染色观察。向诱导培养基中加入利培酮研究其对3T3‐L1前脂肪细胞分化的影响。结果用激素鸡尾酒法成功地将3T3‐L1前脂肪细胞诱导为成熟的脂肪细胞。0.1、1、10μmol/L的利培酮均能够抑制3T3‐L1前脂肪细胞的分化。结论利培酮能够抑制3T3‐L1前脂肪细胞的分化。

  15. Observation of the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症的临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘卫平

    2015-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的疗效。方法:收治精神分裂症患者60例,随机分为对照组和观察组,对照组采用利培酮治疗,观察组采用阿立哌唑治疗,比较两组治疗效果。结果:对照组总有效率86.7%,观察组总有效率90.0%,P>0.05;对照组出现不良反应18例(60.0%),观察组出现不良反应6例(20.0%),P<0.05。结论:在精神分裂症的治疗中利培酮与阿立哌唑均具有显著的疗效,然而相对于利培酮而言,阿立哌唑具有较低的不良反应发生率,因此其具有较高的安全性。%Objective:To explore the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia.Methods:60 patients with schizophrenia were selected.They were randomly divided into the control group and the observation group.The control group was treated with risperidone,and the observation group was treated with aripiprazole.We compared the treatment effect of the two groups.Results:In the control group,the total efficiency was 86.7%;in the observation group,the total efficiency was 90%,P>0.05.In the control group,18 cases(60%) had adverse reactions;in the observation group,6 cases(20%) had adverse reactions,P<0.05.Conclusion:In the treatment of schizophrenia,risperidone and aripiprazole all had significant curative effect,but compared with risperidone,aripiprazole had low adverse reaction rate,so it had a high safety.

  16. 中医辨证联合维思通治疗精神分裂症96例疗效研究

    Institute of Scientific and Technical Information of China (English)

    聂榕春

    2013-01-01

    目的:探究中医辨证联合维思通治疗精神分裂症的疗效。方法本研究以中医辨证联合维思通治疗精神分裂症,在治疗2个月后比较他们间的PANSS阳性症状总分、PANSS总分间的差异。结果中西医结合治疗组疗效高于维思通组,在治疗2个月末时,其PANSS阳性症状总分、PANSS总分与维思通组有差异;生理职能、社会功能、一般健康状况分值高于维思通组。结论中西医结合治疗精神分裂症不仅有利于提高疗效,还能有效地缩短病程。%Objective Efficacy studies of Schizophrenia with the treatment based on syndrome differentiation combined Risperdal. Methods In this research, we try the treatment based on syndrome differentiation combined Risperdal, and compare the difference of the PANSS positive symptoms total score, PANSS total score with risperidone group. Results The efficacy of the combination therapy group is higher than the risperidone group;at the late of second month, PANSS positive symptoms total score, PANSS total score with risperidone group is different from the treatment of risperidone group, physical function, social function, general health scores is also higher than the risperidone group. Conclusion The integrative Medicine schizophrenia not only help to improve the effect, but also effectively shorten the course.

  17. Topiramate Versus Valproate Sodium as Adjunctive Therapies to a Combination of Lithium and Risperidone for Adolescents with Bipolar I Disorder: Effects on Weight and Serum Lipid Profiles

    Directory of Open Access Journals (Sweden)

    Javad Alaghband-Rad

    2012-04-01

    Full Text Available Objective: To compare the effects of topiramate versus valproate sodium as an add-on therapy to a combination of lithium and risperidone (Li+Ris on body weight and serum lipid profile in children and adolescents with bipolar disorder. Methods: In a single-blind randomized clinical trial, thirty children and adolescents with bipolar disorder type I in the manic or mixed phase ,treated with the combination of Li+Ris at therapeutic doses for at least 4 weeks who had the indication of add-on therapy due to a recurrent episode; a partial response or non response in the current episode or relapse were included. Participants were randomly assigned to receive either topiramate or sodium valproate as the third drug add-on therapy for a total of 6 weeks. Weight, height and serum lipid profiles were determined at baseline and at the end of week 6. Results: Differences in the mean levels of lipid profiles at baseline and after week 6 evaluation were not significant in both treatment groups. BMI z-score increased in both treatment groups, being significant only in the Li+Ris/Valproate group, increasing from (mean ±SD 0.38 ±0.55 to 0.72 ±1.23 (p<0.05. Between group changes in BMI z-score was not significant.Among the BMI percentile categories, participants in the normal weight subgroup showed a significant increase in BMI z-score during the 6 week trial, compared to overweight/obese subgroup, in both Li+Ris/Valproate and Li+Ris/Topiramate treatment groups. Elevated mean serum level of triglyceride and a high proportion of participants with elevated total cholesterol (≥ 170 mg/dl, triglyceride (≥ 110 mg/dl, and BMI percentile 85-<95 at baseline (before randomization and at the end of 6 week study were noted. Conclusion: When topiramate and valproate sodium are used for six weeks as adjunctive treatment to a combination of Li+Ris, they act alike on lipid milieu of children and adolescents with bipolar disorder. Both Li+Ris/Valproate and Li

  18. Il trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici: una valutazione comparativa di costo/efficacia in una realtà psichiatrica locale

    Directory of Open Access Journals (Sweden)

    Egidio Filippelli

    2005-09-01

    Full Text Available BACKGROUND: Several clinical trials demonstrated that atypical antipsychotics are more effective but also more expensive (as drug cost compared with the typical neuroleptics by treating psychotic disorders. The present study aimed to evaluate this result using an observational approach which better reflects the real clinical practice. OBJECTIVE: To evaluate clinical effectiveness (including work and social functioning and overall direct costs in a group of patients affected by psychotic disorders (schizophrenia and bipolar and treated with typical and atypical (olanzapine and risperidone antipsychotics. METHODS: With a multicentre observational design - two years long - 89 patients (in charge by Psychiatric Centers of Regione Campania - Italy were assessed using CGI (Clinical Global Impression and GAF (Global Assessment of Functioning scales. Moreover economic data were collected with reference to pharmacological and non-pharmacological (hospitalization, medical/nurse visits, etc. resources consumption. The pharmacoeconomic analysis were conducted choosing the perspective of the local Psychiatric Services for costs attribution. RESULTS: Considering the treatment outcomes, the use of the atypical drugs provided better performances with reference to the patients quality of life. The results in terms of work and social functioning indicated an advantage in the olanzapine group of patients. Overall direct costs of treatment (drugs and healthcare resources didn’t generate significant differences among the groups of therapy despite the pharmacological cost evidentiated an economic advantage (p<0,05 in the typical group due to the cheaper cost of these drugs. The use of olanzapine was associated to a lower number of hospitalizations and showed a general reduction (- 16% of total treatment costs between 1st and 2nd year of observation. CONCLUSIONS: The lack of side effects, the improvement in work and social functioning, associated to a more efficient

  19. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.

    Science.gov (United States)

    Sacristán, J A; Gómez, J C; Montejo, A L; Vieta, E; Gregor, K J

    2000-05-01

    The objectives of this study were to determine the doses of olanzapine (OLZ), risperidone (RIS), and haloperidol (HAL) used in clinical practice in outpatients with schizophrenia and the rates of occurrence of extrapyramidal symptoms (EPS) and other adverse events, clinical response, and use of concomitant medications. The present study involved a subset of patients from a 6-month, open-label, prospective observational study. Data were collected by 293 psychiatrists at mental health centers and other outpatient treatment facilities in Spain. Medications and doses used, occurrence of EPS and other adverse events, and scores on the Clinical Global Impression (CGI) of Severity Scale and Global Assessment of Function (GAF) were recorded. Clinical response was defined as a decrease of > or = 2 points on the CGI, with a final CGI score or = 5 received significantly higher overall mean daily doses than did patients with an initial CGI score < 5 (P < 0.001). A significantly lower proportion of OLZ-treated patients (10.2%) were receiving concomitant anticholinergic medication at the end of the study (month 6) compared with RIS-treated (19.9%) and HAL-treated (44.0%) patients (P < 0.001). The mean daily doses recorded in this analysis based on data from a naturalistic setting are consistent with recommendations based on clinical trials. Compared with both RIS- and HAL-treated patients, OLZ-treated patients were less likely to experience EPS or other adverse events, and less likely to use concomitant anticholinergic medications. OLZ-treated patients were also more likely to respond to treatment than were RIS-treated patients.

  20. Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone: Preliminary Evidence.

    Science.gov (United States)

    Hendouei, Narjes; Hosseini, Seyed Hamzeh; Panahi, Amin; Khazaeipour, Zahra; Barari, Fatemeh; Sahebnasagh, Adeleh; Ala, Shahram

    2016-01-01

    Recently, extensive efforts have been made to understand the rate of energy expenditure and the weight gain associated with atypical antipsychotic treatment, including identification of markers of obesity risk. In recent years, leptin, an adipocyte hormone, has gained significant interest in psychiatric disorders. S100B has been considered as a surrogate marker for astrocyte-specific damage in neurologic disorders. Also, S100B has been detected in adipose with concentration as high as nervous tissue as a second release source. In this study we evaluated the relationship between S100B and leptin in schizophrenic patients under treatment with clozapine and risperidone.This study included 19 patients meeting the DSM-IV-TR criteria for schizophrenia, having body mass index (BMI) of 16- 25 kg/m(2) and suffering schizophrenia for more than 3 years and from this study. Twenty five healthy controls were group matched for age and gender whose BMI was 16-25 kg/m(2). Serum S100B and leptin levels and positive and negative symptom scale (PANSS) were assessed at admission and after six weeks. During the study, S100B showed a strong and negative correlation with leptin (r = -0.5, P = 0.01). Also, there were negative correlation between serum S100B level and PANSS negative subscale after 6 weeks of treatment (r = -0.048, P = 0.8). Positive correlation between leptin level and PANSS suggested a potential role for leptin which can mediate the link between antipsychotic induced weight gain and therapeutic response in schizophrenia.

  1. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.

    Science.gov (United States)

    Mehnert, Angelika; Nicholl, Deborah; Pudas, Hanna; Martin, Monique; McGuire, Alistair

    2012-01-01

    To model the cost effectiveness of paliperidone palmitate (paliperidone long-acting injectable; PLAI), a new once-monthly long-acting antipsychotic therapy, compared with risperidone long-acting injectable (RLAI) and olanzapine pamoate (OLAI), in multi-episode patients (two or more relapses) with schizophrenia in Sweden. A Markov decision analytic model was developed to simulate the history of a cohort of multi-episode patients transitioning through different health states on a monthly basis over a 5-year time horizon from the perspective of the Swedish healthcare system. Therapeutic strategies consisted of starting treatment with RLAI (mean dose 37.5 mg every 2 weeks), PLAI (mean dose 75 mg equivalent (eq.) every month) or OLAI (150 mg every 2 weeks or 300 mg every 4 weeks). Probability of relapse, level of adherence, side-effects (extrapyramidal symptoms, tardive dyskinesia, weight gain and diabetes) and treatment discontinuation (switch) were derived from long-term observational data when feasible. Incremental cost-effectiveness outcomes, discounted at 3% annually, included cost per quality-adjusted life-year (QALY) and cost per relapse avoided (expressed in 2009 Swedish Krona SEK). Relative to RLAI and OLAI, PLAI is economically dominant: more effective (additional QALYs, less relapses) and less costly treatment option over a 5-year time horizon. The results were robust when tested in sensitivity analysis. The impact of once-monthly treatment on adherence levels is not yet known, and not all variables that could impact on real-world outcomes and costs were included in this model. PLAI was cost saving from a Swedish payer perspective compared with RLAI and OLAI in the long-term treatment of multi-episode (two or more relapses) schizophrenia patients.

  2. Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.

    Science.gov (United States)

    Baylé, Franck Jean; Tessier, Arnaud; Bouju, Sophie; Misdrahi, David

    2015-01-01

    Maintaining antipsychotic therapy in psychosis is important in preventing relapse. Long-acting depot preparations can prevent covert non-adherence and thus potentially contribute to better patient outcomes. In this observational survey the main objective is to evaluate medication adherence and its determinants for oral treatment in a large sample of patients with psychosis. In this cross-sectional survey medication adherence for oral treatment was assessed by patients using the patient-rated Medication Adherence Questionnaire (MAQ). Data were collected by physicians on patients with a recent acute psychotic episode before switching to long-acting injectable risperidone. Other evaluations included disease severity (Clinical Global Impression - Severity), patients' insight (Positive and Negative Syndrome Scale item G12), treatment acceptance (clinician-rated Compliance Rating Scale), and therapeutic alliance (patient-rated 4-Point ordinal Alliance Scale). A total of 399 psychiatrists enrolled 1,887 patients (mean age 36.8±11.9 years; 61.6% had schizophrenia). Adherence to oral medication was "low" in 53.2% of patients, "medium" in 29.5%, and "high" in 17.3%. Of patients with psychiatrist-rated active acceptance of treatment, 70% had "medium" or "high" MAQ scores (Padherence was significantly associated with therapeutic alliance (4-Point ordinal Alliance Scale score; PPatient age was significantly associated with adherence: mean age increased with greater adherence (35.6, 36.7, and 38.6 years for patients with "low", "medium", and "high" levels of adherence, respectively; P=0.0007), while age adherence was also associated with a diagnosis of schizophrenia (P=0.0083), more severe disease (Clinical Global Impression - Severity ≥4; Padherence was low in most patients, with a strong positive association between self-reported adherence and psychiatrists' assessment of treatment acceptance. Understanding factors associated with poor medication adherence may help

  3. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

    Science.gov (United States)

    Olivares, J M; Rodriguez-Morales, A; Diels, J; Povey, M; Jacobs, A; Zhao, Z; Lam, A; Villalobos Vega, J C; Cuéllar, J Alonso; de Castro, F J Alberca; Quintero, C Morillo-Velarde; Martíin, J F Román; Domínguez, P Tabares; Ojeda, J L Prados; Cortés, S Sanz; Cala, F I Mata; Marín, C Gutiérrez; Castro, L Moyano; Duaso, M A Haza; Albarracín, J Requena; Vergara, G Narbona; Benítez, A Fernández; Cleries, F Mayoral; Pérez-Brian, J M García-Herrera; Aragón, A Bordallo; Navarro, J C Rodríguez; Biedma, J A Algarra; de Pedro, R Bravo; González, J F Delgado; López, M E Jaén; Moreno, H Díaz; López, J A Soto; Rodríguez, E Ojeda; de Hoyos, C Martínez; Sacristán, M Pardilla; Martín, M D Molina; Ballesteros, E Martín; Rodríguez, P A Sopelana; Menéndez, L Fernández; Rivas, R Santos; del Pino Cuadrado, P; Lauffer, J Correas; Solano, J J Rodríguez; Martínez, J M Fernández; Solano, F García; Rodríguez, P García-Lamberde; Rodríguez, J A Romero; Cano, T Rodríguez; Fortacin, M Ducaju; Lobeiras, J M Blanco; Sampedro, J M Piñeiro; Bravo, A Pérez; Pellicer, A Fernández; López, M D Alonso; Liste, J Fraga; Fernández, M Riobo; Losada, A Casas; Mendez, R Vazquez-Noguerol; Romero, S Agra; Blanco, J J Blanco; Bonaselt, I Tortajada; Mahia, M C García; del Valle, E Ferrer Gómez; Yañez, P Quiroga; Camarasa, M Gelabert; Alonso, J A Barbado; Mendez, G Florez; Feliz, F Doce; Lamela, M A López; Piñero, M Vega; Alvarado, P Fuentes; Gómez, I López; Martín, P Fadon; Gómez, J L Santos; López, A García; Jiménez, A Rodríguez; Nafs, A Escudero; Barquero, N Casas; Ortiz, R Fernández-Villamor; Noguera, J L Velez; Carrasco, P Ruiz; Muñoz, J Martín; Palma, M Masegoza; Hortelano, C Marín; Bonome, L Sánchez; Sevilla, J Sánchez; Juan, J M Mongil San; Ramos, J M García; Muñoz, J L Vallejo; Guisasola, J Elorza; Vazquez, L Santamaria; Guerras, F Campo; Nebot, F J Arrufat; Fernández, F J Baron; Nicolau, A L Palomo; Subirats, R Catala; Kidias, M Messays; Navarro, V Fabregat; García, B Frades; del Rosal, F Mejias; de Vicente Muñoz, T; Ballester, J Año; Lieb, P Malabia; Martel, A Delgado; Bea, E Roca; Joaquim, I Grau; Enjuanes, F Boatas; Piñol, M Bañuelos; Carbonell, E Fontova I; Muñoz, R Martín; Giribets, C Argila; Sans, L Albages; Blanco, A Serrano; Felipe, M Arcega; Muñoz, P González; Villanueva, A Pons; Arroyo, M Bernardo; Borri, R Coronas; Fallada, S Miret; Merola, M Celma; Rodon, E Parellada; Palmes, J R Pigem; Martínez, E Pérez; Catala, J Matarredona; Coca, A Sandoval; Ferrandiz, F Pascual; Paya, E Ferrandiz; Caballero, G Iturri; Bonet, A Franco; Figueras, J Fluvia; Pagador, P Moreno; Garibo, M Medina; Camo, V Pérez; Carrillo, C Sanz; Valero, C Pelegrin; Rebollo, F J Caro; García Campayo, J; Sala Ayma, J M Sala; Roig, M Martínez; de Uña Mateos, M A; Bertolin, R García; García, A Martín; Mazo, F Jiménez; Velasco, J L Galvez; Pérez, L Santa Maria; Casado, C Jiménez; Barba, J J Mancheño; Diaz, M Conde; Rubio, J P Alcon; Mandoli, A Soler; Herrero, A Uson; Martínez, A Rodríguez; Serrano, P Salgado; Rodríguez, E Nieto; Montesinos, J Segui; Macia, J Ferragud; Mateos Marcos, A Mateos; Soto, J V Pérez-Fuster; Dumont, M Verdaguer; Pagan, J Parra; Martínez, V Balanza; Santiuste de Pablos, M; Delgado, C Espinosa; Quiles, M D Martínez; López, F J Manzanera; Navarro, P Pozo; Torres, A Micol; Ingles, F J Martínez; Arias-Camison, J M Salmeron; Manzano, J C López; Peña, R Villanueva; Guitarte, G Petersen; Fontecilla, H Blasco; Romero, J Barjau; Gil, R Sanz; Lozano, J Marín; Adanez, L Donaire; Zarranz Herrera-Oria, I; Jiménez, J Pérez; Vaz, F Carrato; García, O Sanz; Anton, C Contreras; Casula, R Reixach; Hernandez, M C Natividad; Escabias, F Teba; Torresano, J Rodríguez; Pérez-Villamil, A Huidobro; Estevez, L; Figuero, M Aragües; Muñoz de Morales, A; Calvin, J L Rodríguez; Criado, M Delgado; Rodríguez, V Molina; Ambrosolio, E Balbo; Madera, P M Holgado; Alfaro, G Ponce; Vidal, M M Rojas; Valtuille, A García; Ruiz, O; Cabornero, G Lucas; Echevarria Martínez de Bujo, M; Mallen, M J Maicas; Puigros, J Santandreu; Martorell, A Liñana; Forteza, A Clar; Arrebola, E Rodríguez; Rodríguez de la Torre, M; Saiz, C G Anton; Bardolet I Casas, C; Linde, E Rodríguez; De Arce Cordon, R; Molina, E M Padial; Carazo, F J Ruiz; Romero, J J Muro; Cano, D Vico; Dorado, M Soria; Velazquez, S Campos; Sánchez, A J Rodríguez; Leon, S Ocio; Sánchez, K Pachas; Benitez, M Henry; Zugarramurai, A Intxausti; Contreras, M A; De la Varga González, M; Marín, P Barreiro; Robina, F Gómez; García, M Sánchez; Pérez, F J Otero; Bros, P Cubero; Gómez, A Carrillo; de Dios Molina Martín, J; Perera, J L Carrasco; Averbach, M C; Perera, J L Carrasco; Palancares, E Goenaga; Gallego de Dios, M T; Rojo, C Fernández; Iglesias, S Sánchez; Merino, M I Rubio; Mestre, N Prieto; Urdaniz, A Pérez; Sánchez, J M Martínez; Seco, R Gordo; Muñoz, J Franco; Agut, M Mateos; Lozano, M L Blanco; Herguedas, F Martín; Pena, A Torcal; García, J Vicente; Martínez, A Varona; Sanz Granado, O Sanz; Fernández, M A Medina; Canseco, J M Moran; López, P A Megia; Martín, M A Franco; Barrio, J A Espina; Ubago, J Giner; Bennassar, M Roca; Díez, J M Olivares; Fleta, J L Hernandez; Fortes, F Porras; López, C Arango; Medina, O; Alvarez, D Figuera; Roca, J M Peña; Valladolid, G Rubio; Tavera, J A Furquet; García-Castrillon Sales, J A; Llordes, I Batalla; Melgarejo, C Anchuistegui; Cañas de la Paz, F; Callol, V Vallés; García, M Bousoño; García, J Bobes; Leal, F J Vaz; Corrales, E Cáceres; Iglesias, E Sánchez; Gómez, M A Carreiras; Serrano, G García; Chillarón, E G Román; Aguado, F J Samino; Castillo, J J Molina; González, A González; Vázquez, J Gallardo; Peralvarez, M Bolivar; Diaz, M Rios; Mesa, M Ybarzabal; Artiles, F J Acosta; Chao, M Ajoy; Mesa, M Ybarzabal; del Rosario Santana, P; Escudero, M A García; Berenguer, M Molla; Llacer, J M Bonete; Berna, J A Juan; Ortiz, J Barragán; Pardell, L Tost; Hernández-Alvarez de Sotomayor, C; Méndez, M R Cejas; Garate, R Cabrera; Múgica, B Díaz; González, M Caballero; Domingo, J Pujol; Navarro, C Sáez; Vera, G Selva; Cuquerella, M A; Monzo, J Lonjedo; Boada, P Cervera; Pérez, M F Martín; Parrado, E Carrasco; Sánchez, J J Yañez; Fernández, J Calvo

    2009-06-01

    The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is a prospective, observational study of patients with schizophrenia designed to evaluate long-term treatment outcomes in routine clinical practice. Parameters were assessed at baseline and at 3 month intervals for 2 years in patients initiated on risperidone long-acting injection (RLAI) (n=1345) or a new oral antipsychotic (AP) (n=277; 35.7% and 36.5% on risperidone and olanzapine, respectively) in Spain. Hospitalization prior to therapy was assessed by a retrospective chart review. At 24 months, treatment retention (81.8% for RLAI versus 63.4% for oral APs, p<0.0001) and reduction in Clinical Global Impression Severity scores (-1.14 for RLAI versus -0.94 for APs, p=0.0165) were significantly higher with RLAI. Compared to the pre-switch period, RLAI patients had greater reductions in the number (reduction of 0.37 stays per patient versus 0.2, p<0.05) and days (18.74 versus 13.02, p<0.01) of hospitalizations at 24 months than oral AP patients. This 2 year, prospective, observational study showed that, compared to oral antipsychotics, RLAI was associated with better treatment retention, greater improvement in clinical symptoms and functioning, and greater reduction in hospital stays and days in hospital in patients with schizophrenia. Improved treatment adherence, increased efficacy and reduced hospitalization with RLAI offer the opportunity of substantial therapeutic improvement in schizophrenia.

  4. The Comparison of the Effectiveness of Risperidone and Fluoxetine in Combination with Impulse Control Group Therapy on Improving of Impulsivity, and Relapse in Heroin Crack Addicts under Methadone Maintenance Therapy

    Directory of Open Access Journals (Sweden)

    Rohoallah Hadadi

    2013-05-01

    Full Text Available Aim: The aim of the study was to compare the effectiveness of Risperidone and Fluoxetine in combination with impulse control group therapy on improving of impulsivity, and relapse in heroin crack addicts under methadone maintenance therapy. Method: In a semi-experimental study, 39 heroin crack addicts who were under Methadone maintenance treatment selected of addiction withdrawal centers in Tehran. The selected sample was randomly assigned to three groups. First group was under (Risperidone 1 mg daily, impulse control group therapy for 8 sessions of 90 minutes, and methadone maintenance treatment, the second group was under (Fluoxetine 20 mg daily, impulse control group therapy for 8 sessions of 90 minutes, and methadone maintenance therapy, and the third group was under (impulse control group therapy for 8 sessions of 90 minutes, and methadone maintenance therapy. All participants completed the Barratt impulsivity scale (BIS-11 before and immediately after the end of intervention and follow up. Also, Morphine and stimulating drugs in urine were analyzed. Results: The results showed that total impulsivity scores was decreased in post-test but not in follow up. That is, impulsivity decreased in both experimental groups. Results also showed that relapse rate was not significantly differed. Conclusion: The combination of Fluoxetine with Methadone maintenance therapy and impulse control group therapy, was the most effective treatment on reduction of impulsivity, but not on relapse rate, in heroin crack abusers, in the short term.

  5. 氯氮平与利培酮对血清催乳素水平的影响%The effects of clozapine and risperidone on serum prolactin levels of female schizophrenia

    Institute of Scientific and Technical Information of China (English)

    侯静; 徐贵云; 马崔; 吴福喜; 黎德美; 陆欣乔; 朱海兵

    2001-01-01

    Objective:To assess the serum prolactin levels of female firstonset schizophrenia in the treatment of clozapine and risperidone. Method:ELISA had been used to determine the serum prolactin levels. Results:The serum prolactin levels of risperidone-treated patients increased significantly 10 weeks later, while those of clozapine-treated patients showed no obvious change. Conclusion:Neither can the serum prolactin levels explain the pathogenesis and severity of schizophrenia, nor predict the clinical outcome of atypical antipsychotics.%目的:了解氯氮平或利培酮对首发女性精神分裂症患者血清催乳素水平的变化。 方法:采用ELISA方法测定血清催乳素水平。 结果:治疗后氯氮平组血清催乳素水平没有显著变化,而利培酮组血清催乳素水平显著升高。 结论:催乳素水平不能说明精神分裂症发病及严重程度,也不能作为非典型抗精神病药疗效的指标。

  6. Clinical Observation of Risperidone in the Treatment of Postoperative Delirium in Elderly Orthopedics Patients%利培酮治疗老年骨科患者术后谵妄的临床观察

    Institute of Scientific and Technical Information of China (English)

    吴晓; 王利宏

    2013-01-01

    目的:观察利培酮治疗老年骨科患者术后谵妄的临床疗效和安全性.方法:将符合标准的骨科术后并发谵妄的老年患者68例按年龄、性别、病种、手术种类为条件均分为对照组和观察组.对照组肌肉注射氟哌啶醇注射液,起始剂量为2.0 mg/d,经调整剂量后平均用量(7.0±0.4)mg/d,每日1~2次;观察组口服利培酮片,起始剂量为0.5 mg/d,经调整剂量后平均用量(1.5±0.3)mg/d,每日1~2次.两组患者均治疗7d.治疗过程中采用谵妄分级量表进行谵妄症状(DRS)评分,并观察不良反应发生情况.结果:两组患者治疗期间DRS评分较治疗前均显著下降(P<0.05),但两组患者同期DRS评分比较差异无统计学意义(P>0.05);对照组2例患者出现锥体外系反应,而观察组未见不良反应发生,两组患者不良反应发生率比较差异有统计学意义(P<0.05).结论:利培酮治疗老年骨科患者手术后谵妄与氟哌啶醇疗效相近,但利培酮较氟哌啶醇更安全.%OBJECTIVE:To observe clinical efficacy and safety of risperidone in the treatment of delirium in elderly orthopedic patients after surgery.METHODS:68 elderly patients with delirium after orthopedic surgery met criteria were randomly divided into control group and observation group according to age,gender,disease type and operation tyes.Control group was given Haloperidol injection intramuscularly with starting dose of 2.0 mg/d,1 to 2 times a day,average dose of (7.0 ± 0.4) mg/d after adjustment; observation group was given Risperidone tablet orally with t starting dose of 0.5 mg/d,1 to 2 times a day,average dose of (1.5 + 0.3) mg/d after adjustment.Treatment course of 2 groups both were 7 days.The symptems was scored by using Delirium Rating Scale (DRS) score and adverse drug reactions were observed during treatment.RESULTS:DRS scores of two groups were decreased significantly during treatment (P<0.05),there was no statistical significance between 2

  7. Clinical Study on Shaoyao Gancao Decoction for Treating Risperidone-induced Hyperprolactinemia%芍药甘草汤治疗利培酮所致高催乳素的临床研究

    Institute of Scientific and Technical Information of China (English)

    向小妹; 潘彬斌; 李红; 丁跃庆; 桂琴; 虞贝贝; 吴洪军

    2013-01-01

    目的:探讨芍药甘草汤治疗利培酮所致的高催乳素血症的临床应用价值及安全性。方法:回归性分析研究2011年1月-2012年3月在本院接受治疗的92例因服用利培酮导致高催乳素血症的精神病患者(催乳素水平≥1888.5μg/ml),分析所有患者服用芍药甘草汤后利培酮血浆浓度及9-羟利培酮血浆浓度、催乳素、血药浓度、PANSS评定等指标。结果:与治疗前相比,患者在治疗后的血清泌乳素水平显著下降(P<0.05),但雌二醇、睾酮、孕酮浓度治疗前后的浓度、TESS评分和治疗后的利培酮血浆浓度及9-羟利培酮血浆浓度无显著差异。结论:芍药甘草汤治疗利培酮所致的高催乳素血症可快速改善月经不调、闭经、男性女性化等症状,提高患者服药依从性,且服药方便,疗效明显,价格低廉,安全可靠,值得临床推广应用。%Objective:To investigate the clinical application value shaoyao-gancao decoction in the treatment of hyperprolactinemia induced by risperidone and its safety.Method:92 psychiatric patients with hyperprolactinemia induced by risperidone from 2011 January to 2012 March in our hospital were analyzed resrospectively(prolactin levels≥1888.5μg/ml),analyzed the indices of plasma concentration of risperidone and 9-hydroxyrisprridone, prolactin,blood concentration,PANSS evaluation were observed in all patients.Result:Compared with before treatment,the serum prolactin level after treatment decreased significantly(P<0.05),but there were no differences in the estradiol,testosterone,progesterone concentrations,the TESS score before and after treatment and the plasma concentration of risperidone and 9-hydroxyrisprridone after treatment.Conclusion:Shaoyao-gancao decoction treatment of risperidone caused by high blood prolactin can rapidly improve the male feminine irregular menstruation,amenorrhea,Male female etc, enhance patient medication adherence

  8. 利培酮、氯氮平合并碳酸锂治疗躁狂症的临床对照研究%Clinical control study of risperidone,clozapine combined with lithium carbonate in the treatment of mania

    Institute of Scientific and Technical Information of China (English)

    孙锦红

    2014-01-01

    目的:观察利培酮与氯氮平分别合并碳酸锂治疗有精神病性症状躁狂症的疗效及安全性。方法:将符合DSM-Ⅳ诊断标准的躁狂症患者60例,随机分为两组,在使用碳酸锂的同时,分别合并利培酮或氯氮平平进行为期8周的治疗。采用躁狂量表(BRMS)评定疗效,采用不良反应量表(TESS)评定不良反应。结果:利培酮与氯氮平平疗效相当,利培酮起效时间迟于氯氮平,但不良反应较轻,依从性好。结论:利培酮合并碳酸锂与氯氮平合并碳酸锂治疗躁狂症总体疗效相当,但安全性较高。%Objective:To observe the effects of risperidone and clozapine both combined with lithium in treatment efficacy and safety of psychotic symptoms of mania.Methods:60 patients with mania were selected,all of them meet the DSM-Ⅳ diagnostic criteria on mania.They were randomly divided into 2 groups,at the same time of the use of lithium carbonate combined with risperidone or clozapine respectively,the treatment time is 8 weeks.The treatment efficacy assessed by Mania Rating Scale(BRMS), the adverse reactions assessed by side effects scale(TESS).Results:The treatment efficacy of risperidone and clozapine is equalized,the onset time of risperidone later than clozapine,but the adverse reaction of risperidone less than clozapine,and the former has better compliance.Conclusion:The efficacy of risperidone combine with lithium carbonate and clozapine combined with lithium in treatment of mania are equivalent,but risperidone has higher security.

  9. Analyzing effect and safety of quetiapine and risperidone on mental and behavioral of alzheimer disease%喹硫平与利培酮治疗阿尔茨海默病精神行为异常的临床疗效及安全性

    Institute of Scientific and Technical Information of China (English)

    许晓英; 曾媛媛; 张易

    2013-01-01

    目的 探讨喹硫平与利培酮治疗阿尔茨海默病精神行为异常的临床疗效及安全性.方法 将86例阿尔茨海默病患者随机分为喹硫平组和利培酮组,分别给予喹硫平及利培酮口服治疗,疗程8周.采用痴呆病理行为评定量表评估临床疗效,并比较2组不良反应发生率.结果 喹硫平组与利培酮组治疗有效率分别为79.5%和76.2%,差异无统计学意义(P>0.05);治疗后8周,喹硫平组痴呆病理行为评定量表昼夜节律紊乱及攻击行为因子显著优于利培酮组(P<0.05);2组不良反应发生率无显著差异(P>0.05).结论 喹硫平与利培酮治疗阿尔茨海默精神行为异常临床疗效相当,但喹硫平抗焦虑及镇静的作用优于利培酮.%Objective To explore the effect and safety of quetiapine and risperidone on mental and behavioral of alzheimer disease.Methods Eighty-six patients with alzheimer disease were randomly divided into quetiapine group and risperidone group.The two groups received quetiapine and risperidone treatment respectively.The course of treatment was 8 weeks.BEHAVE-AD scale was used to evaluate the clinical effect.Adverse rates were compared between two groups.Results The effectiveness rates of treatment were 79.5 % and 76.2 % in quetiapine group and risperidone group without significant difference (P >0.05).Aggressiveness and diurnal rhythm disturbances of BEHAVE-AD 8 weeks after treatment in quetiapine group were superior to risperidone group (P < 0.0 5).There was no significant difference of adverse reactions between the two groups (P >0.05).Conclusion Quetiapine and risperidone have equivalent effects on mental and behavioral of alzheimer disease,while the anti-anxiety effects and sedative effect of quetiapine is superior to risperidone.

  10. 银杏叶提取物合并利培酮口腔崩解片治疗精神分裂症的临床研究%A clinical study of combined utization of ginkgo biloba extract and risperidone orally disintegrating tablets in the treatment of schlzophrenia

    Institute of Scientific and Technical Information of China (English)

    龚飞中; 曾骥; 余瑞; 龚昌群; 刘均富

    2012-01-01

    Objective To compare clinical efficacy and the side effects between combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets and only the use of risperidone orally disintegrating tablets in the treatment of schizophrenia. Methods Seventy-five patients with schizophrenia were treated randomly with combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets or risperidone orally disintegrating tablets only for six weeks,and measured with the brief psychiatric rating scale (BPRS) and treatment emergent symptom scale(TESS) before treatment and 1,2,4,6 weeks after treatment. Results The both programes were different in efficacy, combined utilization of ginkgo biloba extract and risperidone o-rally disintegrating tablets is more effective than risperidone orally disintegrating tablets only in treating schizophrenia, and the side effects combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets is no more effective than risperidone orally disintegrating tablets only in treating schizophrenia. Conclusion The therapeutic effect of combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets take a active part earlier than only the use of risperidone orally disintegrating tablets in the treatment of schizophrenia, however, the reduced rate of BPRS was no significant difference after 2 weeks, itcould be necessary to continue the joint use of ginkgo biloba extract.%目的 比较银杏叶提取物合并利培酮口腔崩解片与单用利培酮口腔崩解片治疗精神分裂症的疗效及不良反应.方法 将符合标准的75例精神分裂症患者分为两组,一组给予银杏叶提取物合并利培酮口腔崩解片治疗(治疗组,n=40),另一组给予利培酮口腔崩解片治疗(对照组,n=35),疗程6周.用简明精神量表(BPRS)在治疗前及治疗1、2、4、6周末评定疗效,用副反应量表(TESS)评定不良反应.结果

  11. CONTROL STUDY BETWEEN RISPERIDONE ORAL SOLUTION AND OLANZAPINE FOR ALCOHOL -INDUCED MENTAL DISORDER%利培酮口服液与奥氮平治疗酒精所致精神障碍对照研究

    Institute of Scientific and Technical Information of China (English)

    王丽莉; 吕浩; 杨建立

    2012-01-01

    目的:探讨利培酮口服液与奥氮平治疗酒精所致精神障碍的疗效和安全性.方法:将68例男性酒精所致精神障碍患者随机分为利培酮口服液治疗组和奥氮平治疗组.采用阳性与阴性症状量表( PANSS)评定临床疗效;采用治疗副反应量表( TESS)评定药物不良反应.结果:利培酮口服液与奥氮平两组疗效差异无显著性.利培酮口服液主要不良反应为锥外系反应,奥氮平为体重增加.结论:利培酮口服液与奥氮平治疗酒精所致精神障碍疗效及耐受性均好,可根据用药对象对不良反应的耐受等情况进行选择.%Objective: To compare the efficacy and safety of risperidone oral solution and olanzapine in the treatment of alcohol - induced mental disorder. Methods: Sixty - eight male patients with alcohol - induced mental disorder were randomly divided into risperidone oral solution group and olanzapine group. Clinical effect was evaluated by Positive and Negative Syndrome Scale (PANSS) ,and the adverse drug reactions were assessed with Treatment Emergent Symptom Scale ( TESS) . Results: No significant differences were observed in the clinical effect of the two groups. The main side effect experienced by the olanzapine group was body weight gain, while the resperidone oral solution group showed extrapyramidal responses. Conclusion: Both olanzapine and risperidone oral solution are safe and effective for the treatment of alcohol - induced mental disorder,and can be clinically selected according to patients' tolerance of the side effects.

  12. 利培酮治疗难治性分裂情感性精神病临床研究%Clinical research on risperidone in the treatment of refractory schizoaffective psychosis

    Institute of Scientific and Technical Information of China (English)

    刘元华

    2014-01-01

    Objective To evaluate the clinical efficacy of risperidone for the treatment of refractory schizoaffective psychosis. Methods 84 patients with refractory schizoaffective psychosis were randomly divided into observation group and control group, and 42 cases were in each group.The two groups were received lithium treatment, and risperidone was added in observation group, while the control group added clozapine. The clinical efficacy of two groups were compared. Results After treatment, the HAMD, BRMS and the PANSS factor scores were significantly lower, but the observation group was significantly lower than the control group(P<0.05);the total effective rate of HAMD,BRMS and PANSS in observation group were significantly higher than the control group (P<0.05);the TESS score of observation group was significantly lower than the control group(P<0.05). Conclusion Risperidone for the treatment of refractory schizoaffective psychosis has a significant effect and less adverse reactions, it should be widely applied.%目的:探讨利培酮用于治疗难治性分裂情感性精神病的临床疗效。方法84例分裂情感性精神病患者随机分为观察组与对照组,各42例,两组均予以碳酸锂治疗,观察组加用利培酮,对照组加用氯氮平,比较两组的临床疗效。结果两组治疗后HAMD、BRMS以及PANSS各项因子评分均降低,且观察组各因子评分低于对照组,差异具统计学意义(P<0.05);观察组的临床总有效率均高于对照组,差异具统计学意义(P<0.05);观察组的TESS评分显著低于对照组,差异具统计学意义(P<0.05)。结论利培酮用于治疗难治性分裂情感性精神病疗效显著,不良反应少。

  13. Effect of Risperidone Combined with Sertraline on Curative Effect of Patients with Obsessive-Compulsive Disorder%利培酮合并舍曲林对强迫症患者疗效的影响

    Institute of Scientific and Technical Information of China (English)

    段海水; 吕贝

    2016-01-01

    ABSTRACT:Objective To observe the effect of risperidone combined with sertraline on the obsessive-compulsive disorder patients. Methods 80 cases of obsessive-compulsive disorder in our hospital were selected as the observation objects, the patients were divided into the observation group and the control group according to the random grouping method, 40 cases in each group, the control group were treated with sertraline treatment alone, patients in the observation group were treated with risperidone on the basis of the contral group. The Yale Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD) were used to evaluate the curative effect. Results After treatment, the indexes of the two groups were signiifcantly decreased, and the observation group was signiifcantly higher than the control group, the difference between the groups was signiifcant (P<0.05). Conclusion Patients with obsessive-compulsive disorder accepting sertraline combined with risperidone treatment can receive signiifcant effect, can improve the symptoms of patients, high safety, it is worth to be popularized in clinical application.%目的:观察利培酮合并舍曲林对强迫症患者的影响。方法选取本院收治的80例强迫症患者作为观察对象,并按照随机分组法将患者分为观察组和对照组,每组40例,对照组患者给予单纯的舍曲林治疗,观察组患者在对照组治疗的基础上联合应用利培酮。采用耶鲁-布郎强迫量表(Y-BOCS)、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评定疗效。结果经过治疗后两组患者的以上指标均有明显的下降,且观察组的下降幅度显著大于对照组,组间差异具有显著性(P均<0.05)。结论对于强迫症患者在舍曲林的基础上联合应用利培酮治疗能够收到显著的效果,有助于改善患者的症状,安全性高,值得在临床中进行推广应用。

  14. 比较氨磺必利与利培酮治疗精神分裂症的效果评价%Analysis of clinical effects and adverse reactions of amisulpride and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈建新; 王艳娉

    2014-01-01

    Objective To analyze clinical effects and adverse reactions of amisulpride and risperidone in the treatment of schizophrenia.Methods A total of 130 patients diagnosed with schizophrenia were divided into research group and control group. 65 cases in the research group were treated with amisulpride, and the other 65 cases in the control group were treated with risperidone. The course of treatment lasted for 8 weeks, and the positive and negative symptoms scale (PANSS) and adverse event scale (TESS) were applied to evaluate the clinical effects and adverse reactions.Results The total effective rate of the research group was 83%, and that of the control group was 77%. Difference between the two groups was not statistically significant (P>0.05). After 8 weeks, PANSS score values were significantly decreased both in the research group and the control group (P0.05). Conclusion The clinical effect of amisulpride is better than risperidone in the treatment of schizophrenia, and they have similar adverse reactions.%目的:分析氨磺必利与利培酮治疗精神分裂症的临床效果和不良反应。方法精神分裂症患者130例,分为研究组和对照组,研究组65例予以氨磺必利治疗,对照组65例采用利培酮治疗,疗程共计8周,采用阳性与阴性症状量表( PANSS)和副反应量表(TESS)评定其疗效和不良反应。结果研究组总有效率为83%,对照组总有效率为77%,两组间差异无统计学意义(P>0.05)。8周末研究组和对照组PANSS总分值均显著下降(P0.05)。结论氨磺必利治疗精神分裂症疗效优于利培酮,且不良反应与利培酮相似。

  15. 氨磺必利与利培酮治疗精神分裂症对照研究%A control study of amisulpride vs .risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张华江; 徐清

    2014-01-01

    Objective To explore the efficacy and safety of amisulpride vs .risper-idone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly divided into two groups of 30 ones each ,research group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and adverse re-actions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week obvious effective and effective rate were respectively 70 .0% and 93 .3% in research and 66 .7% and 93 .3% in con-trol group ,which showed no significant differences (P> 0 .05) .Incidences of extrapyramidal reactions , dysfunction of liver and weight gain were significantly lower in research than in control group (P<0 .05) . Conclusion Amisulpride has an evident effect equivalent to risperidone ,higher safety and better compli-ance in the treatment of schizophrenia .%目的:探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组,每组30例,研究组口服氨磺必利治疗,对照组口服利培酮治疗。观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末,研究组显效率为70.0%、有效率为93.3%,对照组分别为66.7%、93.3%,两组比较差异无显著性(P>0.05)。研究组锥体外系反应、肝功能异常及体质量增加发生率均显著低于对照组(P<0.05)。结论氨磺必利治疗精神分裂症疗效显著且与利培酮相当,安全性高,依从性好。

  16. 氯氮平与利培酮对精神分裂症患者认知功能的影响比较%Comparison of effect between clozapine and risperidone in treating social cognition of patients with schizophrenia.

    Institute of Scientific and Technical Information of China (English)

    高磊

    2016-01-01

    目的 比较氯氮平与利培酮对精神分裂症患者认知功能的影响.方法 选取徐州精神病院 2014 年2 月—2015 年 2 月收治的 82 例精神分裂症患者,按照随机数字表法将患者分为氯氮平组和利培酮组,各 41 例.氯氮平组患者给予氯氮平治疗,利培酮组患者给予利培酮治疗,比较两组患者的阴性和阳性症状量表( PANSS)评分、简易智力量表(MMSE)评分、临床疗效和锥体外系反应发生情况.结果 治疗前后两组患者 PANSS 阳性和阴性症状及一般病理评分比较,差异均无统计学意义(P > 0. 05).两组患者总有效率比较,差异无统计学意义(P > 0. 05);治疗前两组患者 MMSE 评分比较,差异无统计学意义(P > 0. 05);治疗后利培酮组 MMSE 评分高于氯氮平组,差异有统计学意义(P 0. 05) . The total effective rate showed no significant differences between the two groups(P > 0. 05). Before treatment,MMSE score showed no significant differences between the two groups(P > 0. 05);after treatment,MMSE score of risperidone group was higher than that of clozapine group(P < 0. 05). Incidence of extrapyramidal reactions of risperidone group was higher than that of clozapine group(P < 0. 05). Conclusion Risperidone in the treatment of social cognition of patients with schizophrenia is better than that of clozapine,but has high incidence of extrapyramidal reactions

  17. Cost-effectiveness analysis of Risperidone and Aripiprazole in the treat-ment of outpatients with schizophrenia%利培酮、阿立哌唑治疗门诊精神分裂症患者成本-效果分析

    Institute of Scientific and Technical Information of China (English)

    吴宇杰; 李君; 杜鹏; 饶顺曾; 吴彦

    2015-01-01

    Objective To compare therapeutic cost-effects and safety between Risperidone and Aripiprazole in treatment of outpatients with schizophrenia. Methods The schizophrenia patients, who were going on treating with Risperidone or Aripiprazole at discharge, were followed-up 1 year in outpatient. While economic cost-effectiveness and adverse reaction were observed and analyzed. Results Comparing the efficacy between the two groups, it was better in Risperidone group than Aripiprazole group, but there was no statistically significant difference (字2= 0.804, P= 0.84). Drug costs in the Risperidone group was slightly lower than the Aripiprazole group, but there was no statistically significant difference (t = 0.39, P=0.69). The cost-effectiveness of Risperidone was better than Aripiprazole (62.41 v s 64.40). The incidence of high prolactin was up to 26.19% (11/42) in Risperidone group, while in Aripiprazole group had no high prolactin occurring. Conclusion The expenses and efficacy are considerably between Risperidone and Aripiprazole, but the adverse reaction of high prolactin often appears in Risperidone treatment, must be cause caution, for young female patients chosen Risperidone is better.%目的:比较单用利培酮或阿立哌唑治疗门诊精神分裂症患者的经济效果及安全性。方法对出院时使用利培酮治疗方案或阿立哌唑治疗方案的精神分裂症患者门诊随访1年,运用经济学成本-效果分析比较两组优劣,观察治疗不良反应。结果两组在疗效方面比较,利培酮组较阿立哌唑组差,但差异无统计学意义(字2=0.804,P=0.84);利培酮组药物费用略低于阿立哌唑组,但差异无统计学意义(t=0.39,P=0.69);成本-效果方面利培酮组优于阿立哌唑组(62.41比64.40);利培酮组高泌乳素发生率高达26.19%(11/42),而阿立哌唑无高泌乳素发生。结论使用利培酮及阿立哌唑费用及疗效相当,而利培酮引起的高泌乳素副作用发生率较高,

  18. Comparison of Efficacy and Prolactin Concentrations between Aripiprazole and Risperidone Treat-ments in Patients with Schizophrenia%阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    马筠; 李轶琛; 李毅; 房茂胜; 钟宝亮

    2013-01-01

    Objective: To compare the prolactin concentrations between aripiprazole and risperidone treatment in patients with schizophrenia. Methods: One hundred and twenty-eight schizophrenic patients with hy-perprolactinemia were randomly divided into risperidone group and aripiprazole group. Patients in the risperidone group were treated with risperidone and in the aripiprazole group were treated with aripiprazol instead of risperidone for 8 weeks. The prolactin concentrations were assessed and compared between two groups at weeks 0, 1,2, 4, 6, and 8. The clinical status was assessed by using the positive and negative syndrome scale (PANSS) and the clinical global impressions scale (CGIS) atweeks0 and 8. Results: Fifty-three in the risperidone group and 48 in the aripiprazole group were available for analyzing. Shift risperidone to aripiprazole was effective in reducing serum prolactin levels. The serum prolactin levels in the risperidone group was significantly lower than that in the aripiprazole group at week 8 (P<0.001). No significant changes was found in the PANSS and CGI-S scores between the two groups. Conclusion: Shift risperidone to aripiprazole was effective in reducing serum prolactin levels of schizophrenia patients with hyperprolactinemia.%目的:研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响.方法:伴有高催乳素血症的精神分裂症患者128 例,随机分为利培酮组(维持利培酮治疗)和阿立哌唑(阿立哌唑替代利培酮治疗)组,治疗8 周.于第0、1、2、4、6 及8 周测血清催乳素水平及身体质量指数(BMI);在入组时和治疗8 周时采用阳性与阴性症状量表(PANSS)和临床总体印象量表(CGIS)测定疗效.结果:可用于评估的数据101 例,利培酮组53 例,阿立哌唑组48 例.阿立哌唑组替换治疗后第1 周血清催乳素水平即明显下降,第8 周时,显著低于利培酮组(P<0.001);2 组BMI 、PANSS 及CGIS 评分及变化差异无统计

  19. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine Taxas de re-hospitalização de pacientes após alta hospitalar em uso de haloperidol, risperidona ou clozapina

    Directory of Open Access Journals (Sweden)

    Ana Paula Werneck de Castro

    2007-09-01

    Full Text Available OBJECTIVE:The purpose of this study was to evaluate the rehospitalization rates of patients discharged from the Institute of Psychiatry of the Hospital das Clínicas of the Universidade de São Paulo Medical School while being treated with haloperidol, risperidone or clozapine. METHOD: This is a naturalistic study designed to monitor rehospitalization rates for patients discharged on haloperidol (n = 43, risperidone (n = 22 or clozapine (n = 31. Time to readmission over the course of three years was measured by the product-limit (Kaplan-Meier method. Risk factors associated with rehospitalizations were examined. RESULTS: At 36 months, remained in the community 74% of the haloperidol-treated patients, 59% of the risperidone-treated patients and 84% of the clozapine-treated patients. The haloperidol group showed a higher proportion of women, a late age of onset and shorter length of illness than the other groups, whereas the opposite was observed in the clozapine group. CONCLUSIONS: This study suggests that the rehospitalization rates of patients taking clozapine are lower than the rate for patients treated with haloperidol and risperidone. However confounding variables such as gender distribution and age of onset represent limitations that should be taken into account for the interpretation of the results.OBJETIVO: O propósito desse estudo foi observar as taxas de re-hospitalização de pacientes com esquizofrenia que receberam alta do Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo em uso de haloperidol, risperidona ou clozapina. MÉTODO: Este foi um estudo naturalístico conduzido de forma a observar as taxas de re-hospitalizações dos pacientes que receberam alta em uso de haloperidol (n = 43, risperidona (n = 22 ou clozapina (n = 31. O tempo de re-hospitalização foi analisado de acordo com a fórmula produto-limite (Kaplan-Meier por três anos. Fatores de risco associados

  20. 利培酮治疗不同型精神分裂症患者疗效及安全性研究%Study on efficacy and safety of risperidone in treatment of different kinds of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王继禹; 白丽娟; 段媛卿; 原洁; 李志锐; 李新义

    2013-01-01

    目的 探讨利培酮治疗不同型精神分裂症的疗效及安全性.方法 收集100例偏执型及未分化型精神分裂症患者,分别给予利培酮治疗,观察8周,分别于治疗前及治疗第1,2,4,6,8周末分别进行阳性和阴性症状量表(PANSS)、临床总体印象量表、不良反应量表、锥体外系不良反应量表评分,比较不同型精神分裂症患者对利培酮的疗效及不良反应.结果 不同型精神分裂症患者治疗后同一时间点PANSS评分比较差异无统计学意义(P>0.05);不同型精神分裂症患者同一时间点所用剂量比较差异无统计学意义(P>0.05);利培酮治疗前后PANSS评分比较差异有统计学意义(P<0.01);入组前体重基线值为(63.91±11.75) kg,治疗8周后为(65.48±10.92) kg,差异有统计学意义(P<0.01).结论 利培酮对偏执型及未分化型精神分裂症疗效肯定,并具有较好的安全性及耐受性.%Objective To explore the safety and efficacy of risperidone in treatment of different kinds of schizophrenia.Methods Collected 100 cases of paranoid and undifferentiated schizophrenia patients,all patients were given risperidone treatment and observed for 8 weeks.Before treatment and at the 1st,2nd,4th,6th,8th weeks respectively by means of positive and negative symptom scale (PANSS),the Clinical Global Impression scale,adverse reaction scale,extrapyramidal system adverse reactions to scale score,comparison of different types of schizophrenia patients on risperidone' s efficacy and adverse reaction.Results The total PANSS score of different kinds of schizophrenia didn' t have great difference (P>0.05); the dose also didn' t have great statistical difference between different kinds of schizophrenia (P>0.05); the total PANSS score had great statistical difference between treatment (P<0.01); the group before the baseline weight value was (63.91 ± 11.75) kg,after 8 weeks of treatment it was (65.48 ± 10.92) kg,the difference was

  1. 阿立哌唑联合利培酮治疗慢性精神分裂症对照研究%A controlled study on aripiprazole combined with risperidone in the treatment of chronic schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨永秀; 陈斌华; 徐小杰; 陶云海; 施剑飞

    2013-01-01

    目的 评价阿立哌唑联合利培酮治疗慢性精神分裂症的疗效和安全性.方法 212例慢性精神分裂症患者随机分为阿立哌唑联合利培酮组(治疗组,105例)和利培酮组(对照组,107例).分别于治疗前及治疗后第2,4,8周末用阳性症状和阴性症状量表(PANSS)评价疗效,副反应量表(TESS)评价药物不良反应.结果 治疗组完成105例,对照组完成104例.治疗组有效率为92.38%,显著率为77.14%;对照组有效率为85.58%,显著率为66.35%,2组疗效差异无统计学意义(P>0.05).PANSS总分减分及PANSS阴性因子减分在第2,4,8周末治疗组均优于对照组(P <0.05或P<0.01).2组药物不良反应均较轻微,经对症处理大多能缓解,其中在震颤、静坐不能、体重增加及泌乳、月经紊乱等发生率,治疗组明显低于对照组(P<0.05).结论 利培酮联合阿立哌唑治疗慢性精神分裂症疗效良好,不良反应小,患者治疗依从性好.%Objective To evaluate the effectiveness and safety of aripiprazole combined risperidone in the treatment of chronic schizophrenia.Methods A total of 212 patients diagnosed as chronic schizophrenia were randomly divided into aripiprazole combined risperidone group (treatment group,n =105) and risperidone group (control group,n =107).Clinical effectiveness was assessed with the positive and negative syndrome scale(PANSS)and adverse reactions with the treatment emergent symptom scale (TESS) before treatment and at the end of the 2,4,8 week.Results One hundred and five patients of the treatment group and 104 patients of the control group had completed the course.The effective rate and the apparent effect rate in treatment group was 92.38% and 77.14%,whereas that was 85.58% and 66.35% in control group.There was no significant difference between two groups (P > 0.05).Effectiveness of treatment group was superior to control group at the end of the 2,4,8 week by PANSS total scores'subtraction and

  2. 利培酮对精神分裂症患者血脂和甲状腺激素的影响%Effects of risperidone on lipid and thyroid hormones in schizophrenic patients

    Institute of Scientific and Technical Information of China (English)

    赵明坤; 刘叶红; 张平; 韩彦超; 万爱华; 周雪丽

    2015-01-01

    目的:观察利培酮对精神分裂症患者血脂和甲状腺激素的影响。方法入选2011年5月至2011年10月上海精神卫生中心收治的精神分裂症患者41例为研究对象,单用利培酮治疗,疗程8周。分别于治疗前、治疗8周末测定总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL -C)、高密度脂蛋白(HDL-C);检测血清三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离三碘甲状腺原氨酸( FT3)、游离甲状腺素( FT4)和促甲状腺激素( TSH)。比较分析自身治疗前后的差异。结果利培酮治疗后,三酰甘油明显升高,与治疗前比较差异有统计学意义(P<0.01);T3、FT3、FT4显著下降,差异有统计学意义( P<0.01)。结论临床上用利培酮治疗精神分裂症患者时,可致血脂异常和甲状腺激素水平下降,应加强血脂及甲状腺激素水平监测,保证其治疗的安全性。%Objective To observe the effects of risperidone on lipids and thyroid hormone in patients with schizophrenia.Methods Forty-one cases of schizophrenia patients were enrolled from May to October in 2011 , respectively and were treated with risperidone alone for 8 weeks.The data of the total cholesterol (TC), triglyceride (TG), low density cholesterol ( LDL-C ) , and high density cholesterol ( HDL -C ) were measured before and after treatment.The data of three serum triiodothy-ronine (T3), thyroxine three (T4), free triiodothyronine (FT3), free thyroxine ( FT4) and thyroid stimulating hormone ( TSH) were detected.The changes were recorded and compared.Results After risperidone therapy, TG increased significantly compared with before treatment ( P<0.01).The data of T3, FT3 and FT4 decreased significantly ( P<0.01) .Conclusion Risperidone may cause abnormal drop of blood lipid and thyroid hormone level, therefore, related monitors should be strengthened to ensure the safety during treatment of schizophrenia

  3. Risperidone combined with clozapine in the treatment of refractory schizophrenia research%利培酮联合氯氮平治疗难治性精神分裂症的临床研究

    Institute of Scientific and Technical Information of China (English)

    谢玲银; 张智勇

    2015-01-01

    目的:探讨使用利培酮联合氯氮平两种药物来治疗难治性精神分裂症的临床效果。方法选取我院收治的难治性精神分裂症患者100例为研究对象,随机将其分为观察组和对照组,其中观察组50例,采用利培酮联合氯氮平进行治疗,对照组50例则只服用氯氮平进行治疗,观察12周,分别于入组前、治疗6周末、12周末应用简明精神病评定量表(BPRS)评定治疗效果,同时应用副反应量表(TESS)评价不良反应发生情况。结果观察组在治疗6周末及12周末的BPRS 评定总分明显低于对照组,差异有统计学意义(P<0.05)。两组TESS总分比较差异无统计学意义(P>0.05)。结论临床上对于难治性精神分裂症这一疾病的治疗可采用利培酮联合氯氮平两种药物进行尝试,其临床效果显著,且安全性有较大程度的保障,值得临床推广应用。%Objective To discuss the clinical effect of risperidone combined with clozapine in the use of two kinds of drugs for the treatment of refractory schizophrenia.Methods 100 patients with refractory schizophrenia of our hospital was selected as the research object, randomly divided into observation group and control group,50 cases in each group,the cases in the observation group was treated by risperidone combined with clozapine,while the cases in the control group only received risperidone treatment,observation of 12 weeks,before entering the group,respectively treatment of 6 weeks and 12 weeks,the efficacy of treatment was assessed by the Brief Psychiatric Rating Scale (BPRS). And using the TESS to evaluate adverse reaction.ResultsIn the observation group,BPRS total score after 6 weeks and 12 weeks were significantly lower than the control group,the difference was statistically significant (P0.05).Conclusion For refractory schizophrenia,we may try to treat them with the combination of risperidone and clozapine,it is safety and

  4. 氯氮平联合利培酮治疗难治性精神分裂症临床对照研究%A Clinical Control Study on Effects of Clozapine with Risperidone on Refractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    姚献虎; 陈敬兰; 沈建华

    2012-01-01

    Objective To explore the curative effect and safety of Risperidone with Clozapine in the treatment of refractory schizophrenia,and to provide the basis for clinical medication. Methods The 76 patients with refractory schizophrenia were randomly divided into the study group(36 cases) and the control group(40 cases) .the study group was treated by Risperidone and Clozapine, while the control group by Risperidone alone. The curative effect and side effect were evaluated by BPRS and TESS at the time points: before treatment,4,8 and 12 weeks after the treatment. Results The BPRS total scores of the study group were obviously lower than that of the control group at the end of the fourth week,eighth week and twelfth week. The TESS total scores between the two groups had no significant difference (P > 0.05 ) ; The side effect such as salivation, sleepiness, white blood cell reduction were obviously higher in the study group than as compared to the control group, but it' s well tolerated. Conclusion The combination of Clozapine and Risperidone for the refractory schizophrenia can shorten the response latency in the treatment, it is effective and safe.%目的 研究探索氯氮平联合利培酮治疗难治性精神分裂症的疗效及安全性,为临床用药提供依据.方法 76例难治性精神分裂症患者随机分为研究组和对照组,分别服用氯氮平联合利培酮(36例)、利培酮(40例)治疗,于入组前、治疗4周、治疗8周、治疗12周分别应用BPRS及TESS来观察评定疗效及副作用.结果 研究组于治疗4周末、8周末及12周末BPRS评定总分明显低于对照组,差异有统计学意义(P<0.05),两组TESS总分比较差异无统计学意义(P>0.05),但流涎、嗜睡、白细胞减少等副反应两组比较差异具有统计学意义(P<0.05),研究组较对照组明显为重,临床患者尚可以耐受.结论 氯氮平联合利培酮治疗难治性精神分裂症缩短治疗反应期、安全且疗效可靠,可以用

  5. 溴隐亭治疗利培酮致女性中度高催乳素血症的临床研究%Clinical study of Bromocriptine in treatment of moderate hyperprolactinemia caused by Risperidone

    Institute of Scientific and Technical Information of China (English)

    秦卫红; 魏时懿; 张军勐

    2014-01-01

    Objective:To discuss the efficacy of Bromocriptine in treatment of hyperprolactinemia cause by Risperidone and an-alyze the possibility of psychiatric symptom fluctuation for female patients with schizophrenia. Methods:According to the ICD-10, 59 female inpatients diagnosed as schizophrenia and got the mild hyperprolactinemia (100ug/ Lt0. 001(59), Pt0.001(59),P<0.001〕,BPRS 量表前后3次评定结果进行比较无显著差异。结论:本研究证实溴隐亭治疗利培酮所致女性中度高催乳素血症有实际临床应用价值,其有效性和安全性均非常可靠。

  6. Comparison of efficacy and safety of ziprasidone hydrochloride and risperidone in treatment of schizophrenia%盐酸齐拉西酮与利醅酮治疗精神分裂症的疗效及安全性比较

    Institute of Scientific and Technical Information of China (English)

    卢殿军; 宁洁; 吴胜

    2011-01-01

    Objective To evaluate clinical efficacy and safety of ziprasidone hydrochloride and risperidone in treatment of schizophrenia. Methods 60 patients with schizophrenia in hospital were selected and randomly divided into ziprasidone group (n=30,ziprasidone administrated orally) and risperidone group(n=30 ,risperidone tablet administrated orally), with a 6 week course of treatment. Positive and negative syndrome scale(PANSS) was used to assess their clinical efficacy and the treatment emergent symptom scale(TESS) was adopted to investigate their safety. Results At the end of treatment, PANSS reduced score rate of ziprasidone group was(60.98±24.04)% ,and that of risperidone group was (62.03±28.29)% ,with no statistically significant difference between the two groups(P>0.05). Compared incidence rate of side effects of patients in ziprasidone group with that in risperidone group,no statistically significant difference was found between the two groups(P>0.05). Conclusion Ziprasidone hydrochloride is an effective and safe antipsychotic agent with similar curative efficacy and adverse reaction to risperidone.%目的 评价盐酸齐拉西酮与利培酮治疗精神分裂症的临床疗效及安全性.方法 选择住院精神分裂症患者60例,随机分为齐拉西酮组(n=30,口服盐酸齐拉西酮片)与利培酮组(n=30,口服利培酮片),疗程6周.采用精神分裂症阳性与阴性症状评定量表(PANSS)评价其临床疗效,不良反应量表(TESS)评价其安全性.结果 治疗结束时,齐拉西酮组PANSS减分率为(60.98±24.04)%,利培酮组PANSS减分率为(62.03±28.29)%,组间比较差异无统计学意义(P>0.05);齐拉西酮组不良反应发生率与利培酮组比较差异无统计学意义(P>0.05).结论 盐酸齐拉西酮的疗效及不良反应与利培酮相当,是有效、安全的抗精神病药物.

  7. Clinical comparison and investigation of curative effects by olanzapine and risperidone in the treatment of behavioral and psychological symptoms of Alzheimer’s disease%奥氮平、利培酮治疗老年痴呆精神行为症状疗效的临床比较探讨

    Institute of Scientific and Technical Information of China (English)

    慕经纬

    2016-01-01

    Objective To compare clinical effects by olanzapine and risperidone in the treatment of behavioral and psychological symptoms of Alzheimer’s disease. Methods A total of 102 patients with Alzheimer’s disease were randomly divided into olanzapine group and risperidone group, with 51 cases in each group. The olanzapine group received olanzapine tablets for treatment, and the risperidone group received risperidone tablets for treatment. Improvements of clinical symptoms were observed in 2, 4, and 8 weeks of treatment. Mini mental state examination (MMSE), dementia pathological behavior score (BE-HAVE) and positive and negative syndrome scale (PANSS) were taken. Condition of adverse drug reactions was evaluated. Results The olanzapine group had total effective rate as 92.2%, and the risperidone group had that as 90.2%. Their difference had no statistical significance (P>0.05). There was no statistically significant difference of scores in hostile suspicion, disturbance of thought, behavior disorders, anxiety-depression, and bigotry between the two groups after 2, 4 and 8 weeks of treatment (P>0.05). The olanzapine group had lower PANSS score in 2 and 4 weeks of treatment than the risperidone group, and the difference had statistical significance (P0.05)。两组治疗后2、4、8周敌对猜疑、思维障碍、行为紊乱、焦虑抑郁、偏执等评分比较差异均无统计学意义(P>0.05)。奥氮平组在治疗2、4周时 PANSS 评分低于利培酮组,差异有统计学意义(P<0.05)。利培酮组发生锥体外系反应和恶心例数多于奥氮平组,差异有统计学意义(P<0.05)。结论奥氮平和利培酮治疗老年痴呆精神行为症状均有较好的疗效,但奥氮平起效更快,不良反应较少,患者耐受性更好。

  8. 乌鸡白凤丸与阿立哌唑治疗利培酮所致闭经临床对比研究%Comparative clinical study on effect of Wuji Baifeng pills and aripiprazole in the treatment of risperidone induced amenorrhea

    Institute of Scientific and Technical Information of China (English)

    许勤伟; 刘向来; 黄胜; 黄兹高

    2013-01-01

    Objective:To explore clinical therapeutic effect and adverse reaction of Wuji Baifeng pills on risperidone induced amenorrhea.Methods:85 female schizophrenia patients with amenorrhea induced by risperidone were randomly divided into the treatment group of Wuji Baifeng pills (43 cases) and risperidone for aripiprazole contrast group (42 cases),90 days was a course.Results:Wuji Baifeng pills in the treatment of risperidone induced amenorrhea total clinical curative effect was obviously superior to risperidone,there was significant difference in effective rate between two groups (P < 0.05).Common adverse reactions were mild in two groups,and there was no significant difference in the score of TESS scale between the two groups (P > 0.05).Conclusion:Wuji Baifeng pills in the treatment of amenorrhea induced by risperidone has good clinical curative effect and adverse reaction is mild.%目的:探讨乌鸡白风丸治疗利培酮所致闭经的临床疗效及不良反应.方法:对85例利培酮治疗出现闭经的女性精神分裂症患者随机分为乌鸡白凤丸治疗组(43例)及停利培酮换用阿立哌唑的对比组(42例),以90天为一疗程.结果:乌鸡白凤丸治疗利培酮所致闭经的临床总疗效明显优于利培酮换用阿立哌唑的治疗,两治疗组有效率比较差异有统计学意义(P<0.05);两治疗组常见不良反应均较轻微,两组治疗不良反应采用TESS量表定期跟踪测评比较差异无统计学意义(P>0.05).结论:乌鸡白凤丸治疗利培酮所致闭经的临床疗效好,不良反应轻.

  9. 60例脑血管疾病所致精神障碍奥氮平与利培酮治疗效果对比%Effect of olanzapine and risperidone in the treatment of 60 cases of mental disorder caused by cerebrovascular disease comparison

    Institute of Scientific and Technical Information of China (English)

    高晨

    2015-01-01

    Objective To observe the effect of mental disorder caused by olanzapine and risperidone in the treatment of cerebral vascular disease. Methods will randomly olanzapine group and risperidone group. According to the grouping of olanzapine in the treatment group received olanzapine treatment of risperidone in treatment group were given risperidone, treatment. Results In the total effective rate of treatment group was 96.66%, treatment with olanzapine, risperidone group 93.33%, two groups are basically the same. However, olanzapine has fewer adverse effects of the treatment group was 16.66%, risperidone in treatment group was 30%, statistically significant difference contrast. Conclusion Olanzapine can significantly reduce the incidence of adverse reaction of patients, more worthy of clinical promotion and practice of strengthening the.%目的:分析奥氮平与利培酮治疗脑血管疾病所致精神障碍的疗效。方法将该院于2013年1月—2013年12月选取的60例患者随机划分为奥氮平治疗组与利培酮治疗组。根据分组对奥氮平治疗组患者予以奥氮平进行治疗,对利培酮治疗组予以利培酮进行治疗。结果在治疗的总有效率方面,奥氮平治疗组为96.66%,利培酮治疗组为93.33%,两组基本一致,对比差异不具有统计学意义。但奥氮平治疗组患者的不良反应更少为16.66%,利培酮治疗组为30%,对比差异具有统计学意义。结论奥氮平治疗脑血管疾病所致精神障碍的效果与利培酮基本一致,但是却能够明显降低患者的不良反应发生率,更加值得加强临床推广与实践。

  10. The effects of aripiprazole,risperidone and clozapine administrated for schizophrenia treatment on glucose and lipid metabolism%阿立哌唑、利培酮和氯氮平治疗精神分裂症对糖脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    马达休; 李永华; 冉庆国; 陈大坤; 周琳钧

    2011-01-01

    Objective To compare the effects of aripiprazole, risperidone and clozapine used for treating schizophrenia on serum glucose and lipids of patients. Methods 270 patients with schizophrenia were divided randomly into 3 groups of 90 patients each; aripiprazole group, risperidone group and clozapine group, and aripiprazole, risperidone and clozapine were administrated for 12 weeks,respectively. Levels of fast blood glucose (FBG) ,total cholesterol (TC) ,triglycericle(TG) and body mass index (BMX) before and after treatment were compared. Results FBG levels of patients in 3 groups after treatment were increased as compared to those before treatment(P0. 05) ,all those in risperidone and clozapine groups increased after treatment as compared with treatment before(P<0. 05) ,and those in clozapine group increased greater than in risperidone group(P<0. 05). Conclusion Aripiprazole,risperidone and clozapine used for schizophrenia treatment can lead to adverse effects of glucose and lipid metabolism which are relatively milder for aripiprazole.%目的 比较阿立哌唑、利培酮和氯氮平治疗精神分裂症对患者血糖、血脂影响.方法 将270例精神分裂症患者随机分为3组:阿立哌唑组、利培酮组及氯氮平组(各90例),分别给予口服阿立哌唑、利培酮及氯氮平治疗12周.比较治疗前后空腹血糖(FBG)、总胆固醇(TC)、三酰甘油(TG),体质量指数(BMI)的变化.结果 3组患者治疗后,FBG较治疗前增高(P<0.05),氯氮平组增高最明显;阿立哌唑组治疗后TC、TG,BMI值较治疗前差异无统计学意义(P>0.05);利培酮及氯氮平组治疗后TC、TG、BMI较治疗前均有升高(P<0.05),且氯氮平组增高大于利培酮组(P<0.05).结论 阿立哌唑、利培酮及氯氮平治疗精神分裂症均可导致糖脂代谢异常的不良反应,阿立哌唑的不良反应相对较小.

  11. To observe the clinical effect of aripiprazole and risperidone in the treatment of female schizophrenia%阿立哌唑与利培酮治疗女性精神分裂症的临床效果探讨

    Institute of Scientific and Technical Information of China (English)

    龚日东; 黄书梅

    2014-01-01

    Objective To investigate the clinical effect of aripiprazole and risperidone in the treatment of female schizophrenia. Methods 100 cases of female spirit admitted in our hospital in 2012 January to 2014 January between the schizophrenia patients for clinical research,The patients were randomly divided into aripiprazole group and risperidone group, compared two groups of patients with clinical curative effect. Results In the two groups before treatment PANSS clinical psychopathology, negative symptoms, positive symptoms and score of contrast was no significant statistical difference (P>0.05), the clinical treatment for 2 weeks, 4 weeks of treatment and 8 weeks after the treatment, PANSS psychopathology, negative symptoms, positive symptoms and total score compared with the statistically significant difference (P0.05),临床治疗2周、治疗4周和治疗8周后PANSS精神病理、阴性症状、阳性症状和总分对比差异具有统计学意义(P<0.05)。两组女性精神分裂症患者临床治疗的总有效率和不良反应发生率对比差异具有统计学意义(P<0.05)。结论该次医学研究结果证实,阿立哌唑用于女性精神分裂症的临床治疗,具有更高的有效率和安全性,因而临床推广和应用价值更高。

  12. 阿立哌唑与利培酮治疗女性精神分裂症的临床疗效分析%Effective analysis of aripiprazole and risperidone for patients with first-episode female Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张加明

    2014-01-01

    目的:对阿立哌唑与利培酮对女性首发精神分裂症的临床疗效以及对患者认知功能的影响进行观察和分析。方法:将我院2010年4月~2013年11月收治的128例女性首发精神分裂患者随机分为阿立哌唑组和利培酮组,每组各64例。2组患者分别于治疗前后采用阳性与阴性症状量表(PANSS)、临床总体印象量表(CGI)以及副反应量表(TESS)对患者的临床疗效和副反应进行评定和比较。结果:2组患者治疗后其阳性症状、阴性症状、一般病理、PANSS总分以及CGI总分均较治疗前显著降低(P<0.01),但组间比较并无明显差异(P>0.05)。治疗后阿立哌唑组和利培酮组的临床显效率和有效率分别为73.44%、96.88%和70.31%、90.62%,差异均不具有统计学意义( P>0.05),而TESS评定结果显示,阿立哌唑组患者评分8.31±4.20分明显低于利培酮组患者评分9.29±4.16分。结论:阿立哌唑和利培酮治疗女性首发精神分裂症上均可有效改善患者的阳性症状、阴性症状、一般病理而起到良好的临床疗效,但相比而言阿立哌唑在治疗过程中副反应更小,因而更加安全有效。%Objective:To explore the efficacy of aripiprazole and risperidone in the treatment of first -episode female schizophrenia . Methods:To select 128 cases of patients with first-episode female schizophrenia who were treated in our hospital from April 2010 to No-vember 2013,and were randomly divided into the saripiprazole group and the risperidone group ,each group was 64 cases.Two groups of patients were take the positive and negative symptoms scale ( PANSS) , the clinical general impression scale (CGI) and the treatment e-mergent symptom scale ( TESS) respectively before and after treatment to evaluated the clinical efficacy and the adverse event .Results:The positive symptoms , negative symptoms , general pathology , PANSS

  13. Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone

    Directory of Open Access Journals (Sweden)

    Baylé FJ

    2015-09-01

    Full Text Available Franck Jean Baylé,1 Arnaud Tessier,2,3 Sophie Bouju,4 David Misdrahi2,3 1Sainte-Anne Hospital (SHU, Paris V-Descartes University, Paris, 2Hôpital Charles Perrens, Pôle de Psychiatrie Adulte, 3CNRS UMR 5287-INCIA, Bordeaux University, Bordeaux, 4Janssen-Cilag France, Issy Les Moulineaux, Paris, France Background: Maintaining antipsychotic therapy in psychosis is important in preventing relapse. Long-acting depot preparations can prevent covert non-adherence and thus potentially contribute to better patient outcomes. In this observational survey the main objective is to evaluate medication adherence and its determinants for oral treatment in a large sample of patients with psychosis.Methods: In this cross-sectional survey medication adherence for oral treatment was assessed by patients using the patient-rated Medication Adherence Questionnaire (MAQ. Data were collected by physicians on patients with a recent acute psychotic episode before switching to long-acting injectable risperidone. Other evaluations included disease severity (Clinical Global Impression – Severity, patients’ insight (Positive and Negative Syndrome Scale item G12, treatment acceptance (clinician-rated Compliance Rating Scale, and therapeutic alliance (patient-rated 4-Point ordinal Alliance Scale.Results: A total of 399 psychiatrists enrolled 1,887 patients (mean age 36.8±11.9 years; 61.6% had schizophrenia. Adherence to oral medication was “low” in 53.2% of patients, “medium” in 29.5%, and “high” in 17.3%. Of patients with psychiatrist-rated active acceptance of treatment, 70% had “medium” or “high” MAQ scores (P<0.0001. Medication adherence was significantly associated with therapeutic alliance (4-Point ordinal Alliance Scale score; P<0.0001. Patient age was significantly associated with adherence: mean age increased with greater adherence (35.6, 36.7, and 38.6 years for patients with “low”, “medium”, and “high” levels of adherence

  14. Clinical Efficacy of Risperidone and Olanzapine in the Treatment of first Episode Schizophrenia%利培酮与奥氮平治疗首发精神分裂症患者的临床疗效与安全性

    Institute of Scientific and Technical Information of China (English)

    任丽

    2015-01-01

    Objective To investigate the effect of risperidone and olanzapine in the treatment of first-episode clinical eficacy and safety in patients with schizophrenia.Methods Methods 68 patients with first episode schizophrenia were randomly divided into risperidone group in 34 cases and 34 cases of olanzapine group, risperidone group were treated with oral risperidone treatment,olanzapine group were treated with oral olanzapine treatment,after 8 weeks of treatment with PANSS reduction rate of curative effect evaluation.Results Risperidone group of patients,the total effective rate was 94.1%(32/34),olanzapine group of patients,the total effective rate was 91.2%(31/34),the difference between the two groups had no statistical significance(P>0.05).Olanzapine group drowsiness,dry mouth and body mass increase adverse effects than risperidone group,risperidone group akathisia, insomnia and headache adverse reactions than olanzapine group(P<0.05).Conclusion Equivalent efficacy of olanzapine and risperidone on schizophrenia,but the adverse reactions of two different,clinicians should take according to the regimen of according to the clinical characteristics of the patients with.%目的:探讨利培酮与奥氮平治疗首发精神分裂症患者的临床疗效与安全性。方法将68例首发精神分裂症患者随机分为利培酮组34例及奥氮平组34例,利培酮组患者给予口服利培酮进行治疗,奥氮平组患者给予口服奥氮平进行治疗,治疗8周后采用阳性和阴性症状量表(PANSS)减分率评估疗效。结果利培酮组患者总有效率为94.1%(32/34),奥氮平组患者总有效率为91.2%(31/34),两组比较差异无统计学意义(P>0.05)。奥氮平组嗜睡、口干和体质量增加不良反应多于利培酮组,利培酮组静坐不能、失眠和头痛不良反应多于奥氮平组(P<0.05)。结论奥氮平与利培酮对首发精神分裂症的疗效相当,但二者不良反应不同,临床

  15. 阿立哌唑与利培酮治疗精神分裂症的疗效与安全性对比分析%Analysis of Efficacy and Safety of Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    程道猛; 刘靖雯; 黄鹏; 徐世超; 王春江

    2013-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的收益和风险,优化临床治疗效果与安全性,指导临床合理治疗。方法:将60例符合入组标准的精神分裂症按随机数字表分为阿立哌唑组与利培酮组,各30例,分别给予阿立哌唑与利培酮,8周为1个疗程,治疗前、后观察患者症状,进行阳性症状量表和阴性症状量表(PANSS)评分及不良反应量表(T ESS )评分,评价两组患者的临床疗效与安全性。结果:阿立哌唑组和利培酮组的总有效率均为93.33%,P>0.05;阿立哌唑组和利培酮组的阳性症状量表(PANSS)评分、阴性症状量表(PANSS)评分及量表总评分差异均无统计学意义,均 P>0.05;阿立哌唑组和利培酮组头痛、口干、血压降低、失眠差异无统计学意义,均 P>0.05,但阿立哌唑组锥体外系反应、体质量增加、闭经溢乳的发生率明显低于利培酮,差异具有统计学意义,均 P<0.05。结论:阿立哌唑起效速度、安全性、依从性明显优于利培酮,尤其能明显降低现锥体外系反应、体质量增加、闭经溢乳的副反应,是治疗精神分裂症的首选药物。%Objective :To investigate benefits and risks of aripiprazole and risperidone in the treatment of schizophreni-a ,to optimize clinical efficacy and safety ,guide clinical treatment .Methods :60 schizophrenia patients met the inclusion criteria were randomly divided into aripiprazole group and risperidone group ,30 cases of each group ,each group were given aripiprazole and risperidone ,8 weeks for an effect ,observed symptoms ,made a positive and negative symptom scale symptom scale (PANSS) scores and adverse reactions scale (TESS) scores ,to evaluate the clinical efficacy and safety .Results:The total effective rate of aripiprazole group and risperidone group was 93 .33% ,P>0 .05 ;the positive symptom scale (PANSS) score ,negative

  16. 利培酮联合丙戊酸钠治疗男性精神分裂症伴有冲动和攻击行为的疗效观察%Risperidone Combined Sodium Valproate Treatment of Male Schizophrenia with Impulsive and Aggressive Behavior

    Institute of Scientific and Technical Information of China (English)

    蒋特成; 谢宇宽

    2013-01-01

    Objective to study the risperidone with valproic acid therapy with impulse and at ack the ef icacy and safety of male patients with schizophrenia. Methods:74cases with impulse and aggressive behavior of male schizophrenia patients were randomly divided into research group (risperidone combined valproate treatment)37cases,control group (risperidone therapy)37 cases, course of six weeks. Results:two groups after treatment PANSS scores and MOAS score was a significant reduction in the (al P0. 05) conclusion:risperidone with valproic acid therapy with impulse and aggressive behavior of male schizophrenia patients work fast,can increase the curative ef ect,good safety.%目的:探讨利培酮联合丙戊酸治疗伴有冲动和攻击行为的男性精神分裂症患者的疗效和安全性。方法对74例伴有冲动和攻击行为的男性精神分裂症患者随机分成研究组(利培酮联合丙戊酸钠治疗)37例,对照组(单用利培酮治疗)37例,疗程6w。结果两组在治疗后PANSS评分及MOAS评分均较治疗前显著下降(均P0.05)。结论利培酮联合丙戊酸治疗伴有冲动和攻击行为的男性精神分裂症患者起效快,可增加疗效,安全性好。

  17. Curative effect and safety of sertraline combined with risperidone in the treatment of negative symptoms of schizophrenia%舍曲林联合利培酮治疗精神分裂症阴性症状的效果和安全性

    Institute of Scientific and Technical Information of China (English)

    孔庆伟

    2016-01-01

    目的:分析舍曲林联合利培酮治疗精神分裂症阴性症状的效果和安全性。方法:将50例精神分裂症阴性症状患者随机分为对照组与观察组,各25例。对照组给予单纯利培酮治疗,观察组给予舍曲林联合利培酮治疗,比较两组患者的疗效及不良反应。结果:观察组的治疗总有效率明显高于对照组(P<0.05);观察组的不良反应发生率与对照组相比,差异无统计学意义(P>0.05)。结论:对精神分裂症阴性症状患者应用舍曲林联合利培酮治疗,临床效果显著。%Objective:To analyze the curative effect and safety of sertraline combined with risperidone in the treatment of negative symptoms of schizophrenia.Methods:50 patients with negative symptoms of schizophrenia were randomly divided into the control group and the observation group with 25 cases in each.The control group was given risperidone treatment.The observation group was given sertraline combined with risperidone treatment.The curative effects and adverse reaction were compared between groups.Results:The treatment total effective rate of the observation group was significantly higher than that of the control group(P0.05). Conclusion:The patients with negative symptoms of schizophrenia should be given sertraline combined with risperidone treatment, and the clinical curative effect is remarkable.

  18. On Risperidone Combined with Sertraline for Analysis of Curative Effect in the Treatment of Negative Symptoms of Schizophrenia%论利培酮联用舍曲林用于治疗阴性症状为主的精神分裂症的疗效分析

    Institute of Scientific and Technical Information of China (English)

    宋长海

    2014-01-01

    目的:研究利培酮联用舍曲林治疗以阴性症状为主的精神分裂症的临床效果。方法选取2009年~2012年收治的70例阴性症状为主的精神分裂症患者为研究对象,35例观察组采用利培酮联用舍曲林的药物治疗法,35例对照组采用利培酮单纯药物治疗法,观察两组患者临床反应。结果两组患者症状均有缓解,观察组治疗效果明显优于对照组。结论利培酮联用舍曲林对治疗以阴性症状为主的精神分裂症有很好的效果,值得临床大力推广。%Objective To study the risperidone combined sertraline treatment is given priority to with negative symp-toms of schizophrenia clinical effect.Methods In our hospital from 2009 to 2009 treated 70 cases of negative symptoms of schizophrenia patients as the research object , the observation group of 35 cases with risperidone combined drug therapy of sertraline, 35 cases of control group with risperidone pure drug therapy , observe two groups of patients with clinical re-sponse.Results Symptoms in both two groups of patients , the treatment effect of observation group was obviously better than the control group.Conclusions Risperidone group with sertraline treatment is given priority to with negative symp-toms of schizophrenia have very good effect , is worth promoting in the clinical practice.

  19. 认知行为与利培酮联合治疗精神分裂症残留型的临床疗效分析%Analysis of the Clinical Efficacy of Cognitive Behavior Combined With Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王永良

    2015-01-01

    目的:分析认知行为配合利培酮治疗残留型精神分裂症的疗效。方法将72名残留型精神分裂症患者分成Og(观察)组和Cg(对照)组。Cg组单纯用利培酮治疗,Og组用利培酮时配合认知行为治疗。结果 Og组治疗后阴性症状、语言记忆、表达流畅、HAMD、HAMA等得分比治疗前降低,同时也比Cg组治疗后降低,而PSP得分增加。病理状态、阳性症状、SES得分及总分治疗前后无明显差别。结论认知行为疗法配合利培酮对于治疗残留型精神分裂患者获得的疗效比单纯服用药物好。%Objective To analyze the effect of cognitive behavior combined with risperidone in the treatment of residual type of schizophrenia.Methods 72 patients with schizophrenia were divided into Og (observation) group and Cg(control) group. Cg group was treated with risperidone alone, while the Og group was treated with the cognitive behavioral therapy and risperidone. ResultsThe negative symptoms,language memory, expression, HAMA and HAMD in the Og group were significantly less than those in Cg group,while the PSP score increased after treatment. There was no obvious difference in the pathological status, positive symptoms,SES score and total score.Conclusion Cognitive behavior therapy combined with risperidone in the treatment of residual type of schizophrenia patients has good efficacy.

  20. 齐拉西酮与利培酮对精神分裂症患者体质量、血糖、血脂的影响%Effect of Ziprasidone and Risperidone on Schizophrenia Patients' Body Weight, Blood Glucose, Blood Lipid

    Institute of Scientific and Technical Information of China (English)

    朱肖飞

    2012-01-01

      Objective To investigate the effect of ziprasidone and risperidone on schizophrenia patients' body weight, blood lipid, blood glucose. Methods 85 cases of schizophrenia patients' from our hospital in 2008 June to 2011 June were selected, ziprasidone and risperidone respectively given to the patient, the effect of body weight, blood sugar, blood lipid were observed. Results ziprasidone treatment group before and after weight, blood glucose, blood lipid have no statistical difference (P>0.05), risperidone treatment before and after weight, blood lipid, blood glucose have statistics difference (P0.05),利培酮治疗前后体质量、血脂、血糖有统计学差异(P <0.05).结论齐拉西酮相比利培酮治疗精神分裂症患者,对其体质量、血脂、血糖的影响具有明显优势,安全性更高.

  1. Clinical efficacy of Risperidone combined with Paroxetine in treatment of methamphetamine-induced mental disorder patients%利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的临床疗效

    Institute of Scientific and Technical Information of China (English)

    文卫

    2015-01-01

    目的::对比分析利培酮单用与利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的治疗效果。方法:将68例甲基苯丙胺所致精神障碍患者的临床资料,采用数字单双号的模式随机分为对照组(利培酮)与治疗组(利培酮合并帕罗西汀),每组各34例。结果:对照组患者的总有效率为82.35%,治疗组患者的总有效率为94.12%,治疗组明显高于对照组,(P0.05)。结论:针对甲基苯丙胺所致精神障碍患者,采用利培酮合并帕罗西汀进行治疗能够显著改善患者的精神病性状态和抑郁、焦虑情绪,临床疗效明显,值得临床推广应用。%Objective: To comparatively analyze effects of Risperidone alone and Risperidone combined with Paroxetine in treatment of methamphetamine-induced mental disorder patients. Methods: A retrospective analysis of clinical data of 68 cases with methamphetamine-induced mental disorder was done by using digital odd and even numbers modes, and these cases were randomly di-vided into control group ( Risperidone) and treatment group ( Risperidone merger Paroxetine) , 34 cases in each group. Results:The total effective rates of control group and treatment group were 82. 35% and 94. 12%, and the difference was statistically significant (P0. 05). Conclusions:For the methamphetamine-induced mental disorder patients, Paroxetine combined with Risperidone can significantly improve the patient's mental state and de-pression and anxiety emotions with a significant clinical efficacy, and is worthy of clinical application and promotion.

  2. Effect of amisulPride and risPeridone on Prolactin and metabolic syndrome in schizoPhrenic Patients:case-control study%氨磺必利与利培酮对精神分裂症患者催乳素及糖脂代谢影响

    Institute of Scientific and Technical Information of China (English)

    魏立和; 陈景旭; 范宏振

    2014-01-01

    Objective:To investigate the differences between the effect of amisulpride and risperidone on prolactin and metabolism in schizophrenic patients. Method:Fourty-five schizophrenic patients was divided into amisulpride group(22 cases enrolled,20 completed)and risperidone group(20 cases enrolled,19 comple-ted). Prolactin levels and various indictors of metabolism were detected before the treatment,4 weeks and 8 weeks after the treatment respectively. Results:Compared with baseline the serum prolactin levels in two groups,4 weeks and 8 weeks after the treatment increased significantly(P ﹤ 0. 02);but the prolactin of risperi-done group increased more significantly than amisulpride risperidone group. Insulin resistance and body mass in-dex were increased in both groups(P ﹤ 0. 02). Conclusion:Compared with risperidone,amisulpride has rela-tively less impact on prolactin,while two drugs had a similar impact on the metabolism.%目的:探讨氨磺必利与利培酮对精神分裂症患者催乳素及糖脂代谢的影响。方法:精神分裂症患者按治疗方案分为氨磺必利组(入组22例,完成20例)及利培酮组(入组20例,完成19例),分别在治疗前及治疗后4周、8周监测催乳素及糖脂代谢方面的各项指标,并分析治疗前后两组之间的差异。结果:两组治疗4周及治疗8周与治疗前相比,催乳素水平均有显著升高(P ﹤0.02);利培酮组较氨磺必利组催乳素升高更为显著。两组胰岛素抵抗指数及体质量指数均升高(P ﹤0.02)。结论:与利培酮相比,氨磺必利对催乳素的影响相对较轻,而两种药物对代谢方面的影响相当。

  3. A control study of aripiprazole vs .risperidone in type II schiz-ophrenia%阿立哌唑与利培酮治疗Ⅱ型精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    徐烨; 何益群

    2013-01-01

    目的:探讨阿立哌唑与利培酮治疗Ⅱ型精神分裂症患者的临床疗效和安全性。方法将120例Ⅱ型精神分裂症患者随机分为两组,观察组口服阿立哌唑治疗,对照组口服利培酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定临床疗效,采用韦氏成人智力量表、韦氏记忆量表及韦斯康星卡片分类测验评定认知功能,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降,言语量表、操作量表、全量表和记忆量表评分均较治疗前显著升高( P<0.01);治疗12周末,观察组有效率为85.0%,对照组为88.3%,两组比较差异无显著性( P>0.05)。两组不良反应均轻微,但观察组锥体外系反应、泌乳/闭经、体质量增加、血糖升高发生率显著低于对照组( P<0.05或0.01)。结论阿立哌唑治疗Ⅱ型精神分裂症疗效显著,总体疗效与利培酮相当,但阿立哌唑治疗安全性更高,依从性更好。%Objective To explore the efficacy and safety of aripiprazole vs .risperidone in type II schizo-phrenia .Methods A total of 120 patients with type Ⅱ schizophrenia were randomly divided into two groups ,observation group took orally aripiprazole and control group did risperidone for 12 weeks .Before and after treatment efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) ,cog-nitive fundions with the WAIS-R ,WMS and WCST and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total and each factor scores of both groups lowered more significantly compared with pre-treatment ,verbal ,performance ,full and memory scale score height-ened (P 0 .05) .Adverse reactions of both groups were mild ,but the incidence of extrapyramidal reaction ,lactation/amenorrhea ,weight gain ,blood glu-cose elevation were

  4. 二甲双胍联合行为干预治疗利培酮所致的代谢紊乱%Efficacy of metformin combined behavior intervention in the treatment of metabolic disorders caused by risperidone

    Institute of Scientific and Technical Information of China (English)

    夏金校; 王一冰; 甘建光; 曹世林; 段迪; 钱佩华; 沈妃

    2011-01-01

    目的 观察二甲双胍(降血糖药)联合行为干预治疗利培酮(抗精神分裂症药)所致体质量增加及糖、脂代谢紊乱的临床疗效.方法 对口服利培酮所致肥胖的150例精神分裂症患者,随机分为A组(75例)和B组(75例),2组均给予行为干预;但A组加服二甲双胍,治疗6个月,测相关生化指标并进行比较.结果 除DBP、HDL-C和PRL外,A组余各指标,6个月末与入组时比较有极显著性差异;除DBP、TC、PRL、HDL-C外,B组余各指标,做相应地比较也有显著性差异.6个月末,除血压、脂蛋白、AST、PRL外,余各指标,A组与同期B 组比较有显著性差异;不良反应(主要为轻度恶心)发生率,A、B 2组分别为8%,7%,2组比较无显著性差异.结论 二甲双胍与行为干预单一或联合治疗利培酮所致体质量增加及代谢紊乱均有较好效果,尤以二甲双胍联合行为干预效果更好.%Objective To explore the clinical efficacy of metformin combined behavior intervention in treating metabolic disorders caused by risperidone, such as weight gain, glucose and lipid metabolism disorders.Methods A total of 150 schizophrenia patients who become obese after treated with risperidone were randomly divided into groups A (n =75) and B (n = 75).Both groups were given the same behavioral intervention for 6 months, but patients in group A also received treatment with metformin.At the point of baseline and the 6th month end, patients in both two groups received physical examination as well as a series of serological tests followed by statistic analysis.Results All the examine indexes except diastolic blood pressure, HDL -C and PRL were different between the point of baseline and the 6th month end in group A.All the examine indexes in addition to diastolic blood pressure, TC, PRL and HDL - C were different between the point of baseline and the 6th month end in group B.A lot of exam indexes were definitely different between two groups at the 6th month end

  5. 齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性评价%Clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈统献; 闫耀宇; 鲍佑元

    2015-01-01

    Objective To evaluate the efficacy and safety of ziprasidone versus risperidone in the treatment of schizophrenia .Methods A total of 120 patients with schizophrenia were randomly divided into treatment group (n=62) and control group(n=58).Patients in the control group were administered risperidone 0.25 mg・ d-1 initially with maximum of 4.0 mg・ d-1 orally, qd. And patients in the treatment group were administered of ziprasidone 40 mg・ d -1 initially with maximum of 160 mg・ d-1 orally, bid.All the patients received 8 weeks treatment.After treatment, the clinical efficacy ,quality of life score and side effects were compared between the two groups.Results After treatment, the clinical efficacy were 89.66% and 91.94% in control and treatment group respectively, with no statistical difference(P>0.05).The score evalua-ted by the short from health survey ( SF-36 ) was significant higher in treatment group compared with control group ( P <0.05 ) . The side effects incidence rate were 20.69% in control group and 8.06% in treatment group, which was significantly difference ( P <0.05 ) . Conclusion The clinical efficacy was not different between ziprasidone and risperidone.But ziprasidone can improve patients′quality of life much more significantly with and less adverse events .%目的:评价齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性。方法将120例精神分裂症患者随机分为对照组58例和试验组62例。对照组予以利培酮起始给药剂量为0.25 mg・ d-1,最大给药剂量4.0 mg・ d-1,每日1次;试验组予以齐拉西酮初始剂量为40 mg・ d-1开始,分2次服用,按照控制情况逐渐加量,根据患者病情和耐受情况,1周之内达到最大剂量160 mg・ d-1,2组均治疗8周。比较2组的临床疗效、生活质量评分及不良反应发生率有无差别。结果对照组临床总有效率为89.66%,试验组临床总有效率为91.94%,2组比

  6. Efficacy of Clozapine Combined with Risperidone in Refractory Schizophrenia%氯氮平联合利培酮治疗难治性精神分裂症的疗效

    Institute of Scientific and Technical Information of China (English)

    李晓波; 韦伟香

    2014-01-01

    Objective To explore the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia.Methods A total of 118 patients with refractory schizophrenia were randomly treated with clozapine tablets alone(control group,n = 59)or in combination with risperidone tablets(observation group,n=59).Clinical efficacy and adverse re-actions were observed in both groups.Patients were scored using the Positive and Negative Syn-drome Scale(PANSS)before and after treatment for 2,4,8 and 12 weeks.Results PANSS scores significantly decreased in both groups after treatment for 8 and 12 weeks(P <0.05),and the de-crease in observation group was more obvious than that in control group(P <0.05).In addition, the total effective rate in observation group was significantly higher than that in control group (96.6% vs 81.4%,P < 0.05),and the incidence of adverse reactions in observation group was significantly lower than that in control group(15.3% vs 27.1%,P < 0.05).Conclusion The combination of clozapine and risperidone is an effective,safe and reliable treatment and can reduce adverse reactions in the treatment of refractory schizophrenia.%目的:探讨氯氮平联合利培酮治疗难治性精神分裂症的临床疗效和安全性。方法将118例难治性精神分裂症患者按入院的先后顺序分为2组:观察组和对照组,每组59例。2组均采用氯氮平片治疗。在此基础上,观察组加用利培酮片治疗。观察2组临床疗效以及不良反应发生的情况,并对2组治疗前及治疗2、4、8和12周后采用阳性与阴性症状量表(PANSS)进行评分。结果2组治疗8、12周后 PANSS 得分均较治疗前明显降低(均 P <0.05),观察组治疗8、12周后 PANSS 得分均较对照组下降更明显(均 P <0.05)。观察组总有效率明显高于对照组(96.6%比81.4%,P <0.05),不良反应发生率明显低于对照组(15.3%比27.1%,P <0.05

  7. 阿立哌唑治疗利培酮所致精神分裂症女性患者高催乳素血症的研究%Aripiprazole in treatment of female schizophrenics with risperidone induced hyperprolactinemia

    Institute of Scientific and Technical Information of China (English)

    纪菊英; 宋梓祥; 徐乐平; 孙剑; 施建安; 赵汉清; 王焕林

    2008-01-01

    Objective To explore the efficacy and safety of aripiprasole in treatment of female schizophrenics with risperidone induced hyperprolactinemia. Methods All 117 female schizophrenics with hyperprolactinemia after fixed dose risperidone treatment were randomly assigned to aripiprazole group (n=60) and control group (n=57), and received additional aripiprazole 5 nag daily or placebo for 6 weeks respectively. The plasma prolactin (PBL) level was measured at weeks 0 and 6, and the Brief Psychiatric Bating Scale (BPBS) and Treatment Emergent Symptom Scale (TESS) were assessed. Results (1)Plasma prolactin levels were significantly reduced after the study compared with the baseline [(26±6) μg/L vs. (112±40)μg/L] in aripiprazole group (P= 0.000), however there were no significant difference between pre- and post treatment in control group (P =0.180). (2) At weeks 6, the decline rate and the normal ratio of plasma prolactin levels were significantly higher in aripiprazole group [(75±8) % vs. 82%]than in control group [(5±30) % vs. 4%] respectively (beth P = 0.000 ). (3) Compared with the baseline, the BPRS score showed significant reduction in both groups at the end of the study (both P=0.045). The incidence of side effects showed no significant difference between aripiprazole and control group(P =0.553). Conclusion The results indicate that aripiprazole may be effective and safe for the treatment of female schizophrenics with risperidone induced hyperprolactinemis.%目的 探讨阿立哌唑治疗利培酮所致女性患者高催乳素血症的疗效及安全性.方法 117例利培酮所致高催乳素血症的女性患者,随机分为治疗组(60例)和对照组(57例).维持原有利培酮治疗不变,治疗组加用阿立哌唑5 mg,对照组加用安慰剂治疗,疗程均为6周.于治疗第0,6周末检测催乳素,评定简明精神病量表(BPRS)、治疗中需处理的不良反应症状量表(TESS).结果 (1)治疗第6周末,治疗组催乳素[(26±6)

  8. rTMS vs Risperidone in the Treatment of BPSD of Alzheimer's Disease%rTMS与利培酮治疗阿尔茨海默病患者精神行为症状的疗效观察

    Institute of Scientific and Technical Information of China (English)

    杨婵娟; 张若曦; 方雅秀; 王丹逢; 韩海英; 刘文滔; 谭燕

    2015-01-01

    目的:观察重复经颅磁刺激( rTMS)和利培酮对阿尔茨海默病患者精神行为症状( BPSD )的临床疗效。方法:将45例患有阿尔茨海默病且伴有BPSD的患者随机分为研究组(20例)和对照组(25例),研究组患者接受20次5HZ rTMS,对照组接受利培酮治疗,两组治疗期间维持原有的胆碱酯酶抑制剂。治疗前及治疗2周和6周后进行神经精神科问卷( Neuropsychiatric Inventory ,NPI)和简明精神状态检查( MMSE)等评分观察疗效。结果:45例患者完成治疗,治疗6周后两组NPI得分均有降低,组内治疗前后比较,差异达统计学意义( t=12.18,2.29;P<0.05);两组间评分比较无显著性差异(t=0.68,0.42,0.66;P>0.05);两组的MMSE评分有所上升,治疗6周后两组内前后比较,差异有统计学意义(t=2.45,2.92;P<0.05)两组间评分无显著性差异(t=0.17,0.92,0.26;P>0.05)。结论:重复经颅磁刺激可能是控制轻中度阿尔茨海默病患者BPSD的一种有效而安全的治疗方法。%Objecti ve:To explore the effects of repetitive Transcranial Magnetic Stimulation ( rTMS ) in treatment of behavioral and psychological symptoms of dementia ( BPSD) of patients with mild-to-moderate Alzheimer's disease ( AD ) .Methods:45 mild -to moderate AD patients accompanied with BPSD were randomly divided to active rTMS group (20 cases) and Risperidone group (25 cases).Sub-jects of rTMS group were treated with rTMS respectively for 20 times during 6 weeks,and the subjects of Risperidone group were treated with risperidone ,all patients were received with stable cholinesterase in-hibitors.Neuropsychiatric Inventory ( NPI)and Mini -Mental Status Examination ( MMSE) were as-sessed before treatment and 2 weeks and 6 weeks after treatment .Results:45 subjects completed the trial . The NPI improved significantly after 6 weeks of active

  9. 氨磺必利与利培酮治疗精神分裂症对照研究%A control study of amisulpride vs .risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    邵国艳; 常双海

    2014-01-01

    Objective To explore the efficacy and safety of amisulpride vs .risperidone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly assigned to two groups of 30 ones each ,re-search group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were as-sessed with the Positive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total and each factor score of the PANSS of both groups lowered continuously compared with pretreatment (P0 .05);at the end of the 8th week obvious effec-tive and effective rate were respectively 60 .0% and 83 .3% in research and 66 .7% and 86 .7% in control group ,which showed no significant differences (χ2 = 0 .29 ,0 .13 ,P> 0 .05) .There were no significant group differences in incidences of adverse reactions (P>0 .05) .Conclusion Amisulpride has an efficacy equivalent to risperidone ,higher safety and better compliance in the treatment of schizophrenia .%目的:探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组,每组30例,研究组口服氨磺必利治疗,对照组口服利培酮治疗,观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前呈持续性下降(P<0.01),治疗各时段两组评分比较差异均无显著性( P>0.05);治疗8周末研究组显效率60.0%、有效率83.3%,对照组分别为66.7%、86.7%,两组比较差异无显著性(χ2=0.29、0.13,P>0.05)。两组不良反应发生率比较差异均无显著性(P>0.05)。结论氨磺必利治疗精神分裂症的疗效与利培酮相当,安全性高,依从性好。

  10. Comparison of efficacy and safety of amisulpride ang risperidone in treating patients with schizophrenia%氨黄必利与利培酮治疗患者精神分裂症患者的对照研究

    Institute of Scientific and Technical Information of China (English)

    杨奎娟; 刘超

    2013-01-01

    目的比较氨黄必利与利培酮治疗精神分裂症患者的疗效与不良反应。方法 120例符合中国精神障碍分类与诊断标准第3版精神分裂症诊断标准的患者随机分为两组,每组60例,分别给予氨黄必利和利培酮治疗8周,采用阳性与阴性症状量表(PANSS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应,用世界卫生组织编制的生活质量量表(WHOQOL-100)评定生活质量。结果 治疗8周后,氨黄必利组显效率73.3%,有效率90%,利培酮组显效率66.7%,总有效率86.7%,两组疗效比较差异无统计学意义(P>0.05);两组WHOQOL-100各领域评分较治疗前均明显差异(P>0.01);氨黄必利组不良反应发生率16.7%,利培酮组为13.3%两组差异无统计学意义(P>0.05)。结论 氨黄必利与利培酮治疗精神分裂症患者的疗效相当,不良反应小,明显改善患者生活质量。%Objective: To compare the efficacy and safety between amisulpride and rispeeidone in treatment of schizophrenia. Method: one hundred and twenty Patients with schizophrenia who met the schizophrenia critetion of Chinese classification of mental disorders were devided into two groups ramdomly and treated with amisulpride or riseridone for 8weeks respectively .The positive and negative scale (PANSS) and treatment Emergent side effect scale (TESS) were used to evaluate the efficacy and adverse effect respectively, the quality of life was measured by World Health Organization quality of life questionnaire (WHOQOL-100). Results:The significant efficacy rate of amisulpride group Was 73.3%and the efficacy rate was 90.0% after 8 weeks, while 66.7% and 86.7% in risperidone group . There were no statistical difference between two groups (P>0.05).The two groups showed similar improvement on quality of life. The incidence rate of adverse effect was 16.7% in amisulpride group and that was 13.3% in risperidone group, without

  11. 齐拉西酮与利培酮治疗精神分裂症对照研究%A control study of ziprasidone vs risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈卉

    2009-01-01

    Objective To explore the efficacy and safety of ziprasidone vs risperidone in the treatment of schizophrenia. Methods 78 schizophrenics were randomly divided into two groups of 36 patients each, research group took orally ziprasidone and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale( PANSS) and Clinical Global Impression(CGI), adverse reactions with the Treatment Emergent Symptom Scale(TESS) before treatment and at the end of the 8th week. Results At the end of the 8th week,total effective rate was 83.33% in the research and 77.78% in the control group, which showed no significant difference(χ2=0.355,P>0.05).After treatment, the CGI total,PANSS total and each factor score of both groups lowered more significantly compared with pretreatment(P0.05). Adverse reactions of both groups were mild,mostly emerged in initial stage of treatment and could relieve with time of therapy lasting or by symptomatic treatment. Incidences of weight gain,galactorrhea and menstrual disorder were significantly lower in the research than in the control group. Conclusion Ziprasidone is more effective in first-episode schizophrenia equivalent to risperidone, scarcely causes weight gain and changes of serum prolaction,blood sugar and fat, its adverse reactions are mild and is a safe and effective novel antipsychotic.%目的 探讨齐拉西酮与利培酮治疗精神分裂症的临床疗效及安全性. 方法 将72例精神分裂症患者随机分为两组,每组36例,研究组口服齐拉西酮治疗,对照组口服利培酮治疗,观察8 w.于治疗前及治疗8 w末采用阳性与阴性症状量表、临床总体印象量表评定临床疗效,副反应量表评定不良反应.结果治疗8 w末,研究组总有效率为83.33%,对照组为77.78%,两组总有效率无显著性差异(χ2=0.355,P>0.05).治疗后两组临床总体印象量表总分、阳性与阴性症状量表总分及各因子分均

  12. Synergistic function study of risperidone combined buspirone in the treatment of homeless patients with mental disorders%利培酮合并丁螺环酮治疗流浪精神障碍患者的效果分析

    Institute of Scientific and Technical Information of China (English)

    王勇健

    2016-01-01

    Objective To investigate the synergistic function and safety of risperidone combined buspirone in the treatment of homeless patients with mental disorders.Methods 96 homeless patients with mental disorders were divided into the control group and the observation group according to the random number table,48 cases in each group.The control group was given ris-peridone and the observation group was given buspirone based on the control group.After 8 weeks,the clinical efficacy was com-pared between two groups by the reduction rate of PANSS scale and symptom group score of PANSS,and the side effects of the two groups were also evaluated.Results Total efficiencies of the two groups had significant difference (P 0.05).Conclusion Risperidone combined buspirone treatment for homeless patients with mental disorders have syn-ergistic function and better security,and it should be widely applied.%目的:探讨利培酮合并丁螺环酮对流浪精神障碍患者治疗的增效作用及安全性。方法选取96例流浪精神障碍患者,根据数字法随机分为对照组和研究组,每组48例。对照组给予利培酮治疗,研究组在对照组基础上合并丁螺环酮,8周后根据 PANSS 量表减分率及 PANSS 量表症状群评分比较两组临床疗效,同时观察两组不良反应发生情况。结果研究组总有效率明显高于对照组,差异统计学意义(P <0.05)。两组治疗前后 PANSS 症状群评分比较,差异有统计学意义(P <0.05),研究组 PANSS 症状群评分下降更明显(P <0.05),两组不良反应发生率比较,差异无统计学意义(P >0.05)。结论利培酮合并丁螺环酮对流浪精神障碍患者治疗有明显的增效作用,且安全性较好,值得推广应用。

  13. Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia%奥氮平与利培酮治疗老年精神分裂症患者疗效及执行功能比较

    Institute of Scientific and Technical Information of China (English)

    杭荣华; 程万良; 王瑞权; 吴明飞

    2012-01-01

    AIM: To explore the difference on efficacy and executive function between olanzapine and risperidone in treatment of elderly patients with schizophrenia. METHODS: 84 eider-ly patients with schizophrenia were randomly divided into olanzapine group (43 cases) and ris-peridon group (41 cases) treated for 8 weeks. The efficacy was assessed with the positive and negative symptoms scale (PANSS) and the executive function was evaluated with Wisconsin Card Sorting Test (WCST) in baseline and after 8 weeks of treatment. RESULTS: After 8 weeks of treatment, the efficacy rate of olanzapine was 90. 6 % . in which 67. 4% was improved markedly. The efficacy rate of risperidon was 92. 6%, in which 68.3% were improved markedly. There were no differences between two groups (P>0. 01). The score of negative symptom of olanzapine group was significantly lower than that of risperidon group(P<0. 05). The score of categories control in risperidon group was significantly lower than that in olanzapine group, persistent errors and response error were higher than that in olanzapine group(P<0. 01). CONCLUSION; Both olanzapine and risperidon can improve the symptom and executive function of elderly patients with schizophrenia. Olanzapine is better than risperidon in improving negative symptom and executive function.%目的:比较奥氮平与利培酮治疗老年精神分裂症的疗效及对执行功能的影响.方法:84例老年精神分裂症患者随机分为奥氮平组(43例)和利培酮组(41例),于治疗前及治疗后第8周末采用阳性与阴性症状量表(PANSS)和威斯康星卡片分类测验( WCST)评定疗效和执行功能,分别比较每组治疗前后及两组间的结果.结果:治疗后奥氮平组的有效率及显效率分别为90.6%和67.4%,利培酮组的有效率及显效率分别为92.6%和68.3%,两者差异无统计学意义(P>0.05).治疗后奥氮平组的阴性症状分低于利培酮组(P<0.01).利培酮组WCST的完成分类数低于奥氮平组,

  14. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia%利培酮合并知母皂甙元治疗阴性症状为主的精神分裂症的双盲随机对照研究

    Institute of Scientific and Technical Information of China (English)

    肖世富; 薛海波; 李霞; 陈超; 李冠军; 苑成梅; 张明园

    2011-01-01

    Objective To identify whether sarsasapogenin,a sapogenin from the Chinese medicinal herb Anemarrhena Asphodeloides Bunge,would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia.Methods The trial was a double-blind,placebo-controlled,parallelgroup design.The eligible patients were randomized into 2 treatment groups:sarsasapogenin group (sarsasapogenin plus risperidone for 8 weeks,n = 41) and placebo group (risperidone only for 8 weeks,n = 39).At the baseline,as well as at weeks 2,4 and 8 of treatment,the therapeutic response was measured by using scales including Positive and Negative Symptoms Scale (PANSS),Wechsler Memory Scale (WMS),modified Chinese Wechsler Adult Intelligence Scale (mWAIS),Clinical Global Impression (CGI) and Brief Psychiatry Rating Scale (BPRS).The study period for each subject was 8 weeks and duration of overall trial was 2 years.Results Patients treated with sarsasapogenin plus risperidone demonstrated no statistically significant differences in changes in PANSS,WMS or mWAIS score at the end-point of the trial compared with patients treated with placebo plus risperidone.The incidence of treatment-emergent adverse events in patients treated with sarsasapogenin was not different from that observed in placebo group.Conclusion Sarsasapogenin did not augment the efficacy of risperidone in treating negative symptoms dominated schizophrenia.Sarsasapogenin at a dosage of 200 mg per day added to a flexible dosage of risperidone at 2-4 mg per day is safe and well tolerated by patients with negative symptoms dominated schizophrenia.%目的 探讨知母皂甙元是否能增强利培酮的治疗作用,以及两者联用是否能显著提高阴性症状为主的精神分裂症病人的认知功能.方法 本研究采用双盲、安慰剂对照的平行设计方案.研究对象随机分为知利培酮合并母皂甙组(n= 41)和利培酮合并安慰剂组(n=39

  15. Effects of risperidone, clozapine and the 5-HT6 antagonist GSK-742457 on PCP-induced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats.

    Science.gov (United States)

    de Bruin, N M W J; van Drimmelen, M; Kops, M; van Elk, J; Wetering, M Middelveld-van de; Schwienbacher, I

    2013-05-01

    Reasoning and problem solving deficits have been reported in schizophrenic patients. In the present study, we have tested rats in a two-lever reversal learning task in a Skinner box to model these deficits. In other studies using the Skinner box, atypical antipsychotics fully reversed phencyclidine (PCP)-induced impairments in reversal learning which is in contrast to clinical observations where antipsychotics lack the ability to fully reverse cognitive deficits in schizophrenia. Therefore, it can be argued that the outcome of these tests may lack predictive value. In the present study, after training on a spatial discrimination between two levers, rats were exposed to a reversal of the previously learned stimulus-response contingency during 5 days. We first investigated the effects of sub-chronic treatment with the non-competitive N-methyl-d-aspartate (NMDA) antagonists dizocilpine (MK-801) and PCP on reversal learning and extinction in male Sprague Dawley rats. Subsequently, we studied the effects of different PCP treatment regimes. Then, we investigated whether the atypical antipsychotics risperidone and clozapine and the 5-hydroxytryptamine6 (5-HT6) antagonist GSK-742457 could reverse the PCP-induced deficits. All drugs were administered subcutaneously (s.c.). MK-801 did not impair reversal learning, while PCP (1.0 and 2.0 mg/kg) induced a clear deficit in reversal learning. Both compounds, however, disrupted extinction at all tested doses. Risperidone and clozapine were both ineffective in significantly ameliorating the PCP-induced deficit in reversal learning which fits well with the clinical observations. The lowest dose of clozapine (1.25 mg/kg) had an intermediate effect in ameliorating the deficit in reversal learning induced by PCP (not different from control or PCP-treated rats). The lowest dose of GSK-742457 (0.63 mg/kg) fully reversed the PCP-induced deficits while the higher dose (5.0 mg/kg) had an intermediate effect. Copyright © 2013 Elsevier B

  16. 氨磺必利与利培酮治疗精神分裂症对照研究%Comparative Study of Amisulpride and Risperidone in Treating 60 Cases of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    曹国兴; 古淑敏; 程雪

    2014-01-01

    Objective To observe the efficacy and safety of amisulpride in the treatment of schizophrenia. Methods 60 cases of first episode schizophrenia were randomly divided into the amisulpride group and the risperidone group with 30 cases in each group and treated for 8 weeks. The positive and negative symptom scale ( PANSS ) was adopted to evaluate the efficacy and the treatment emergent symptoms effect scale ( TESS ) was used to evaluate the adverse reactions. Results The total effective rate after treatment in the amisul-pride group was 83. 33%, while which in the risperidone group was 80. 00% without statistically significant difference between the two groups ( P > 0. 05 ) . The weight gain of the amisulpride group was significantly less than that of the rispefidone group ( P < 0. 05 ) . Conclusion Amisulpride and rispefidone have a similar therapeutic effect, but the case number of weight gain caused by amisulpride is significantly decreased, amisulpride deserves to be clinically popularized.%目的:观察氨磺必利治疗精神分裂症的临床疗效与安全性。方法将60例首发精神分裂症患者,随机分为氨磺必利组30例,利培酮组30例,疗程8周。采用阳性与阴性症状量表( PANSS )评定疗效,采用副反应量表( TESS )评定治疗中出现的不良反应。结果氨磺必利组的治疗总有效率为83.33%,利培酮组为80.00%,两组疗效差异无统计学意义( P>0.05);氨磺必利组的体重增加明显少于利培酮组( P<0.05)。结论氨磺必利与利培酮治疗精神分裂症疗效相当,且氨磺必利引起体重增加数例明显较少,值得临床推广。

  17. Cognitive behavioral therapy for stable schizophrenia with risperidone treatment: A case report%精神分裂症的认知行为治疗个案报告

    Institute of Scientific and Technical Information of China (English)

    郭志华; 李占江

    2013-01-01

    本文介绍了1例康复期精神分裂症患者在利培酮治疗基础上联合认知行为治疗的整个治疗过程.在12次的认知行为治疗过程中,在前、中、后三个阶段如何进行治疗设置、不同阶段的治疗重点、具体治疗方法的应用以及效果评估进行了案例示范,并对该案例治疗的不足和精神分裂症认知行为疗法的未来发展进行了讨论.%The current paper described the complete process of cognitive behavioral therapy combined with risperidone for a patient with schizophrenia in rehabilitative period.The therapeutic setting,focus of three different stages,treatment technologies and effect evaluation were illustrated in this paper.Treatment weakness for this case and future direction of cognitive behavioral therapy for schizophrenia were also discussed.

  18. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial.

    Science.gov (United States)

    Jahangard, Leila; Akbarian, Shahrokh; Haghighi, Mohammad; Ahmadpanah, Mohammad; Keshavarzi, Amir; Bajoghli, Hafez; Sadeghi Bahmani, Dena; Holsboer-Trachsler, Edith; Brand, Serge

    2017-05-01

    Children with ADHD often show symptoms of oppositional defiant disorders (ODD). We investigated the impact of adjuvant risperidone (RISP) to a standard treatment with methylphenidate (MPH) in children with ADHD and symptoms of ODD. Eighty-four children with ADHD and ODD (age: M=8.55; range: 7.28-9.95 years; 73.8% males) took part in a double-blind, randomized, placebo-controlled, clinical trial lasting eight weeks. Participants were randomly assigned either to the MPH+RISP (1mg/kg/d+0.5mg/d) or to the MPH+PLCO (1mg/kg/d+placebo) condition. Symptoms of ADHD, weight, height, and blood pressure were assessed at baseline, and at weeks 2, 4, 6 and 8. Symptoms of ADHD decreased over time, but more so in the MPH+RISP than in the MPH only condition. In the MPH+RISP condition weight, waist circumference and prolactine levels increased over time. Data suggest that adjuvant RISP improved symptoms in children with ADHD and ODD, but weight gain and higher prolactine levels were also observed, which are two alarming side effects. This may become an issue, once children become adolescents, a period of life in which body shape and body self-image are closely linked to self-confidence and peer acceptance. Health care professionals should carefully balance the short-term and long-term costs and benefits of administration of RISP.

  19. 不同剂量利培酮治疗首发精神分裂症的疗效观察%Clinical observation of various dosages of risperidone in treatment of first episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    隗春玲

    2015-01-01

    Objective To observe the effect of various dosages of Risperidone Tablets in treatment of first episode schizophrenia and safety evaluation.Methods Patients (127 cases) with first episode schizophrenia from Beijing Fangshan District Mental Health Care Hospital from April 2012 to April 2014 were randomly divided into high-dosage group ( 62 cases) and low-dosage group (65 cases). The patients in the high-dosage group werepo administered with Risperidone Tablets 0.5 — 1 mg/d at beginning, then gradually added to 6 mg/d according to patient's condition and adverse reactions in the second and third day, and maintained the dosage of 6 mg/d. The patients in the low-dosage group were same to those in the high-dosage group except added dosage and maintenance dosage of 3 mg/d. Two groups were treated for 8 weeks. After treatment, the efficacy was evaluated, and PANSS score, EPS occurrence and TESS scores in two groups were compared.Results The efficacies in the high-dosage and low-dosage groups were 93.85% and 82.26%, respectively, and there were differences between two groups (P < 0.05). After treatment, negative symptom scale scores, positive symptom scale score, the psychopathology scale scores, and PANSS total score in two groups were significantly lower, and the difference was statistically significant in the same group (P < 0.05). The observational indexes of the low-dosage group were significantly lower than those in the same period in the high-dosage group treated for 4 and 8 weeks, with significant difference between two groups (P < 0.05). The incidence of EPS and TESS scores at 4 and 8 week in the low-dosage group were obviously lower than those in the high-dosage group, and the difference was statistically significant between two groups (P < 0.05).Conclusion Low-dosage of Risperidone Tablets has curative effect in treatment of first episode schizophrenia with better clinical efficacy, less PANSS score, incidence of EPS, and TESS scores, which be superior to

  20. Effective comparison of ziprasidone and risperidone in young female patients with schizophrenia and the influ-ence on metabolism%齐拉西酮与利培酮治疗青年女性精神分裂症的疗效及对代谢的影响

    Institute of Scientific and Technical Information of China (English)

    李杰

    2014-01-01

    Objective To compare the effectiveness of ziprasidone and risperidone in young female patients with schizo-phrenia and the influence on metabolism.Methods 116 young female patients with schizophrenia were randomly divided into zi-prasidone group and risperidone group.The two groups received ziprasidone and risperidone treatment respectively.The course of treatment was 8 weeks.Clinical effectiveness ,adverse reactions and the influence on metabolism were compared between the two groups.Results There were no significant difference of PANSS scores on 8 weeks after treatment between two groups (P >0.05);The occurrence of extrapyramidal symptom ,weight gain and lactation and menstruation abnormality in risperidone group were much higher than those in ziprasidone group (P0.05);Compared with ziprasidone group ,BMI and prolactin greatly increased in ris-peridone group (P< 0.05).Conclusion Ziprasidone and risperidone have equivalent effectiveness for young female patients with schizophrenia ,while ziprasidone is more favorable for young female patients for less influence on metabolism.%目的:探讨齐拉西酮与利培酮治疗青年女性精神分裂症的临床疗效及对代谢的影响。方法将116例青年女性精神分裂症患者随机分为利培酮组与齐拉西酮组,分别接受利培酮及齐拉西酮治疗,疗程8周。比较2组临床疗效、不良反应及对代谢的影响。结果治疗8周后,2组阳性及阴性症状量表(PANSS)各项评分差异无统计学意义(P>0.05);利培酮组锥体外系症状、体质量增加、月经改变及泌乳等不良反应发生率显著高于齐拉西酮组(P<0.05);齐拉西酮组治疗前后BMI及泌乳素无显著变化,利培酮组治疗后上述指标显著高于齐拉西酮组( P<0.05)。结论齐拉西酮与利培酮治疗青年女性精神分裂症临床疗效相当,但齐拉西酮对代谢影响小,更适合青年女性的治疗。

  1. A controlled study on effect of olanzapine and risperidone on quality of life in first-episode schizophrenia patients%奥氮平与利培酮治疗精神分裂症首次发病患者的疗效

    Institute of Scientific and Technical Information of China (English)

    徐彩; 李美银; 邓文

    2012-01-01

    目的:探讨奥氮平与利培酮治疗首发精神分裂症的疗效以及对生活质量的影响. 方法:68例首发精神分裂症患者随机分为奥氮平组和利培酮组各34例,分别给予奥氮平和利培酮治疗8周,随访6个月.于治疗前后采用阳性与阴性症状量表(PANSS)及治疗中出现的症状量表(TESS)评定疗效及不良反应;于治疗6个月前后,采用生活质量综合评定问卷(GQOLI)评定生活质量. 结果:两组PANSS评分治疗后均有显著下降(P<0.05或P<0.01).奥氮平组GQOLI总分及各维度与利培酮组GQOLI总分及躯体功能、心理功能维度治疗前后差异均有统计学意义(P均<0.01);两组间比较,治疗前两组GQOLI评分差异无统计学意义,6个月后随访,在躯体功能及社会功能差异有统计学意义(P均<0.01). 结论:奥氮平与利培酮治疗首发精神分裂症疗效相当,但奥氮平在提高生活质量方面略优于利培酮.%Objective: To study the curative powers and effect of olanzapine and risperidone on quality of life in the treatment of first onset schizophrenia patients. Method: 68 first onset schizophrenia patients were randomly divided into olanzapine group and risperidone group, each of which (n = 34 ) received the olanzapine or risperidone treatment respectively for 8 weeks and 6 months follow-up. The efficacy was assessed using positive and negative syndrome scales (PANSS) , and the adverse reaction using treatment emergent symptom scale (TESS). Generic quality of life inventory (GQOLI) was conducted before and 6 months after the treatment for assessmet of patients quality of life. Results: PANSS score of two groups decreased singnificanty after the treatment ( P < 0.05 or P < 0.01). The significant differences were found on GQOLI total score and each dimension score in olanzeoine group and GQOLI total score, physical function,psychological function in risperidone group between before and after treatment (all P<0.01). After 6

  2. The inlfuence of serum prolactin between amisulpride and risperidone in female patients%氨磺必利与利培酮对女性精神分裂症患者血清催乳素的影响研究

    Institute of Scientific and Technical Information of China (English)

    迟勇

    2016-01-01

    ObjectiveComparing the therapeutic effect of amisulpride and risperidone in female patients with schizophrenia and its influence on serum prolactin.MethodThe 78 cases accord with the DSM-5 diagnostic criteria of schizophrenia patients were randomly divided into 38 cases of amisulpride treatment group and 40 cases of risperidone treatment group, observation period for 6 months, respectively before treatment, after treatment of 4 weeks, 8 weeks, 3 months, 6 months for positive and negative symptoms scale, treatment emergent symptom scale and serum prolactin.ResultThe therapeutic effect of amisulpride and risperidone was no significant difference, the two groups before treatment and after treatment of 4 weeks, 8 weeks, 3 months, 6 months PANSS score and each factor score significantly reduced (P<0.01). Amisulpride treatment group and risperidone treatment group after treatment of 4 weeks, 8 weeks, 3 months, 6 months the serum prolactin levels were significantly increased, there was no significant difference. Risperidone treatment group appears amenorrhoea, lactation adverse reactions of patients is more, there are significant difference (P<0.05).Conclusion The therapeutic effect of amisulpride and risperidone is equivalence with schizophrene, the level of serum prolactin has increased significantly, but the adverse reactions of amisulpride treatment group is lighter.%目的:比较氨磺必利与利培酮对女性精神分裂症患者的疗效及其对血清催乳素的影响。方法将78例符合《美国精神障碍诊断统计手册》(第5版)精神分裂症诊断标准的患者随机分为氨磺必利治疗组38例和利培酮治疗组40例,观察期为6个月,分别于治疗前及治疗后4周、8周、3个月、6个月进行阳性与阴性症状量表、副反应量表及血清催乳素测定。结果氨磺必利组与利培酮治疗效果差异无显著性(P>0.05),两组治疗前及治疗后4周、8周、3个月、6个月的阳性与阴性

  3. Change of Blood Drug Concentration and Effect Analysis by Risperidone and Magnesium Valproate in Patients with Schizophrenia%丙戍酸镁合并利培酮治疗精神分裂症血药浓度变化及临床疗效

    Institute of Scientific and Technical Information of China (English)

    刘忠; 李和军; 裴双义

    2014-01-01

    Objective To investigate change of blood drug concentration and effect in patients with schizophrenia by risperidone and magnesium valproate .Methods 60 patients with schizophrenia were randomly divided into observation group ( 30 cases ) and control group(30 cases).The observation group applied risperidone and magnesium valproate ,the control group applied risperidone .The blood drug concentration of risperidone and clinical effect (PANSS scores) were observed in different time (2 weeks,4 weeks,,6 weeks,8 weeks,12 weeks)in two groups.Results Blood drug concentration of risperidone were higher in the observation group than in the control group(t=2.09,2.96,7.02,5.04,6.12;P<0.05 or P<0.01).The clinical effect were better after treatment in observation group (t=7.24,10.88,18.68,24.08,27.42;P<0.01)and control group(t=4.03,8.76,13.73,21.05,25.85;P<0.01).But the effect were higher in the observation group than in the control group (t=4.86,3.52,10.17,10.94,6.12;P<0.01).Conclusion Risperidone and magnesium valproate can improve effect in patients with schizophrenia .The mechanism is correlated with magnesium valproate's special effect.%目的:探讨丙戍酸镁合并利培酮治疗精神分裂症对利培酮血药浓度的影响及临床疗效。方法60例精神分裂症患者随机分为研究组与对照组各30例,研究组丙戍酸镁合并利培酮治疗;对照组单一利培酮治疗。于治疗开始,治疗2、4、6、8、12周对两组患者进行利培酮血药浓度检测,同时使用阳性与阴性评定量表( PANSS)进行临床疗效评定并进行组间组内对比。结果研究组各周利培酮血药浓度均高于对照组(t=2.09,2.96,7.02,5.04,6.12;P<0.05或P<0.01),研究组(t=7.24,10.88,18.68,24.08,27.42;P<0.01)和对照组(t=4.03,8.76,13.73,21.05,25.85;P<0.01)临床疗效与治疗开始比较均有显著疗效,但研究

  4. Curative Effect of Risperidone in The Treatment of Patients with Senile Dementia Accompanied with Psychiatric Symptoms%利培酮口服液促进老年痴呆精神行为症状康复的效果观察

    Institute of Scientific and Technical Information of China (English)

    刘艳华; 徐小童; 吴彦清; 顾培

    2013-01-01

      目的:观察利培酮口服液促进老年痴呆行为异常康复的临床效果与安全性。方法:将笔者所在医院精神科2010年6月-2012年6月收治的具有完整病例资料的30例表现为行为异常的老年痴呆患者,给予利培酮口服液治疗8周,观察其治疗前、后的疗效及不良反应。结果:利培酮口服液治疗有效,相对剂量低,不良反应少,耐受性较好。结论:利培酮口服液更适宜于治疗和促进老年痴呆精神行为异常的康复,利于生活质量的提高。%Objective :To explore the curative effects and side effects of risperidone for oral use in the behavioral and psychiatric symptoms of senile dementia .Methods :The clinical data of 30 patients with the behavioral and psychological symptoms of dementia in our hospital from June 2010 to June 2012 were retrospectively analyzed .They were adminis-tered with riperidone oral solution for 8 weeks .Results:The effective treatment of risperidone oral solution ,relatively low dose ,less adverse reaction ,good tolerability.Conclusion:Risperidone oral solution is more suitable for the treat-ment of senile dementia and promoting mental abnormal ,conducive to improving the quality of life .

  5. Clinical Effects of Risperidone Combined With Modified Electric Shock Therapy in the Treatment of Refractory Schizophrenia%利培酮合并无抽搐电休克治疗难治性精神分裂症的临床效果探究

    Institute of Scientific and Technical Information of China (English)

    高天飞; 张雄; 苑杰

    2016-01-01

    Objective To study the clinical effect of risperidone combined with modified electric shock therapy in the treatment of refractory schizophrenia. Methods 60 cases of refractory schizophrenia patients treated in our hospital from January 2013 to January 2016 were randomly divided into 2 groups,30 cases in each group. Single implementation of risperidone treatment in control group,combined use of risperidone and modified electric shock therapy in observation group. The indexes of two groups of patients with refractory schizophrenia were compared.Results The PANSS score,clinical total effective rate and TESS score of the patients in the observation group were better than those in the control group(P<0.05).ConclusionThe combination of modified electric shock and risperidone in the treatment of patients with refractory schizophrenia is safe and effective.%目的:研究利培酮合并无抽搐电休克治疗难治性精神分裂症的临床效果。方法本次研究选取的研究对象为2013年1月~2016年1月在我院进行治疗的难治性精神分裂症患者,将60例患者简单随机分为2组,每组30例。其中,一组患者单一实施利培酮治疗(对照组),另一组联合使用利培酮和无抽搐电休克治疗(观察组)。对比两组难治性精神分裂症患者的PANSS评分、临床总有效率和TESS评分。结果观察组难治性精神分裂症患者的PANSS评分、临床总有效率和TESS评分均优于对照组患者(P<0.05)。结论无抽搐电休克与利培酮联合治疗难治性精神分裂症患者安全有效。

  6. A Study on the Changes of Prolaction Levels of Female Patients with Schizophrenia after the Treatment of Aripiprazone, Ziprasidone and Risperidone%阿立哌唑、齐拉西酮、利培酮治疗女性精神分裂症患者后催乳素的变化研究

    Institute of Scientific and Technical Information of China (English)

    李文学; 孔德荣; 殷晓; 李猛; 赵青霞; 赵中健

    2014-01-01

    Objective To study the changes of prolaction levels of female patients with schizophrenia after the treatment of arip-iprazone, ziprasidone and risperidone and the causes of amenorrhea. Methods A double-blind randomized-controlled study was adopted. 180 cases of first-episode female schizophrenic patients diagnosed in our hospital from July, 2012 to September, 2013, were selected and they were divided into aripiprazone group and risperidone group, ziprasidone group, 60 cases in each group. They were treated for 6 months. The prolaction level and the number of cases of amenorrhea before and 1, 3, 6 months after treat-ment were detected. Results The prolactin levels of risperidone group were elevated significantly after treatment ( P0.05), the cases of amenorrhea were less. Conclusion Prolactin elevation, amenorrhea and other symptoms easily occur in the patients who take risperidone, but seldom occur in the patients who take aripiprazole and ziprasidone, and the efficacy of aripiprazole and ziprasidone is better, so they are recommended to use.%目的:探讨女性精神分裂症患者在用阿立哌唑、齐拉西酮、利培酮治疗后催乳素水平变化及闭经原因分析。方法采用随机双盲对照研究,收集本院2012年7月—2013年9月首发确诊女性精神分裂症患者180例,分为阿立哌唑组、利培酮组,齐拉西酮组,每组各60例,疗程6个月,治疗前及治疗后1个月、3个月及3个月分别检测催乳素水平及闭经例数。结果利培酮组治疗后催乳素水平显著升高(P0.05),出现闭经例数比较少。结论利培酮用药的患者容易出现催乳素升高、闭经等现象,而阿立哌唑及齐拉西酮却很少出现这种情况,疗效也比较好,建议使用。

  7. Comparative of effects of clozapine, risperidone and ziprasidone on body weight and blood glucose%氯氮平、利培酮与齐拉西酮对精神分裂症患者体重及血糖的影响研究

    Institute of Scientific and Technical Information of China (English)

    宋春联; 赵青霞; 付慧鹏; 周梦煜; 袁海; 康瑞; 高新立; 孔德荣; 张岩滨; 张丽霞; 赵星梅; 胡雄; 霍军; 王体宾; 胡海涛

    2012-01-01

    Objective To investigate the effects of clozapine, risperidone and ziprasidone on body weight and blood glucose of patients with schizophrenia. Methods A total of 190 patients who met the criteria of CCMD -3 for schizophrenia were assigned to clozapine group, risperidone group and ziprasidone group. Using single drug for 6 months. Body weight and fasting plasma glucose were measured before and 1、2、 3、6 months after drug administration. Results After 2 months treatment, body weight in clozapine group and risperidone group were highter than before (P 0. 05). Conclusions Clozapine and Risperidone can effect body weight and blood glucose of patients with schizophrenia. Ziprasidone has no effects on body weight and blppd glucose.%目的 探讨氯氮平、利培酮、齐拉西酮三种抗精神病药物对精神分裂症患者体重及血糖的影响.方法 将190例精神分裂症患者随机分成氯氮平、利培酮、齐拉西酮三组,分别给予单药治疗6个月.于治疗前、及治疗第1、2、3、6个月末监测患者体重及空腹血糖.结果 治疗2个月后,氯氮平组、利培酮组体重较治疗前增加,差异具有统计学意义(P<0.05),治疗3个月后,氯氮平组、利培酮组血糖较治疗前增加,差异具有统计学意义(P<0.05),齐拉西酮组治疗前后体重和血糖差异无显著性(P>0.05).结论 氯氮平、利培酮对患者的体重及血糖均有影响,而齐拉西酮的影响不显著.

  8. 氨磺必利与利培酮治疗精神分裂症疗效和安全性的Meta分析%Meta-analysis on the Efficacy and Safety of Amisulpride and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈志强; 周峰; 陈惠萍

    2015-01-01

    Objective:To evaluate the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia. Meth-ods:The RCTs literatures on amisulpride and risperidone in the treatment of schizophrenia were retrieved and screened, and the quali-fied ones were analyzed by meta-analysis. Results:A total of 10 literatures were included involving 802 patients. Meta-analysis results showed that the difference between the two groups after the treatment was not statistically significant by comparing the clinical efficien-cy, PANSS score and TESS score. About the incidence of adverse reactions, amisulpride was better than risperidone in the endocrine function, extrapyramidal symptoms, weight gain and cardiovascular system. The incidence of nausea and vomiting of amisulpride was more than that of risperidone. There was no statistical significance in insomnia, headache, dizziness and the others. Conclusion:Ex-isting literature analysis shows that amisulpride is safe and effective in the treatment of schizophrenia.%目的::评价氨磺必利与利培酮治疗精神分裂症的疗效和安全性。方法:检索氨磺必利与利培酮治疗精神分裂症相关的随机对照研究文献,纳入合格文献进行Meta分析。结果:共纳入10篇文献,802例患者纳入分析。 Meta分析结果显示:两组治疗后临床有效率、阳性和阴性症状量表( PANSS)评分及治疗中出现的症状量表( TESS)评分比较,差异无统计学意义(P>0.05);药品不良反应发生率:内分泌功能、锥体外系症状、体重增加及心血管系统不良反应比较,氨磺必利少于利培酮(P0.05)。讨论:现有文献分析结果表明,氨磺必利治疗精神分裂症安全、有效。

  9. Study on Clozapine combined with Risperidone in replacement of single Clozapine in treatment of schizophrenia%氯氮平联合利培酮替代单用氯氮平治疗精神分裂症患者的研究

    Institute of Scientific and Technical Information of China (English)

    胡小平

    2014-01-01

    Objective:To observe clinical efficacy and safety of Clozapine combined with Risperidone and single Clozapine in treatment of schizophrenia. Methods:60 patients with schizophrenia were randomly divided into Clozapine combined with Risperidone group (30 cases) and Clozapine group (30 cases), and the treatments lasted for 12 weeks. Clinical global impression scale (CGI) was used to assess the efficacy, and treatment emergent symptom scale ( TESS) was selected to assess the adverse reactions and safety. Results:At the end of the treatment, there was no significant difference in the efficacy between the two groups; however, there were less adverse reactions in Clozapine combined with Risperidone group. Conclusions:Clozapine Combined with Risperidone can replace single Clozapine in the treatment of schizophrenia, their curative effects are similar, but the former has less adverse reactions.%目的::观察氯氮平联合利培酮与单用氯氮平治疗精神分裂症患者的临床疗效和安全性。方法:将60例精神分裂症患者随机分为观察组(氯氮平联合利培酮治疗)30例和对照组(氯氮平治疗)30例,疗程12周,采用临床总体疗效量表CGI评定疗效,用不良反应量表TESS评估患者出现的不良反应和安全性。结果:疗程结束时,两组患者疗效无显著性差异,观察组不良反应较少。结论:氯氮平联合利培酮可以替代单用氯氮平治疗精神分裂症,疗效与单用氯氮平相当,不良反应比单用氯氮平小。

  10. Effect of ziprasidone and risperidone on the blood lipid of first-episode male patients with schizophrenia%齐拉西酮与利培酮对首发男性精神分裂症患者血脂的影响

    Institute of Scientific and Technical Information of China (English)

    张超; 张彦华

    2015-01-01

    Objective:To explore the effect of ziprasidone and risperidone on the blood lipid of first-episode male patients with schizophrenia.Methods:100 first-episode male patients with schizophrenia were randomly divided into the ziprasidone group and the risperidone group with 50 cases in each.Before treatment and at 4,8,12 weeks of treatment,the blood lipid levels of patients were compared between the two groups.Results:At 4,8,12 weeks of treatment,the ziprasidone group and the risperidone group all had effect on the each indicators of blood lipid.But with the extension of the treatment,the increased value had a downward trend, and the ziprasidone group had less increased effect,it had significant difference(P<0.05).Conclusion:The ziprasidone and risperidone all have effects on the blood lipid of first-episode patients with schizophrenia,but the effect of ziprasidone is lighter.%目的:探讨齐拉西酮与利培酮对首发男性精神分裂症患者血脂的影响。方法:将100例首发男性精神分裂症患者随机分为齐拉西酮组和利培酮组各50例。于治疗前及治疗第4、8、12周,对两组患者的血脂水平进行比较。结果:齐拉西酮组与利培酮组对血脂各项指标在治疗第4、8、12周均有影响,但是随着治疗的延长,升高的值有下降趋势,且齐拉西酮组升高值较小,差异具有统计学意义(P<0.05)。结论:齐拉西酮与利培酮对首发精神分裂症患者血脂均有影响,但齐拉西酮的影响较轻。

  11. Safety evaluation of iloperidone and risperidone in the treatment of schizophrenia%伊潘立酮与利培酮治疗精神分裂症的安全性评价

    Institute of Scientific and Technical Information of China (English)

    王宏燕; 韩宝杰; 双梅; 张鸿燕

    2015-01-01

    Objective To evaluate the safety of iloperidone in the treat-ment of schizophrenia.Methods Two hundred and sixty patients with schizophrenia were randomly divided into control group (130 cases) and treatment group (130 cases).Risperidone 3-6 mg・ d-1 was given to the control group, and the treatment group was poured iloperidone 12-24 mg・ d-1 .Both treated for 6 weeks, oral, twice a day.Com-pared the adverse drug reactions rate between the two groups.Results The common adverse reactions were prolactin increasing, extrapyramidal symptoms, elevated aminotransferase, weight gain, abnormal electrocar-diogram, low blood pressure and high blood lipid, etc.The incidence of prolactin increasing and extrapyramidal symptoms were significantly lower in the group of iloperidone(P<0.05).The iloperidone group demonstra-ted lower weight gain increasing than risperidone.Conclusion Iloperi-done has good safety in the treatment of schizophrenia with fewer extrapy-ramidal symptoms, prolactin increasing and weight gain.%目的:评价伊潘立酮片治疗精神分裂症的安全性。方法将260例精神分裂症的患者随机分为对照组130例和试验组130例。对照组予以口服利培酮片3~6 mg・ d-1,每日两次;试验组予以口服伊潘立酮片12~24 mg・ d-1,每日两次。2组患者均治疗6周。治疗后,比较2组患者的不良反应发生率。结果2组患者常见的不良反应有泌乳素升高、锥体外系反应、转氨酶升高、体重增加、心电图异常、低血压、血脂升高等,其中试验组泌乳素升高和锥体外系反应的发生率明显低于对照组(P<0.05),且试验组体重增加的幅度较对照组低。结论伊潘立酮治疗精神分裂症引起锥体外系反应、泌乳素升高、体重增加的可能性较利培酮小,安全性较好。

  12. 利培酮对精神分裂症患者社会功能的研究%A comparative study of social function in schizophrenic patient s treated with risperidone or clozapine

    Institute of Scientific and Technical Information of China (English)

    梅其一; 朱雄伟; 沈建红

    2001-01-01

    Objective:To compare the social function in schizo phrenic patients treated with risperidone or clozapine. Method: Sixty patients with the diagnosis of schizophrenia were randomly entered into ri speridone group (n=30) and clozapine group (n=30).The therapeutic response and s ide effects were evaluated with the positive and negative symptom scale (PANSS) and the treatment emergent symptom scale (TESS).All patients were assessed with the social disability screening schedule (SDSS) at the sixth month after dischar ge. Results:It was found that the social functions (including p rofession,marriage,parental responsibility,et al) were significantly better in r isperidone group than in clozapine group.With multiple regression analysis,the m ain associated factors of impaired social function were high impaired scores of BPRS,male,bad personnel relationship and using clozapine. Conclusion:[ WTBZ〗Risperidone is superior clozapine to improve the condition of social funct ion in schizophrenic patients.%目的:比较利培酮与氯氮平治疗的精神分裂症患者 出院后社会功能状况。 方法:随机抽取30例服用利培酮、30例服 用氯氮平的精神分裂症患者,用阳性症状和阴性症状量表(PANSS)、简明精神病评定量表(BP RS)、不良反应症状量表(TESS)评定;出院后半年用社会功能缺陷量表(SDSS)评定,并与某 些因素进行相关分析及多元逐步回归分析。 结果:半年随访发现 ,服用利培酮的精神分裂症患者在职业工作、婚姻职能、父母职能和社会退缩等社会功能方 面明显好于氯氮平。多元逐步回归分析显示,影响社会功能的因素为经济损失多、男性、不 能积极参加组织活动、不能与他人和睦相处、BPRS评分高者社会功能差,服用氯氮平的比利 培酮差。 结论:利培酮和氯氮平相比,治疗的优势主要不在于副 反应方面,而在于能较好地改善社会功能。

  13. A Control Study of Risperidone in Combination with Clozapine in Treating Refractory Schizophrenia%利培酮合并氯氮平治疗难治性精神分裂症的对照研究

    Institute of Scientific and Technical Information of China (English)

    彭红军; 邝如意; 黄雄; 王玲芝; 朱福坚

    2001-01-01

    目的探讨利培酮合并氯氮平治疗难治性精神分裂症的疗效及副作用.方法将101例难治患者用配对半随机法分成利培酮组(A)、氯氮平组(B)及二药联用组(AB),疗期8周,用PANSS、CGI、TESS评定疗效及副作用.结果三组8周疗效相似(p>0.05),有效率A组60.0%、B组61.8%、AB组62.5%;AB组与A组均于第一周起效,治疗2周时AB 组疗效较单用组佳(p0.05) among group AB(62.5%), group A(60.0%) and group B(61.8%) after 8 weeks treatment. Both group AB and group A responded at the first week, and the efficacy of group AB was superior to that of the other two groups (p<0.05) after 2 weeks, especially for positive symptoms(p<0.05). There were fewer side effects in group AB than the other two groups.Conclusions Risperidone was a effective treatment for refractory schizophrenia as well as Clozapine, and it could be a more safe and effective treatment if two drugs were used in combination.

  14. 百乐眠胶囊联合氟西汀和利培酮治疗抑郁症的疗效观察%Clinical observation of Bailemian Capsules combined with fluoxetine and risperidone in treatment of depression

    Institute of Scientific and Technical Information of China (English)

    舒忙巧; 罗利玲; 张婷

    2016-01-01

    Objective To observe the clinical effect of Bailemian Capsules combined with fluoxetine and risperidone in treatment of depression. Methods Patients (84 cases) with depression in Changan Hospital of Xi’an from May 2015 to March 2016 were enrolled in this study and divided into control (42 cases) and treatment (42 cases) groups according to different treatments. The patients in the control group were po administered with Fluoxetine Hydrochloride Dispersible Tablets, 20 mg/time, once daily. At the same time, the patients were po administered with Risperidone Tablets, 2 mg/time, once daily. The patients in the treatment group were po administered with Bailemian Capsules on the basis of the control group, 4 grains/time, twice daily. The patients in two groups were treated for 4 weeks. After treatment, clinical efficacy was evaluated, and the changes of HAMD and WHOQOL-BREF scores in two groups were compared before and after treatment. Results After treatment, the clinical effect in the control and treatment groups were 80.95%and 95.24%, respectively, and there was difference between two groups (P<0.05). After treatment for 1, 2, and 4 weeks, HAMD scores of two groups were obviously decreased, and the difference was statistically significant in the same group (P<0.05);After treatment for 2 and 4 weeks, HAMD scores of the treatment group decreased more obviously than those of the control group with significant difference (P<0.05). After treatment, the WHOQOL-BREF scores of physical health, psychological status, social relations, and surrounding environment in two groups were increased (P<0.05);And WHOQOL-BREF scores in the treatment group were higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Bailemian Capsules combined with fluoxetine and risperidone has a significant clinical effect in treatment of depression, can relieve the depression state, and improve the quality of life, which has a certain clinical

  15. A control of schizophrenia ’ s metabolic syndrome caused by olanzapine and risperidone%奥氮平与利培酮治疗精神分裂症所致代谢综合征对照研究

    Institute of Scientific and Technical Information of China (English)

    于君; 郝增平; 徐鹏波; 王志敏; 林晓东; 孙军伟; 李红梅

    2014-01-01

    Objective To explore schizophrenia’s metabolic syndromes caused by olanzapine and risperi-done .Methods Eighty-six schizophrenics were randomly assigned to two groups taking orally olanzapine or risperidone for 12 weeks .Mental symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and changes of BP ,body height (BH) ,body mass (BM) ,waist circumference (WC) ,fasting blood sugar (FBS) and blood fit (BF) detected simultaneously .Results Af-ter treatment the PANSS scores of both groups lowered more significantly compared with pretreatment (P0 .05) .Af-ter treatment BM and BMI of both groups increased more significantly ,FBS ,triacylglycerol ,total choles-terol (TC) ,LDL levels heightened and HDL lowered ,and differences had significances since the end of the 8th week (P0 .05) .There were no significant group differences in over-standard WC ,the elevation of FBS ,tria-cylglycerol .TC and LDL ,the reduction of HDL and the detection rate of metabolic syndrome (P>0 .05) . Conclusion Olanzapine and risperidone have therapeutic equivalence in schizophrenia ,different influences on patients’ glucose and lipid metabolism and the risk of causing metabolic syndromes ,so clinically all metabolic indexes should be closely watched .%目的:探讨奥氮平与利培酮治疗精神分裂症导致代谢综合征的发生状况。方法将86例精神分裂症患者随机分成两组,分别口服奥氮平及利培酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定精神症状,同时检测血压、身高、体质量、腰围及空腹血糖、血脂水平的变化。结果治疗后两组阳性与阴性症状量表评分均较治疗前显著下降( P<0.05或0.01),治疗各时段两组评分比较差异均无显著性(P>0.05)。治疗后两组体质量及体质量指数均较治疗前显著增加,空腹血糖、三酰甘油、总胆固醇、低密度脂

  16. Influences of risperidone,quetiapine,or ziprasidone on metabolic parameters of first-episode schizophrenics%利培酮喹硫平齐拉西酮对首发精神分裂症患者代谢指标的影响

    Institute of Scientific and Technical Information of China (English)

    王明进; 张宗顺; 寻广磊

    2016-01-01

    Objective To explore the influences of risperidone ,quetiapine ,or ziprasidone on metabolic parameters of first‐episode schizophrenics .Methods A total of 120 first‐episode schizophrenics were ran‐domly divided into 3 groups taking orally risperidone ,quetiapine or ziprasidone for 12 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment ,the changes of blood pressure (BP) ,waist circumference (WC) ,fasting plasma glucose (FPG) ,triacylglycer‐ol (TG) and high density lipoprotein cholesferol (HDL‐c) detected at the same time ,and the incidences of metabolism syndrome at each time point were added up .Results After treatment the total effective rate was respectively 89 .2% in risperidone ,88 .9% in quetiapine and 86 .5% in ziprasidone group ,which showed no significant group differences (P> 0 .05) .Since the end of the 4th week WC ,TG and FPG levels heightened more significantly in risperidone and quetiapine group compared with pretreatment ,so did those of the 3 groups at the end of the 12th week (P<0 .05 or 0 .01) ,HDL‐c levels lowered more significantly in risperidone and quetiapine group compared with pretreatment (P<0 .05);WCs ,TGs and the incidences of metabolic syndrome were significantly higher in risperidone and quetiapine than in ziprasidone group at each time point (P<0 .05 or 0 .01) .Conclusion Risperidone ,quetiapine and ziprasidone are all effective in first‐epi‐sode schizophrenia ,their total efficacies equivalent ,but have different influences on metabolism , risperidone and quetiapine influences are obvious .%目的:探讨利培酮、喹硫平、齐拉西酮对首发精神分裂症患者代谢指标的影响。方法将120例首发精神分裂症患者按随机数字表法分为3组,分别口服利培酮、喹硫平、齐拉西酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定临床疗效,同时检测血压、腰围及空腹血糖、三酰

  17. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of efficacy and safety of aripiprazole and risperidone treating behavioral and psychological symptoms of dementia

    Institute of Scientific and Technical Information of China (English)

    罗克勇; 刘克祥; 王瑞超; 付华斌

    2013-01-01

    目的 观察阿立哌唑和利培酮治疗老年痴呆精神行为症状的疗效及安全性.方法 采用随机对照研究,将具有精神行为症状的痴呆患者68例完全随机分为阿立哌唑组及利培酮组,各34例.阿立哌唑组患者服用阿立哌唑,起始剂量2.5 mg/d,最大剂量不超过15 mg/d;利培酮组患者口服利培酮,起始剂量0.5 mg/d,最大剂量不超过3 mg/d.疗程均为8周.治疗前和治疗第2、4、8周末采用痴呆病理分析评定量表(BEHAVE-AD)评定疗效,用副反应量表(TESS)评定不良反应,并于入组时和治疗第8周末分别检测2组患者空腹血糖、餐后2h血糖、TC、TG、LDL-C、HDL-C及体重.结果 阿立哌唑组和利培酮组患者治疗2、4、8周后BEHAVE-AD评分均明显低于治疗前[阿立哌唑组:(14.8±4.2)、(10.2±3.6)、(6.8±2.8)分比(16.4±4.6)分;利培酮组:(15.2±3.9)、(11.8±3.8)、(7.2±3.0)分比(17.2±5.0)分,P <0.05或P<0.01].2组患者间治疗前及治疗后BEHAVE-AD评分比较,差异均无统计学意义(P>0.05).2组不良反应发生率均为8.8% (3/34),差异无统计学意义(P>0.05).利培酮组治疗8周末体重较治疗前增加明显[(71±6)kg比(66±6) kg,P<0.05],TG及LDL-C升高[分别为(1.62±0.46) mmol/L比(0.96±0.29) mmol/L,(3.82±0.86) mmol/L比(3.08±0.74) mmol/L],而阿立哌唑组则改变不明显(均P>0.05).结论 阿立哌唑治疗老年痴呆精神行为症状总体疗效、安全性与利培酮相当,但阿立哌唑对患者血糖、血脂及体重影响小于利培酮.%Objective To assess the effect and safety of aripiprazole and risperidone in the treatment of behavioral and psychological symptoms of dementia (BPSD).Methods All 68 dementia were randomly divided into aripiprazole group (n =34) and risperidone group (n =34) with a course of 8 weeks.Aripiprazole was administered by patients in aripiprazole group with a starting dose of 2.5 mg/d and less than the maximum dose 15 mg/d,risperidone was administered

  18. Association between polymorphisms of rs194072,rs187269 in GABRB2 gene and first-episode schizophrenia and the efficacy of risperidone%GABRB2基因 rs194072和 rs187269位点遗传多态性与首发精神分裂症及利培酮疗效的关联性研究

    Institute of Scientific and Technical Information of China (English)

    刘延辉; 寇海燕; 王福华; 田博; 张心华

    2015-01-01

    Objective To explore the association between polymorphisms of Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2 ) gene and first-episode schizophrenia,as well as the association with efficacy of risperidone.Methods Polymorphisms of rs194072 and rs187269 in GABRB2 gene was genotyped by using a SYBR Green based real time PCR assay in 277 schizophrenic patients (study group)and 315 healthy controls (control group).Patients in study group were treated with risperidone for 8 weeks and were assessed with Positive and negative Syndrome Scale (PANSS)at baseline and at the end of the treatment.Results There were significant differences in genotypic frequency and allelic frequency of rs194072 (χ2 =7.93,8.64 respectively;P =0.02,0.003 respectively)and rs187269 (χ2 =9.79,8.23 respectively;P =0.008,0.004 respectively) between study group and control group.The haplotype frequency of CC in study group was significantly higher than that in control group (P =0.003)and the haplotype frequency of TT in study group was significantly lower than that in control group (P =0.004).There were significant differences in distribution of genotypes and alleles of rs187269 between patients response to risperidone and patients invalid to risperidone (P =0.003,0.004 respectively).Conclusion The polymorphisms of rs194072 and rs187269 in GABRB2 gene are likely associated with the pathogenesis of schizophrenia and polymorphism of rs187269 is likely associated with the efficacy of risperidone.%目的:探讨γ-氨基丁酸β2受体(GABRB2)基因多态性与首发精神分裂症及其利培酮疗效的相关性。方法采用 SYBR Green I 荧光等位基因特异性实时 PCR 基因分型法完成277例精神分裂症患者(研究组)和315例正常对照者(对照组)的 GABRB2基因 rs194072和 rs187269两个位点多态性的测定。研究组采用利培酮治疗8周,于治疗前及治疗后第8周末用阳性和阴性综合征量表(PANSS)评估疗效。结果两组 rs

  19. 肥胖相关基因rs9939609多态性与利培酮4周治疗所致体质量增加的关联分析%Association study of FTO gene polymorphism with weight gain associated with 4 week risperidone treatment

    Institute of Scientific and Technical Information of China (English)

    王芳; 宓为峰; 卢天兰; 阮燕燕; 张岱; 岳伟华

    2013-01-01

    目的:探讨肥胖相关基因与利培酮治疗所致体质量增加的关联.方法:收集符合美国精神障碍诊断与统计手册第4版(DSM-Ⅳ)诊断的236名汉族精神分裂症患者,所有患者均采用利培酮单一药物治疗,分别于治疗前和治疗4周后测量患者体质量与身高,计算体质量指数(BMI);本研究采用DNA测序检测方法对肥胖相关基因上的rs9939609多态性位点进行基因分型,采用stepwise线性多元回归的方法探索肥胖相关基因rs9939609多态性与利培酮治疗4周所致体质量增加的关联.结果:关联分析结果显示肥胖相关基因rs9939609多态性与基线BMI值无显著关联[AA/AT vs.TT=(23.0±3.6) vs.(22.7±3.5),P=0.245];4周末时,AA/AT基因型携带者与TT基因型携带者BMI值也无显著性差异[AA/AT vs.TT=(23.4±3.6)vs.(22.7±3.5),P=0.090];4周BMI变化值与rs9939609显著关联[AA/AT vs.TT=(0.6±1.1)vs.(0.2±1.3),P =0.040].结论:本研究结果提示在中国汉族样本人群中,肥胖相关基因rs9939609多态性可能与利培酮所致体质量增加有关联.%Objectives:To explore the association between the Fat Mass and Obesity Associated (FTO) gene polymorphism and weight gain associated with risperidone treatment Methods: Totally 236 schizophrenic patients met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria were enrolled in our study. All the patients were treated with risperidone. The body weight and height of the patients were measured before and after 4week risperidone treatment to calculate body mass index. The FTO rs9939609 polymorphism was genotyped by using direct DNA sequencing method, and was analyzed for association with risperidone-induced weight gain. Results: There was no significant association between rs9939609 and baseline BMI[ AA/AT vs. TT = (23.0 ±3.6) vs. (22.7 ±3. 5),P>0.05] and rs9939609 was neither associated with 4-week BMI [AA/AT vs. TT = (23.4 ± 3. 6) vs. (22. 7 ± 3. 5

  20. Analysis of correlation between 3 single nucleotide polymorphisms of catechol-O-methyltransferase gene and therapeutic effect of risperidone in first-episode schizophrenics%精神分裂症患者儿茶酚胺氧位甲基转移酶基因单核苷酸多态位点与利培酮疗效的关联研究

    Institute of Scientific and Technical Information of China (English)

    吕路线; 贾梅志; 李文强

    2008-01-01

    目的 分析利培酮治疗首次发病(以下简称首发)的精神分裂症患者疗效与儿茶酚胺氧位甲基转移酶(COMT)基因多态性的关联,探讨利培酮疗效的敏感基因.方法 对203例首发精神分裂症患者给予利培酮治疗8周(2~8 ms/d),分别于治疗前和治疗第2~8周末采用阳性和阴性症状量表(PANSS)评分,以减分率评定疗效.并采用限制性片段长度多态技术和序列特异性引物聚合酶链反应技术测定基因型.对痊愈组(29例)、进步组(153例)及无效组(21例)精神分裂症患者与COMT基因单核苷酸多态位点(SNPs)进行关联分析.结果 COMT基因3种多态性基因型及基因频率在利培酮不同疗效患者组间分布差异均无统计学意义(P均>0.05).COMT的3个单核苷酸多态位点单体型分析,利培酮治疗痊愈组与进步组、有效组与无效组间的差异无统计学意义(P>0.05).结论 COMT基因可能不是首发精神分裂症患者抗精神病药利培酮的疗效敏感基因.%Objective To analyze the correlation between therapeutic effect of antipsychotic agent risperidone and catechol-O-methyltransferase(COMT)gene polymorphisms in first-episode schizophrenics,to further study the mechanisms of psychiatric symptoms,and to identify genes sensitive to risperidone medication.Methods 203 first-episode schizophrenics were treated with risperidone(2~8 ms/day)for 8 weeks. Reduction rate in PANSS total score from baseline to week 8 Was used for efiectiveness evaluation.Patients were divided into 3 groups based on reduction rate of PANSS total score,i.e.,remitted (≥75%,n=29),improved(75%~25%,n=153)and unresponsive(≤25%,n=21).Restriction fragment length polymorphism analysis as well as sequence-special primers PCR amplification technique were used to determine the genotypes.Results There Was on statistically significant difference in the 3 COMT polymorphism genotypes as well as allele frequency between the 3 schizophrenic groups

  1. 改良性电抽搐联合利培酮治疗甲基苯丙胺所致精神障碍的对照研究%Comparative study of modified electroconvulsive therapy combined with risperidone in the treatment of methamphetamine-induced psychiatric disorder

    Institute of Scientific and Technical Information of China (English)

    姚刚

    2012-01-01

    目的 探讨改良电抽搐治疗(MECT)联合药物治疗甲基苯丙胺所致精神障碍患者的临床疗效及安全性.方法 84例甲基苯丙胺所致精神障碍患者随机分为联合治疗组及单纯药物组各42例,单纯药物组给予利培酮治疗,联合治疗组给予MECT合并利培酮治疗.采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效和不良反应.结果 治疗一周后联合治疗组有效率为61.90%,单纯药物组有效率为38.10%,两组差异具有统计学意义(P<0.05).治疗3周后,联合治疗组有效率为88.10%,单纯药物组有效率为85.43%,两组差异无统计学意义(P>0.05).联合治疗组副反应较少,且消失较快.结论 MECT合并利培酮治疗甲基苯丙胺所致精神障碍起效更快,副作用小,且安全.%Objective To evaluate clinical efficacy and safety of modified electroconvulsive treatment (m-ECT) combined with risperidone in the treatment of methamphetamine-induced psychiatric disorder. Methods Eighty-four patients with methamphetamine-induced psychiatric disorder were consecutively divided into the study group and the control group, with 42 cases in each group. Patients in the study group were treated with m-ECT combined with risperidone, while those in the control group were treated with risperidone solely, Positive and Negative Syndromes Scale (PANSS) as well as Treatment Emergent Symptoms Scale (TESS) were used to evaluate the clinical efficacy and side effects. Results After one week of treatment, the effective rates of the study group and the control group were 61.90% and 38.10%, respectively, which showed difference between the two groups (P0.05). The study group was observed with few side effects, which disappeared quickly. Conclusion in For treating of methamphetamine-induced psychiatric disorder, modified electroconvulsive treatment combined with risperidone has better efficacy and less side effects than risperidone.

  2. 利培酮和氯氮平治疗精神分裂症疗效评价及其对糖、脂代谢的影响分析%Clinical efficacy of risperidone and clozapine treatment for schizophrenia and the impact on glucose and lipid metabolism

    Institute of Scientific and Technical Information of China (English)

    刘洪光; 曾志强; 王元彬; 叶昌斌

    2013-01-01

    目的 探讨利培酮和氯氮平治疗精神分裂症初诊患者的临床疗效及其对糖脂代谢的影响.方法 94例精神分裂症初诊患者分为利培酮组和氯氮平组,治疗8周后评价临床疗效,测定并比较治疗前后患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、空腹血糖(FBG)、空腹胰岛素(Fins)、胰岛素抵抗指数(IRI)及胰岛素敏感指数(ISI)水平.结果 两组患者治疗总有效率无统计学差异(P>0.05).两组患者治疗后血浆TC、TG、LDL、FBG、Fins、IRI水平升高,HDL、ISI水平降低(P<0.05),氯氮平组TC、TG、LDL水平升高幅度、HDL降低幅度大于利培酮组(P<0.05).结论 氯氮平和利培酮对精神分裂症初诊患者临床疗效确切,二者均对患者糖、脂代谢有影响;利培酮对患者脂代谢的影响相对较小,可作为患者临床治疗的首选用药.%Objective To investigate the clinical efficacy of risperidone and clozapine for treating patients with first-case schizophrenia and the impact on glucose and lipid metabolism.Methods 94 patients with first-case schizophrenia were randomly divided into risperidone group and clozapine group.After treatment of 8 weeks, clinical efficacy was evaluated.The pre-treatment and pro-treatment total cholesterol(TC),triacylglycerol(TG),low density lipoprotein(LDL) ,high density lipoprotein(HDL),fasting blood glucose(FBG) and fasting insulin(Fins), insulin resistance index(IRI) .insulin sensitivity index(ISI) levels of the two groups were detected and compared.Results The total effective rate of the two groups was with no statistical difference(PX).05).After treatment, the plasma TC,TG,LDL,FBG,Fins and IRI levels of two groups significantly increased,the HDL,ISI levels significantly de-creased(P<0.05),and the increase extent of TC,TG and LDL level and the decrease extent of HDL level of the clozapine group was more obvious than the risperidone group(P<0.05).Conclusion The

  3. Curative effect observation of Risperidone combined with Clozapine in treatment of chronic schizophrenia%利培酮在慢性精神分裂症患者治疗中与氯氮平合并使用的疗效观察

    Institute of Scientific and Technical Information of China (English)

    吴胜; 吕捷

    2014-01-01

    Objective:To observe curative effects and adverse reactions of Risperidone combined with Clozapine in treatment of long-term hospitalization chronic schizophrenics, who had taken Clozapine for a long time. Methods:40 long-term hospitalization chronic schizophrenics took Risperidone based on Clozapine. Before and 4, 8, and 12 weeks after the treatment, positive and negative syndrome scale (PANSS) was applied for the evaluation of curative effects; treatment emergent symptom scale (TESS), Extrapyramid-al symptom rating scale (ESRS), as well as the relevant laboratory examination record of the number of cases were used to access the adverse drug reactions. Results: The effective rate of Risperidone combined with Clozapine was 22. 5% . There were statistical differ-ences in the PANSS total score, positive symptom scale score, and general psychopathology scale score before and after the treatment (P0. 05). After the treatment, the number of the cases of the adverse reactions decreased. Conclusions: For the long-term hospitalization chronic schizophrenics, Risperidone combined with Clozapine can improve the positive symptoms and general psychopathological symptoms, but can not improve the negative symptoms. Although Risperidone combined with Clozapine does not have a high total effective rate, it can reduce the dosage of Clozapine and decrease the occurrence rate of the adverse reactions.%目的::观察长期住院服用氯氮平治疗的慢性精神分裂症患者合用利培酮治疗后的疗效及不良反应。方法:对40例长期住院并服用氯氮平治疗的慢性精神分裂症患者联合使用利培酮治疗,治疗前,治疗后4、8、12周末,采用阳性症状和阴性症状量表(PANSS )进行疗效评定,采用不良反应量表(TESS )、锥体外系症状评定量表(ESRS)及有关实验室检查记录对患者药物不良反应例数。结果:联合使用利培酮后患者的治疗有效率为22.5%,治疗前后 PANSS 量表总分、阳性量

  4. 奥氮平与利培酮治疗痴呆患者精神行为症状的对照研究%The comparative study of olanzapine and risperidone in the treatment of dementia patients with behavioral and psychological symptoms

    Institute of Scientific and Technical Information of China (English)

    黄文平; 赵祖安; 白玉红; 曾丽苹

    2012-01-01

    Objective To observe the efficacy and safety of Olanzapine and Risperidone in the treatment of dementia patients with behavioral and psychological symptoms. Methods 80 senile dementia patients were selected and divided into two groups randomly, Olanzapine group (40 cases) and Risperidone group (40 cases). Before the treatment and the treatment for two, four and eight weeks, the two groups were both given the BEHAVE-AD scale to evaluate the efficacy and TESS scale to evaluate the adverse reactions. Results In the treatment of the 8th week, the differences of all the BE-HAVE-AD scales compared with before the treatment in the two groups were statistically significant (P < 0.01). In the treatment of the 2nd week, the difference of total scales compared with before the treatment in the Olanzapine group was statistically significant (P < 0.01), the Risperidone group was not; but at the 8th week the difference of efficiency rate between the two groups was not statistically significant. In security, the difference of total adverse reactions rate was not statistically significant, but the incidence of extrapyramidal side effects (EPS) in the Risperidone group was higher than in the Olanzapine group(P < 0.05). Conclusion The efficacy of Olanzapine and Risperidone in the treatment of dementia patients with behavioral and psychological symptoms are equal, but Olanzapine works faster, side effects are less, so Olanzapine is more suitable to treat dementia patients with behavioral and psychological symptoms.%目的 观察奥氮平和利培酮治疗老年痴呆患者精神行为症状的疗效和安全性.方法 将80例老年痴呆患者随机分为奥氮平组和利培酮组,每组各40例,共观察8周.治疗前及治疗第2、4、8周末分别用BEHAVE-AD量表评定疗效,用TESS量表评定不良反应.结果 奥氮平组和利培酮组在治疗第8周末,BEHAVE-AD量所有项目评分与治疗前比较,差异均有高度统计学意义(均P < 0.01),

  5. Study of effects of Risperidone and Chlorpromazine on cognitive function in patients with chronic schizophrenia%利培酮和氯丙嗪对慢性精神分裂症患者认知功能影响的对照研究

    Institute of Scientific and Technical Information of China (English)

    马文华; 王兆琴; 喻慧; 石莎莎; 林丽群

    2015-01-01

    目的::探讨利培酮对慢性精神分裂症患者认知功能的影响。方法:将符合入组标准的精神分裂症60例患者随机分为利培酮组和氯丙嗪组,每组30例。两组患者分别进行12周系统治疗,用阳性与阴性症状量表(PANSS)、修订韦氏记忆量表(WMS-RC)、中国成人智力量表( CISA)进行检查与评估,比较两组患者疗效和对认知功能的影响。结果:利培酮组患者的PANSS总分、阴性症状和一般病理性症状因子分均显著低于氯丙嗪组,两组患者之间差异有显著性(P<0.05),利培酮组患者的认知功能(包括认知总分、心智、再认、背数、图形识别)优于氯丙嗪组,两组患者存在显著差异(P<0.05)。结论:利培酮对慢性精神分裂症患者认知功能和阴性症状的疗效优于氯丙嗪疗效。%Objective:To study effects of Risperidone on cognitive function in patients with chronic schizophrenia. Methods:60 patients with schizophrenia were randomly divided into Risperidone group ( n=30 ) and Chlorpromazine group ( n=30 ) , and were treated for 12 weeks. The therapeutic response and cognitive function of the two groups were assessed by positive and negative symptom scale ( PANSS) , Wechsler adult memory scale ( WMS-RC) , and Chinese adult intelligence scale ( CISA) and compared. Results:The total score of PANSS, and the factor scores of negative symptoms and general pathological symptoms of Risperidone group were sig-nificantly lower than those of Chlorpromazine group, and the differences between the two groups were significant (P<0. 05). The scores of WMS-RC and CISA ( including total score of cognitive function, intelligence, recognition, digit remembering, pattern recog-nition) of Risperidone group were higher than those of Chlorpromazine group, and the differences between the two groups were signifi-cant (P<0. 05). Conclusions: The effects of Risperidone on cognitive function and negative symptoms in the patients

  6. 精神分裂症患者的多药耐药基因多态性与利培酮的疗效及不良反应的相关性%Relationship between MDR1 gene polymorphisms and therapeutic response to risperidone in schizophrenic patients

    Institute of Scientific and Technical Information of China (English)

    王晓志; 宓为峰; 邹连勇; 卢天兰; 李玲芝; 张鸿燕

    2012-01-01

    目的 观察中国汉族精神分裂症患者多药耐药基因多态性与利培酮临床疗效和不良反应的相关性.方法 入选192例符合DSM-Ⅳ精神分裂症诊断的患者,给予利培酮每天2~6mg,治疗8周.在治疗基线、第4,8周,用阳性与阴性症状量表(PANSS)评估临床疗效.用聚合酶链式反应(PCR)和限制酶切法,检测患者rsl045642和rs2235048的基因多态性.不良反应观察指标为锥体外系不良反应(EPS)发生率、各实验室检查值的变化.结果 PANSS减分率在rs1045642和rs2235048不同基因型及等位基因间分布差异无统计学意义(P>0.05);药物不良反应和EPS的发生率在各基因型和等位基因间差异无统计学意义(P>0.05).结论 多药耐药基因rs1045642和rs2235048的基因多态性与利培酮的疗效和安全性可能无关联.%Objective To investigate the relationship between MDRl gene polymorphism and clinical response in Chinese schizophrenic patients treated with risperidone. Methods One hundred and ninety two patients affected by schizophrenia were treated with risperidone (2-6 rag · d-1) for 8 weeks. The clinical response was evaluated with PANSS. Adverse drug reactions were evaluated by rate of EPS and level change of other variables. PCR - RFLP was used to detect rslO45642 and rs2235048 gene polymorphism. Results There were no statistical significant differences of main clinical response and adverse drug reactions a-mong different genotypes and allele carriers. Conclusion Non - significant associations were found between the polymorphisms of rslO45642, rs2235048 and treatment response of risperidone.

  7. 汉族女性精神分裂症首发患者利培酮治疗所致闭经的危险因素%Risk factors for medication-induced amenorrhea in first-episode female Chinese patients with schizophrenia treated with risperidone

    Institute of Scientific and Technical Information of China (English)

    陈海支; 任丽华; 沈仲夏; 钱敏才; 沈鑫华; 杨胜良; 杨剑虹; 宋娟芬; 费小聪; 陶百平; 宋宝华

    2013-01-01

    Background:Amenorrhea is a common adverse effect of treatment with antipsychotic medications that influences both fertility and adherence to medication regimens. Most research suggests that medication-induced prolactinemia is the main cause of amenorrhea but few prospective studies have assessed this hypothesis. Aim:Identify risk factors for amenorrhea following treatment with antipsychotic medication. Methods:The study used a prospective, nested case-control design. First-episode, drug naïve female patients with schizophrenia who were in the middle of their menstrual cycle at the time of admission were enrolled. Serum levels of six reproductive hormones were assessed before and after a 12-week course of treatment with risperidone:progesterone, estradiol, prolactin, follicular stimulating hormone, luteinizing hormone, and testosterone. The hormone levels of 31 patients who had no menstruation during the entire 12 weeks of treatment (the amenorrhea group) were compared to those of 31 age-matched subjects who had normal menstrual periods over the 12 weeks of treatment (the control group). Results:We found a dramatic 4-fold increase in prolactin levels in women of childbearing age treated with risperidone, but the pretreatment and posttreatment levels of prolactin were not different between patients who did and did not develop amenorrhea with treatment. However, there were significantly lower pretreatment levels of estradiol and progesterone in patients who subsequently developed amenorrhea with risperidone treatment than in patients who did not develop amenorrhea. A conditional logistic regression analysis found that pretreatment levels of estradiol remained significantly associated with the development of amenorrhea during treatment even when adjusting for the pretreatment levels of the other five reproductive hormones assessed. Conclusion:These findings do not support the suggestion that amenorrhea associated with the use of antipsychotic medication is the result

  8. Control study of Wujibaifeng pills and aripiprazole in the treatment of female schizophrenia patients with hyperprolactinemia split caused by risperidone%乌鸡白凤丸与阿立哌唑治疗利培酮所致女性精神分裂症患者高催乳素血症的对照研究

    Institute of Scientific and Technical Information of China (English)

    于丽燕; 丁良; 李玉欣

    2015-01-01

    目的:探讨乌鸡白凤丸与阿立哌唑对女性精神分裂症患者服用利培酮所致高催乳素血症的影响及其安全性。方法将应用利培酮治疗导致高催乳素血症的67例女性精神分裂症患者随机分为乌鸡白凤丸组和阿立哌唑组,疗程4周。结果乌鸡白凤丸组完成28例,阿立哌唑组完成30例,乌鸡白凤丸组血清催乳素明显低于入组前(t=7.624,P=0.000),阿立哌唑组血清催乳素明显低于入组前(t=8.278,P=0.000),两组血清催乳素水平无明显差异(t=1.965,P=0.054)。结论乌鸡白凤丸与阿立哌唑均能降低利培酮所致高催乳素水平,安全性好。%Objective To explore the efifcacy and safety of Wujibaifeng pills and aripiprazole in the treatment of female hyperprolactinemia caused by risperidone.Methods 67 female schizophrenia patients with hyperprolactinemia caused by risperidone and aripiprazole were randomly assigned into Wujibaifeng pills group and aripiprazole group treated for 4 weeks. Results In Wujibaifeng pills group 28 cases were completed the treatment,in aripiprazole group 30 cases completed. In Wujibaifeng pills group, the serum prolactin was significantly lower than before treatment (t=7.624,P=0.000), serum prolactin in aripiprazole group was signiifcantly lower than that before treatment (t=8.278,P=0.000). The serum prolactin levels in the two groups had no significant difference (t=1.965,P=0.054) .Conclusion Wujibaifeng pills and aripiprazole can reduce risperidone induced hyperprolactinemia level with good safety.

  9. 利培酮治疗痴呆患者精神行为的临床疗效及护理效果分析%Risperidone in the treatment of dementia in patients with clinical efficacy and behavioral and psychological care benefits analysis

    Institute of Scientific and Technical Information of China (English)

    冉海珍

    2015-01-01

    目的:探讨利培酮治疗痴呆患者精神行为的临床疗效及护理效果。方法:选取2014年2月至2015年3月我院收治的痴呆患者80例,随机分成两组,每组40例,观察组采用利培酮治疗,对照组采用氟哌啶醇治疗,观察两组治疗效果。结果:经治疗后,观察组患者的治疗有效率明显高于对照组,且观察组患者出现胃肠道反应症状以及锥体外系反应症状的不良反应发生率明显低于对照组(P <0.05),有统计学意义。结论:对痴呆患者实施利培酮治疗以及必要的护理干预,能够有效提升患者的治疗有效率,降低患者的不良反应发生率,效果显著,值得临床推广。%To investigate the risperidone in the treatment of dementia in patients with clinical efficacy and behavioral and psychological care benefits. Methods:patients with dementia from February 2014 to March 2015 in our hospital,80 patients were randomly divided into two groups of40 patients treated with risperidone observation group,the control group,haloperidol,observe two group therapy.Results:After treatment,the treatment of patients in the observation group was significantly higher efficiency,and the observation group were gastrointestinal reactions symptoms and extrapyramidal symptoms of adverse reactions were significantly lower than the control group (P <0.05)there was statistically significant.Conclusion:Risperidone treatment for patients with dementia and the necessary nursing intervention can effectively improve the patient's treatment efficiency,reduce incidence of adverse reactions in patients,the effect is signifi-cant,worthy of promotion.

  10. Efficacy and safetycomparison on the Amisulpride and risperidone in the treatment offirst-episode schizophrenia%氨磺必利与利培酮治疗首发精神分裂症疗效和安全性对照研究

    Institute of Scientific and Technical Information of China (English)

    唐小辉

    2015-01-01

    目的:对照研究氨磺必利与利培酮治疗首发精神分裂症疗效和安全性。方法选取某院2013年6月至2015年3月的首发精神分裂症患者40例,平均分成试验组和对照组,试验组采用氨磺必利的治疗方式,对照组采用利培酮的治疗方式,比较两组的总有效率和不良反应率。结果试验组的总有效率为90%,不良反应率为50%,与对照组对比差异具有统计学意义(P<0.05)。结论氨磺必利在首发精神分裂症的治疗中,较之利培酮疗效更加明显,但副作用较大,需要在临床应用中根据病人的情况将维持剂量调整到最小有效剂量。%ObjectiveTo compare theefficacy and safety on the amisulpride and risperidone in thetreatment of first-episode schizophrenia.Methods To select 40 cases offirst-episode schizophrenia from June 2013 to March 2015 in a hospital and divide them into experiment group(treated with amisulpride) and control group(treated with risperidone). Compare their total efficiency and the rates of adverse reactions.Results The total effective rate of the experimental group was 50%, the adverse reaction rate was 90%, and the difference was statistically significant (P<0.05).Conclusion Amisulpride in first-episode schizophrenia treatment, compared with risperidone efficacy isbetter, yet the side effects is larger. It is need to adjust maintain dose to the minimum effective dose in clinical application according to the patient’s condition.

  11. 帕利哌酮缓释片对精神分裂症疗效及安全性的对照研究%A Controlled Study on the Efficacy and Safety of Paley Risperidone Sustained-release Tablets in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    姜雪晶

    2015-01-01

    目的:对照研究帕利哌酮缓释片对精神分裂症的疗效以及安全性。方法选取某院2014年2月至2015年2月收治的46例精神分裂症患者作为研究对象。按照收治顺序将其随机分为对照组和实验组各23例。对照组患者采用利培酮进行治疗,实验组患者采用帕利哌酮缓释片进行治疗。对比基线、治疗2周后与治疗4周后两组患者的阳性和阴性症状,以及一般精神病理。结果在治疗2周与4周后,实验组患者的阳性症状、阴性症状以及一般精神病理均低于基线时和对照组,差异具有统计学意义(P<0.05)。同时,实验组与对照组均未出现严重的不良反应事件。结论帕利哌酮缓释片对于精神分裂症患者的阳性症状、阴性症状、一般精神病理能够起到明显的改善作用。%ObjectiveTo take a control study on the efficacy andsafety of Paley risperidone sustained-release tablets in the treatment of schizophrenia.Methods 46 cases of schizophrenia patients from Feb.2014 to Feb.2014 are selected and randomly divided into the control group and the experimental group according to the treatment order. Control group were treated by risperidone treatment and the experimental group were treated by Paley risperidone sustained-release tablets for treatment. Compare the baseline, the positive and negative symptomstreatment and general psychopathology of the two groups after 2 weeks and 4 weeks after treatment. Results After treatment for 2 weeks and 4 weeks, the positive symptoms, negative symptoms and general psychopathology of experiment group are lower than the baseline and the control group, whichdifference has statistical significance (P<0.05). And the experimental group and control group has no serious adverse events occurred. Conclusion Paley risperidone sustained-release tablets can obviously improve the positive symptoms, negative symptoms, general psychopathology of schizophrenia patients.

  12. 阿立哌唑治疗利培酮所致高催乳素血症75例疗效观察%Observation on Effect of Aripiprazole in Treatment of Hyperprolactinemia Caused by Risperidone in Schizophrenic Patients in 75 Cases

    Institute of Scientific and Technical Information of China (English)

    唐萍; 冯婧; 夏南

    2015-01-01

    Objective To study the effectiveness and safety of the combined use of small dose of aripiprazole in the treatment of hyper-prolactinemia caused by risperidone. Methods 150 schizophrenic patients with risperidone caused hyperprolactinemia were randomly as-signed to the research group ( n=75 ) and the control group ( n=75 ) . The two groups maintained the original risperidone treatment. The research group was combined with the use of aripiprazole 5-10 mg/d. Serum prolactin levels at the base line, and the ends of 4, 8 and 12 weeks were measured and the scores of PANSS, CGI-S and UKU at the base line and the end of 12 weeks were as-sessed. Results Serum prolactin level at the end of 12 weeks in the research group was ( 17. 01 0 4. 27 )μg/L, which was significantly reduced compared with ( 95. 73 0 48. 77 )μg/L at the baseline ( P ﹤ 0. 05 ) , the effective rate was 84. 00%. However serum prolactin lev-el in the control group had no statistically significant difference between before and after treatment ( P ﹥ 0. 05 ) . The scores of PANSS and CGI-S and the incidence rate of adverse reactions in the two groups had no statistical differences between before and after treat-ment ( P ﹥ 0. 05 ) . Conclusion Aripiprazole can effectively decrease risperidone caused hyperprolactinemia with few adverse reactions. But the long-term effect needs to be further observed.%目的:探讨利培酮所致高催乳素血症的精神分裂症合并应用小剂量阿立哌唑的有效性和安全性。方法将150例患者随机分为研究组和对照组,各75例。对照组维持原有利培酮治疗不变,研究组在对照组基础上合并用阿立哌唑5~10 mg/d;两组于基线及治疗4,8,12周末检测血清催乳素水平,于基线及治疗12周末评定阳性和阴性综合征量表( PANSS )、临床总体印象量表( CGI-S )、UKU副作用评定量表。结果研究组在第12周末催乳素水平为(17.0104.27)μg/L,较基线(95.73048.77)

  13. The role of COMT polymorphism in risperidone-induced hyperprolactinemia in female ;schizophrenia patients%儿茶酚氧位甲基转移酶基因多态性对利培酮治疗女性精神分裂症患者所致高泌乳素血症的影响

    Institute of Scientific and Technical Information of China (English)

    陈钰; 钱程; 戢秋明; 高树贵; 周东升

    2014-01-01

    Objective To study the association between COMT polymorphism and the hyperprolactinemia of Risperidone in female schizophrenia patients. Methods A total of 62 Chinese Han schizophrenic patients that examined by trained psychiatrists using the Chinese Classification of Mental Disorders (CCMD-3) criteria were recruited in this retrospective study. A microparticle enzyme immunoassay was used for measuring the serum prolactin levels at the beginning of the study and the time of receiving risperidone treatment on the 8th week. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for COMT genotypes determined. Results There was no significant association between the COMT Val158Met polymorphism and demographic characteristics of the patients in this study. The prolactin level increases significantly after risperidone treatment (P<0.001). However, the Val/Val genotype of the patients showed the lowest prolactin level in all subjects (P=0.003). Conclusion The COMT Val158/108Met polymorphism may be a potential biomarker with predictive value in Risperidone-induced hyperprolactinemia in female schizophrenia patients.%目的:探讨儿茶酚氧位甲基转移酶(COMT)的基因多态性与利培酮在女性精神分裂症(SCZ)患者中所致的泌乳素升高之间的相关性。方法按照符合美国精神病学会的精神障碍诊断和统计手册第四修订版(DSM-Ⅳ)诊断标准,收集湖北省武汉市武东医院和宁波市康宁医院62例中国汉族女性SCZ患者作为研究对象,对照组选取社区汉族女性健康志愿者,共完成65人。两组民族、性别相同,年龄、文化程度差异无统计学意义。利培酮药物治疗前与治疗8周后分别抽取其外周血液样本,采用微粒酶免疫分析法对用药前后的泌乳素含量进行测定,利用聚合酶链式反应-限制性片段长度多态分析(PCR-RFLP)技术对患者外周血所取提取的基因

  14. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of Efifcacy and Safety of Aripiprazole and Risperidone Treating Behavioral and Psychological Symptoms of Dementia

    Institute of Scientific and Technical Information of China (English)

    李洪涛

    2015-01-01

    目的:通过临床试验对阿立哌唑和利培酮对于痴呆精神行为的疗效和安全性进行观察和探讨。方法将本科室近来收治的有痴呆精神行为症状的患者72人进行随机分组,每组36人,并分别用阿立哌唑(A组)和利培酮来(B组)对患者进行为期8 w的治疗,在治疗之前以及治疗的第2、4以及第8周的最后一天对72名患者采用BEHAV-AD对患者的病理行为进行评定,以此来对两种药物的有效性进行对比;同时采用TESS(不良反应检测表)来对药物的安全性进行分析和比较。结果通过阿立哌唑和利培酮进行治疗的两组患者在治疗后BEHAV-AD评分较治疗之前有了明显的降低,A、B两组患者的治疗之前与治疗之后的BEHAV-AD评分相比较具有较为明显的统计学差异(P<0.05)。另外服用阿立哌唑的A组患者的不良反应发生率明显比服用利培酮的B组患者的不良反应发生率低,通过对差异进行分析发现,此差异同样具有统计学意义(P<0.01)。结论阿立哌唑和利培酮对于痴呆精神行为都具有较为明显的疗效,但是利培酮的安全性相比阿立哌唑较差。%Objective Observe and investigate the efficacy and safety of aripiprazole and risperidone for spirit behavior of dementia. Methods 72 patients with behavioral and psychological symptoms of dementia were randomly assigned into two groups, 36 people in each group , they were treated with aripiprazole (A group) and risperidone to (group B) respectively for a period of 8 w, assessed the behavior of the patients by BEHAV-AD at the points of prior to treatment, treatment of 2, 4 and 8 weeks , and the last day, compared the effectiveness of the two drugs, at the same time using the TESS (adverse reaction detection table) to assess the safety of the drugs. Results After the treatment of aripiprazole and risperidone, BEHAV-AD score signiifcantly reduced in two groups, there were

  15. 奥氮平与利培酮治疗老年痴呆伴精神行为症状对照观察%A control study of olanzapine vs .risperidone in senile demen-tia with behavioral and psychological symptoms

    Institute of Scientific and Technical Information of China (English)

    韩曙林; 孟红凤

    2015-01-01

    目的:比较奥氮平与利培酮治疗老年痴呆伴精神行为症状患者的疗效及安全性。方法将52例老年痴呆伴精神行为症状患者随机分为奥氮平组与利培酮组,分别予以奥氮平与利培酮治疗,观察8周。治疗前后采用痴呆病理行为评定量表、副反应量表评定临床疗效及不良反应。结果奥氮平组治疗第2周末起,利培酮组治疗第4周末起痴呆病理行为评定量表评分较治疗前显著降低(P<0.01),治疗第2周末奥氮平组显著低于利培酮组(P<0.05或0.01);奥氮平组有效率为92.3%,利培酮组为88.5%,两组比较差异无显著性( P>0.05);奥氮平组不良反应发生率显著低于利培酮组(P<0.05)。结论奥氮平与利培酮治疗老年痴呆伴精神行为症状患者疗效显著且相当,但奥氮平起效更快,安全性更高。%Objective To compare the efficacy and safety between olanzapine and risperidone in senile de‐mentia with behavioral and psychological symptoms (BPS) .Methods Fifty‐two senile dementia patients with BPS were randomly assigned to olanzapine and risperidone group treated with olanzapine or risperi‐done for 8 weeks .Efficacies were assessed with the Rating Scale of the Behavioral Pathology in Alzheime‐r′s Disease (BEHAVE‐AD) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results The BEHAVE‐AD score lowered more significantly since the end of the 2nd week in olanzapine group and since the 4th in risperidone group compared with pretreatment (P0 .05);the incidence of adverse reactions was significantly lower in olanzapine than in ris‐peridone group (P<0 .05) .Conclusion Both olanzapine and risperidone have an equivalent and evident effect in senile dementia with BPS ,but the former takes effect more rapidly and has higher safety .

  16. 氨磺必利与利培酮治疗首发精神分裂症的随机双盲双模拟平行对照试验%Parallel Control Method with Random Double-blind and Double-simulation in Treatment with Amisulpride and Risperidone of First-onset Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    韩刚亚; 严冬梅; 张新风

    2012-01-01

    [目的]:探讨氨磺必利与利培酮治疗精神分裂症的疗效及安全性.[方法]:采用随机、双盲、双模拟、平行对照试验方法,将34例符合诊断标准的首发精神分裂症患者随机分为氨磺必利组和利培酮组,每组17例.氨磺必利和利培酮的治疗剂量分别为800~1 200 mg·d-1和2 ~6 mg·d-1.疗程均为8周.于治疗前及治疗第1,2,4,8周末采用阳性和阴性症状评定量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)及实验室检查来评价安全性.[结果]:治疗后第2,4,8周末,两组PANSS总分较治疗前均显著降低(P<0.05);氨磺必利组和利培酮组总有效率分别为88.2%和82.4%,差异无统计学意义(P>0.05).两组不良反应发生率比较差异亦无统计学意义(P>0.05).[结论]:氨磺必利和利培酮对治疗精神分裂症的疗效相当,不良反应轻,值得临床应用.%Objective:To explore the efficacy and safety of amisulpride and risperidone in treatment of schizophrenia. Methods: A randomized, double blind, double-dummy, parallel controlled clinical trial was conducted. The 34 rases of first episode schizophrenia patients met the diagnostic criteria were randomly divided into amisulpride group and risperidone group, 17 cases in each group. The doses range of amisulpride and risperidone were 800-1200 mg and 2-6 mg per day, respectively. The treatment was 8 weeks. The efficacy and adverse events were assessed with the Positive and Negative Symptom Scale (PANSS), Treatment Emergent Symptom Scale(TESS) and the laboratory tests before and at 1st, 2nd, 4th, 8th weekend after treatment. Results :The scores of PANSS in the two groups decreased significantly compared with ihe baseline at 2nd, 4th, 8th weekend after treatment( P 0.05). Conclusion: Amisulpride is as effective as risperidone for the treatment of schizophrenia with fewer side effects and worth clinical application.

  17. Effect comparison of olanzapine and risperidone treating patients with Alzheimer disease associated with psychiatric symptom%奥氮平与利培酮治疗阿尔茨海默病患者伴精神行为症状的效果比较

    Institute of Scientific and Technical Information of China (English)

    钟华; 刘少华

    2015-01-01

    Objective To compare the effect of olanzapine and risperidone treating patients with Alzheimer disease as-sociated with psychiatric symptom. Methods 68 patients with Alzheimer disease received by our hospital from January 2013 to January 2015 of our hospital were selected as study object and were randomly divided into observation group and control group.Observation group was treated by olanzapine and control group was treated by risperidone. Clinical effect of patients in two groups was compared. Results The total effective rate of observation group was 91.2% and the control group was 88.2%,and there was no statistical difference (P>0.05).After treatment,the total score of BEHAVE-AD and BPRS of patients in two groups had no statistical difference when compared with before treatment (P0.05).The incidence rate of adverse reaction in observation group was 20.6% and the control group was 50.0%,and there was a statistical difference (P0.05)。治疗后,两组患者的痴呆病理行为评定量表(BEHAVE-AD)总分、简明神经精神量表(BPRS)总分与治疗前比较,差异有统计学意义(P0.05)。观察组的不良反应发生率为20.6%,对照组为50.0%,两组的不良反应发生率比较,差异有统计学意义(P<0.05)。结论奥氮平与利培酮治疗阿尔茨海默病伴精神行为症状患者具有良好效果,但奥氮平药物起效快,且安全性高。

  18. The exploration of clinical effectiveness of haloperidol and risperidone on improving behavioral and psycho-logical symptoms of dementia%氟哌啶醇与利培酮改善痴呆患者行为症状和精神状态的临床实效性探讨

    Institute of Scientific and Technical Information of China (English)

    穆军山; 叶建新; 林航; 林敏; 崔晓萍; 张敏

    2016-01-01

    Objective To observe and explore the effect of haloperidol and risperidone on improving behavioral and psy-chological symptoms of dementia (BPSD).Methods Eighty cases with dementia in the hospital from August 201 1 to October 2013 were selected,who were randomly divided into observation group treated by risperidone and control group treated with haloperidol,40 patients in each group.PANSS-EC and PANSS Rating Scale were used as the primary methods to effciently e-valuate the efficacy of two groups.Results After 6-week therapy,no significant difference was observed in two groups in terms of PANSS total score and PANSS-EC scores (P >0.05)between two groups,we found statistical difference when compared with before treatment in both groups (P 0.05)。而给药6周后与治疗前2组比较差异均具有统计学意义(P <0.05)。用药后观察组、对照组锥体外系不良反应发生率分别为42.5%、67.5%,差异有统计学意义(P <0.05)。观察组有效率为87.5%,对照组为65.0%,2组比较差异有统计学意义(P <0.05)。结论RPD 口服对改善 BPSD 与 HPL 疗效相当,但 RPD 的临床实效性更好,锥体外系不良反应发生率低,值得临床推广应用。

  19. 氨磺必利、利培酮、奋乃静对分裂症患者生活质量影响的对照研究%Comparative study on the effects of amisulpride,risperidone,perphenazine upon the life quality of schizophrenia patients

    Institute of Scientific and Technical Information of China (English)

    徐瑞华; 黄小振; 郭平

    2015-01-01

    目的:比较氨磺必利、利培酮、奋乃静对分裂症患者生活质量的影响。方法将2013年2月~2014年6月我院住院和门诊治疗的240例分裂症患者随机分为3组,分别给于氨磺必利、利培酮、奋乃静治疗8周。采用生活质量问卷(WHO.QOT-100),在治疗前,第2、4、8周末分别进行评定。结果氨磺必利组在第2周末生活质量总体分数及生理、心理、独立、社会领域分数均明显升高,与治疗前和另2组比较差异有统计学意义(P0.05).Compared with base line,every date in-creased significantly after a 4 weeks treatment,with statistical difference (P<0.01).Compared with perphenazine,the scores of quality of life,physiology also increased significantly in amisulpride and risperidone,with statistical difference (P<0.05),and the physiology scores significantly change continued to the end of the study in smisulpride,with statistical difference (P<0.05). Conclusion On improving the quality of life in schizophrenia patients,amisulpride is the best,the next is risperidone,the last is perphenazine.

  20. Pharm GKB: risperidone [PharmGKB

    Lifescience Database Archive (English)

    Full Text Available pram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine ...lorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan...m clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine flu...ne clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gef...ine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine ge

  1. An association study of the cytochromes P4502D6, the dopamine D2 receptor gene polymorphisms and efficacy of risperidone%细胞色素P4502D6及多巴胺D2受体基因多态性与利培酮疗效的关联

    Institute of Scientific and Technical Information of China (English)

    杨鸽; 李文强; 张红星; 吕路线

    2012-01-01

    目的 探讨细胞色素P450 2D6(cytochromes P450 2D6,CYP2D6)基因多态性、多巴胺D2受体(dopamine D2 receptor,DRD2)基因多态性与利培酮疗效的相关性.方法 对199例首发精神分裂症患者给予利培酮治疗8周,治疗前后采用阳性和阴性症状量表(Positive and Negative Syndrome Scale,PANSS)评定疗效,同时收集198例正常对照进行病例-对照分析.采用聚合酶链反应序列特异性引物扩增技术检测CYP2D6/C188T、DRD2 TaqIA基因型,分析二者与利培酮临床效应的相关性.结果 病例组和对照组CYP2D6/C 188T的基因型和等位基因频率相比,差异有统计学意义(CC:40.7% vs.21.2%,CT:25.6% vs.45.5%,TT:33.7%vs.33.3%,P<0.05;C:53.5% vs.43.9%,T:46.5% vs.56.1%,P<0.05),病例组和对照组DRD2 TaqIA的基因型和等位基因频率相比,差异有统计学意义(A1A1:29.1% vs.35.9%,A1A2:37.7% vs.47.5%,A2A2:33.2% vs.16.6%,P<0.05; A1:48.0% vs.59.6%,A2:52.0% vs.40.4%,P<0.05);CYP2D6/C 188T与DRD2TaqIA的交互作用对PANSS减分率的影响没有统计学意义(F=0.735,P>0.05);CYP2D6/C188T,DRD2TaqIA与性别的交互作用对PANSS减分率的影响具有统计学意义(F=3.214,P<0.05).结论 CYP2D6基因C188T多态性和DRD2基因TaqIA多态性不是影响精神分裂症患者利培酮临床疗效的易感因素,但是在协变量性别的作用下,上述基因多态性的交互作用可能影响利培酮的疗效.%Objective To investigate the correlation of polymorphisms of cytochromes P450 2D6, dopamine D2 receptor and efficacy of risperidone treatment. Methods One hundred ninety-nine first episode schizophrenics were treated with Risperidone for 8 weeks and 198 healthy people served as controls. Positive and Negative Syndrome Scale was used to evaulate the efficacy of risperidone. PCR-RFLP was used to detect the polymorphisms of the CYP2D6 C/T188and DRD2TaqIA genotypes. Results There were significant differences in the ratio of

  2. A comparative study on risperidone orally disintegrating tablets and retard tablets of magnesium valproate treatment in hallucination of schizophrenia%利培酮联合丙戊酸镁治疗伴有幻觉的精神分裂症患者的疗效观察

    Institute of Scientific and Technical Information of China (English)

    王小全; 马素杰; 穆小梅; 周海晓

    2016-01-01

    Objective:Observation of risperidone orally disintegrating tablets combined treatment with retard tablets of magne-sium valproate of the efficacy and safety in hallucination of schizophrenia. Methods:80 schizophrenic patientsmet ICD-10 criteria for schizophrenia and haiiucination with schizophrenia were randomly divided in to groups. With one treated with retard tablets of magnesi-um valproate combined treatment risperidone orally disintegrating tablets and the other with only using risperidone orally disintegrating tablets. Effects and side effects and social function were assessed with Positive And Negative Syndrome Scale ( PANSS) , Treatment E-mergent Symptoms Scale(TESS) and the A Rating Scale for Extrapyramidal Side Effects(RSESE) respectively beforeand after 2,4,6 weeks treatment. Efficacy and safety of the treatment were assessed respectively by Hallucinatory behavior ( p3 ) points reduction in PANSS. Results:The clinical efficiency of experimental and control groups were 90% and 72. 5%, respectively. The difference was significant between the groups(P<0. 05). P3 in PANSS scale points of the clinical efficiency of experimental in the first week has dropped significantly (P<0. 05), While the control group decreased significantly in the second week(P<0. 05). Positive symptoms scale score of the clinical efficiency of experimental in the first week has decreased obviously (P<0. 05) ,While the control group de-creased significantly in the second week(P<0. 05);Team's activation and aggressive factor points of the clinical efficiency of experi-mental in the first weekend have declined significantly (P<0. 05),While the control group decreased significantly in the second week (P<0. 05). Conclusions: Risperidone combined valproic acid magnesium combination than risperidone for schizophrenia hallucina-tions effect more apparent.%目的:观察利培酮联合丙戊酸镁治疗伴有幻觉的精神分裂症患者的疗效及安全性。方法:将80例符合ICD-10

  3. Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia%利培酮和奥氮平对首发精神分裂症患者治疗前后认知功能的对比观察

    Institute of Scientific and Technical Information of China (English)

    赵瑾; 吕路线; 张燕; 晁阳阳; 马骏; 杨勇锋; 赵晶媛; 杜云红; 李文强; 宋学勤

    2016-01-01

    目的:观察首发精神分裂症患者部分认知功能领域损害情况以及利培酮和奥氮平对其治疗前后认知功能的潜在作用。方法选取2015年1—10月在新乡医学院第二附属医院住院治疗的57例首发精神分裂症患者和周边社区年龄、性别匹配的30名健康人(健康对照组),采用随机数字表法将患者分为2组,分别给予利培酮和奥氮平单一治疗。因不良反应难以耐受、药物疗效不佳、换用药物共脱落4例,53例患者完成研究。患者组分别于治疗前和治疗8周后评估患者临床症状(PANSS)和认知功能(连线测试、符号编码、言语记忆、工作记忆、Stroop 测试),健康对照组仅评估一次。结果 PANSS 减分率对比两组并无显著差异。治疗前,利培酮组和奥氮平组均较健康对照组表现出显著的操作速度、言语记忆(t =3.191,t =3.743)、工作记忆(t =2.151,t =2.602)和执行功能领域的差异(P <0.05);经过8周的抗精神病药物治疗,利培酮治疗组表现出连线测试(t =3.862, P <0.05)、言语记忆领域(t =-3.073,P <0.05)功能的改善,奥氮平治疗组表现出连线测试(t =3.587,P <0.05)和工作记忆(t =-2.891,P <0.05)功能的改善。抗精神病药物剂量与认知功能减分率相关分析发现利培酮服用剂量与患者连线测试减分率呈负相关(r =-0.391,P =0.048)。结论利培酮和奥氮平对首发精神分裂症患者临床症状和整体认知功能在8周内作用差异无统计学意义,首发精神分裂症患者存在显著的认知功能损害,利培酮和奥氮平能够在改善精神症状的同时一定程度上改善患者的某些认知领域损害,利培酮服用剂量越大,操作速度领域改善情况越差。%Objective To study the impairments of cognitive function in first-episode schizophrenia and the potential effectiveness of risperidone and olanzapine

  4. Clinical observation of aripiprazole orally disintegrating tablets in the improvement of women's weight,prolactin increase caused by risperidone,sulpiride,olanzapine%阿立哌唑口腔崩解片改善利培酮、舒必利、奥氮平致女性体重、泌乳素增加的临床观察

    Institute of Scientific and Technical Information of China (English)

    卓子禄; 王群英; 熊英; 胡俊英

    2015-01-01

    目的:探讨阿立哌唑口腔崩解片改善利培酮、舒必利、奥氮平等精神类药物所致体重、泌乳素增加的临床效果。方法:收治因服用利培酮、舒必利、奥氮平等精神类药物后引起体重增加及高催乳素血症患者60例,所有患者均维持原抗精神类药物的治疗方案,根据随机数字表将患者分为阿立哌唑口腔崩解片组(观察组)30例和安慰剂组(对照组)30例,两组患者干预12周后测量患者体质指数(BMI)变化及催乳素(PRI)的水平,同时采用不良反应量表(TESS)评定阿立哌唑口腔崩解片治疗的不良反应。结果:与对照组相比,观察组治疗后 BMI 及PRL 显著下降,差异有统计学意义(P<0.01)。观察组总有效率93.33%,对照组总有效率76.67%,两组比较有统计学意义(P<0.05)。TESS 评分观察组(5.12±1.12)分,对照组(4.98±1.08)分,两组比较差异无统计学意义(P>0.05)。结论:阿立哌唑口腔崩解片能有效改善利培酮、舒必利、奥氮平等抗精神病药所致体重、泌乳素增加症状,且安全、可靠,值得临床应用和推广。%Objective:To explore the clinical effect of aripiprazole orally disintegrating tablets in the improvement of women's weight,prolactin increase caused by sulpiride,risperidone,olanzapine.Methods:60 cases of weight gain and hyperprolactinemic patients caused by sulpiride,risperidone,olanzapine were selected.All patients maintained antipsychotic drug treatment scheme of the original.According to the random number table,they were divided into the aripiprazole orally disintegrating tablets group(observation group) with 30 cases and the placebo group(control group) with 30 cases.After 12 weeks of treatment,we measured body mass index patients(BMI) changes and prolactin(PRI) level.At the same time,we evaluated the adverse reactions of aripiprazole orally disintegrating tablets treatment using side effects scale

  5. 孤独症患儿听觉感觉门控电位P50变异及利司哌酮治疗的随访研究%Study on change of auditory sensory gating potential P50 in childhood autism and follow-up of risperidone treatment

    Institute of Scientific and Technical Information of China (English)

    吴荣琴; 张少觐; 张广岐; 陈兴时

    2011-01-01

    AIM To investigate the change of auditory sensory gating potential P50 in childhood autism and the change before and after risperidone treatment.METHODS P50 was recorded from 30 childhood autisms (autisms group) before and after risperidone treatment (0.5 mg, po, for 20 wk) using American Brova instrument with the paradigm of S1 (conditioning stimulus) -S2 (test stimulus) , and Autism Behavior Checklist (ABC) and Childhood Autism Rating Scale (CARS) were employed in the same time.Normal control group included 40 normal children.RESULTS After risperidone treatment, the scores of ABC and CARS in the autisms group decreased significantly (P < 0.01) compared with pretreatment.Compared with the normal control group, the amplitude of S1-P50 decreased, amplitude of S2-P50 increased, and the difference between S1 and S2 increased in the autisms group with significant difference (all P < 0.01 ).There were no significant difference%目的 探讨孤独症患儿听觉感觉门控电位P50的改变及随治疗的变化.方法 30例孤独症患儿在利司哌酮(0.5 mg,po,bid×20 wk)治疗前后应用美国Bravo脑电生理仪,采用条件刺激(S1)-测试刺激(S2)模式检测P50,并进行孤独症行为评定量表(ABC)和儿童期孤独症评定量表(CARS)评分,另设40名正常同龄儿童为正常对照组.结果 孤独症组治疗后ABC评分和CARS评分均显著下降(P<0.01).孤独症组治疗前与正常对照组相比,S1-P50波幅降低,S2-P50波幅增高,S1-S2的差值降低(均P<0.01);2组S1-P50和S2-P50的潜伏期无显著差异(P>0.05).孤独症组治疗20 wk后与治疗前相比,S1-P50和S2-P50的潜伏期和波幅均无显著变化(P>0.05).结论 P50变化可能是孤独症患儿所具有的特定生物学指标之一.

  6. The effect ofShaoyao-Gancao grain on serum prolactin level in female schizophrenia patients with high prolactin induced by risperidone%芍药甘草颗粒对利培酮所致的女性精神分裂症高催乳素血症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    谢姗姗; 陈亚青; 宁征远; 于丽燕

    2016-01-01

    目的:探讨芍药甘草颗粒对利培酮所致的女性精神分裂症高催乳素血症患者血清催乳素水平的影响。方法将符合入选标准的100例女性精神分裂症患者采用随机数字表法分为2组,每组50例。对照组口服利培酮治疗,观察组在对照组基础上联用芍药甘草颗粒。2组均治疗12周。采用免疫化学发光法检测血清催乳素、雌激素水平,采用阳性及阴性症状量表(Positive and Negative Syndrome Scale, PANSS)评价患者的精神症状。结果治疗后,观察组血清催乳素[(46.28±14.06)ng/ml比(117.89±22.11)ng/ml,t=10.242]水平明显低于对照组(P<0.01)。观察组治疗后 PANSS 评分[(67.45±7.00)分比(96.53±11.88)分,t=7.125]、对照组 PANSS 评分[(68.73±7.71)分比(97.93±12.65)分,t=6.541]均较同组治疗前降低(P<0.01),但2组治疗后比较,差异均无统计学意义(t=0.682,P>0.05)。结论芍药甘草颗粒可降低利培酮所致的精神分裂症高催乳素血症患者的血清催乳素水平,且不影响其体内雌激素水平。%Objective To study the effect of Shaoyao Gancao Grain on serum prolactin level in female schizophrenia patients with high prolactin induced by risperidone.Methods 100 patients were randomly divided into the control group 50 cases,which were given risperidone. The study group 50 cases,which were given Shaoyao Gancao Grain on the basis of the control group. The two groups were treated for 12 weeks. Positive And Negative Syndrome Scale,serum prolactin and Estrogen level were measured by immunohistochemistry before and after 12 weeks of treatenmt.Results After 12 weeks of treatenmt,serum prolactin levels were decreased in the study group than control group (46.28 ± 14.06 ng/mlvs. 117.89 ± 22.11 ng/ml;t=10.242,P0.05). ConclusionsShaoyao-Gancao grain can decrease serum prolactin level in female schizophrenia patients with high prolactin induced by risperidone,does not affect estrogen

  7. 利培酮致甲状腺功能改变与糖脂代谢异常的相关性分析%Correlation analysis of risperidone-induced changes on serum thyroxin with disorders of glucose and lipid metabolism

    Institute of Scientific and Technical Information of China (English)

    陈晓慧; 王彦青; 赵鹏辉; 徐东; 张淑芳; 赵倩

    2015-01-01

    Objective To study the correlation of risperidone-induced changes on serum thyroxin with changes on blood glucose and lipid. Methods 35 schizophrenia patients were given risperidone 1-6mg/d for 8 weeks. Triiodothyronine (T3), thyroxin (T4), free triiodothyronine (FT3), free thyroxin (FT4), glucose (GLU) and triglyceride (TG) of all patients were measured before and after treatment. Before and after treatment, T3, T4, FT3, FT4, GLU and TG were compared respectively (t test), and the correlation of T3, T4, FT3, FT4 changs with GLU and TG changes were analyzed (Pearson test). Results After 8 weeks treatment, there was no significant difference in T3 compared with pre-treatment. T4, FT4 and GLU were significantly decreased than before treatment(P<0.05, P<0.05, P<0.01);TG were significantly increased (P<0.05). Changes between T4, FT4 and GLU were positively correlated (P<0.01, and P < 0.05). Changes between T3, FT3 and GLU were not related. And changes between T3, FT3, T4, FT4 and GLU had no correlation. Conclusion Risperidone could reduce thyroid, glucose and elevated blood lipid. There were positive correlations between the decrease of thyroid and the reduce blood glucose.%目的:研究利培酮致血清甲状腺激素水平改变与血糖、血脂水平改变之间的相关性。方法给予35例精神分裂患者利培酮8周治疗,治疗前后分别测定血清三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、血糖(GLU)和甘油三酯(TG)水平。分别对比治疗前后各因素水平的变化情况(t检验),并对因素水平改变差值之间进行相关性分析(Pearson检验)。结果与治疗前比,治疗后血清T3水平无统计学差异,T4、FT4水平显著降低(P<0.05);GLU水平和TG水平分别有极显著性降低和升高(P<0.01)。T4、FT4变化与GLU变化呈正相关,有统计学意义(P<0.01、P<0.05);T3、FT3变化

  8. Comparative Study on Effects of Clozapine and Risperidone on Psychological Theory of Schizophrenia Patients%氯氮平与利培酮对精神分裂症患者心理理论疗效的比较研究

    Institute of Scientific and Technical Information of China (English)

    赵彩荣; 卫玲; 汪凯

    2012-01-01

    目的 比较氯氮平与利培酮对精神分裂症患者心理理论的疗效.方法 入组的130例被试者中精神分裂症患者家属32例(亲属组)、正常者32例(正常对照组)、精神分裂症患者66例,再将 66例精神分裂症患者随机分为两组:服用氯氮平组(34例)和服用利培酮组(32例).四组患者分别予以失言识别测试,并进行对照研究.结果 四组被试者在对照问题上差异无统计学意义(P>0.05);四组失言1、失言2、失言3以及失言4比较差异有统计学意义(P<0.05).结论 精神分裂症存在前额叶认知功能障碍,两种药物对精神分裂症患者心理理论影响无明显差别.%Objective To compare the efficacy of clozapine and risperidone on the psychological theory of schizophrenia patients. Methods 130 cases were included in the study, including 32 cases of family member of schizophrenia( kin group ),32 normal cases( normal control group ),66 cases of patients with schizophrenia; then the 66 cases of schizophrenia were randomly divided into two group:clozapine group( n = 34 )and risperidone group( n = 32 ). The four groups of patients took the faux pas recognition test, and were comparatively studied. Results The differences of the control issue among the four groups were not statistically significant(P >0.05 );faux pas test differences of the four groups were statistically significant P < 0.05 ). Conclusion Schizophrenia has prefrontal cognitive dysfunction, no significant difference between the two drugs in influence on the psychological theory of patients with schizophrenia.

  9. 精神分裂症患者HTR2A基因多态性与帕利哌酮和利培酮临床疗效及安全性的关联研究%Association study of the HTR2A polymorphisms with efficacy and safety of risperidone or paliperidone in Chinese schizophrenic patients

    Institute of Scientific and Technical Information of China (English)

    杜波; 刘永桥; 刘飞虎; 肖卫东; 卢天兰; 李玲芝; 黄兰; 宓为峰; 张鸿燕

    2011-01-01

    目的 观察中国汉族精神分裂症患者的5-羟色胺2A受体(HTR2A)基因多态性与帕利哌酮和利培酮治疗精神分裂症患者临床疗效与安全性的关联.方法 入组201名精神分裂症患者,133例门诊或住院患者,随机接受12周帕利哌酮棕榈酸盐(50~150 mg/4周)或利培酮长效注射针剂(25~50 mg/4周)治疗,每2周进行1次疗效和安全性的评定;68例住院患者,接受4周利培酮片(2~6 mg·d-1)治疗,每周进行1次疗效和安全性评定;以试验结束时阳性阴性症状评定量表(PANSS)总减分率为主要疗效评价指标.共选择3个多态性位点,采用限制性酶切片段长度多态性或直接测序,获得基因型.结果 rs7997012各基因型可能与I临床疗效相关联(P<0.05),位点rs6313和rs6311的各基因型间临床疗效的差别无统计学意义(P>0.05);位点rs6313和rs6311的各基因型与BARS、SAS评分变化及血AST、ALT升高的水平相关联(P<0.05).结论 HTR2A 基因与帕利哌酮及利培酮治疗的临床疗效和安全性可能有关联.%Objective To study the relationship between gene polymorphisms of 5 - hydroxytryptamine receptor 2A (HTR2A) genes and the clinical efficacy and safety in Han Chinese schizophrenic patients who were treated with risperidone or paliperidone. Methods Two hundreds and one schizophrenic patients were included in this study, one hundred and thirty thee inpatients or outpatients were randomized to take paliperidone palmitate (50 - 150 mg/4 week) or risperidone LAI (25 -50 mg/2 week) for 12 weeks' therapy, efficacy and safety examines were taken at every visit. Sixty eight inpatients or outpatients who were treated with risperidone tablets (2 - 6 mg· d - 1 ) for 4 weeks were chosen. Efficacy and security examines was taken by every week. The main effect assessment was the final and baseline positive and negative syndrome scale(PANSS)total score reduced rate. The trial had chosen 3 SNPs, genotypes were detected by PCR

  10. Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients%利培酮对首发精神分裂症S1OOB蛋白含量影响与疗效关系

    Institute of Scientific and Technical Information of China (English)

    刘林晶; 修梅红; 张向阳; 陈大春

    2012-01-01

    AIM: To study if S100B levels is abnormity, to study the effect of risperidone on S100B levels and relationship between S100B levels and treatment response in first-episode schizophrenic patients. METHODS- Fifty-three first-episode schizophrenia inpatients according to DSM-IV were treated only with risperidone for 12 weeks, the Positive and Negative Syndrome Scale (PANSS), Clinical General Impression (CGI) and Hamiton Depression Rating Scale (HAMD) were estimated at the baseline and the endpoint to evaluate the clinical efficacy. The serum S100B levels of the patients at the baseline and the endpoint and the 58 healthy controls were assayed using Enzyme Linked Im-munosorbent Assay (ELISA). RESULTS: The serum S100B levels of the patients groups were significantly higher than the controls (P<0. 01) at the baseline, were significantly decreased after 12 weeks treatment with risperidone but remained significantly higher than controls (F< 0. 05). The serum S100B levels was negative correlated with the age of onset and score of HAMD(r= —0.28, -0.31, P all <0.05)at baseline, The serum S100B levels were significantly lower in the treatment responders comparing no-responders, were negative correlated with reduction of PANSS total score and negative subscore from baseline to 12 weeks O= — 0.28, -0.31, P all <0. 05). CONCLUSION: The serum S100B levels of the schizophrenic patients are significantly higher than the healthy controls, Risperidone treatment reduced the S-100B levels that were associated with treatment response, indicating that patients with schizophrenia may suffer structural damage in central nervous system.%目的:探讨首发精神分裂症S100B蛋白是否异常;利培酮对S100B影响与疗效之间关系.方法:收集符合美国精神障碍诊断与统计手册第4版诊断标准首发精神分裂症住院患者53例,正常对照58例.患者组单一利培酮治疗12周,阳性和阴性综合症量表(positive and negative syndrome scale,PANSS)

  11. 利培酮合并短期肌注氟哌啶醇治疗精神分裂症急性期激越行为疗效的随机对照研究%Randomized controlled trial of effectiveness of Risperidone combining short-term intramuscular Haloperidol in the treatment of the agitated behavior of psychotic patients

    Institute of Scientific and Technical Information of China (English)

    刘锟; 刘云; 宁南义; 孙建中; 孙亚军; 孙同勋; 曹长杰

    2012-01-01

    Objective To compare the efficacy and adverse events of Risperidone combining short-term intramuscular Haloperidol or clonazepam and intramuscular Haloperidol in the treatment of the agitated behavior of patients in the acute phase of schizophrenia. Methods 150 patients associated with impulsive behavior who met the diagnostic criteria of CCMD-3 for schizophrenia were randomly divided into three groups. Group A was treated with Risperidone combining short-term intramuscular Haloperidol, group B with Risperidone combining short-term intramuscular donazepam and group C with only Haolperidol for 2 weeks. The efficacy and adverse events were evaluated by PANSS and TESS. Results After treatment, factor-scores of excitement of PANSS in each group were reduced compared to baseline, and there were significant differences among them (P 0.05). Meanwhile, no significant difference was found among the three groups taking the reduce rate of factor-scores of excitement of PANSS as the standard of efficacy level. There was a significant difference among three groups on the incidence rate of adverse drug reactions (ADR) (P < 0.05). The incidence of EPS (muscle rigidity, tremor and akathisia) of group A was significantly higher than that in group B, and group B was a significantly lower than that in group C on muscle rigidity, tremor and the torsion movement of EPS, while there were no sig-nifcant differences between group A and group C. Conclusion Risperidone combined with short-term Haloperidol intramuscular can greatly improve patient's tolerability and control agitated behavior of patients in the acute phase of schizophrenia quickly and efficiently. It can be a good means for them.%目的 对比氟哌啶醇或氯硝西泮短期肌注合并利培酮与氟哌啶醇肌内注射对急性期精神分裂症患者兴奋激越行为的疗效.方法 将符合CCMD-3诊断标准的150例新入院伴有兴奋冲动行为的精神分裂症患者,随机分为利培酮合并氟哌啶醇组(A

  12. 利培酮对首发精神分裂症患者血清α-肿瘤坏死因子的影响%Effect of risperidone and chlorpromazine on plasma level of TNF-α in patients with first-episode schizophrenia.